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Abstract 
Title: Identification and Investigation of Novel Membrane Proteins in Colon and Pancreatic Cancer 
for Potential Therapeutic Antibody Targeting. 
Author: Edel McAuley 
Advanced colorectal cancer (CRC) and pancreatic ductal adenocarcinoma (PDAC) are highly 
aggressive and heterogeneous diseases which urgently require the development of more effective 
treatment strategies. Novel membrane proteins overexpressed in CRC and PDAC, could have the 
potential to represent attractive molecular targets for development of antibody-based targeted 
therapeutics. 
Candidate molecular targets were identified by Bioinformatic, transcriptomic analysis of publicly 
available colon cancer gene microarray datasets. Lists were generated of genes overexpressed in colon 
adenoma and adenocarcinoma vs. normal colon with predicted membrane localisation. Seven novel 
candidate targets (LY6G6F, IL1RAPL1, IL20RA, BACE2, NTM, LRRC8E and EPHX4) were 
selected for protein validation in normal and colon cancer tissue sections. Two targets, LY6G6F and 
IL1RAPL1, both previously unexploited in cancer were found to be minimally expressed in normal 
colon and show strong expression in CRC, warranting further investigation and functional 
characterisation.  
LY6G6F is a type 1 transmembrane protein, first identified as a novel platelet plasma membrane 
protein, linking to downstream signal transduction pathways upon platelet activation. However, a 
ligand for LY6G6F remains unknown. LY6G6F was found in this study to be significantly 
overexpressed in colon adenocarcinoma, PDAC and gastric adenocarcinoma, with minimal 
expression observed in normal proliferating cells and tissues. IHC analysis of a 57 PDAC patient 
cohort revealed that 78.9% showed strong LY6G6F immunoreactivity; using Kaplan-Meier survival 
analysis, a clear trend was observed between high LY6G6F expression and decreased survival in this 
cohort, however this failed to reach significance (p-value: 0.182). High LY6G6F mRNA expression 
is significantly associated with decreased survival in gastric cancer using KM plotter survival analysis 
(logrank-p: 4.3e-05). Transient protein knockdown of LY6G6F in the colon cancer cell line HCT116 
and the PDAC cell line MIA PaCa-2 significantly inhibits proliferation, 2D colony formation, 
migration and invasion of these cells in vitro. These effects were found to be potentially mediated by 
a decrease in FAK activation and an increase in apoptosis. Thus, taken together these results implicate 
LY6G6F in the proliferation and survival of these cancers.  
IL1RAPL1 is a type 1 transmembrane protein highly expressed in brain neurons, with a reported role 
in synapse formation. Deletions and mutations in IL1RAPL1 have been associated with X-linked 
intellectual disability. IL1RAPL1 was found to be significantly overexpressed in all CRC subtypes 
vs. normal colon and showed limited expression in a range of other normal tissues and highly 
proliferating cells. Furthermore, IL1RAPL1 expression was associated with oesophageal squamous 
cell carcinoma (OSCC), with significant overexpression compared to normal oesophagus and also 
other oesophageal cancer subtypes. The potential functional role of IL1RAPL1 in the colon cancer 
cell phenotype could not be determined. 
LY6G6F and IL1RAPL1 both represent novel candidate proteins overexpressed in these cancer types 
with restricted expression in normal tissues and should be investigated further as potential molecular 
targets for antibody-based therapeutic targeting. 
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Chapter 1. Introduction 
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1.1. Colorectal Cancer 
Colorectal cancer (CRC) has a high incidence rate worldwide. It is the third most commonly 
diagnosed cancer and ranks 4th in mortality. Approximately one third of CRC patients die 
from the disease. (Aslam et al., 2010) The development of CRC typically follows several 
consecutive steps, from a benign adenomatous polyp, which develops into an advanced 
adenoma with high-grade dysplasia and then progresses to an invasive cancer. The model of 
progressive step-wise accumulation of genetic events leading to CRC, was first described by 
Fearon and Vogelstein (1990), with the progression of adenomas to CRC probably occurring 
over years to decades. Early stage CRC tumours confined within the wall of the colon are 
curable, but if left untreated they spread to regional lymph nodes and then metastasise to 
distant sites. (Markowitz and Bertagnolli, 2010) Whilst the primary CRC tumour can take 
decades to develop, once the tumour invades the colonic wall, dissemination and metastasis 
to predominantly the liver can rapidly ensue. The second most frequent sites of metastasis 
are the lungs, with metastatic spread thought to progress sequentially in many patients, from 
liver to lung, then to bone and brain as late sites of involvement. (Nguyen, Bos and Massagué, 
2009; Yaeger et al., 2015)  
Metastatic disease is estimated to develop in 50% of CRC patients, and despite significant 
advances in the treatment of metastatic CRC, which have prolonged median overall survival 
up to 28 months, 5-year survival rates of just 10% remain disappointingly low. (Dietvorst 
and Eskens, 2013) Treatment of metastatic CRC includes targeted therapeutics and a range 
of cytotoxic chemotherapeutics, with fluoropyrimidines, oxaliplatin and irinotecan, 
representing the main chemotherapy regimens utilised. (Dienstmann et al., 2017) Target 
specific agents that are used in metastatic CRC treatment, include the monoclonal antibody 
(mAb) Bevacizumab which targets vascular endothelial growth factor (VEGF), thereby 
inhibiting angiogenesis and the mAb Cetuximab, which targets epidermal growth factor 
receptor (EGFR) on tumour cells, thereby blocking ligand-induced EGFR tyrosine kinase 
activation, initiating cell cycle arrest. (Ciardiello and Tortora, 2008; Dienstmann et al., 2017) 
However, despite great promise observed in preclinical models, the overall added value of 
angiogenesis inhibition in the treatment of metastatic CRC is modest at best. The suitability 
of patients for anti-EGFR therapy is based on the absence of activating KRAS mutations, 
which confer innate resistance. There is a need for new and more active targeted therapeutics 
in the treatment of metastatic CRC. (Dietvorst and Eskens, 2013) 
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It is estimated that 15-30% of CRCs may have a hereditary component and studies of the 
molecular basis of inherited cases have greatly improved the understanding of the specific 
factors and mechanisms that contribute to sporadic CRC development. The bulk of hereditary 
CRC cases are attributable to hereditary nonpolyposis colon cancer (HNPCC), also known 
as the Lynch syndrome, or to familial adenomatous polyposis (FAP). A relatively limited 
number of oncogenes and tumour suppressor genes (most prominently the APC, KRAS and 
p53 genes) are mutated in the majority of CRCs, with a larger collection of genes that are 
mutated in subsets of CRC beginning to be defined. (Markowitz and Bertagnolli, 2010) 
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1.1.1. Genetics of Colorectal Cancer  
CRC arises from epithelial cells at the base of intestinal crypts, which accumulate activating 
oncogenic mutations with concomitant loss of tumour suppressor genes, that confer selective 
growth advantages, leading to the progression from benign adenoma to adenocarcinoma, as 
shown in Figure 1.1. (Fearon and Vogelstein, 1990) Inactivation of the tumour suppressor 
gene adenomatous polyposis coli (APC) is viewed as an early initiating event in CRC. The 
APC protein is an inhibitor of β-catenin, sequestering it in the cytoplasm. In the absence of 
APC, β-catenin binds to nuclear partners to activate the Wnt signalling pathway, enabling 
rapid cell division and migration. APC mutations were first identified as giving rise to the 
FAP form of inherited CRC. Individuals with FAP carry a mutation in one APC allele, with 
the second APC allele typically inactivated through loss of heterozygosity within the first 30 
years of life, which can lead to more than 100 adenomatous polyps developing and an almost 
100% risk of developing CRC by the age of 40 years for carriers of the mutated gene. (Groden 
et al., 1991; Nishisho et al., 1991; Kinzler and Vogelstein, 1996) APC plays an even more 
prominent role in sporadic colorectal tumours, with 70–80% showing somatic mutations and 
deletions that inactivate both copies of APC. (Markowitz and Bertagnolli, 2010) In the 
absence of APC mutations, colorectal tumours can also be initiated by mutations in β–catenin 
itself, that render the protein resistant to the β-catenin degradation complex. Mutations in 
other components of the Wnt signalling pathway can also lead to its activation. Mutations in 
glycogen synthase kinase 3b (GSK3B), a regulator of the Wnt signalling pathway, can also 
lead to β–catenin activation. GSK3B phosphorylates β-catenin, leading to ubiquitin-mediated 
degradation. (Morin et al., 1997; Shakoori et al., 2005)  
The second key genetic step in CRC development involves mutation of the TP53 gene 
resulting in inactivation of the p53 pathway. (Baker et al., 1989) Both TP53 alleles are 
typically inactivated, usually combining a missense mutation that inactivates the 
transcriptional activity of p53 and a chromosomal deletion of the second TP53 allele. (Baker 
et al., 1990) Wild-type p53 functions as a key transcriptional regulator of genes that mediate 
cell-cycle arrest and cell-death upon activation by multiple cellular stresses. Therefore, 
mutations in p53 may facilitate continued growth and the acquisition of invasive properties 
in the face of stresses that might otherwise limit tumour cell survival, with TP53 inactivation 
often coinciding with the transition of large adenomas into invasive carcinomas. (Baker et 
al., 1990; Markowitz and Bertagnolli, 2010) 
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The third step in the progression to CRC is the mutational inactivation of transforming 
growth factor-beta (TGF-β) signalling, which is involved in many cellular processes, 
including the control of cell growth, cell proliferation, cell differentiation and apoptosis. 
(Markowitz et al., 1995) In about one third of CRC cases somatic mutations or frameshift 
deletions inactivate the TGF-β Receptor 2 (TGFBR2) gene. TGF-β signalling can also be 
abolished by mutations or deletions that inactivate downstream TGF-β pathway components, 
such as SMAD4 or its partner transcription factors, SMAD2 and SMAD3. (Eppert et al., 
1996) Mutations that inactivate the TGF-β pathway often correspond with the transition from 
adenoma to high-grade dysplasia or carcinoma. (Markowitz and Bertagnolli, 2010) 
 
 
 
Figure 1.1 Genes and growth factor pathways that drive the progression of colorectal cancer. 
(Adapted from Markowitz and Bertagnolli, 2010) 
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In addition to the inactivation of tumour suppressor genes, several oncogenes play key roles 
in promoting CRC, including KRAS, BRAF, PIK3CA and PTEN. Table 1.1 lists some of 
the commonly mutated oncogenes and tumour suppressor genes in CRC. Oncogenic 
mutations of Ras and BRAF, which activate the mitogen-activated protein kinase (MAPK) 
signalling pathway, occur in approximately 40% and 5-10% of CRCs respectively. (Bos et 
al., 1987; Davies et al., 2002) The Ras family of small-G proteins function as molecular 
switches downstream of multiple different receptor tyrosine kinase (RTK) growth factor 
receptors, such as the EGFR family. The three Ras family members, KRAS, HRAS and 
NRAS, are common targets for somatic mutations in many human cancers. (Malumbres and 
Barbacid, 2003) Mutations in KRAS are most commonly found in CRC, and whilst not 
required for adenoma initiation, KRAS mutations appear to play a key role in driving the 
behaviour of advanced CRC cells. (Shirasawa et al., 1993) BRAF is a protein kinase that 
activates the MAPK effectors MEK1 and MEK2. BRAF mutations have been associated with 
an altered DNA-methylation phenotype found in CRC, known as CpG island 
hypermethylation phenotype (CIMP). (Kodama et al., 2002; Jass, 2007)  
Phosphatidylinositol-3,4,5-triphosphate (PIP3) is a key second messenger of the 
phosphatidylinositol 3-kinase (PI3K) pathway which plays a significant role in cellular 
proliferation, survival and other processes. The formation of PIP3 from PIP2 occurs at the 
cell membrane by the activity of the class I PI3Ks. (Zhao and Vogt, 2008) Activating somatic 
mutations of the PI3KCA gene occur in approximately 15-25% of CRCs. (Samuels et al., 
2004; Wood et al., 2007) PI3KCA encodes the catalytic subunit of PI3K. These mutations 
activate PIK3CA kinase activity, increasing production of PIP3, allowing for increased cell 
growth and survival. (Carson et al., 2008) 
Less common genetic alterations that may substitute for PI3KCA mutations include loss of 
PTEN protein, a phospholipid phosphatase that mediates de-phosphorylation of PIP3 to PIP2, 
inhibiting PI3K signalling. (Chalhoub and Baker, 2009) Somatic mutations that inactivate 
PTEN are found in around 10% of CRCs, however some studies suggest PTEN protein 
expression may be lost in around 15-20% of CRCs. (Wood et al., 2007; Danielsen et al., 
2008) Loss of PTEN expression is observed in both KRAS mutant and KRAS wildtype CRC 
tumours. (Chalhoub and Baker, 2009; Laurent-Puig et al., 2009; Fearon, 2011)  
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Table 1.1 Selected recurrent somatic mutations in oncogenic and tumour suppressor genes in CRC. 
(Adapted from Fearon, 2011)  
Gene Type of mutation Estimated frequency of alterations 
Oncogenes 
KRAS Point mutations (codons 12, 13, 61) 40% (>75% of mutations are at codon 12) 
NRAS Point mutations (codons 12, 13, 61) <5% 
PIK3CA Point mutations activating kinase activity 15–25% 
BRAF Point mutations activating kinase activity 
(e.g., V600E) 
5–10% (mutations linked to CIMP-positive CRCs) 
EGFR Gene amplification 5–15% 
CDK8 Gene amplification 10–15% 
CMYC Gene amplification 5–10% 
CCNE1 Gene amplification 5% 
CTNNB1 Stabilizing point mutations and in-frame deletions 
near N terminus 
<5% 
NEU (HER2) Gene amplification <5% 
MYB Gene amplification <5% 
Tumour-suppressor genes 
p53 Point mutation, allele loss 60–70% (>95% of point mutations are missense) 
APC Frameshift, point mutation, deletion, allele loss 70–80% (nearly all mutations lead to truncated 
proteins) 
FBXW7 Nonsense, missense, deletion 20% 
PTEN Nonsense, deletion 10% 
SMAD4 Nonsense, missense, allele loss 10–15% 
SMAD2 Nonsense, deletion, allele loss 5–10% 
SMAD3 Nonsense, deletion 5% 
TGFβIIR Frameshift, nonsense 10–15% (>90% of MSI-H CRCs have mutations) 
TCF7L2 Frameshift, nonsense 5% (mutations in both MSI-H and MSS CRCs) 
ACVR2 Frameshift 10% (>80% of MSI-H CRCs have mutations) 
BAX Frameshift 5% (often one allele in ∼50% of MSI-H CRCs) 
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1.1.2. Genomic Instability: Chromosomal Instability vs. Microsatellite Instability 
The acquisition of genomic instability is a crucial feature in CRC tumour development and 
there are at least 2 distinct pathways in CRC pathogenesis: the chromosomal instability (CIN) 
and microsatellite instability (MSI) pathways. (Fearon, 2011) Early karyotyping analyses of 
CRC tumours revealed that many had numerous chromosomal alterations, including frequent 
losses of chromosomes 18 and 17p, as well as gains of chromosomes 13 and 20. (Muleris et 
al., 1985; Muleris, Salmon and Dutrillaux, 1990) It was subsequently determined that the 
majority (~85%) of CRC cases arise through this CIN pathway, which is characterised by 
widespread imbalances in chromosome number (aneuploidy), loss of heterozygosity and 
gene deletions or duplications. (Lengauer, Kinzler and Vogelstein, 1997) Key factors that 
underlie CIN in CRC are poorly defined, but defects in genes that regulate formation of the 
mitotic spindle, chromosomal segregation and the DNA damage response, contribute to the 
CIN phenotype. (Leary et al., 2008) Chromosomal instability is an efficient mechanism for 
causing the loss of a tumour suppressor gene copy, such as APC, p53 and SMAD4. (Grady 
and Markowitz, 2002; Markowitz and Bertagnolli, 2010)   
The MSI pathway is caused by the loss of DNA mismatch repair genes, primarily MLH1 and 
MSH2, and accounts for the remaining 15% of CRC cases. The inactivation of mismatch 
repair genes can be inherited, such as in HNPCC, also known as the Lynch syndrome, where 
patients have germ-line defects in mismatch repair genes. Subsequent inactivation of the 
second gene allele, gives HNPCC patients an 80% risk of developing CRC within their 
lifetime. (Bronner et al., 1994; Lynch et al., 2008) Approximately 3% of MSI CRC cases are 
associated with the Lynch syndrome and the other 12% with sporadic CRC, where 
methylation-associated silencing of the promotor region of the MLH1 gene inactivates 
mismatch repair. (Veigl et al., 1998) MSI is characterised by alterations of microsatellite 
sequences (short tandem repeats of repeated nucleotide sequences ranging in length from 2-
7 nucleotides per unit) at many loci across the genome, due to the loss of DNA mismatch 
repair gene function. High frequency MSI (MSI-H) is characterised by more than 40% of a 
panel of mononucleotide and dinucleotide sequences. (Thibodeau, Bren and Schaid, 1993) 
Mutations in microsatellite sequences can inactivate tumour suppressor genes that contain 
mononucleotide or dinucleotide repeat sequences. The TGFBR2 gene is inactivated in over 
90% of MSI-H CRC cases, due to frameshift mutations of a polyadenine tract in the coding 
region of the gene. (Markowitz et al., 1995) The majority of CRCs are classified as 
microsatellite stable (MSS), i.e. they display no microsatellite instability. Some CRC cases 
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show low-frequency MSI (MSI-L), which have no evidence of mutations of mismatch repair 
genes. (Vilar and Gruber, 2010) The MSI-L cases do not appear to be significantly different 
from MSS cases, with regards to tumour pathological features. However, MSI-H CRC 
tumours have distinct pathological features compared to MSS, including a tendency to arise 
in the proximal colon, lymphocytic infiltrate (high infiltration with activated CD8+ cytotoxic 
T-lymphocyte and activated T helper 1 (Th1) cells), and a poorly differentiated, mucinous or 
signet ring appearance. MSI cases also have improved survival compared to MSS tumours 
and do not have the same response to chemotherapeutics. (Redston, 2001; Kakar et al., 2004)  
Another pathogenic pathway associated with MSI tumours is the CpG island methylator 
phenotype (CIMP), which is characterised by widespread hypermethylation of CpG islands 
at several genomic loci. (Issa, Shen and Toyota, 2005) CpG islands is the term used for 
localised regions of high CpG-dinucleotide content within the genome. The promoter regions 
of approximately 50% of all genes contain CpG islands. (Issa, 2008) Hypermethylation of 
CpG islands in the promoter regions of tumour suppressor genes has been linked to their 
silencing in human malignancies, including CRC. (Esteller, 2008; Berman et al., 2012) The 
CIMP mechanism suggests that epigenetic events contribute to CRC carcinogenesis. The 
contribution of epigenetic silencing events to CRC onset/progression remains an ongoing 
area of study.  
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1.1.3. The Tumour Microenvironment in Colorectal Cancer  
Whilst the emphasis on tumour pathogenesis has previously focused on epithelial cell 
behaviour and the genetic and epigenetic alterations involved, the importance of the tumour 
microenvironment and the interaction between stromal and epithelial cells is now widely 
recognised. During tumour development, a complex tissue is formed composed of cancer 
cells and multiple distinct cell types, which are derived mainly from the neighbouring 
mesenchymal stroma. This complex ecology of cells forming the tumour microenvironment, 
evolves with and provides support to tumour cells during the transition to malignancy, with 
the functional interactions between tumour and stromal cells sustaining growth and invasion. 
A major contributor to the tumour microenvironment is inflammation, with chronic 
inflammation now recognised as both a tumour initiator and promoter. Persistent 
inflammatory conditions are known to increase the risk of cancer development, e.g. viral 
infections are related to cervical and liver cancer, and inflammatory bowel diseases such as 
ulcerative colitis and Crohn’s disease increase the risk of developing CRC. (Peddareddigari, 
Wang and DuBois, 2010; Colangelo et al., 2017) 
The tumour microenvironment consists of tumour-infiltrating cells, vasculature, extracellular 
matrix (ECM) and other matrix associated molecules, as well as an abundance of cytokines 
and chemokines. The induction of angiogenesis is an important event in the development of 
most cancers, promoting tumour growth and invasion. In CRC, the microvascular density of 
a tumour is a prognostic indicator. (Choi et al., 1998) The ECM is composed of 
macromolecules, including collagen, laminins, fibronectin and proteoglycans, that form a 
highly organised three-dimensional structure of basement membrane (BM) and interstitial or 
stromal matrix. The BM is composed of a dense network of collagen type IV and laminin, 
and acts as a mechanical barrier and organiser of tissue structure. Breakdown of the BM is 
required for invasive tumour growth, with various types of proteinases involved in ECM 
turnover, such as matrix metalloproteinases (MMPs). Colon cancer cells can induce secretion 
of MMP-2 and MMP-9 by stromal cells. (Toda et al., 2006) ECM remodelling is critical for 
tumour progression and the ECM also provides a reservoir of cytokines and growth factors. 
(Peddareddigari, Wang and DuBois, 2010) 
Local inflammation at the site of a solid malignancy and the secretion of soluble 
chemoattractants by both cancer and stromal cells results in the infiltration of a large variety 
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of cells into the tumour microenvironment. CRC tumours are infiltrated by various cell types, 
such as cancer-associated fibroblasts (CAFs), tumour-associated macrophages (TAMs) and 
lymphocytes, with the role of these three types in CRC progression described in greater detail 
in Sections 1.1.3.1-1.1.3.3. Other cell types involved in tumour infiltration include 
neutrophils, dendritic cells, natural killer (NK) cells, myeloid-derived suppressor cells, 
endothelial progenitor cells, platelets and mesenchymal stem cells. The dynamic interaction 
between cancer and stromal cells often promotes tumour cell proliferation, survival and 
metastasis. The tumour microenvironment can also play a critical role in the development of 
more advanced and therapy-refractory cancers. Therefore, further understanding of the 
complex interactions between tumour epithelial and stromal elements will enhance 
development of therapeutic options and improve clinical outcome in CRC. (Peddareddigari, 
Wang and DuBois, 2010; Colangelo et al., 2017) 
 
1.1.3.1. Cancer-Associated Fibroblasts (CAFs) 
Fibroblasts compose the major stromal population in normal colonic mucosa, responsible for 
the synthesis and turnover of basement membrane components. (Colangelo et al., 2017) In 
CRC, the major cellular component of the tumour stroma are CAFs. (Östman and Augsten, 
2009) The secretion of factors by cancer cells, such as, platelet-derived growth factor 
(PDGF), TGF-β, Interleukins 4/6 (IL-4/6) and prostaglandin E (PGE), have been identified 
as being responsible for fibroblast differentiation into CAFs. (Cirri and Chiarugi, 2011; 
Hawinkels et al., 2014) Local tissue fibroblasts and fibroblast precursors are generally 
considered to be the main source of CAFs. However various other cell types, including 
stellate cells, circulating mesenchymal stem cells and CD34+ fibrocytes, have also been 
considered as potential sources of CAFs, once recruited into the CRC stroma. (Gascard and 
Tlsty, 2016) CAFs are still not fully understood, and are mostly defined based on the 
expression of α-smooth muscle actin (α-SMA), fibroblast activating protein, fibroblast-
specific protein-1, platelet-derived growth factor receptors α and β (PDGFR-α, - β) and 
neuron-glial antigen-2. (Sugimoto et al., 2006; Östman and Augsten, 2009; Augsten, 2014; 
Chen et al., 2014) CAFs morphologically appear as large, spindle shaped cells with 
prominent nucleoli and enlarged endoplasmic reticulum and Golgi complex, which reflects 
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the enhanced secretion of enzymes, growth factors and ECM proteins, involved in tumour 
microenvironment remodelling. (Paunescu et al., 2011) 
CAFs are a source of a large range of growth factors, including TGF-β, epidermal growth 
factor (EGF), hepatocyte growth factor (HGF), insulin-like growth factor (IGF)-1, IGF-2 and 
VEGF, that promote tumour growth and invasion. (Östman and Augsten, 2009) CAFs also 
express chemokines, interleukins, cell-surface molecules like integrin-α11, proteases such as 
MMP-2 and ECM constituents like osteopontin, that stimulate processes such as 
inflammation and angiogenesis, and promote tumour cell proliferation, migration, invasion 
and survival. (Joesting et al., 2005; Yang, Lin and Liu, 2006; Taniwaki et al., 2007; Zhu et 
al., 2007; Cirri and Chiarugi, 2011) CAF-derived chemokines such as CXCL12 and CXCL14 
recruit macrophages and other immune cells into the tumour microenvironment, which also 
contributes to tumour growth. (Orimo et al., 2005; Östman and Augsten, 2009) CAFs have 
also been found to mediate tumour cell resistance to chemotherapeutics in CRC. Soluble 
factors secreted by CAFs trigger a cell signalling cascade, inducing the translocation of AKT, 
Survivin and p38 to the nucleus of CRC tumour cells, protecting them from the action of 
conventional chemotherapy used in CRC treatment. (Gonçalves-Ribeiro et al., 2016) CAFs 
in CRC typically express high levels of PDGFR-β, which is associated with advanced stage 
of disease and an increased metastatic potential. The blockade of PGFR signalling pathways 
in tumour-associated stromal cells using drugs such as imatinib, has been shown to inhibit 
the progressive growth and metastasis of colon cancer cells. (Kitadai et al., 2006)  
 
1.1.3.2. Tumour-Associated Macrophages (TAMs) 
TAMs are usually the most abundant immune population found in the tumour 
microenvironment. (Colangelo et al., 2017) TAMs derive from circulating blood monocytes 
that are recruited to the tumour site by chemokines such as CCL2/3/4/5/22, cytokines such 
as colony-stimulating factor-1 (CSF-1), and growth and angiogenic factors such as VEGF-A 
and PDGF. (Lewis and Pollard, 2006; Sica and Bronte, 2007; Sica, Allavena and Mantovani, 
2008) The presence of low IL-12 and high IL-10 levels in the tumour microenvironment 
induces the differentiation of monocytes into mature TAMs. (Fricke and Gabrilovich, 2006) 
Macrophages are highly plastic and can polarise into two subtypes with different phenotypes 
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depending on microenvironment stimuli: classical M1 (anti-tumour) or alternate M2 (pro-
tumour). (Mantovani et al., 2004; Martinez and Gordon, 2014; Chanmee et al., 2014)  
M1 macrophages are classified as pro-inflammatory and are activated in response to 
microbial products or interferon-γ (IFN-γ), and produce high levels of IL-12, IL-23, nitric 
oxide and oxygen intermediates, and promote adaptive immunity through increased antigen 
presentation and expression of costimulatory molecules. M1 macrophages are part of the Th1 
response and are potent effectors against intracellular pathogens and tumour cells. (Chanmee 
et al., 2014) M2 macrophages are classified as anti-inflammatory and are activated in 
response to signals such as IL-4, IL-13, IL-10, immunoglobulin complexes and Toll-like 
receptor (TLR) ligands. M2 macrophages are part of the Th2 response, they downregulate 
MHC class II expression, stimulate regulatory T-cell differentiation and influence the anti-
inflammatory response with increased expression of IL-12 and TGF-β. TAMs with M2 
polarisation are a major tumour infiltrating cell population, where they promote tumour 
growth and metastasis through the induction of angiogenesis by secreting VEGF, and 
enhance tumour cell invasion by the secretion of MMP-1, -2, -9, and cathepsins B and D, 
which are involved in ECM breakdown. (Martinez and Gordon, 2014; Stockmann et al., 
2014) High TAM density in the tumour microenvironment is now recognised as a poor 
prognostic sign in various human cancers. (Lewis and Pollard, 2006) However their role in 
CRC, and whether they exert pro- or anti-tumour activity, is controversial.  
Some studies indicate that macrophages have anti-tumour activity in CRC and are associated 
with improved disease free survival. Whilst other studies indicate that high macrophage 
infiltration is correlated with tumour growth, progression and aggressiveness. (Ohno et al., 
2002; Erreni, Mantovani and Allavena, 2011) Studies on the pro-tumour activity of TAMs 
in CRC, include a study by Kaler et al., (2009) showing that IL-1β secreted by TAMs 
promote Wnt signalling in colon cancer cells, supporting tumour growth. TAM-derived IL-
6 has been shown to induce STAT3-mediated IL-10 production in tumour cells, which has 
been correlated with poor prognosis. (Herbeuval et al., 2004) The role of TAMs in CRC 
seems to depend on their density and localisation within the tumour mass. TAM 
accumulation along the tumour margin has been most frequently associated with longer 
patient survival. This could perhaps be due to TAMs at the invasive margin being more likely 
to be outside of the suppressive tumour microenvironment and may produce cytotoxic 
molecules such as reactive oxygen species, nitric oxide and tumour necrosis factor-α (TNF-
  14 
α). Macrophages along the tumour margin have been shown to induce apoptosis in cancer 
cells by a Fas ligand-dependent manner. (Sugita et al., 2002) High levels of macrophage 
infiltration at the invasive front of CRC tumours has been correlated with improvement in 
both hepatic metastasis and overall survival, indicating a protective role for TAMs in CRC. 
Conversely, low levels of macrophage infiltration have been associated with more advanced 
disease and a higher rate of vascular invasion and lymph node metastasis. (Funada and 
Moouchi, 2003; Forssell et al., 2007; Zhou et al., 2010) However, in contrast with these 
studies, Bailey et al., (2007) reported that counting macrophages not only at the tumour 
margin but in all areas within the tumour, including necrotic areas, macrophage accumulation 
was not a good prognostic indicator. 
It therefore appears that macrophages have contradictory roles within the CRC tumour 
microenvironment, with the localisation of TAMs appearing to be of importance as to 
whether they exhibit pro- or anti-tumour activity. Macrophages along the tumour margin are 
likely to have less exposure to cancer cell derived cytokines and are located in a less hypoxic 
area, perhaps enabling differentiation into an anti-tumour phenotype. Whereas macrophages 
within the tumour mass, are susceptible to cancer cell signals, creating a positive feedback 
loop between cancer cells and TAMs, promoting tumour progression.  
 
1.1.3.3. Tumour-Infiltrating Lymphocytes 
T-lymphocytes are part of the adaptive immune response, which can shape the development 
of malignancy and its response to therapy through direct or indirect contact with tumour cells. 
Antigens expressed by tumour cells can become targets for T-cell-mediated adaptive immune 
response. Galon et al., (2006) first demonstrated the relevance of specific immune cell 
populations on prognosis in CRC patients, with the type, density and location of T-cells 
within the tumour found to be a better predictor of patient survival compared to the 
histopathological methods currently used to stage CRC. High lymphocyte infiltration of 
CD8+ cytotoxic T-lymphocytes (CTLs) and T helper 1 (Th1) cells is associated with relapse-
free and overall survival in CRC. T helper cells are also known as CD4+ T-cells. They 
directly interact with MHC class II molecules on the surface of antigen-presenting cells and 
influence the behaviour of cell types that they “help”, including CTLs, B-cells and 
macrophages. T helper cells can differentiate into several subtypes, including Th1, Th2, Th3, 
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Th17, Th9 or TFH, which facilitate different types of immune response based on the secretion 
of different cytokines. The anti-tumour activity associated with the Th1 response is facilitated 
through IFN-γ secretion and the control of macrophage killing of tumour cells. (Zhu, Yamane 
and Paul, 2010; Tosolini et al., 2011) 
It was subsequently discovered that virtually all primary CRC tumours displaying high 
infiltration with activated CD8+ CTLs and Th1 cells belong to the MSI phenotype. The 
density of CTL infiltration was found to positively correlate with the total number of 
frameshift mutations within the MSI tumours, suggesting that these lead to the production of 
immunogenic neo-peptides that are recognised by antigen-specific tumour-infiltrating 
lymphocytes. (Llosa et al., 2015; Maby et al., 2015) The anti-tumour activity of a Th1/CTL-
dominant immune response is selectively counterbalanced in MSI tumours by upregulation 
of multiple immune checkpoints, including cytotoxic T-lymphocyte-associated antigen 4 
(CTLA-4), programmed cell death protein 1 (PD-1), and PD1 ligand 1 (PD-L1). This 
explains why MSI tumours are not naturally eliminated despite a hostile Th1/CTL 
microenvironment. The blockade of immune checkpoints is an emerging strategy in cancer 
treatment, with anti-CTLA-4, anti–PD-1 and anti–PD-L1 antibodies shown to induce 
significant and durable tumour regression in patients with melanoma, renal cancer and non-
small-cell lung cancer. (Hodi et al., 2010; Brahmer et al., 2012; Hamid et al., 2013; Topalian 
et al., 2014) CRC had been considered a non-responding histology to PD-1 pathway 
blockade, after studies demonstrated a very low response rate to PD-1 or PD-L1 blockade in 
CRC patient cohorts. However, there was an insufficient number of patients to potentially 
define subsets of CRC that might be more amenable to checkpoint blockade. Based on the 
above findings, that suggest blockade of immune checkpoints may be selectively efficacious 
in the MSI subset of CRC, clinical trials have been initiated to test PD-1 blockade in CRC 
patients identified as MSI. (Llosa et al., 2015)  
Conversely, T-cell infiltrations associated with poor outcomes, include Th17 and regulatory 
T (Treg) cell infiltration. Th17 cells produce high levels of TNF-α, IL-2, and IFN-γ, with 
high Th17 cell infiltration in CRC tumours associated with a poor prognosis. (Tosolini et al., 
2011) CD4+ T-cells that express the forkhead box P3 (FOXP3) transcription factor, function 
as Treg cells, pivotal mediators of immune suppression. Treg cells suppress the activation, 
proliferation and effector functions of a wide range of immune cells, including CD4+ and 
CD8+ T-cells, NK and B-cells in vitro and in vivo, hindering an effective immune response 
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against cancer cells. Treg cells regulate the immune response by a number of mechanisms, 
including secretion of immunosuppressive molecules (IL-10, TGF-β and IL-35), cytolytic 
functions via a variety of mediators such as granzyme B, and IL-2 deprivation-mediated 
apoptosis of effector CD4+ T-cells. (Zhang et al., 2015) The accumulation of Treg cells at 
tumour sites has been associated with faster angiogenesis through VEGF production. 
(Facciabene, Motz and Coukos, 2012) CRC tumours infiltrated with Treg cells have 
significantly worse prognosis. (Saito et al., 2016)  
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1.2. Pancreatic Cancer  
Pancreatic cancer is the fourth leading cause of cancer death in the Western world. Pancreatic 
ductal adenocarcinoma (PDAC) is the most common pancreatic malignancy, with a median 
survival lasting months and a dismal 5-year survival rate of just 5%. (Wood and Hruban, 
2015) Survival rates have remained relatively unchanged over the past 25 years. This poor 
prognosis is due to a lack of early symptoms, meaning PDAC is generally not diagnosed until 
an advanced stage of disease, with presentation of distant metastases. PDAC is also highly 
resistant to both radiation and chemotherapy. (Hermann et al., 2007) The liver is the most 
common site of metastasis, followed by the peritoneum and lungs. (Iacobuzio-Donahue et 
al., 2009) Surgery remains the only treatment with curative potential, however approximately 
just 20% of patients are eligible for surgical resection at the time of diagnosis. Moreover, 
those patients who do undergo resection frequently exhibit a high incidence of local 
recurrence, lymph node and hepatic metastasis, and peritoneal dissemination. (Pierantoni et 
al., 2008; Birnbaum et al., 2016) The chemotherapeutic drug gemcitabine remains the 
standard of care for patients with advanced PDAC. Studies on combining gemcitabine with 
other chemotherapeutics and targeted agents, often gave disappointing results. A 
chemotherapy regimen combining 5-FU, leucovorin, irinotecan, and oxaliplatin 
(FOLFIRINOX) was shown to nearly double overall survival compared to gemcitabine, at 
the expense of a manageable but increased toxicity, limiting its use to good performance 
status patients. But overall survival was still less than 12 months. (Teague, Lim and Wang-
Gillam, 2015) Therefore, there is a desperate need for new and targeted therapeutic strategies 
that can overcome the drug-resistance of PDAC and improve the clinical outcome for 
patients. (Iovanna et al., 2012)  
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1.2.1. Genetics of PDAC 
PDAC arises from precursor lesions that develop in the pancreas. Three main pre-invasive 
lesions have been identified, pancreatic intraepithelial neoplasia (PanIN), intraductal 
papillary mucinous neoplasms (IPMNs) and mucinous cystadenomas (MCNs). The majority 
of PDACs arise from PanINs, with IPMN- or MCN-induced PDAC occurring only 
sporadically. PanINs show a spectrum of divergent morphological alterations relative to 
normal ducts with increasing cell proliferation and dysplastic growth. PanINs display three 
different stages of progression before giving rise to PDAC -  PanIN-1, PanIN-2 and PanIN-
3, which are categorised based on their morphological degree of dysplasia. PanIN-1 and -2 
are low grade, with PanIN-3 classified as high grade and is essentially a carcinoma-in-situ. 
The genetic evolution from early PanIN to invasive PDAC takes approximately 12 years, 
involving the sequential acquisition of the driver gene mutations that characterise PDAC. 
Figure 1.2 shows a representation of the progression from PanIN to PDAC, and the genetic 
and microenvironmental factors involved. (Bardeesy and DePinho, 2002; Brosens et al., 
2015) 
The genes most commonly altered in PDAC are KRAS, CDKN2A, TP53 and SMAD4, and 
are referred to as the four driver genes of PDAC development. (Iovanna et al., 2012) KRAS 
encodes a small GTPase involved in signal transduction of growth factor mediated signal 
transduction pathways, such as EGF signalling. Activating KRAS mutations are the earliest 
genetic change that occur in the progression to PDAC, and are the most commonly mutated 
oncogene, occurring in >90% of PDACs. Point mutations are found at codons 12, 13 and 61 
in KRAS, leading to the generation of a constitutively active form of ras, which binds to 
GTP, giving uncontrolled stimulation signals to downstream signalling cascades. This has a 
number of cellular effects, including the induction of proliferation, survival and invasion. 
(Moskaluk, Hruban and Kern, 1997; Shields et al., 2000; Fokas et al., 2015) 
The tumour suppressor gene p16/CDKN2A, which encodes a critical cell cycle regulator, is 
inactivated in >90% of PDACs. Loss of CDKN2A function can occur by mutation, 
homozygous deletion or epigenetic silencing by promotor hypermethylation. Loss of 
CDKN2A typically occurs in moderately advanced, PanIN-2 precursor lesions. (Schutte et 
al., 1997) Germline mutations in CDKN2A are associated with the familial atypical mole-
malignant melanoma (FAMMM) syndrome, which in addition to a very high incidence of 
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melanoma, also confers a 13-fold increased risk of developing pancreatic cancer. (Borg et 
al., 2000; Fokas et al., 2015) 
Mutations in the tumour suppressor gene TP53 are reported in approximately 75% of PDACs. 
The p53 protein is a master regulator of genome integrity and plays an important role in cell 
cycle regulation and induction of apoptosis. Loss of p53 typically occurs through a missense 
mutation and loss of the second allele, which can lead to uncontrolled cell growth and 
increased cell survival. (Vogelstein, Lane and Levine, 2000) Inactivation of TP53 occurs 
later in the malignant progression to PDAC, in PanIN-3 precursor lesions. (Costa, Kern and 
Hruban, 1994) PDAC tumours have profound aneuploidy and complex cytogenetic 
rearrangements, and loss of TP53 probably facilitates the widespread genetic instability that 
occurs in PDAC. (Gorunova et al., 1998; Bardeesy and DePinho, 2002) 
Loss of the tumour suppressor gene SMAD4, occurs in approximately 50% of PDACs. 
(Cowgill and Muscarella, 2003) SMAD4 inactivation occurs by either intragenic mutation 
and loss of the second allele or by homozygous deletion, and occurs relatively late in 
pancreatic carcinogenesis, in PanIN-3 lesions. (Yachida and Iacobuzio-Donahue, 2013) 
SMAD4 encodes a transcriptional regulator that is a key component in the TGF-β signalling 
cascade. TGF-β inhibits the growth of most normal epithelial cells and promotes apoptosis. 
Remarkably, the inactivation of SMAD4 abolishes the tumour suppressive functions of TGF-
β but maintains some tumour-promoting TGF-β responses, such as epithelial-mesenchymal 
transition (EMT), which makes cells more invasive. (Massagué, Blain and Lo, 2000) Loss of 
SMAD4 is more frequent in poorly differentiated PDAC tumours, and is associated with 
poorer survival and presence of distant metastases. (Levy and Hill, 2005; Iacobuzio-Donahue 
et al., 2009; Fokas et al., 2015) 
However, only a minority of patients have mutations in all four driver genes of PDAC 
development, highlighting the genetic heterogeneity of PDAC. Several other genes are 
involved in PDAC formation, such as the tumour suppressor genes BRCA2 and LKB1, and 
less common genetic alterations in PDAC continue to be described. (Bardeesy and DePinho, 
2002) A recent transcriptional classification of PDAC defined 4 subtypes: squamous, 
pancreatic progenitor, immunogenic and aberrantly differentiated endocrine exocrine 
(ADEX), that correlate with histopathological characteristics. Squamous tumours are 
enriched for TP53 and KDM6A mutations, hypermethylation of pancreatic endodermal cell-
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fate determining genes and are associated with poor prognosis. Pancreatic progenitor tumours 
express genes involved in early pancreatic development. ADEX tumours display 
upregulation of genes involved in KRAS activation, and exocrine and endocrine 
differentiation. Whilst immunogenic tumours contain upregulated immune networks 
including pathways involved in acquired immune suppression, such as CTLA-4 and PD-1, 
inferring therapeutic opportunities with immune checkpoint inhibitors. (Bailey et al., 2016) 
This shows the importance in identifying the various genetic profiles associated with PDAC, 
as it could be utilised to help stratify patients to different therapies. 
PDACs also overexpress many growth factors and their receptors, including the EGF family, 
VEGF, fibroblast growth factor (FGF), Cripto-1 growth factor (CRGF), TGF-α and many 
cytokines such as, TGF-β, TNF-α, and IL-1, -6 and -8. (Fokas et al., 2015) The Sonic 
hedgehog (Shh) and Notch signalling pathways, are two common pathways involved in 
pancreatic organogenesis and development, and have been implicated in PanIN initiation and 
tumour growth. Shh is not expressed in normal adult pancreas but is found in up to 70% of 
PDAC tumours. Shh promotes cell migration and invasion and also contributes to the 
formation of stromal desmoplasia by modifying the differentiation of pancreatic stellate cells 
and fibroblasts. Shh also enhances tumour growth via a paracrine mechanism, whereby Shh 
secreted by tumour cells induces hedgehog-target genes in the surrounding stromal tissue. 
(Berman et al., 2003; Feldmann et al., 2007) The multiple alterations in oncogenes and 
tumour suppressor genes in conjunction with the overexpression of mitogenic and angiogenic 
growth factors and their receptors that activate aberrant autocrine and paracrine pathways 
combine to contribute to the biological aggressiveness of PDAC. (Gorunova et al., 1998; 
Bardeesy and DePinho, 2002) 
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Figure 1.2 Tumour microenvironment and progression in PDAC. PDAC develops from PanIN, 
a well-defined precursor lesion. Tumour progression is associated with genetic and biological 
alterations. Telomere shortening and KRAS mutations occur early during pancreatic tumourigenesis 
(PanIN-1) followed by inactivating mutations of CDKN2A (PanIN-2) and late mutations in TP53, 
SMAD4 and BRCA2 (PanIN-3). In a similar fashion, progression of PanIN to PDAC is characterised 
by accumulation of the desmoplastic stroma that drives immunosuppression, tumour growth, 
invasiveness and metastatic spread. Genetic studies have shown that the average time from early 
tumourigenesis to patient death from metastatic disease is approximately 22 years. CAF, cancer-
associated fibroblast; Treg, regulatory T cell; MDSC, myeloid-derived suppressor cell. (Adapted 
from Fokas et al., 2015) 
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1.2.2. The Tumour Microenvironment in PDAC  
PDAC is characterised by an intense stromal desmoplastic reaction surrounding the cancer 
cells, that constitutes more than 80% of the tumour volume. (Kleeff et al., 2007) Desmoplasia 
results from the extensive proliferation of CAFs and the significant overproduction of ECM, 
which results in increased stiffness, solid stress and interstitial fluid pressure in the tumour. 
The PDAC tumour microenvironment is also characterised by a chaotic vascular morphology 
with low vessel density, and immature, leaky, collapsed vessels. This all contributes to the 
overall tissue heterogeneity in PDAC, the impaired delivery of oxygen and nutrients, and to 
chemotherapy and radiation resistance. (Provenzano et al., 2012; Neesse et al., 2013) Other 
components of the desmoplastic stroma include, pancreatic stellate cells (PSCs), 
macrophages, inflammatory cells, blood vessels, lymphatic vessels, pericytes, bone marrow-
derived cells (BMDCs) and stem cell-like cells. The components of the desmoplastic stroma 
are displayed in Figure 1.3. The complete mechanisms of stroma formation are still being 
uncovered. PDAC cells produce several modulating growth factors that can alter the adjacent 
stroma, which in turn release cytokines, pro-tumour growth factors and proteases that form 
a positive feedback interaction loop to activate both cancer and stromal cells to enhance 
tumour growth and progression. (Fokas et al., 2015; Nielsen, Mortensen and Detlefsen, 2016) 
CAFs are the main effector cells in the desmoplastic reaction, producing a wide variety of 
ECM molecules and cytokines. They display a myofibroblast-like phenotype, characterised 
by a spindle shape and the expression of a-SMA. CAFs can originate from different cellular 
sources, with the most important source in PDAC, considered PSCs. PSCs are also the main 
effector cells in the fibrotic process of chronic pancreatitis. (Luttenberger et al., 2000; Erkan 
et al., 2012) PSCs are characterised by their stellate morphology and the presence of vitamin 
A storing lipid droplets. (Bachem et al., 1998) Quiescent PSCs (qPSCs) in normal pancreas 
become activated during tissue injury or carcinogenesis, attaining a state called activated 
PSCs (aPSCs), where they develop a myofibroblast-like phenotype. Factors that activate 
qPSCs include, PDGF, TGF-β, TNF-α, IL-1, IL-6 and IL-10. (Mews et al., 2002) Other 
cellular sources of CAFs include resident fibroblasts and BMDCs. (Scarlett, 2013; Augsten, 
2014) The cross talk between CAFs and PDAC cells promotes their mutual proliferation and 
differentiation. CAFs have also been implicated in the metastasis of PDAC cells. CAFs 
modulate the expression of adhesion molecules and downregulate the expression of E-
cadherin, cytokeratin 19 and β-catenin in PDAC cells, increasing their invasiveness. 
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(Froeling et al., 2009; Kikuta et al., 2010) In a mouse model of PDAC, CAFs followed PDAC 
cells to the metastatic sites, suggesting CAFs could play a role in the settlement of metastatic 
PDAC cells. (Xu et al., 2010)  CAFs have also been shown to protect PDAC cells from 
radiation and chemotherapy. (Hwang et al., 2008)  
The desmoplastic stroma in PDAC also contains large numbers of inflammatory cells, 
including macrophages, T-cells, mast cells and neutrophilic granulocytes. Inflammatory cells 
play multiple opposing roles in PDAC progression, with both anti- and pro-tumour 
phenotypes. High levels of M2 macrophages and neutrophils are associated with shorter 
survival in PDAC, whilst high levels of M1 macrophages are associated with longer survival. 
M2 macrophages express angiogenic and proliferation-promoting cytokines and chemokines 
which contribute to tumour progression. Large numbers of M2 macrophages correlate with 
lymph node metastases, which could be explained by their production of VEGF, leading to 
an increased number of peritumoural lymph vessels. (Schoppmann et al., 2002; Ino et al., 
2013) High mast cell infiltration has also been correlated with the number of lymph node 
metastases in PDAC. (Esposito et al., 2004) Cytotoxic CD8+ T-cells are anti-carcinogenic, 
resulting in the elimination of PDAC cells. High levels of CD4+ or CD8+ T-cells are 
associated with longer survival, whilst high levels of Treg cells are associated with shorter 
survival in PDAC. Treg cell infiltration suppresses the anti-cancer immune response through 
inhibitory cytokines, inducing immune invasion in PDAC. PDAC cells are suggested to 
promote the upregulation of Treg cells in part through the secretion of TGF-β. (Liyanage et 
al., 2002, 2006) 
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Figure 1.3 Desmoplastic reaction in PDAC. A: Normal pancreas consists of acini with acinar cells 
and pancreatic ducts lined by epithelial cells. Quiescent pancreatic stellate cells (qPSCs) and 
interlobular fibroblasts are located in the periacinar space. Small numbers of T-cells are observed, 
and B-lymphocytes, plasma cells, and eosinophilic and neutrophilic granulocytes are very rare. The 
extracellular matrix (ECM) is largely limited to thin interlobular septa and pancreatic ducts. B: In 
PDAC, cancer cells permeate the basal membrane of dysplastic pancreatic ducts and invade the 
surrounding tissue. This invasion is accompanied by a strong desmoplastic reaction in which CAFs, 
arising mainly from qPSCs, synthesise an abundance of ECM proteins. Lymphocytes, macrophages, 
and mast cells infiltrate the peritumoural stroma. There is an increased need for oxygen and nutrients, 
leading to increased angiogenesis. (Adapted from Nielsen, Mortensen and Detlefsen, 2016) 
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1.2.2.1. Targeting the PDAC Tumour Microenvironment  
The standard chemotherapeutic drug used in PDAC treatment has limited effect on patient 
survival. Numerous studies have documented the tumour-promoting functions of key 
components of the desmoplastic stroma, leading to significant interest in developing new 
treatment strategies to target the PDAC microenvironment. However, promising preclinical 
trials have often not effectively translated into the clinical setting. Subsequent conflicting 
reports on the precise role of the tumour microenvironment in PDAC, suggests further 
research is required to effectively target stromal components that will improve clinical 
outcome for patients.  
Due to the observed tumour promoting role of CAFs, it was assumed that a decrease in the 
CAF population would result in a decrease in PDAC proliferation and migration and an 
increased response to chemotherapy. However, studies on the consequences of CAF 
depletion in the PDAC stroma have been conflicting. Olive et al., (2009) first demonstrated 
the potential in disrupting stromal desmoplasia in a mouse model of PDAC. Treatment with 
IPI-926, an inhibitor of the Shh pathway, led to depletion of a-SMA positive CAFs and the 
desmoplastic stroma, increasing tumour vascularisation and drug delivery, and improving 
overall survival compared to controls. These findings suggest that stromal desmoplasia 
confers chemoresistance to PDAC, at least partly through decreased drug penetrance. 
However, phase I and II trials with IPI-926 in combination with FOLFIRINOX or 
gemcitabine, were closed early due to poor clinical performance, with a shorter median 
survival indicated in patients receiving the treatment. (Ko et al., 2016) Studies have found 
that the desmoplastic stroma does not only form a barrier that reduces tumour perfusion and 
hampers effective drug delivery, it might also reduce the ability of PDAC cells to invade 
surrounding tissues and metastasise. A smaller number of a-SMA positive CAFs in the 
PDAC tumour microenvironment has been associated with more invasive tumours and 
decreased survival. (Özdemir et al., 2014) The Vitamin D analogue calcipotriol, decreases 
a-SMA expression and induces quiescence in CAFs in vitro. In a mouse model of PDAC, 
the administration of calcipotriol with gemcitabine resulted in a significant reduction in 
tumour size and increase in median survival. (Sherman et al., 2014) This suggests that 
stromal reprogramming to a more quiescent state rather than its total depletion could have 
therapeutic effect in PDAC.  
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The dense desmoplastic stroma in PDAC is associated with high interstitial pressure and 
collapsed blood vessels. This hypoxic microenvironment stimulates the production of pro-
angiogenic molecules, such as VEGF and FGF, by PDAC cells and stromal cells, such as 
TAMs and mast cells. (Koong et al., 2000; Büchler et al., 2003) VEGF is an important 
unfavourable prognostic marker in PDAC, with a significant association found between high 
VEGF expression and PDAC recurrence. (Niedergethmann et al., 2002) However, clinical 
trials combining the VEGF inhibitors, Bevacizumab or Axitinib, with gemcitabine found no 
improvement in overall survival compared to patients receiving gemcitabine alone. (Kindler 
et al., 2010, 2011) The failure of VEGF inhibitors to improve outcomes in PDAC, could be 
explained by the poor vascularisation already present in PDAC tumours. Inhibitors of 
angiogenesis could result in further reduction of chemotherapeutic drug delivery to the 
tumour. This is supported by studies in mouse models of PDAC, where stromal depletion, 
resulted in increased tumour vascularisation and drug diffusion, and improved overall 
survival. (Olive et al., 2009) Therefore, it appears that a more precise modulation of tumour 
vascularisation is likely required to achieve therapeutic effect in PDAC.  
The PDAC tumour microenvironment displays several immunosuppressive properties, 
suggesting the potential for immune checkpoint therapy in PDAC treatment. Three well 
described inhibitory checkpoint molecules, CTLA-4, PD-1 and PD-L1, are expressed in the 
PDAC tumour microenvironment, enabling the tumour to suppress and evade the T-cell 
mediated immune response. Inhibitors of these immune checkpoints, allow the recognition 
of tumour cells by T-cells, enabling their elimination. Promising results have been achieved 
with immune checkpoint inhibitors in the treatment of malignant melanoma, non-small-cell 
lung cancer and renal cancer, in terms of tumour regression and overall survival. (Sharma 
and Allison, 2015) Similar strategies are under investigation for PDAC treatment, but have 
so far achieved limited success. A phase II trial of the anti-CTLA-4 mAb Ipilimumab did not 
show an acceptable response as a single-agent therapy in PDAC. (Royal et al., 2010) A phase 
I trial of the PD-LI inhibiting antibody BMS-936559 in patients with selected advanced 
cancers, showed no objective response in PDAC patients, compared to patients with ovarian 
cancer, renal cancer, melanoma and non-small-cell lung cancer. (Brahmer et al., 2012) These 
initial results of immune checkpoint inhibitor treatment in PDAC have not been promising, 
however studies are still in the relatively early stages, and indicate that further research is 
needed. Further knowledge on the complex PDAC microenvironment and the identification 
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of patients most likely to respond to immune checkpoint blockade, could increase the efficacy 
and response rate to immune checkpoint inhibitors in PDAC. (Nielsen, Mortensen and 
Detlefsen, 2016) 
Other strategies to target the tumour microenvironment and enhance the anti-tumour immune 
response have shown more promising results. CD40, a member of the TNF-receptor 
superfamily, is expressed in a wide variety of cells, including monocytes, macrophages, B-
cells, dendritic cells and fibroblasts. (van Kooten and Banchereau, 2000) CD40 activation is 
involved in the T-cell dependent anti-tumour response. Activation of CD40 by agonist 
antibodies was found to increase the effect of gemcitabine in PDAC, through the activation 
of macrophages in the tumour stroma. (Beatty et al., 2011) A subsequent phase I trial of CP-
870,893, a mAb specific for the agonist CD40, in combination with gemcitabine, was well 
tolerated in patients with advanced PDAC, and was associated with immune activation and 
anti-tumour activity. This promising result calls for Phase II studies. (Beatty et al., 2013) 
Overall, attempts at targeting the tumour microenvironment in PDAC have been 
disappointing to date. The precise role of the tumour stroma in PDAC is currently 
controversial, due to conflicting reports on the activity of various stromal components. Early 
studies suggested that large numbers of CAFs indicated a poor prognosis in PDAC, whereas 
more recent studies have indicated that depletion of CAFs promotes tumour aggressiveness. 
It appears that stromal reprogramming, such as the induction of quiescence in CAFs, rather 
than stromal depletion, could represent a more appropriate treatment strategy in PDAC. Such 
strategies might also only be effective at certain stages of PDAC development and 
progression. Due to the complex interplay of the main components of the tumour stroma, 
treatment strategies that block single isolated factors are likely to be ineffective. Further 
understanding is required of the complex interplay of stromal components, and the distinction 
of various molecular subtypes in PDAC, to identify distinct combination therapies that can 
be given to increase efficacy and response rate. (Nielsen, Mortensen and Detlefsen, 2016) 
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1.3. Antibodies in Cancer Therapeutics 
Chemotherapy is the main mode of systemic therapy for cancer treatment and can effectively 
treat advanced cancer, especially when combined with surgery and radiation therapy for 
locally advanced disease. (Landmann and Weiser, 2005) However, chemotherapeutic agents 
do not preferentially accumulate in tumours and toxicity to rapidly dividing and other normal 
cells limit the clinical application of chemotherapeutic drugs. (Krall, Scheuermann and Neri, 
2013; Damelin et al., 2015) Molecular targeted therapies, that target specific molecules in 
cancer cells can overcome some of these limitations. Antibodies have historically been 
considered as ideal for molecular targeting because of their highly specific binding to 
antigens. The development of monoclonal antibody (mAb) technology provided the 
capability to feasibly generate antibodies with required specificities to a molecular target. 
(Kohler and Milstein, 1975) First generation antibodies were derived from immunised hosts 
(mainly rodent) that, despite being a significant achievement, had limited clinical application 
due to their immunogenicity in humans and poor ability to induce human immune effector 
responses.  
The development of genetic engineering approaches and newly developed antibody 
engineering techniques provided the ability to generate chimeric or humanised antibodies to 
circumvent these problems. (Winter and Milstein, 1991) They also provided the ability to 
alter antibody characteristics including size, affinity, half-life and bio-distribution, and to 
produce structurally modified antibodies, such as bispecific antibodies (BsAbs). Typical 
antibodies, such as IgG, are divalent but monospecific, with each Fab arm recognising the 
same epitope of the target antigen. BsAbs exhibit dual functionality, with each Fab arm 
capable of binding two different epitopes, either of the same or different target antigens. 
BsAbs can more effectively redirect immune effector cells to tumour cells compared with 
monospecific antibodies. (Fan et al., 2015) A number of BsAbs have been approved for 
clinical use including Catumaxomab, which binds to CD3 and EpCAM, and is used for the 
treatment of malignant ascites in patients with metastatic cancer. (Linke, Klein and Seimetz, 
2010) Based on these advancements in antibody engineering techniques, antibody-based 
therapies have achieved considerable success in recent years, with a range of antibody-based 
biopharmaceuticals produced to treat major diseases, including cancer, inflammation and 
autoimmune disorders. The field of antibody-based therapeutics is continuing to grow and 
evolve. (Scott, Wolchok and Old, 2012; Ayyar, Arora and O’Kennedy, 2016; Gébleux and 
Casi, 2016) 
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1.3.1. Unconjugated mAbs 
Monoclonal antibodies used in cancer therapy, include unconjugated mAbs, which elicit their 
effect by binding to soluble or membrane bound antigens, such as growth factors and 
receptors, thus blocking the target signalling pathway. When the signalling through these 
pathways is diminished in the tumour, it can result in loss of cellular activity, inhibition of 
proliferation, activation of apoptosis or cells being re-sensitised to chemotherapeutic agents. 
(Suzuki, Kato and Kato, 2015) Unconjugated mAbs have been approved for the treatment of 
both haematological and solid malignancies. Rituximab, targeting CD20, has seen 
considerable success in the treatment of non-Hodgkin’s lymphoma and chronic lymphocytic 
leukaemia. In solid tumours, unconjugated mAbs have been most successful targeting VEGF 
and the ERBB family, which includes EGFR and HER2. The HER2 targeting mAb 
Trastuzumab is approved for use in breast cancer patients with high levels of HER2 
expression. (Vogel et al., 2002) Unconjugated mAbs targeting VEGF and EGFR have been 
approved for use in metastatic CRC patients. Anti-EGFR therapy is limited to CRC patients 
with wildtype KRAS, as activating KRAS mutations confer innate resistance to anti-EGFR 
therapies. (Watkins and Cunningham, 2007) The anti-EGFR mAb Cetuximab, selectively 
binds to EGFR, blocking it from binding to its ligand EGF, and thus blocking signal 
transduction. Cetuximab has also been approved for use in squamous cell carcinoma of the 
head and neck. (Harding and Burtness, 2005; Cohen et al., 2013) A second anti-EGFR mAb, 
Panitumumab has also been approved for use in metastatic CRC. (Amado et al., 2008) VEGF 
expression is increased in most solid tumours, where it is the main factor that controls 
angiogenesis, leading to tumour proliferation and metastasis. The anti-VEGF mAb 
Bevacizumab binds to soluble VEGF in the tumour microenvironment thus preventing it 
from binding to its receptors, VEGFR-1 and -2. Bevacizumab has been approved for use in 
a number of cancers, including colon cancer, non–small cell lung cancer and breast cancer. 
(Lyseng-Williamson and Robinson, 2006) 
In general, unconjugated mAbs are most effective when they also engage host defence 
mechanisms, resulting in antibody-dependent cell-mediated cytotoxicity (ADCC) or 
complement-dependent cytotoxicity (CDC). In ADCC, after the mAb binds to its tumour 
antigen, the Fc domain of the mAb binds to Fc gamma receptors on the surface of effector 
cells, such as macrophages, monocytes, eosinophils and natural killer cells. This triggers the 
effector cells to secrete various substances such as cytokines, lytic enzymes, perforin and 
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granzymes that mediate the destruction of the target cell. (Li et al., 2013) CDC is triggered 
when the C1 complex binds the antibody-antigen complex, activating a cascade of 
complement proteins which leads to the formation of a membrane attack complex on the 
surface of the target cells, resulting in cell lysis. (Moore et al., 2010) ADCC and CDC have 
been demonstrated to play a major role in antibody efficacy, with ADCC shown to be a key 
mechanism of action of Cetuximab and Trastuzumab. (Scott, Wolchok and Old, 2012)  
Despite this, unconjugated mAbs are generally not potent enough to be used alone and are 
used in combination with chemotherapy to treat cancer. 
 
 
1.3.2. Antibody-Drug Conjugates (ADCs) 
ADC technology utilises mAbs to deliver cytotoxic agents specifically to cancer cells. 
Altered protein expression in cancer cells can involve cell-surface proteins being selectively 
expressed, overexpressed or mutated, which differentiates them from normal cell-surface 
proteins, allowing them to be exploited with antibody-based therapeutics. (Damelin et al., 
2015; Diamantis and Banerji, 2016) A simple ADC design comprises three main 
components, a mAb, a linker and a toxic payload. To date, chimeric, humanised and fully 
human mAbs have been used in ADCs. The antibody isotype is also an important 
consideration in ADC design, with IgG1 the most commonly used isotype, followed by IgG4. 
IgG1 antibodies could provide additional anti-tumour activity by engaging effector cells and 
activating ADCC or CDC. (Goldmacher and Kovtun, 2011) The mAbs are generally 
covalently conjugated to toxins via linkers that need to be sufficiently stable to maintain the 
drug-conjugate in circulation until the antibody binds to its specific cancer cell-surface 
antigen and is internalised, then the linker should be labile enough to release the drug once it 
reaches the cytoplasm. (Ayyar, Arora and O’Kennedy, 2016) Both cleavable and non-
cleavable linkers are currently being utilised in ADC design. Cleavable linkers are designed 
to be cleaved upon internalisation by lysosomal proteases present in the cell cytoplasm, as 
shown in Figure 1.4. The clinically approved ADC, Brentuximab vedotin utilises a cleavable 
linker. In non-cleavable linkers, the antibody is completely degraded upon internalisation, 
releasing the linker with attached toxin into the cell, which is successfully utilised in the 
ADC, ado-trastuzumab emtansine. (Goldmacher and Kovtun, 2011; Perez et al., 2014)  
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The cytotoxic payloads of ADCs are extremely potent drugs capable of cell killing with 
minute quantities. Two classes of cytotoxic drug currently in use are mitotic inhibitor drugs, 
which interfere with microtubule assembly causing cell cycle arrest and subsequent 
apoptosis, and DNA-damaging agents, that cause DNA cleavage or bind the minor groove of 
DNA causing DNA alkylation resulting in cell death. Most ADCs in clinical development 
use mitotic inhibitor drugs, such as auristatins and maytansinoids, which target rapidly 
dividing cells more than normal cells. (Alley, Okeley and Senter, 2010; Govindan and 
Goldenberg, 2012; Ayyar, Arora and O’Kennedy, 2016b) 
 
 
 
Figure 1.4 Delivery of cytotoxic drugs to cancer cells by ADCs. The mAb component of an ADC 
selectively binds a cell-surface tumour antigen, resulting in internalisation of the ADC-antigen 
complex through the process of receptor-mediated endocytosis. This complex then traffics to 
lysosomal compartments and is degraded, releasing the active cytotoxic drug inside the cell, leading 
to cell death. (Adapted from Panowski et al., 2014) 
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1.3.2.1. Target Antigen Selection 
In general, optimal targets for ADCs should be homogenously and selectively expressed at 
high density on the surface of tumour cells and upon antigen recognition and binding the 
resulting ADC-antigen receptor complex needs to be internalised through receptor-mediated 
endocytosis, for delivery of the toxic payload. Not all cell-surface molecules will internalise 
upon antibody binding. The antigen should ideally have low expression on normal tissues, 
however expression on normal tissues can be tolerated if expression on vital organs is 
minimal or absent. (Perez et al., 2014) Figure 1.5 displays some of the critical features 
deemed necessary for successful ADC design. The internalisation of the ADC-receptor 
complex was believed to be crucial for ADC therapeutic activity. However non-internalising 
ADCs have recently been proven to show potent therapeutic activity in mouse models of 
human cancer. ADCs equipped with peptide-based linker-payload combinations, were shown 
to efficiently liberate disulphide-linked drugs at the extracellular tumour site, leading to 
potent anti-cancer activity in preclinical animal models. (Gébleux et al., 2017) This shows 
promise for the utilisation of molecular targets that may be overexpressed on the surface of 
cancer cells but do not initiate receptor-mediated endocytosis. In a similar way ADCs that 
target the tumour stroma or vasculature could show therapeutic benefit by dismantling the 
tumour microenvironment and exposing the tumour cells to drug indirectly. (Perrino et al., 
2014)  
Minimal target expression in normal tissues is required to limit off-target toxicities. Target 
expression on normal tissues can also reduce ADC exposure in the tumour, impacting 
efficacy as well as safety. However, predicting ADC toxicity based on normal tissue 
expression is surprisingly challenging. For example, the anti-CD44v6-ADC (Bivatuzumab 
mertansine) with target antigen expression present in normal skin keratinocytes, caused not 
surprisingly, toxicity in skin. (Tijink et al., 2006)  In contrast, target antigen SLC34A2, has 
notable expression in normal lung tissue, yet the anti-SLC34A2-ADC has shown 
encouraging safety and pharmacokinetics in the clinic. (Burris et al., 2014) Various 
parameters such as the biodistribution of the ADC and the particular normal cell type that 
expresses the target may determine the translation of target expression to a dose-limiting 
toxicity. (Damelin et al., 2015) 
 
  33 
 
Figure 1.5 Critical factors that influence ADC therapeutics. ADCs consist of a cytotoxic drug 
conjugated to a mAb by means of a select linker. Optimisation of these components is essential for 
development of successful conjugates. (Adapted from Panowski et al., 2014) 
 
 
1.3.2.2. ADCs for Solid Malignancies 
There are currently no ADCs approved for the treatment of CRC or PDAC. Until recently 
only ADCs targeting CD20 or CD33 on haematological malignancies, such as lymphoma 
and leukaemia, were in clinical use. (Diamantis and Banerji, 2016) Antibody therapeutics for 
solid malignancies were confined to unconjugated mAbs. However, the ADC ado-
trastuzumab emtansine (T-DM1) was recently approved for use in metastatic breast cancer. 
(Boyraz et al., 2013) This ADC made use of the already established unconjugated mAb 
Trastuzumab, which targets HER2-overexpression in breast cancer. T-DM1 combines 
Trastuzumab through a stable non-cleavable linker to the microtubule-inhibitory agent, DM1. 
This allows intracellular drug delivery specifically to HER2-overexpressing cells and was 
found to significantly improve overall survival in patients with HER2-positive metastatic 
breast cancer and further exemplifies the clinical potential of ADCs. (Carvalho et al., 2016) 
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T-DM1 is one of two currently FDA approved ADCs. The second one is Brentuximab 
vedotin, a CD30 targeted mAb covalently linked to the synthetic tubulin inhibitor 
monomethyl auristatin-E (MMAE). It is approved for the treatment of patients with relapsed 
or refractory Hodgkin’s lymphoma or systemic anaplastic large cell lymphoma. (Senter and 
Sievers, 2012) There are approximately 50 ADCs currently in clinical trials targeting various 
molecular targets and for application in a wide number of cancers, including gastrointestinal 
cancers. Table 1.2 displays several of the ADCs currently in the clinical pipeline. 
 
 Target 
 
Cytotoxic payload Main indication Phase 
Sacituzumab govitecan 
(IMMU-132)  
TROP2 SN-38 Triple-negative breast cancer 3 
Inotuzumab ozogamicin 
(CMC-544)  
CD22 Calicheamicin Acute lymphoblastic leukaemia 3 
Anetumab ravtansine 
(BAY 94-9343)  
Mesothelin DM4 Mesothelioma 2 
Gemtuzumab 
ozogamicin 
CD33 Calicheamicin Acute myeloid leukaemia, acute 
promyelocytic leukaemia 
2 
Depatuxizumab 
mafodotin (ABT-414)  
EGFR MMAF Glioblastoma 2 
Glembatumumab vedotin 
(CDX-011)  
GPNMB MMAE Osteosarcoma, melanoma, triple-
negative breast cancer 
2 
Denintuzumab 
mafodotin (SGN-
CD19A) 
CD19 MMAF Diffuse large B-cell lymphoma 2 
Mirvetuximab 
soravtansine (IMGN-
853)  
Folate receptor 
α 
DM4 Folate receptor α-positive 
epithelial ovarian cancer 
2 
AGS-16C3F ENPP3 MMAF Renal cell carcinoma 2 
Rovalpituzumab tesirine 
(Rova-T; SC16LD6.5)  
DLL3 Pyrrolobenzodiazepine Small-cell lung cancer 1/2 
  (IMMU-130)  CEACAM5 SN-38 Colorectal cancer, epithelial 
cancers 
1/2 
BMS-986148 Mesothelin ND Mesothelin-expressing cancers 1/2 
Humax-TF-ADC Tissue factor MMAE Tissue factor expressing tumours 1/2 
Vadastuximab talirine 
(SGN-CD33A) 
CD33 Pyrrolobenzodiazepine Acute myeloid leukaemia 1/2 
TAK-264 (MLN-0264)  Guanylyl 
cyclase C 
MMAE Gastrointestinal cancers 1/2 
Milatuzumab-
doxorubicin (CD74-
DOX) 
CD74 Doxorubicin Chronic lymphocytic leukaemia, 
non-Hodgkin lymphoma, multiple 
myeloma 
1/2 
Table 1.2 ADCs currently in clinical development. SN-38=active metabolite of irinotecan. 
DM4=ravtansine. MMAF=monomethyl auristatin F. MMAE=monomethyl auristatin E. ND=not 
disclosed. (Adapted from Thomas, Teicher and Hassan, 2016) 
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1.3.3. Immune Checkpoint Inhibitors 
Antibodies that restore T-cell responses against tumours have gained considerable attention 
and success over the past few years. Immune checkpoints are inhibitory receptors and ligands 
that hold the immune system ‘in check’ and prevent it from attacking host cells. Tumour cells 
usually escape the host immune response by up-regulating immune inhibitory signals. 
Blocking these immune checkpoints allows the recognition of tumour cells by T-cells, and 
will hopefully lead to their elimination. CTLA-4 and PD-1, along with its ligand PD-L1, are 
the most actively studied checkpoint proteins for clinical cancer immunotherapy. (Pardoll, 
2012) CTLA-4 is expressed exclusively on T-cells and is the immune checkpoint during the 
early stages of T-cell activation. CTLA-4 primarily counteracts the activity of the T-cell co-
stimulatory receptor, CD28, which inhibits T-cell activation resulting in the tumour cell 
evading cellular immunity. (Rudd, Taylor and Schneider, 2009) PD-1 is a secondary 
checkpoint because it is expressed on T-cells later, during the effector phase when T-cells 
become activated. (Ishida et al., 1992) PD-1 binds to its ligands, PD-L1/L2, which are 
commonly upregulated on tumour cells, inhibiting anti-tumour T-cell mediated responses. 
The major PD-1 ligand expressed by solid tumours is PD-L1. (Dong et al., 2002; Iwai et al., 
2002) PD-1 is also expressed on other activated non-T-lymphocyte subsets, including B-cells 
and NK cells, reducing their lytic activity. (Fanoni et al., 2011; Terme et al., 2011) 
Several mAbs targeting these immune checkpoints are either in development, undergoing 
trials, or approved for use. Four immune checkpoint inhibitors have so far been approved, 
Ipilimumab, Pembrolizumab, Nivolumab and Atezolizumab. Ipilimumab targets CTLA-4 
and was approved in 2011 based on two phase-III clinical trials that demonstrated improved 
overall survival in a group of advanced melanoma patients. (Hodi et al., 2010) Ipilimumab 
is currently undergoing clinical trials in several other cancer types, including small-cell and 
non-small-cell lung cancer, bladder cancer and prostate cancer. Atezolizumab targets PD-L1 
and was granted accelerated FDA approval in 2016 for the treatment of locally advanced or 
metastatic urothelial carcinoma after failure of cisplatin-based chemotherapy. (Inman et al., 
2016) Pembrolizumab and Nivolumab both target the PD-1 receptor. Pembrolizumab was 
first granted FDA approval in 2014 for the treatment of advanced melanoma, based on results 
from clinical trials demonstrating an ability to improve progression free survival of 
Ipilimumab-refractory melanoma patients. (Khoja et al., 2015) Nivolumab was also 
approved for melanoma and for squamous-cell non-small-cell lung cancer following phase-
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III trials that demonstrated improvements in overall survival in comparison with 
chemotherapy. (Raedler, 2015) Both Pembrolizumab and Nivolumab were subsequently 
approved for use in several other cancers including head and neck cancer, Hodgkin 
lymphoma, renal cell carcinoma and urothelial carcinoma. They were recently granted 
accelerated FDA approval in 2017 for the treatment of metastatic MSI-H cancers, including 
MSI-H metastatic CRC. Immune checkpoints are selectively upregulated in MSI-H CRC 
tumours, which account for 15% of all CRC cases. (Llosa et al., 2015) Clinical trials of 
immune checkpoint inhibitors in PDAC, have shown unpromising results to date. A phase I 
trial of the PD-LI inhibiting antibody BMS-936559 showed no objective response in PDAC 
patients. (Brahmer et al., 2012) However, further investigation into molecular subtypes of 
PDAC may identify patients that would be likely to respond to immune checkpoint blockade, 
increasing the efficacy of immune checkpoint inhibitors in PDAC.  
The results of clinical trials involving immune checkpoint inhibitors suggest better 
therapeutic potential compared with some conventional therapies in several cancers. 
However, their success fluctuates with patients’ individual immune system response and they 
are also known to stimulate autoimmunity in normal organs leading to adverse events with 
varied severity. In most cases, low or moderate adverse effects are observed that are usually 
reversible. Recent studies are concentrated on combination therapies, including combining 
two or more immune checkpoint inhibitors against different pathways and combining them 
with conventional therapies such as chemotherapy. (Pardoll, 2012) 
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1.3.4. T-cell Receptor Mimic Antibodies  
An emerging strategy to circumvent the fact that mutated and overexpressed oncoproteins 
are typically cytoplasmic or nuclear, and thus not accessible to ADCs, is the development of 
T-cell receptor mimic (TCRm) mAbs. They are based on the identification of tumour 
antigens recognized by T-cells in the context of human leukocyte antigen (HLA). Cells can 
present peptides from intracellular proteins on their cell surface in the context of HLA, which 
the immune system uses to differentiate between self and non-self cells. Tumour specific 
antigens can arise from mutated gene products, such as Ras, although the chances that a 
peptide displaying such a mutation will bind the patient’s HLA and be displayed are small, 
with few documented. However, tumour associated antigens, include proteins that are 
overexpressed in tumour cells, and therefore peptides from these are displayed at a far higher 
rate on the cell surface. Increases in antigenic peptides presented on cancer cells can 
distinguish them from normal cells which display low levels. Ideal TCRm targets for cancer 
therapy therefore are tumour-specific peptide/HLA complexes found in abundance on the 
cell surface. Peptides are most likely to be presented from overexpressed proteins with short 
half-lives that are cleaved and processed into peptides with high affinity to the patient’s HLA.  
TCRm antibodies can then be designed to recognise an epitope within the peptide carried by 
the HLA, recruiting immune cells to mediate cancer cell death or the TCRm mAbs can 
deliver cytotoxic payloads. (Chang et al., 2016) 
However, there are challenges to TCRm antibody efficacy. The general low density of their 
target peptide/HLA epitopes, with only hundreds to a few thousand expressed on a target cell 
surface, versus the tens to hundreds of thousands of epitopes targeted by commercially 
available antibodies is a potential concern. Therefore, strategies should be taken to augment 
the therapeutic index, such as Fc engineering to enhance antibody-dependent cell-mediated 
cytotoxicity. MHC molecules do not in general readily or rapidly internalise, reducing the 
efficacy of drug conjugates, therefore activation of immune effectors will likely be the main 
mode of cytotoxicity for TCRm antibodies. Also, as has been observed with approved 
unconjugated mAbs for cancer treatment, TCRm mAb therapy is not likely to be potent 
enough to eliminate 100% of cells when used as monotherapy, combination with other cancer 
therapies will likely be necessary. The full potential for TCRm mAb therapy remains to be 
realised. (Dubrovsky et al., 2016) 
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1.4. Aims of Thesis: 
The aims of this thesis were as follows: 
• To identify membrane localised proteins overexpressed in colon cancer vs. normal 
colon, and to investigate whether they are also overexpressed in other cancer types, 
including pancreatic and breast cancer.  
• To investigate target expression in normal tissues, including the proliferating cells of 
normal tissues. 
• To confirm cell-surface localisation of targets and investigate antibody internalisation 
upon binding to the target in vitro. 
• To investigate the functional role of identified overexpressed targets in the cancer cell 
phenotype by in vitro functional analysis, including proliferation, migration and 
invasion assays.  
• To identify target protein-protein interactions to discover potential binding partners 
and downstream signalling pathways linked to the target proteins.  
 
v Based on these findings to assess the potential of identified targets as molecular 
targets for therapeutic antibody targeting.  
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Chapter 2. Materials and Methods 
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2.1. Bioinformatic Analysis of Microarray mRNA Expression Datasets 
In order to identify potential membrane cancer targets, colon cancer gene expression arrays 
available for download from the Gene Expression Omnibus (GEO) database 
(https://www.ncbi.nlm.nih.gov/geo/) were analysed. The GEO database contains datasets 
from hundreds of different technologies/platforms, including mRNA gene expression arrays, 
miRNA arrays and RNA-seq. The criteria for our search of the databases were (1): normal 
human colon and colon carcinoma tissue sections (excluding cell line data); 2): the 
microarray platform used was Affymetrix U133 plus 2.0 arrays; (3): the data were presented 
as gene expression level. With this criteria, and excluding small datasets, a dataset by 
Skrzypczak et al., (2010) was chosen for analysis. This dataset (accession number: 
GSE20916) contains whole tissue section samples from 36 colon adenocarcinomas, 45 colon 
adenomas and 24 normal colon samples. The dataset was generated on Affymetrix GeneChip 
HG-U133plus2, and processed using two normalisation algorithms: MAS5 and GCRMA 
with LVS.  
For our study the processed CEL file data for this dataset was downloaded from the GEO. 
Differential gene expression lists were generated using the ebayes function of the limma 
package (Smyth, 2004) from Bioconductor, to generate lists of genes upregulated in (1) colon 
adenocarcinoma vs. normal colon and (2) colon adenoma vs. normal colon. A fold change of 
≥ 2 and an adjusted p-value of  ≤ 1E-5 were considered significant. The p-values were adjusted 
using a Bonferroni multiple testing correction. The literature/pathway mining software 
Pathway Studio Enterprise was then used to identify the genes that express membrane 
localised proteins. The number of upregulated genes identified in adenoma and 
adenocarcinoma compared to normal colon are summarised in Table 2.1. These lists were 
generated by Dr. Stephen Madden and Dr. Padraig Doolan, NICB.  
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 2F UP (Total genes) 2F UP (Membrane 
localised) 
Normal vs. Adenoma 1078 154 
Normal vs. Colon 
adenocarcinoma  
1238 127 
Table 2.1 Differential gene lists generated from publicly available colon cancer datasets. 
 
2.2. Cell Culture 
All cell culture work was carried out in a class II laminar air-flow cabinet (NuAIR), which 
was cleaned with 70% industrial methylated spirits (IMS) before and after each use. Any 
items brought into the cabinet were also sterilised with IMS. Only one cell line was worked 
on at a time in the laminar flow cabinet and upon completion of work with any given cell 
line, 15 minutes clearance was given to eliminate any possibilities of cross-contamination 
between the various cell lines. The cabinet was cleaned routinely with Virkon (Antech 
International, P0550) and IMS. All cells were maintained under standard culture conditions, 
5% CO2 at 37oC. Cells were fed with fresh media or sub-cultured every 2-3 days or as 
required, in order to maintain active cell growth. Cell lines were maintained in T25; T75; and 
T175 flasks (Corning). 
 
2.2.1. Cell Lines and Cell Culture Medium  
Six colon cancer cell lines, eight PDAC cell lines and eight breast cancer cell lines were used 
during this study. All cell lines were originally obtained from the American Type Culture 
Collection (ATCC). Table 2.2 outlines the details and growth conditions for each cell line. 
Complete medium was made up by adding appropriate concentration of foetal calf serum 
(FCS)(PAA) and any required supplements: L-Glutamine (G7513 Sigma). Complete medium 
was prepared and sterility tested before use by incubating at 37oC for up to 7 days to ensure 
no bacterial or fungal contamination was present.  
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Cell	Line		 Source	 Complete	Media	
SW480	 Colorectal	adenocarcinoma	 RPMI	1640,	5%	FCS	
SW620	 Lymph	node	metastasis	of	CRC	 RPMI	1640,	5%	FCS	
HCT116	 Colorectal	carcinoma	 DMEM,	5%	FCS,	2mM	L-Glutamine	
T84	 Lung	metastasis	of	CRC	 DMEM,	10%	FCS,	2mM	L-Glutamine	
HT29	 Colorectal	adenocarcinoma	 DMEM,	10%	FCS,	2mM	L-Glutamine	
CaCo-2	 Colorectal	adenocarcinoma	 DMEM,	10%	FCS,	2mM	L-Glutamine	
BxPC-3	 Pancreas	adenocarcinoma	 RPMI	1640,	10%	FCS	
MIA	PaCa-2	 Pancreas	adenocarcinoma	 DMEM,	5%	FCS,	2mM	L-Glutamine	
PANC-1	 Pancreas	adenocarcinoma	 DMEM,	10%	FCS,	2mM	L-Glutamine	
HPAC	 Pancreas	adenocarcinoma	 RPMI	1640,	10%	FCS	
AsPC-1	 Ascites	PDAC	metastatic	site	 RPMI	1640,	10%	FCS	
Capan-1	 Liver	PDAC	metastatic	site		 DMEM,	20%	FCS,	2mM	L-Glut	
Capan-2	 Pancreas	adenocarcinoma	 DMEM,	10%	FCS,	2mM	L-Glutamine	
SW1990	 Spleen	PDAC	metastatic	site	 DMEM,	10%	FCS,	2mM	L-Glutamine	
MCF-7	 Breast		 DMEM,	10%	FCS,	2mM	L-Glutamine	
T47D	 Pleural	effusion	metastatic	site	of	breast	
ductal	carcinoma	
RPMI	1640,	10%	FCS	
BT474	 Breast	ductal	carcinoma	 RPMI	1640,	10%	FCS	
MDA-MB-361	 Brain	metastasis	of	breast	adenocarcinoma	 RPMI	1640,	10%	FCS	
MDA-MB-468	 Pleural	effusion	metastatic	site	of	breast	
adenocarcinoma	
RPMI	1640,	10%	FCS	
BT20	 Breast	carcinoma	 DMEM,	10%	FCS,	2mM	L-Glutamine	
MDA-MB-157	 Breast/medulla	carcinoma	 RPMI	1640,	10%	FCS	
MDA-MB-231	 Pleural	effusion	metastatic	site	of	breast	
adenocarcinoma	
RPMI	1640,	10%	FCS	
Table 2.2 Cell lines and culture medium used in this study. 
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2.2.2. Subculture of Cell Lines 
Waste cell culture medium was removed from the tissue culture flask and discarded into a 
sterile glass bottle. The flask was then rinsed out with 2-5mls trypsin/EDTA solution (0.25% 
trypsin, Gibco, 043-05090), 0.01% w/v EDTA (Sigma, E9884) solution in phosphate 
buffered saline (PBS) (Oxoid, BRI4a) to ensure the removal of any residual media. 
Depending on the size of the flask, 2-5ml of trypsin was then added to the flask, which was 
then incubated at 37oC, for approximately 5 mins until all of the cells detached from the 
inside surface of the flask, monitored by microscopic observation. An equal volume of 
complete media was added to the flask to deactivate the trypsin. The cell suspension was 
placed in a sterile universal container (Sterilin, 128A) and centrifuged (Beckman, Allergra™, 
6KR centrifuge) at 1000rpm for 5 mins. The supernatant was then discarded from the 
universal and the pellet was suspended gently in complete medium. A cell count was 
performed and an aliquot of cells was used to seed a flask at the required density. All cell 
waste and media exposed to cells were autoclaved before disposal. 
 
2.2.3. Cell Counting 
Following the trypsination of cells and resuspension of the cell pellet, an aliquot of cell 
suspension was applied to the chamber of a glass coverslip-enclosed haemocytometer. For 
each of the four grids, cells in the 16 squares were counted. The average of the four grids was 
multiplied by a factor of 104 (volume of the grid) and the relevant dilution factor to determine 
the average cell number per mL in the original cell suspension. The volume of cell suspension 
for the required cell number could then be calculated.  
  
2.2.4. Cryopreservation of Cells 
Cells for cryopreservation were harvested in the mid-log phase of growth. Cell pellets were 
resuspended in a suitable volume of FCS which had been cooled to 4°C. An equal volume of 
10% (v/v) DMSO (Sigma, D2438) in FCS was added drop-wise giving a final concentration 
of 5% (v/v) DMSO. 1mL of cell suspension was then aliquoted into cryovials (Greiner, 
122278) and immediately placed into the -20°C freezer for 2 hrs. The cryovials were then 
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transferred to -80oC for short term storage, after which the vials were gradually transferred 
to the liquid phase of liquid nitrogen for long term storage (-196°C).  
 
2.2.5. Thawing of Cryopreserved Cells  
A volume of 5mL of fresh culture medium containing serum was added to a sterile universal. 
The cryopreserved cells were removed from the liquid nitrogen and thawed at 37°C quickly. 
The cells were removed from the vials and transferred to the aliquoted media (also at 37°C). 
The resulting cell suspension was centrifuged at 1000rpm for 5 mins. The supernatant was 
removed and the pellet resuspended in fresh culture medium. Thawed cells were then added 
to an appropriately sized tissue culture flask with a suitable volume of growth medium and 
allowed to attach overnight. The following day, flasks were re-fed with fresh media to 
remove any remaining DMSO and non-viable cells. 
 
2.2.6. Mycoplasma Testing 
Mycoplasma testing was carried out every 3 months, using the indirect staining procedure 
for mycoplasma analysis. Normal rat kidney fibroblast (NRK) cells were seeded onto sterile 
coverslips in sterile petri dishes (Greiner, 633 185) at a cell density of 2x103 cells/mL and 
allowed to attach overnight at 37°C in a 5% CO2 humidified incubator. 1 mL of cell-free 
supernatant from each test cell line was inoculated onto an NRK petri-dish and incubated as 
before until the cells reached 20-50% confluency. After this time, the waste medium was 
removed from the dishes, the coverslips (Chance Propper, 22 x 22 mm) were washed twice 
with sterile PBS, once with a cold PBS/Carnoys (50/50) solution and fixed with 2 mL of 
Carnoys solution (acetic acid:methanol, 1:3) for 10 minutes. The fixative was removed and 
dried coverslips were washed twice in deionised water and stained with 2 mL of Hoechst 
stain (BDH) (50ng/mL) for 10 minutes. From this point on, work proceeded without direct 
light to limit quenching of the fluorescent stain. The coverslips were rinsed three times in 
PBS. They were then mounted in 50% (v/v) glycerol in 0.05 M citric acid and 0.1 M disodium 
phosphate and examined using a fluorescent microscope with a UV filter. A Mycoplasma 
infection would be seen as small fluorescent bodies in and sometimes outside the cells. 
Mycoplasma testing was carried out for all cell lines for possible mycoplasma contamination 
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in house by Mr. Michael O’ Donoghue and Ms. Justine Meiller at the NICB. All cell lines 
used in this thesis are confirmed to be Mycoplasma free. 
 
2.3. Western Blot Analysis 
2.3.1. Preparation of Whole Cell Protein Lysates 
Cells were grown to the desired confluency in monolayer culture flasks (T75/T175). Media 
was removed and cells were washed x3 with sterile ice cold PBS. Excess PBS was removed 
and 500 µl (per T75cm2 flask) or 1 mL (per T175cm2 flask) of RIPA lysis buffer (Sigma, 
R0278) containing 1X Halt protease/phosphatase inhibitor cocktail (ThermoScientific, 
78440) was added to the flask. Flasks were then incubated on ice for 30 mins with regular 
agitation, to ensure complete cell lysis of the cell culture monolayer by the lysis buffer. The 
cell lysate was then transferred to a 1.7 mL Eppendorf tube and centrifuged at 16,000 g for 
15 minutes at 4°C, and the supernatant was removed and stored at -80°C for future use. 
 
2.3.2. Preparation of Membrane Enriched Cell Fractions 
Membrane enrichment was carried out using CALBIOCHEM® ProteoExtract Native 
Membrane Protein Extraction Kit (Merck Millipore, 444-810KIT). Membrane enrichment 
was carried out as per manufacturer's recommendations with some modifications. The 
components of the kit were as follows: Wash Buffer, Extraction Buffer I, Extraction Buffer 
II and Protease Inhibitor Cocktail. The following protocol outlines the steps taken to obtain 
a 500 µl membrane protein enriched fraction from ~90% confluent T75 cm2 adherent culture 
flask. All reagents were kept on ice except the Protease Inhibitor Cocktail which was stored 
in DMSO and was allowed to come to room temperature to thaw. Cell culture media was 
removed and cells were washed x2 with 10mL of ice cold PBS. Extraction Buffer I was 
prepared by taking 2 mL and adding 10 µl of Protease Inhibitor Cocktail. 2 mL of Extraction 
Buffer I/Protease Inhibitor Cocktail was added to the washed cells in the flask. The cells were 
then scraped into the buffer using a sterile disposable cell scraper. The 2 mL cell sample was 
then divided into two 1 mL volumes in eppendorf tubes and incubated at 4°C for 10 mins. 
Samples were then centrifuged in a 4°C pre-cooled microcentrifuge at 16,000 x g for 5 mins. 
The supernatant contains soluble proteins and was discarded. Sample pellets containing the 
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insoluble membrane proteins were then resuspended in 500 µl Extraction Buffer II/Protease 
Inhibitor Cocktail + 2.5 µl of Protease Cocktail Inhibitor. Extraction Buffer II solubilises 
integral membrane and membrane associated proteins. Samples were incubated and agitated 
at 4°C for 30 mins. To remove any remaining debris the samples were then centrifuged in a 
4°C pre-cooled microcentrifuge at 16,000 x g for 15 mins. The supernatant containing 
solubilised membrane proteins was removed and stored at -80°C for future use. 
 
2.3.3. Preparation of Conditioned Medium (CM) 
Cells were seeded in T175cm2 flasks and cultured until 50-60% confluent. Cells were then 
washed x 3 in the appropriate serum-free media (SFM) and incubated in SFM for 2 hrs. After 
this time, cells were washed again x 3 in SFM. This is to ensure the complete removal of 
FCS proteins from the cells, so that CM containing only proteins secreted by the cells can be 
collected. 20mL of SFM was then added to the cells and incubated for 72 hrs. The CM was 
then collected, centrifuged for 5 mins at 1000 rpm and filtered through 0.22µm filter. To 
concentrate conditioned media, 20mL was added to a Vivaspin20 concentrator with a 5kDa 
molecular weight cut off (Sartorius, VS.0112) and centrifuged at 4°C at 4000rpm 
(ThermoFisher Scientific, 11175774) until the final volume was reduced x10 (e.g. 10 mL to 
1 mL). The sample was removed and then stored in aliquots at -80°C. 
 
2.3.4. Protein Quantification 
Protein concentrations in whole cell lysates, membrane enriched fractions and CM were 
determined using the Pierce™ BCA Protein assay kit (ThermoFisher Scientific, 23225) as per 
the manufacturer’s instructions. 
 
2.3.5. Gel Electrophoresis 
Protein samples for Western blotting were separated by SDS-PAGE gel electrophoresis, 
using 4-12% gradient gels (ThermoFisher Scientific, NP0335, NP0321). Protein samples 
were prepared for gel electrophoresis by taking the required volume to equalise the protein 
concentration across a sample set from the protein lysate sample preparation and made up in 
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4x sample buffer (ThermoFisher Scientific, NP0007) and 10x reducing agent (ThermoFisher 
Scientific, NP0004). The samples were heated at 95°C for 5 mins on a heating block and 
allowed to cool to room temperature before being centrifuged. 10-20µg of protein and 5-7ul 
of pre-stained molecular weight marker (ThermoFisher Scientific, LC5800) were loaded into 
the wells of a gel. 500 µl of antioxidant (NP0005) was then added to the inner chamber of 
the Xcell SureLock® minicell (EI0001) electrophoresis gel-rig. The samples were 
electrophoretically separated at 200 V constant using a 1X MOPS/SDS running buffer 
(ThermoFisher Scientific, NP001) for 50mins or until the bromophenol blue dye reached the 
bottom of the gel. 
 
2.3.6. Enhanced Chemiluminescence Detection 
Following electrophoresis gels were washed in Ultrapure water (UHP). Proteins were 
transferred to Polyvinylidene fluoride (PVDF) membranes (ThermoFisher Scientific, 
IB4010-01) using the iBlot transfer system (ThermoFisher Scientific, IB1001). The 
membrane was blocked with 5% milk powder (Biorad, 170-6404) in TBS/Tween (1x TBS 
(Sigma, T5912) and 0.1% Tween20 (Sigma, P1379-500ml)) at room temperature for 2 hrs, 
then incubated overnight at 4°C in primary antibody diluted with 0.1 % TBS-Tween in 5 % 
milk powder. The next day the primary antibody was removed and the membrane was given 
three 30 min washes with 0.5 % TBS-Tween and then incubated at room temperature with 
secondary antibody in 0.5 % TBS-Tween for 1 hour. Table 2.3 lists the primary and 
secondary antibodies used in this study. Secondary antibody was removed and the membrane 
was given three 30min washes with 0.5 % TBS-Tween. Following the final wash, membranes 
were incubated for 5mins with a 50:50 mixture of ECL reagent A and ECL reagent B 
(Amersham, ECL, RPN 2105 or Clarity, BioRad, 170506). The ECL reagent mixture was 
completely removed and the membrane was covered in a layer of transparent plastic. All 
excess air bubbles were removed. The membrane was then exposed to autoradiographic film 
(GE Life Sciences, 95017-681) for various times depending on the intensity of the signal. 
The exposed autoradiographic film was developed for the appropriate time in developer 
solution (Kodak, LX24, diluted 1:5 in water) until clear bands developed. The film was then 
briefly washed in water and transferred to a fixative solution (Kodak, FX-40, diluted 1:5 in 
water) for 5 mins. The film was washed with water for 5-10 minutes and left to dry at room 
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temperature. Once dry, the blots were then converted into a digital format using Epson 
Perfection photo scanner 4990 and Epson Scan software version 3.04a. 
 
Primary Antibody Dilution Details 
LY6G6F  0.75µg/ml  Abcam: ab62597 
IL1RAPL1 1:5000  Atlas: HPA00564 
IL1RAPL1 1:2000  Proteintech: 21609-1-A 
IL20RA 1:1000 Abcam: ab135454 
BACE2 1:1000  Abcam: ab135778 
NTM  1:1000  R+D systems: AF1235 
LRRC8E 1:500  Novus: NBP1-82078 
EPHX4 1:500 Novus: NBP1-8930 
Alpha Tubulin 1:10,000 Abcam: ab4074 
Cyclin A 1:1000 Santa Cruz: sc-596 
P27 1:1000 Santa Cruz: sc-528 
PARP 1:500 Cell signalling: 9542 
Phospho-p44/42 MAPK 1:1000 Cell signalling: 4370 
Total-p44/42 MAPK 1:1000 Cell signalling: 4695S 
Phospho-FAK 1:1000 Cell signalling: 3284S 
Total-FAK 1:5000 BD Biosciences: 
610088 
Secondary Antibody Dilution  Details 
Anti-Mouse 1:2000  Dako: P0447 
Anti-Rabbit 1:2000  Dako: P0448 
Table 2.3 List of antibodies and the dilution used in Western blot analysis. 
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2.4. RNA Interference (RNAi) 
RNAi using small interfering RNA (siRNA) was carried out to transiently knockdown 
/attempt to knockdown the expression of LY6G6F and IL1RAPL1 at the protein level. A 
number of siRNAs were used for each target from two different companies (Ambion/Life 
Technologies and Qiagen). These siRNAs were 21-23 bps in length and were introduced to 
the cells via reverse transfection with Lipofectamine 2000 Transfection Reagent (Life 
Technologies, 13778075). 
 
2.4.1. Transfection Optimisation 
In order to determine the optimal conditions for siRNA transfection, cell concentrations 
required were first established for each cell line. Cell suspensions were prepared at 7.5 x 104, 
1 x 105, 1.5 x 105, 2 x 105 and 1.5 x 105 cells per well in a 6 well plate, and allowed to grow 
for 72 hrs. This was carried out in order to determine which cell concentration allows the 
cells to be in late exponential phase at the end of the transfection (i.e. after 72 hrs incubation), 
ensuring healthy proliferating cells will be used in the follow on functional assays. 
Transfections were optimised further to determine the optimal Lipofectamine 2000 
transfection reagent volume required to efficiently transfect each cell type, by transfecting 
cells with a range of Lipofectamine 2000 volumes (1-4µl) and 30nM of Negative siRNA and 
kinesin siRNA, which initiates cell death. Plates were assayed for changes in proliferation 
after 72 hrs using the acid phosphatase assay described in Section 2.5.1. Optimal conditions 
for siRNA transfection were determined as the combination of conditions which gave the 
greatest reduction in cell number with the kinesin siRNA and also the least cell kill in the 
presence of Lipofectamine 2000 alone. The optimised conditions for the cell lines are shown 
in Table 2.4. The general method used for siRNA transfection is as follows: Solutions of 
siRNA at their required concentrations were prepared in optiMEM (GibcoTM, 31985047). 
Separately, a Lipofectamine 2000 solution was made up as a master mix using optiMEM 
with enough volume required for all transfection samples. Both of these solutions were 
incubated at room temperature for 10 minutes before being combined together, with the 
combined siRNA/Lipofectamine solutions incubated for a further 15mins at room 
temperature. 100 µL of the siRNA/Lipofectamine solutions were added in a drop-wise 
fashion to each well of a 6-well plate, with each well containing 1.9 mL of a cell suspension 
  50 
at the required concentration. The plates were mixed gently and incubated at 37°C overnight. 
After this time, the transfection mixture was removed from the cells and the plates were fed 
with fresh complete medium.  
 
Cell Line Cell Number Lipofectamine 2000 
HCT116 2 x 105 2 µl 
MIA PaCa-2 2 x 105 2 µl 
SW480 1.5 x 105 2 µl 
BXPC-3 2 x 105 3 µl 
Table 2.4 Optimisation conditions for cell line transfection.  
 
 
2.4.2. siRNA Transfection for Functional Analyses 
Pre-designed siRNAs to the protein targets were purchased from Life Technologies or 
Qiagen. Three independent LY6G6F siRNAs were used in the functional analysis, with an 
additional three also used for qRT-PCR analysis. Six independent IL1RAPL1 siRNAs were 
used in the attempt to achieve protein knockdown of this target. Table 2.5 lists the siRNAs 
used in this study. For each set of siRNA transfections carried out, the control groups 
included: Non-transfected cells only control; Lipofectamine only control cells; and a 
Negative siRNA transfected cells control. Negative siRNA are sequences that do not have 
homology to any genomic sequence. The Negative non-targeting siRNA used in this study is 
commercially produced, and guarantees siRNA with a sequence that does not target any gene 
product. It has also been functionally proven to have no significant effects on cell 
proliferation, morphology and viability. Therefore, the effects observed by target siRNA 
transfection were compared to cells transfected with Negative siRNA. This takes into account 
any effects due to the siRNA transfection procedure, reagents, and also any random effects 
of the Negative siRNA. Western blots were used to determine if siRNA had an efficient 
knockdown effect at the protein level. 
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Target siRNA Details 
Company and Catalog numbers  
siRNA Concentration  
LY6G6F Qiagen: SI00331744, SI04136027, 
SI04253046  
30nM (used in functional 
analysis + qRT-PCR 
analysis) 
LY6G6F Ambion: s48908, s48909, s48910  30nM (used in qRT-PCR 
analysis only) 
IL1RAPL1 Qiagen: SI00104335, SI00104342, 
SI00104356, SI03044195. Ambion: 
s21968, s21969, s21970 
30nM qRT-PCR analysis. 
10-100nM tested for 
protein knockdown. 
Negative 
siRNA  
Qiagen: 1027310 As required  
Negative 
siRNA A 
Ambion: 4390843 As required  
Kinesin (Kif11) Ambion: 16704 As required  
AllStars Cell 
Death 
Qiagen: S104381048  As required  
Table 2.5 Details of siRNA and concentrations used in this study.   
 
2.5. Functional Analysis  
2.5.1. Acid Phosphatase Assay 
Following the transfection incubation period of 72 hrs, media was removed from the 6 well 
plates. Each well was washed x2 with 1 mL of PBS. This was removed and 1 mL of freshly 
prepared phosphatase substrate (1.5µg/mL p-nitrophenol phosphate (ThermoScientific, 
34045) in 0.1 M sodium acetate (Sigma, S8625), 0.1% triton X-100 (BDH, 30632), pH 5.5) 
was added to each well. The plates were then incubated in the dark at 37°C for 1-2 hours. 
Colour development was monitored during this time. The enzymatic reaction was stopped by 
the addition of 500 µl of 1 M NaOH. A 150 µL aliquot of each sample (3 replicates) was 
transferred to a 96-well plate. The plate was read in a dual beam plate reader at 405 nm with 
a reference wavelength of 620 nm.  
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2.5.2. 2D Colony Formation Assay 
The cell number was first optimised for each cell line being used in the functional analysis. 
Cells were seeded at 100-1200 cells/well in a 6 well plate and assessed after 12 days. The 
optimal cell number chosen was one in which sufficient independent colonies had formed 
but not started overlapping with each other. The optimal cell number chosen for HCT116 
cells was 800 cells/well and for MIA PaCa-2 cells 400 cells/well. For the functional analysis, 
cells were seeded at the optimal cell number in duplicate, 72 hrs post transfection. Cells were 
left to form colonies for 12 days. Media was renewed once during this time. After 12 days, 
wells were washed twice with PBS and colonies fixed in cold Methacare (75% v/v methanol, 
25% v/v acetic acid) for 30 mins. The fixative solution was removed and wells washed once 
with PBS. Fixed colonies were then stained with 1% Crystal violet for 20 mins. Wells were 
rinsed with UHP and left to air dry. Plates were then scanned as 24-bit colour TIFF images 
for analysis. Colony area and intensity was quantified using the ImageJ plugin Colony Area. 
(Guzman et al., 2014) Each assay was performed in biological triplicate. 
 
2.5.3. Invasion Assay 
Matrigel (BD Biosciences, 354234) was diluted to a working stock of 1mg/mL in serum-free 
DMEM. Aliquoted stocks were stored at -20°C for up to 1 year. A volume of 100 µL of 
Matrigel was placed into each insert (BD Biosciences, 353097) (8.0 µm pore size, 24 well 
format) and kept at 4°C for 24 hours. The insert and the plate were then incubated for one 
hour at 37°C to allow the proteins to polymerise. Cells were harvested 72 hrs post transfection 
and re-suspended and made up to an optimised cell number. Excess media was removed from 
the inserts, and they were rinsed with 200 µL of culture media. A 100 µL volume of complete 
cell culture media was added to each insert. A 100 µL volume of cell suspension was added 
to each insert and 500 µL of culture media was added to the well underneath the insert. Cells 
were incubated for an optimised amount of time. The optimised cell number and conditions 
for HCT116 cells: 3x105 cells/insert in serum free culture medium with medium containing 
10% FCS in the well underneath the insert to act as a gradient, incubated for 30 hrs. MIA 
PaCa-2 cells: 1.5x105 cells/insert in culture media containing 5% FCS with the same media 
in the well underneath the insert, incubated for 40 hrs. Following incubation, the media was 
removed from the inside of the insert and the insert was wiped with a cotton swab dampened 
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with PBS. The outer side of the insert was stained with 0.25% crystal violet for 10 mins and 
then rinsed in UHP and allowed to dry. The inserts were viewed and photographed under the 
microscope. The invasion assays were quantified by counting cells in 10 random fields within 
a grid at 40x objective and averaged to get the average number of invaded cells/high power 
field (HPF). These were then compared to the Negative siRNA cells to calculate % invaded 
cells compared to Negative siRNA treated cells. Duplicate inserts were set up for each 
triplicate biological experiment.  
 
2.5.4. Migration Assay 
Migration assays were carried out as described in Section 2.5.3 except inserts were not 
coated with Matrigel. Cell counts were also carried out as for invasion assays. 
 
2.5.5. Statistical Analysis  
To compare the effects found in the target siRNA treated cells compared to Negative siRNA 
treated cells, all functional assays were subjected to statistical analysis using Student’s t-tests 
(2-tailed with unequal variance) on Microsoft Excel. A p-value of  ≤ 0.05 (*) was deemed 
significant, with ≤ 0.01 (**) deemed more significant and ≤ 0.001 (***) deemed highly 
significant.  
 
2.6. Immunohistochemistry 
2.6.1. Tissue Samples 
A combination of full-face tissue sections and commercially available tissue microarrays 
(TMA) were used in this study. For the full-face tissue sections, formalin-fixed, paraffin-
embedded (FFPE) tissue blocks were cut into 5µm sections using a microtome and mounted 
onto poly-l-lysine coated slides. Slides were stored at room temperature until required. Full-
face de-identified sections of normal tissues and cancer tissues (colon adenocarcinoma, 
breast cancer and oesophageal cancer) were obtained courtesy of the Departments of 
Pathology of St. Vincent’s University Hospital (SVUH), Dublin 4 and Royal Victoria Eye 
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and Ear Hospital (RVEEH), Dublin 2. Of the colon adenocarcinoma tissue sections provided, 
as well as pathological diagnosis, the KRAS phenotype was known for 18 sections (9 being 
KRAS wildtype and 9 KRAS mutant phenotype) and the BRAF phenotype was known for 4 
sections (2 being BRAF wildtype and 2 BRAF mutant phenotype). Survival data was not 
available for any of the colon cancer specimens.  
The pancreatic cancer patient cohort provided by SVUH consisted of 57 patients diagnosed 
with pancreatic ductal adenocarcinoma (PDAC) who underwent pancreaticoduodenectomy 
in SVUH between 2007 and 2013. All tissue specimens were de-identified, with survival data 
and clinicopathological features including tumour size, differentiation and stage provided for 
this study. Ethical approval for the use of all tissues was obtained from either SVUH or 
RVEEH.  
The commercial TMAs used in this study contain small 1mm diameter cores of tissue on a 
single glass slide and were obtained from US Biomax, Accumax and Invitrogen. The 
commercial TMAs used in this study were as follows: 
• Colon disease spectrum TMA (CO2081, US Biomax), containing 17 cases of 
adenocarcinoma, 17 of mucinous adenocarcinoma, 2 carcinoid, 20 metastatic 
carcinoma, 5 adenoma and polyp, 8 hyperplasia, 10 inflammation, normal adjacent 
tissue (NAT) and normal colon tissue, with duplicate cores per case. Tumour, node 
and metastasis (TNM) and pathology grade data were provided.  
• Colon cancer tissue with corresponding normal TMA (Accumax A713 VIII), 
containing 12 cases of adenocarcinoma and corresponding normal colon in duplicate 
cores. 
• Gastric adenocarcinoma and normal gastric tissue TMA (ST721, US Biomax), 
containing 18 cases of adenocarcinoma, 3 each of adjacent normal tissue and normal 
tissue, triplicate cores per case. TNM and pathology grade data were provided.  
• Oesophageal carcinoma test TMA (T022a, US Biomax), containing 10 cases of 
oesophageal cancer (1 carcinoma in situ, 4 squamous cell carcinoma, 2 
adenocarcinoma, 1 small cell undifferentiated carcinoma, 1 carcinoma sarcomatodes 
and 1 carcinosarcoma) and 2 normal oesophagus tissues, with duplicate cores per 
case. TNM and pathology grade data were provided.  
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• Pancreas tissue TMA (PAN241a, US Biomax), containing 16 cases of adjacent 
normal pancreatic tissue, 5 cases of normal pancreatic tissue and 3 adenocarcinoma 
tissue, single core per case.  
• Pancreatic cancer TMA (PA1001, US Biomax), containing 40 cases of pancreatic 
cancer, 5 cases of adjacent normal pancreatic tissue and 5 cases of normal pancreas 
tissue, duplicate cores per case. TNM data provided.  
• Multiple organ normal tissue TMA (BN242a/b, US Biomax), containing 12 cases of 
multiple normal organs (stomach, oesophagus, colon, rectum, liver, small intestine, 
thyroid, spleen, larynx, testis, bladder and trachea), duplicate cores per case. 
• Human normal tissue TMA (Catalog No. 75-401, Invitrogen MaxArray), containing 
30 normal tissue samples (Lung, Skin, Skeletal Muscle, Heart muscle, Stomach, 
Oesophagus, Small Intestine, Colon, Liver, Spleen, Pancreas, Salivary Gland, 
Pituitary Gland, Adrenal Gland, Thyroid Gland, Parathyroid Gland, Thymus Gland, 
Tonsil, Bone marrow, Breast, Uterus, Cervix, Ovary, Kidney, Prostate Gland, Testis, 
Omentum, Peripheral Nerve, Cerebral Cortex and Cerebellum). Single cores per case.  
 
2.6.2. Immunohistochemical Staining of Tissue Samples 
All Immunohistochemical (IHC) staining was performed using the Dako Autostainer (Dako, 
S3800). Deparaffinisation and antigen retrieval of FFPE tissue sections was performed using 
Epitope Retrieval 3-in-1 Solution (pH 6) (Dako, S1699) or the Epitope Retrieval 3-in-1 
Solution (pH 9) (Dako, S2375) and the PT Link system (Dako, PT101). For epitope retrieval, 
slides were heated to 97°C for 20 mins and then cooled to 65°C. The slides were then 
immersed in wash buffer (Dako, S3006). On the Autostainer, slides were blocked for 10 mins 
with 200 µl HRP Block (Dako, S2023). Cells were washed with 1 x wash buffer and 200 µl 
of antibody added to the slides at the optimised dilution and time. The antibodies used in the 
IHC analysis and their optimised conditions are shown in Table 2.6. Slides were washed 
again with 1 x wash buffer and then incubated with 200 µl Real EnVision (Dako, K4065) for 
30 mins. A positive control slide was included in each staining run. Each slide was also run 
with Negative Control (Antibody Diluent only), to allow evaluation of non-specific staining. 
All slides were counterstained with haematoxylin (Dako, CS700) for 5 mins, and rinsed with 
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wash buffer, followed by deionised water. All slides were then dehydrated in graded alcohols 
(2 x 3 mins each in 70% ethanol, 90% ethanol and 100% ethanol), and cleared in xylene (2 
x 5 mins), and mounted with coverslips using DPX mounting medium (Sigma, 44581). 
Mounted slides were allowed stand overnight before examination under the microscope. 
Slides were viewed and photographed using Olympus microscope and imaging system. 
Tissues were then scored for target immunoreactivity. Staining intensity was classified using 
a scale of 0-3+ as follows: 0, negative; 1+, weakly positive; 2+, moderately positive; 3+, 
strongly positive. Patients were then stratified into two clinical score categories: high target 
expression (intensity 2+ or 3+) and low target expression (intensity 0 or 1+). Scoring was 
carried out by two independent evaluators (AML, EMcA) blinded to specimen and clinical 
detail. Chi-square tests were carried out using GraphPad Prism (Version 7 GraphPad 
Software, Inc., USA). 
 
Antibody Antibody dilution and 
incubation time 
Antigen Retrieval  
LY6G6F (Abcam: 
ab62597) 
11µg/ml 37mins pH9 20mins 
IL1RAPL1 (Atlas: 
HPA00564) 
1:320 37mins pH6 20mins 
IL20RA (Abcam: 
ab135454) 
1:100 30mins pH6 20mins 
BACE2 (Abcam: 
ab135778) 
1:100 30mins pH6 20mins 
NTM (R+D systems: 
AF1235) 
1:6000 30mins pH6 20mins 
Ki67 (Dako) 1:100 30mins pH6 20mins 
Table 2.6 Optimised antibody conditions and antigen retrieval for target IHC.  
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2.7. Immunocytochemical Analysis on Fixed Cells 
Aliquots of 30 µl of cell suspension were seeded directly onto 10 well 7 mm microscope 
slides (Erie Scientific Company, 465-68X). Cells were allowed to attach overnight. After 
such time, slides were washed 3 x in PBS and cells were then fixed in cold 4% 
paraformaldehyde for 5 mins. Immunostaining was carried out using the Dako Autostainer 
as per Section 2.6.2, without the initial antigen retrieval. 
 
2.8. Immunofluorescence Analysis on Fixed Cells  
Cells were seeded onto 10 well microspore slides and incubated as described in Section 2.7.  
Slides were washed 3 x in PBS and cells were then fixed and permeabilised in either ice-cold 
methanol alone for 5-10 mins or 4% paraformaldehyde for 7 mins followed by ice-cold 
methanol for 5 mins. Slides were washed 3x in PBS and in between the wells were then dried 
using a cotton bud wrapped in lint free tissue, to prevent the primary antibody from running 
into neighbouring wells. The primary antibody was applied to appropriate wells and 
incubated overnight at 4°C. After 24 hrs, the slides were washed 3x in PBS and secondary 
antibody was applied (Alexa Fluor488 goat anti-rabbit; Thermofisher Scientific, A11034) at 
1:2000 dilution and incubated for 1 hr at room temperature in the dark. The secondary 
antibody was removed and cells were washed 3x in PBS. Slides were counterstained using 
DAPI nuclear stain (Sigma, D9542). Slides were mounted with ProLong Gold mounting 
medium (ThermoFisher Scientific, P36930) and covered using a glass cover slip. Cells were 
viewed and photographed using a Nikon phase contrast microscope fitted with an FITC filter.  
	
2.9. Quantitative Real Time-Polymerase Chain Reaction (qRT-PCR) 
2.9.1. RNA Extraction 
TRIzol Reagent (Thermo Fisher Scientific, 15596-026) was used for RNA extraction from 
cells in monolayer. 1 mL of TRIzol Reagent was added to each well of a 6-well plate for 
RNA isolation. These samples were allowed to stand for 5 mins on ice to allow complete 
lysis of the cells. The TRIzol/lysed cells solution was transferred to a clean Eppendorf tube, 
and 200 µL of chloroform (Sigma, C2432) was added. Samples were vortexed at high speed 
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for 15 seconds and allowed to stand for 15 mins at room temperature. The resulting mixtures 
were centrifuged at 13,684 g in a microcentrifuge for 15 mins at 4ºC. The aqueous layer 
containing RNA was carefully removed to a clean fresh Eppendorf tube. To this, 500 µL of 
ice-cold Isopropanol (Sigma, I9516) was added. The samples were mixed and incubated at 
room temperature for 10 mins, and then centrifuged at 13,684 g for 30 mins at 4ºC to pellet 
the precipitated RNA. Taking care not to disturb the RNA pellet, the supernatant was 
removed and the pellet was subsequently washed by the addition of 750 µL of 75% ethanol 
and vortexed. The samples were centrifuged at 7,500 g for 5 mins at 4ºC. The supernatant 
was removed and the wash step was repeated. The RNA pellet was allowed to air-dry for 10 
mins and then re-suspended in 20 µL of RNase free water. 
 
2.9.2. Determination of DNA/RNA Quantity and Quality 
Purified RNA samples were quantified using the Nanodrop® ND-1000 spectrophotometer 
(NanoDrop Technologies). Before applying the RNA/DNA sample, the pedestal was wiped 
down using a lint-free tissue dampened with UHP. The programme ‘RNA-40’ was selected 
on the NanoDrop software main screen to read the samples at 260nm, and the instrument was 
blanked with 1 µL of UHP. The concentration of RNA/DNA was calculated by software 
using the following formula: OD260 nm x Dilution factor x 40 = ng/µL RNA. Samples were 
checked for quality (i.e. Phenol contamination) by assessing the A260/A280 and A260/A230 
ratio values. An A260/A280 ratio ~2, and an A260/A230 of ~1.8-2.2 is indicative of a pure 
RNA. 
 
2.9.3. High Capacity cDNA Reverse Transcription 
Reverse transcription of RNA to cDNA was carried out using the High Capacity cDNA 
reverse transcription kit (Applied Biosystems, 4368814) in accordance with the 
manufacturer’s specifications. A maximum of 2 µg of RNA was made up to 10 µL in a 0.5 
mL PCR tube using nuclease-free water. In a separate 0.5 mL PCR tube, the reverse 
transcription master mix was prepared. 10 µL of the RT master mix was added to the RNA 
sample and mixed using a pipette giving a final volume of 20 µL. The temperature profile 
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and conditions for the reverse transcription reaction carried out using a bench top thermal 
cycler G-Storm GS1 PCR machine are shown in Table 2.7. 
 
 Step1 Step2 Step3 Step 4 
Temperature (°C) 25 37 85 4 
Time (min) 10 120 5 ∞ 
Table 2.7 Cycling conditions for reverse transcription 
 
2.9.4. Quantitative Real-Time PCR (qRT-PCR)  
Taqman® qPCR was used to assess gene expression. Taqman® qPCR involved using 
individual Taqman® gene expression assays (Applied Biosystems 4453320) for each gene. 
These assays contain the individual primers and probe for each gene. Table 2.8 lists the 
Taqman assays used in this study. These assays were used with Taqman® Fast Advanced 
Master Mix (Applied Biosystems 4444556) and MicroAmp® Fast Optical 96 well reaction 
plates (Applied Biosystems 4346907). cDNA sample (from Section 2.9.3) was diluted 
between 40ng to 100ng per reaction. The cDNA was diluted using nuclease-free water and 
1µl was loaded per well with 1µl of Taqman® assay and 10µl of Taqman® Master Mix. The 
plate was then sealed using MicroAmp® Optical Adhesive Film (Applied Biosystems 
4311971) and the cycles listed in Table 2.9 were performed in Applied Biosystems 7900 
Real-Time PCR System. Data was analysed using a Relative Quantification ddCt study. A 
calibrator sample was selected and set to a value of one, allowing for the comparison of all 
other samples in relation to the calibrator. For the analysis of target gene and endogenous 
control amplification, the baseline was set to average, normalised fluorescent signal before 
detectable increase (usually 3-15 cycles) and the cycle threshold was set in the exponential 
part of the curve. The Ct standard error was ideally less than +/-0.161 between replicate wells, 
and Ct errors with values greater than this were removed as outliers. The endogenous control 
(B2M) was used automatically to normalise the data. When this was achieved for both the 
target and endogenous control, the relative quantity values for the run were generated and 
plotted relative to the calibrator samples.  
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Gene Catalogue Number 
LY6G6F (probe #1) Hs00222013_m1 
LY6G6F (probe #2) Hs01561205_g1 
IL1RAPL1 Hs00990788_m1 
B2M Hs00984230_m1 
Table 2.8 TaqMan assays used in this study. 
 
 
Parameter Hold Hold 40 cycles 
Temp. (°C) 50 95 95 60 
Time 2min 20sec 1sec 20sec 
Table 2.9 Thermal cycling conditions for TaqMan assays. 
 
2.10. Target Overexpression 
Overexpression of targets LY6G6F and IL1RAPL1 was carried out using commercial 
transfection ready cloning vectors (GenScript). These ORF cDNA clones come as protein-
coding, expression-ready genes in vectors tagged for protein detection and purification. Both 
the LY6G6F sequence (Clone ID: OHu03468) and the IL1RAPL1 sequence (Clone ID: 
OHu19152) are cloned into pcDNA3.1+/C-(K)DYK vectors, with a C-terminal 
DYKDDDDK tag (FLAG-tag), which will allow confirmation of overexpression by Western 
blot analysis. An empty pcDNA3.1+/C-(K)DYK vector (containing no target ORF) was also 
obtained as a negative control. Figure 2.1 shows the map of the pcDNA3.1+/C-(K)DYK 
vector. The vector contains Amp and Neo genes for antibiotic selection of bacterial and 
mammalian transformed cells.  
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Figure 2.1 Vector map of the cloning vectors used for LY6G6F and IL1RAPL1 overexpression. 
Gene expression is driven by a CMV promoter. Kozak sequence initiates the mRNA translation 
process into protein.  A C-terminal DYKDDDDK tag (FLAG-tag) is attached to the target sequence.  
 
2.10.1. Optimisation of Vector Transfection Conditions 
MIA PaCa-2 and SW480 cells were transfected with overexpression/empty vectors using 
Lipofectamine 2000 transfection reagent. Prior to this the optimal transfection conditions for 
vector transformation were determined. The optimal cell number for transfection of these 
cells was already determined in Section 2.4.1. In order to determine the optimal 
Lipofectamine 2000 and vector concentration, cells were transfected with varying 
concentrations of a N44 constitutive GFP expression plasmid (1µg, 2.5µg, 5µg) and varying 
concentrations of Lipofectamine 2000 (2µl and 3µl), to quickly determine efficiency by 
looking for GFP expression under fluorescent microscope. 72 hrs post transfection, the cells 
were assessed for GFP expression under fluorescent microscope, with the optimal conditions 
taken as those giving maximum GFP expression. The optimal conditions chosen for both 
cells lines were: 2.5 µg vector + 2 µl Lipofectamine 2000. 
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2.10.2. G418 Kill Curve 
Selection of vector transformed cells is carried out by antibiotic selection. The vectors being 
used contain the Neo gene, which enables cells to survive in the presence of Neomycin and 
G418 antibiotics. Therefore prior to target vector transformation of MIA PaCa-2 and SW480 
cells, an antibiotic kill curve needed to be carried out to determine the optimal concentration 
required to kill all cells. Cells were set up in 24 well plates and treated with concentrations 
of G418 (Sigma: 4727878001) ranging from 200-2000µg/ml. The optimal dose is the lowest 
antibiotic concentration at which all cells are dead after one week of antibiotic selection. 
Cells were fed with fresh G418 containing medium every 2-3 days. The optimal G418 dose 
for SW480 cells was determined to be 1400µg/ml and for MIA PaCa-2 cells, 1600µg/ml.  
 
2.10.3. Generation of Stable Target Overexpression Cell Lines 
Following the determination of optimal vector transfection conditions and G418 dose 
required, SW480 / MIA PaCa-2 cells were set up in 6 well plates and transfected with 2.5µg 
of LY6G6F/IL1RAPL1/Empty vector. A cells only well was also set up. 48hrs post-
transfection cells were placed into G418 antibiotic selection. The cells only well acts as a 
control showing the length of time it takes for complete cell death of un-transfected cells. 
Cells that have survived in the transfected wells i.e. that have been successfully transformed 
with the vector are allowed to grow until confluency in the 6 well plate, kept under continuous 
G418 selection. When confluent, cells are transferred to T75 flasks for continuous culture. 
Cells are maintained in G418 selection media for 3 passages to ensure complete selection of 
stably transformed cells. At this stage cells can be cryopreserved as a new cell line, as the 
cell line has been changed from the original to a new stable mixed population. Stable cell 
lines are then grown in regular culture medium, with a routine pulse of G418 containing 
medium every 3 passages, to ensures that the transgene is retained. Confirmation of target 
gene overexpression is determined by qRT-PCR analysis as described in Section 2.9. 
Confirmation of protein overexpression is determined by Western blot analysis as described 
in Section 2.3, with the presence of the FLAG-tag confirming vector protein expression.  
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2.11. Co-Immunoprecipitation (Co-IP) 
Attempts at Co-IP of targets LY6G6F and IL1RAPL1 were carried out using two independent 
LY6G6F antibodies (Abcam ab62597 and LSBIO LS-C148408), and two independent 
IL1RAPL1 antibodies (Proteintech 21609-1-AP and Sigma WH0011141M4). Two different 
methods of IP were tried – Direct/traditional IP and cross-linked IP. However, neither target 
protein was successfully immunoprecipitated by either method.  
 
2.11.1. Direct Immunoprecipitation 
This method is also known as traditional immunoprecipitation. Proteins were isolated from 
cell lines using a gentle lysis buffer (Thermo Fisher Scientific, #87787) to preserve protein 
complexes using the method described in Section 2.3.1. Protein extracts were quantified 
using as described in Section 2.3.4. Samples were diluted to a concentration of 1 mg/mL in 
a final volume of 1 mL using the gentle lysis buffer.  Protein-G agarose beads (Sigma, P3296) 
were washed x3 in PBS before being added to the 1 mL test aliquot of protein extract for pre-
clearing. 60 µL of Protein-G beads were added to the sample using a cut P-1000 pipette tip 
to minimise damage to the beads. All samples were incubated for 4 hours at 4°C on a rocking 
platform for pre-clearing. Beads were removed by spinning at 1000 g for 1 minute at 4°C. 
Supernatants were removed to clean Eppendorf tubes and divided evenly to represent the test 
sample and the negative control.  The primary antibody of interest was added to the test 
sample, and IgG matching the host species of the primary antibody was added to the negative 
control. Antibody/lysate mixtures were incubated at 4°C overnight on a rocking platform. 
The following day, in order to precipitate the antibody-antigen complex, newly prepared 
Protein- G agarose beads were added to the samples as before and incubated at 4°C for 4 
hours on a rocking platform. Beads were removed by spinning at 1000 g for 1 minute at 4°C, 
and the supernatant was saved as the ‘unbound fraction’. The beads were then washed for 5 
x 2-minute periods with gentle lysis buffer and pelleted at 1000 g between each wash for 1 
minute. Following the final wash, the sample/bead solution was transferred to a spin column 
(Sigma, SC1000) before another centrifugation step as before.  70 µL of 2X Laemelli sample 
buffer was added to both sets of Protein-G beads before being heated to 95°C on a heating 
block. Samples were spun at 12000 g for 2 minutes and eluted into fresh Eppendorf tubes. 
Elutions were made to a 1x concentration with PBS and were stored at -20°C until required.  
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2.11.2. Cross-Linked Immunoprecipitation 
Cross Linked IP were carried out using the Pierce Co-Immunoprecipitation Kit (Thermo 
Fisher Scientific, #26149). 200 µL of AminoLink resin was added to a spin column, and spun 
down at 1000 g for 1 minute (all subsequent centrifugation steps were at this speed and 
duration). The resin was washed twice with 0.4 mL of Coupling Buffer, centrifuged and 
excess solution discarded. The primary antibody of interest was added to the resin, along 
with 200 mL of Coupling Buffer (same for negative control IgG). 3 µL of Reducing Agent 
(Sodium Cyanoborohydride) was added to the mixture antibody/resin, which was then 
incubated at RT for 90 minutes. This step is to facilitate cross-linking of the antibody to the 
resin. The resin was then centrifuged and washed 2 times with 0.2 mL Coupling Buffer. 
Following this, 0.2 mL of Quenching Buffer was added to the suspension, centrifuged, and 
excess solution discarded. 0.4 mL of Quenching Buffer was then added to the gel/antibody 
complex, along with 3 µL of Reducing Agent. This suspension was incubated with end-over-
end mixing, for 30 minutes at room temperature, followed by centrifugation and discarding 
of any excess solution. The gel was then washed 2 times with 0.2 mL Quenching Buffer, 
followed by 6 washes in 0.4 mL Wash Solution, with centrifugation following each wash. 
The protein sample was prepared as described in Section 2.11.1, and added to the 
resin/antibody complex. This solution was incubated overnight at 4°C on a rocking platform. 
The following day, the sample was centrifuged, and excess solution discarded. The 
resin/antibody-antigen complex was then washed 3 times in 0.4 mL Immunoprecipitation 
Buffer, with centrifugation after each wash. The antigen/antibody complex was then eluted 
with the addition of 200 µL of a low pH Elution Buffer to the solution, followed by 5-minute 
incubation at room temperature. The low pH of the buffer was neutralised with the addition 
of 5 µL of a Tris-HCl, pH 9.5, solution. Elutions were made to a 1x concentration with PBS 
and were stored at -20°C until required. 
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Chapter 3. Identification and validation of 
novel membrane cancer targets 
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3.1. Identification of Potential Membrane Proteins Overexpressed in Colon Cancer 
Background: Colorectal cancer (CRC) is the 3rd most commonly diagnosed cancer 
worldwide, and also the 4th most common cause of cancer death. There is a huge need for the 
discovery of new treatment strategies for CRC. This study aimed to identify membrane-
localised proteins overexpressed in colon cancer compared to normal colon for investigation 
as potential molecular targets for therapeutic antibody targeting. Identified proteins would 
also be examined for increased expression in a number of other cancers, in particular 
pancreatic ductal adenocarcinoma (PDAC), which has a dismal prognosis with only a 5%      
5 year survival rate. There is an urgent unmet need for both a better understanding of the 
biological phenotype of PDAC and also for new therapeutic targets. There is a current lack 
of exploitable molecular targets for PDAC. 
The search for potential cancer targets began with an analysis of colon cancer gene 
expression microarray data available for download from the Gene Expression Omnibus 
(GEO) database, as described in Section 2.1. The GEO database contains datasets from 
hundreds of different technologies/platforms, including mRNA gene expression arrays, 
miRNA arrays and RNA-seq. The criteria for our search was for colon cancer datasets with:  
1) Normal human colon and colon carcinoma tissue sections used for the analysis (as 
opposed to cell line data). 
2) Data presented as gene expression level. 
3) Microarray platform used was Affymetrix U133 plus 2.0 arrays. 
With these criteria, a dataset by Skrzypczak et al., (2010) was chosen for analysis. This 
dataset contains whole tissue section samples from 24 normal colon, 45 colon adenoma and 
36 colon adenocarcinoma specimens. From this data, two lists were generated in-house of 
genes upregulated in (1) colon adenocarcinoma vs. normal colon and (2) colon adenoma vs. 
normal colon. Genes were then annotated for membrane localisation using Pathway Studio 
Enterprise software and a fold change of ≥ 2 and an adjusted p-value of  ≤ 1E-5 were 
considered significant. This produced the final lists of predicted membrane localised genes, 
with 127 genes found to be upregulated in adenocarcinoma compared to normal colon and 
154 genes upregulated in adenoma compared to normal colon. 
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These gene datasets were then manually curated by literature review and also commercial 
antibody availability to select genes for validation. The literature mining of targets aimed to 
eliminate proteins that had already been associated with a functional role in colon cancer or 
as a potential therapeutic target. Relatively novel cancer targets were sought for validations. 
With these criteria 7 genes were chosen for validation from across the two lists. They are: 
Lymphocyte antigen 6 complex, locus G6D/F (LY6G6D/F), Interleukin 1 receptor accessory 
protein / -like 1 (IL1RAP/L1), Neurotrimin (NTM), Leucine rich repeat containing 8 family, 
member E (LRRC8E), Epoxide hydrolase 4 (EPHX4), Beta-site APP-cleaving enzyme 2 
(BACE2) and Interleukin 20 receptor, subunit Alpha (IL20RA). Whether the genes came 
from the adenoma list, adenocarcinoma list or both, as well as their relevant fold change is 
described in Table 3.1.  
 
Gene Name Full Name  Adenoma 
fold change  
Carcinoma 
fold change 
LY6G6D Lymphocyte antigen 6 complex, locus G6D 9.8 17.6 
IL1RAP Interleukin 1 receptor accessory protein - 2 
NTM Neurotrimin - 5.4 
LRRC8E Leucine rich repeat containing 8 family, 
member E 
4.4 3.2 
EPHX4 Epoxide hydrolase 4 4.8 8.9 
BACE2 Beta-site APP-cleaving enzyme 2 6 2.7 
IL20RA Interleukin 20 receptor, subunit Alpha 4.2 - 
Table 3.1 Candidate gene targets selected for protein validation.  The up linear fold change for 
each target in adenoma and carcinoma compared to normal colon is displayed. No number indicates 
that the candidate target was not present on that list.  
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3.2. Validation of Candidate Target Protein Expression  
As the candidate targets were identified from mRNA overexpression, there is no guarantee 
that the corresponding protein will be similarly overexpressed. Furthermore, confirmation of 
the subcellular localisation of these predicted membrane proteins is required. Target protein 
expression was first examined in a panel of colon cancer cell lines by Western blot analysis, 
followed by a preliminary Immunohistochemistry (IHC) screen for protein expression in 
normal colon and colon adenocarcinoma tissue sections. The initial validations were to 
determine 1) is the protein expressed? and 2) is it expressed at a higher level in colon cancer 
compared to normal colon (with minimal normal colon expression)? 
A panel of 6 colon cancer cell lines (listed in Table 3.2) was used to investigate target protein 
expression. Both the whole cell lysate and a membrane enriched fraction (sample preparation 
is described in Section 2.3.2) of each cell line were examined for target expression, to 
determine if the target protein is expressed across these cell lines and, if it is associated with 
the membrane. The whole cell lysate can be used to determine differences in expression 
between the cell lines, with alpha-tubulin used as an internal loading control, to confirm equal 
loading of samples. However, the membrane enriched fraction in this study is being used as 
a qualitative assessment of whether the protein is membrane associated in the cells. Due to 
sample preparation variation and the lack of a suitable loading control, the membrane 
fractions cannot be used to accurately compare membrane localised expression between cell 
lines, but can validate if target expression is associated with the plasma membrane in these 
cells. The panel of cell lines represent several different mutations commonly found in CRC 
(see Table 3.2). An initial IHC screen of formalin-fixed, paraffin-embedded (FFPE) full-face 
tissue sections of normal colon and colon adenocarcinoma, obtained from St. Vincent’s 
University Hospital, was then carried out. Before this, optimisation of IHC conditions and 
antibody dilutions for each target was completed, with the final conditions used described in 
Section 2.6.2. These results would determine whether candidate targets were suitable for 
wider tissue expression validations and assessment of their functional role, if any, in cancer.  
The protein validation results for each of the seven selected candidate targets are shown in 
Sections 3.2.1-3.2.8. Out of the seven selected candidate targets, only LY6G6F and 
IL1RAPL1, were observed to be strongly expressed in colon adenocarcinoma tissue sections, 
with minimal expression in normal colon. The protein expression of targets LRRC8E and 
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EPHX4 could not be validated in tissue sections by Immunohistochemical analysis. The 
remaining three targets, NTM, IL20RA and BACE2, all showed similar protein expression 
levels in normal colon and colon adenocarcinoma tissue sections, indicating no apparent 
overexpression in cancer vs. normal tissue. Therefore, only LY6G6F and IL1RAPL1 were 
selected to pursue further for wider tissue expression validations, assessment of any 
functional role in cancer in vitro, and investigation as potential molecular targets for 
therapeutic antibody targeting.  
 
 
Cell	line	 KRAS	 BRAF	 PIK3CA	 PTEN	 TP53	 Source	
SW480*	 G12V	 WT	 WT	 WT	 R273H;
P309S	
Dukes’	type	B	colorectal	
adenocarcinoma	
SW620*	 G12V	 WT	 WT	 WT	 R273H;
P309S	
Dukes’	type	C	colorectal	
adenocarcinoma,	derived	from	
lymph	node	metastasis	
HCT116	 G13D	 WT	 H1047R	 WT	 WT	 Dukes’	type	D	colorectal	
carcinoma	
T84	 G13D	 WT	 E542K	 WT	 WT	 Colorectal	carcinoma	derived	
from	lung	metastasis	
HT29	 WT	 V600E	 P449T	 WT	 R273H	 Dukes’	type	C	colorectal	
adenocarcinoma	
CaCo-2	 WT	 WT	 WT	 WT	 E204X	 Colorectal	adenocarcinoma	
Table 3.2 Colon cancer cell line panel used in this study, showing some of the common mutations 
found in CRC and the original source of the cell line. *SW480 and SW620 cell lines are derived 
from the same patient – SW480 from the primary colon adenocarcinoma tumour and SW620 from a 
lymph node metastasis. WT, wildtype genotype. 
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3.2.1. Validation of LY6G6D/F Protein Expression 
LY6G6D showed an increased fold change of 17.6 in the colon adenocarcinoma dataset and 
9.8 in the adenoma dataset compared to normal colon. The Affymetrix probe set for this gene 
is stated to not be unique and unable to distinguish between LY6G6D and LY6G6F. The 
antibody sourced for validations is an anti-LY6G6F antibody (which lists LY6G6D as an 
alias). There is some confusion in the literature surrounding these genes, with LY6G6F being 
described as a transcript of the LY6G6D gene in some sources. (Calvanese et al., 2008) This 
will be described in greater detail in Chapter 4, Section 4.1. LY6G6F is a type 1 
transmembrane protein, belonging to the immunoglobulin (Ig) superfamily and was first 
identified as a novel platelet plasma membrane protein. The cytoplasmic tail of LY6G6F is 
capable of interacting with growth-factor-receptor-bound protein (Grb) 2 and Grb7. (de Vet, 
Aguado and Campbell, 2003; Macaulay et al., 2007) However, a potential ligand for 
LY6G6F activation has not yet been discovered.  
 
3.2.1.1. Western Blot Analysis 
LY6G6F expression was investigated in the whole cell lysate and membrane enriched 
fraction of the colon cancer cell line panel. Representative Western blot images of these 
results are shown in Figure 3.1. LY6G6F specific bands were identified at the predicted 
molecular weight (MW) of 32kDa. LY6G6F is expressed in the whole cell and membrane 
enriched fraction of all of the cell lines probed, indicating an association with the membrane 
in these colon cancer cells. Highest expression is observed in the T84 and HT29 cell lines. 
There appears to be no apparent trend of LY6G6F expression towards a particular mutational 
status in this subset of colon cancer cell lines.  
 
3.2.1.2. Immunohistochemical Analysis  
The investigation of LY6G6F expression in normal colon and colon adenocarcinoma tissue 
sections confirmed the increased expression of LY6G6F at the protein level in colon 
adenocarcinoma. Negative or weak LY6G6F immunoreactivity was observed in normal 
colon. In contrast, intense LY6G6F immunoreactivity was observed in colon 
adenocarcinoma tissue. Figure 3.2 shows representative photomicrographs of these results.  
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Figure 3.1 Representative Immunoblot showing LY6G6F expression in the whole cell and 
membrane enriched fractions of a panel of colon cancer cell lines. LY6G6F bands are identified 
between the 30-40 kDa MW markers, showing the correct MW of ~32kDa. α-tubulin confirms equal 
loading of total proteins in the whole cell lysate. (n=2) 
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Figure 3.2 IHC analysis of LY6G6F expression in normal and malignant colon. Representative 
images showing: (A) Normal colon with negative immunoreactivity. (n=7) (B, C, D) Colon 
adenocarcinoma with strong granular cytoplasmic immunoreactivity. (n=12) Original magnification 
400x. The scale bars represent 100µm. 
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3.2.2. Validation of IL1RAPL1 Protein Expression 
Interleukin 1 receptor accessory protein (IL1RAP) was identified from the datasets, with a 2 
fold increase in colon cancer compared to normal colon. However, a transcription error 
resulted in an antibody against Interleukin 1 receptor accessory protein like 1 (IL1RAPL1) 
being obtained for validation. IL1RAP and IL1RAPL1 are both members of the interleukin-
1 receptor (IL-1R) family. The IL1RAPL1 gene encodes a protein that has homology to 
IL1RAP, however they have distinct functions. IL1RAP is a necessary accessory protein part 
of the interleukin 1 receptor complex, which initiates signalling upon IL-1 binding. (Boraschi 
and Tagliabue, 2013) IL1RAP overexpression has been implicated in a number of 
haematological malignancies, including myelodysplastic syndrome, acute myeloid 
leukaemia (AML) and chronic myeloid leukaemia (CML). (Barreyro et al., 2012; Zhao et 
al., 2014) IL1RAPL1 has been suggested to have a specialised role in physiological processes 
in the brain, including learning abilities, and mutations in the IL1RAPL1 gene have been 
identified in patients suffering from nonspecific X-linked intellectual disability. (Chelly et 
al., 1999; Piton et al., 2008) In this study IL1RAPL1 overexpression was observed in CRC 
vs. normal colon. IL1RAPL1 is a novel CRC target, with no previous links to CRC described 
in the literature. Therefore, it was decided to continue with IL1RAPL1 as a candidate target 
for further validations. 
 
3.2.2.1. Western Blot Analysis  
The investigation of IL1RAPL1 expression in the colon cancer cell line panel, revealed bands 
at ~69kDa, corresponding to the predicted MW of IL1RAPL1. IL1RAPL1 protein is 
expressed in both the whole cell lysate and membrane enriched fraction of all cell lines 
investigated, indicating an association with the membrane in these cell lines. IL1RAPL1 is 
expressed at similar levels across the panel, with highest expression observed in the HCT116 
cell line. Representative Western blot images are shown in Figure 3.3. 
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3.2.2.2. Immunohistochemical Analysis  
The investigation of IL1RAPL1 expression in normal colon and colon adenocarcinoma tissue 
sections showed increased expression of IL1RAPL1 in colon adenocarcinoma compared to 
normal colon. Negligible IL1RAPL1 expression was observed in normal colon, with strong 
IL1RAPL1 immunoreactivity observed in adenocarcinoma tissue, which is shown in Figure 
3.4. The preliminary IHC validation shows that IL1RAPL1 is overexpressed in CRC 
compared to normal colon, and as IL1RAPL1 is a novel target in CRC, we decided to pursue 
it further. 
 
 
 
 
Figure 3.3 Representative Immunoblot showing IL1RAPL1 expression in the whole cell and 
membrane enriched fraction of a panel of colon cancer cell lines. IL1RAPL1 bands are identified 
between the 60-80 kDa MW markers, indicating the correct MW of ~69kDa. α-tubulin levels indicate 
nearly equal loading of total proteins in the whole cell lysate. (n=2) 
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Figure 3.4 IHC analysis of IL1RAPL1 expression in normal and malignant colon. Representative 
images showing: (A) Normal colon with minimal IL1RAPL1 immunoreactivity. (n=7) (B, C, D) 
Colon adenocarcinoma with strong granular cytoplasmic IL1RAPL1 immunoreactivity. (n=12) 
Original magnification 400x. The scale bars represent 100µm. 
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3.2.3. Validation of LRRC8E Protein Expression 
LRRC8E (Leucine-rich repeat-containing protein 8E) is a multi-pass membrane protein 
which contains 13 LRR (leucine-rich) repeats, and is a component of the volume-regulated 
anion channel (VRAC), an anion channel required to maintain a constant cell volume in 
response to extracellular or intracellular osmotic changes. (Ng and Xavier, 2011) LRRC8E 
showed a 4.4 fold increase in expression in the adenoma dataset and 3.2 fold increase in the 
adenocarcinoma dataset compared to normal colon.  
 
3.2.3.1. Western Blot Analysis 
The investigation of LRRC8E expression in the colon cancer cell line panel by Western blot 
analysis, revealed bands at ~90kDa, the predicted MW of LRRC8E. LRRC8E is expressed 
at similar levels across the whole cell line panel, and is also present in the membrane fraction 
of all cell lines analysed. These results are shown in Figure 3.5. 
 
3.2.3.2. Immunohistochemical analysis  
The optimisation of LRRC8E antibody for IHC analysis was unsuccessful. No LRRC8E 
immunoreactivity was detected in normal colon or colon adenocarcinoma, even with high 
antibody dilutions used. (Data not shown) 
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Figure 3.5 Western blot analysis showing LRRC8E expression in the whole cell and membrane 
enriched fraction of a panel of colon cancer cell lines. LRRC8E bands are identified between the 
80-110 kDa MW markers, indicating the correct MW of ~90kDa. α- tubulin levels indicate nearly 
equal loading of total proteins in the whole cell lysate. (n=1) 
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3.2.4. Validation of EPHX4 Protein Expression 
Epoxide hydrolase 4 (EPHX4) is expressed at a 4.8 fold higher level in the adenoma cohort, 
increasing to 8.9 fold higher in the adenocarcinoma cohort, compared to normal colon. 
EPHX4 is a single pass type II transmembrane protein. Epoxide hydrolases are critical 
biotransformation enzymes that activate and detoxify epoxides. (Omiecinski, Yang and 
Laurenzana, 2012) 
 
3.2.4.1. Western Blot Analysis 
The investigation of EPHX4 expression in the colon cancer cell line panel by Western blot 
analysis, revealed bands at ~40kDa, the predicted MW of EPHX4. EPHX4 is expressed in 
both the whole cell lysate and the membrane enriched fraction of every cell line analysed. 
EPHX4 is expressed at similar levels across the whole panel. Figure 3.6 shows the results of 
the Western blot analysis. 
 
3.2.4.2. Immunohistochemical Analysis 
The IHC analysis to investigate EPHX4 expression in normal colon and colon 
adenocarcinoma sections was unsuccessful. No EPHX4 immunoreactivity was detected in 
tissue sections, including positive control tissues, even using high antibody concentrations. 
The antibody may not have been working correctly or EPHX4 protein was not expressed in 
the tissues analysed. (Data not shown) 
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Figure 3.6 Western blot analysis showing EPHX4 expression in the whole cell and membrane 
enriched fraction of a panel of colon cancer cell lines. EPHX4 bands are identified around the 
40kDa MW marker, the predicted MW of EPHX4. α- tubulin levels indicate nearly equal loading of 
total proteins in the whole cell lysate (n=1) 
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3.2.5. Validation of NTM Protein Expression 
Neurotrimin (NTM) is a glycosylphosphatidylinositol (GPI)-anchored membrane protein 
belonging to the IgLON family of neural cell adhesion molecules. IgLONs have been 
identified primarily in the central nervous system, where they are the most abundantly 
expressed GPI-anchored proteins. Ntougkos et al., (2005) investigated the expression 
profiles of the IgLON family in ovarian cancer, and found that NTM expression is increased 
in tumour samples in relation to non-malignant ovary.  NTM displayed a 5.4 fold increase in 
gene expression in colon adenocarcinoma compared to normal colon in the gene microarray 
datasets. 
 
3.2.5.1. Western Blot Analysis 
NTM is described as having 4 isoforms produced by alternative splicing by Uniprot; isoform 
1: 38kDa, isoform 2: 38kDa, isoform 3: 35kDa and isoform 4: 39kDa. Additionally, a 
glycosylated form at ~58kDa has also been reported in the literature. Western blot analysis 
for NTM expression in the colon cancer cell line panel produced very poor results, as shown 
in Figure 3.7. Multiple bands and high background made it impossible to correctly identify 
the NTM protein band. A second anti-NTM antibody was also tested, but this was also unable 
to reliably detect the correct band.  
 
3.2.5.2. Immunohistochemical Analysis  
Investigation of NTM expression in normal colon and colon adenocarcinoma, showed high 
expression in some normal colon tissues, with similar expression in the adenocarcinomas 
analysed. Therefore, NTM does not appear to be upregulated at the protein level in colon 
tumours compared to normal colon. Figure 3.8 shows some representative photomicrographs 
of these results. 
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Figure 3.7 Western blot showing the whole cell and membrane enriched fraction of a panel of 
colon cancer cell lines probed for NTM. Multiple bands and high background prevented the 
identification of the correct NTM band. α-tubulin shows equal loading of total proteins in the whole 
cell lysate. (n=1) 
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Figure 3.8 IHC analysis of NTM expression in normal and malignant colon. Representative 
images showing: (A, B) Normal colon with moderate to strong granular cytoplasmic 
immunoreactivity. (n=16) (C, D) Colon adenocarcinoma with strong granular cytoplasmic 
immunoreactivity. (n=12) Original magnification 400x. The scale bars represent 100µm. 
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3.2.6. Validation of IL20RA Protein Expression 
IL20RA is a single pass type 1 membrane protein that forms a receptor complex with IL20RB 
for IL-20. It is also capable of forming a complex with IL10R2 for IL-26. IL20RA was found 
to be 4.2 fold up in the adenoma dataset compared to normal colon, but was not identified in 
the adenocarcinoma dataset. However, we still sought to validate its expression, as it may 
represent a potential marker for progression from normal colon to adenoma and then 
adenocarcinoma and a role for IL20RA in CRC has not been described to date to our 
knowledge. Elevated levels of IL-20, IL20RA and IL20RB are found in psoriasis and 
rheumatoid arthritis. IL20RA and IL20RB mRNA was also found to be expressed in colon, 
colonic supepithelial myofibroblasts and colonic epithelial cell lines. The expression of IL-
20 and its receptors has also been linked to atherosclerosis. (Blumberg et al., 2001; Wei et 
al., 2006; Wegenka, 2010)   
 
3.2.6.1. Western Blot Analysis 
The investigation of IL20RA expression in the colon cancer cell line panel, revealed bands 
at ~62kDa, corresponding to the predicted MW of IL20RA. IL20RA is expressed across all 
cell lines analysed, in both the whole cell and membrane enriched fractions, as shown in 
Figure 3.9. Considerably higher expression is observed in the metastatic SW620 cell line 
compared to the primary tumour cell line, SW480, derived from the same patient. IL20RA 
also displays higher expression in the T84 cell line, which is derived from a lung metastasis, 
compared to some of the other cell lines. Therefore, IL20RA expression could have a 
potential association with metastatic colon adenocarcinomas.  
 
3.2.6.2. Immunohistochemical Analysis 
IHC analysis of IL20RA expression in normal colon and colon adenocarcinoma tissue 
sections, showed intense membrane immunoreactivity in adenocarcinoma tissue. A tissue 
section of colon cancer metastasised to liver, showed intense IL20RA membrane 
immunoreactivity in the colon cancer metastasis with low levels of IL20RA in surrounding 
liver tissue. However strong immunoreactivity was also observed in normal colon. Figure 
3.10 shows representative photomicrographs of these results. Therefore, this preliminary IHC 
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study shows that there does not appear to be differential expression of IL20RA at the protein 
level between normal colon and colon adenocarcinoma. 
 
 
 
Figure 3.9 Western blot analysis showing IL20RA expression in the whole cell and membrane 
enriched fraction of a panel of colon cancer cell lines. IL20RA bands are identified between the 
60-80 kDa MW markers, indicating the correct MW of ~62kDa. α-tubulin shows equal loading of 
total proteins in the whole cell lysate. (n=1) 
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Figure 3.10 IHC analysis of IL20RA expression in normal and malignant colon. Representative 
images showing: (A) Normal colon with strong cytoplasmic and membranous immunoreactivity. 
(n=2) (B) CRC that has metastasised to liver with intense membrane immunoreactivity. (n=1) (C, D) 
Colon adenocarcinoma with strong cytoplasmic and membranous immunoreactivity. (n=4) Original 
magnification 400x. The scale bars represent 100µm. 
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3.2.7. Validation of BACE2 Protein Expression 
BACE2 is an aspartyl protease that is involved in the production of amyloid-β protein, the 
principal component of the senile plaques that are an early and critical feature of Alzheimer’s 
disease and a frequent complication of Down syndrome. (Farzan et al., 2000) BACE2, an 
integral membrane glycoprotein, showed a 6 fold increase in expression in the adenoma 
dataset and 2.7 fold increase in the adenocarcinoma dataset compared to normal colon.  
 
3.2.7.1. Western Blot Analysis 
The investigation of BACE2 expression in the colon cancer cell line panel by Western blot 
analysis, revealed bands at ~56kDa, the predicted MW of BACE2. BACE2 is expressed in 
all of the colon cancer cell lines analysed, with highest expression observed in the whole cell 
lysate of the SW620 cell line, showing higher expression in the metastatic tumour compared 
to primary (SW480) tumour derived from the same patient. BACE2 is also associated with 
the membrane of all cell lines, as shown in Figure 3.11.  
 
3.2.7.2. Immunohistochemical Analysis 
The IHC analysis of BACE2 confirmed expression in colon adenocarcinoma tissue sections. 
However, the expression in normal colon was also quite high. Figure 3.12 shows some 
representative photomicrographs of this result. Therefore, BACE2 may not be sufficiently 
overexpressed in colon adenocarcinoma compared to normal colon, to warrant further 
investigation as a potential molecular target for therapeutic antibody targeting.  
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Figure 3.11 Western blot analysis showing BACE2 expression in the whole cell and membrane 
enriched fraction of a panel of colon cancer cell lines. BACE2 reactive bands are identified 
between the 50-60 kDa MW markers, indicating the correct MW of ~56kDa. α- tubulin levels confirm 
equal loading of total proteins in the whole cell lysate. (n=1) 
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Figure 3.12 IHC analysis of BACE2 expression in normal and malignant colon. Representative 
images showing: (A, B) Normal colon with moderate cytoplasmic immunoreactivity in areas. (n=3) 
(C, D) Colon adenocarcinoma with moderate to strong granular cytoplasmic immunoreactivity. (n=5) 
Original magnification 400x. The scale bars represent 100µm. 
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3.2.8. Further preliminary investigation of IL20RA and BACE2 expression  
The protein expression of targets IL20RA and BACE2 was validated in both the colon cancer 
cell line panels and in colon adenocarcinoma tissue sections (Sections 3.2.6 and 3.2.7). 
However, the immunoreactivity observed in normal colon tissues, was similar to the levels 
observed in colon adenocarcinoma, indicating that IL20RA and BACE2 are not 
overexpressed in colon cancer compared to normal colon at the protein level. As IL20RA 
and BACE2 both represent potential novel cancer targets, it was decided to carry out some 
further analysis of these targets to investigate their expression in other tissues also. 
Immunohistochemical analysis was carried out to assess their expression in a limited number 
of normal tissues and also in PDAC and oesophageal cancer, to determine if they display any 
relevance in other cancer types, which would warrant further investigation of IL20RA and 
BACE2 as potential molecular targets for therapeutic antibody targeting.  
Table 3.3 and Table 3.4 outline the results of the IHC analysis for BACE2 and IL20RA. 
BACE2 was found to be expressed in all normal colon tissues analysed, with intensity 
ranging from weak to moderate depending on the area of the tissue and only displayed strong 
immunoreactivity in 2/5 CRC tissues analysed. BACE2 expression was assessed in PDAC 
by analysing a commercial TMA that contained 10 normal pancreas and 39 PDAC cores 
(PA1001, US Biomax Inc). BACE2 showed strong cytoplasmic and membrane 
immunoreactivity in 43.6% of the PDAC specimens. However strong cytoplasmic 
immunoreactivity was also observed in 50% of the normal pancreas tissues analysed. Normal 
oesophagus and oesophageal cancer both showed weak BACE2 immunoreactivity. Normal 
gastric tissue had negligible BACE2 expression and normal duodenum showed weak 
expression. Figure 3.13 shows some representative images of this IHC analysis.  
IL20RA showed strong membrane immunoreactivity in CRC, however normal colon also 
had strong expression. A similar result was observed in PDAC, with strong membrane 
immunoreactivity observed in PDAC tissues, but strong cytoplasmic immunoreactivity also 
observed in the small cohort of normal pancreas analysed. IL20RA also showed strong 
expression in normal duodenum and tonsil, with weak expression observed in normal gastric 
tissue and liver. Normal oesophagus and oesophageal cancer both showed weak and diffuse 
IL20RA immunoreactivity. Figure 3.14 shows some representative images of this IHC 
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analysis. This preliminary IHC analysis showed no apparent overexpression of BACE2 or 
IL20RA in the cancer types examined, therefore these targets were not pursued further. 
 
 
BACE2 expression 
Normal tissue  Corresponding cancer tissue  
Duodenum (1/1 some weak expression) - 
Gastric (0/1 negligible expression) - 
Colon (3/3 weak to moderate in different 
areas of tissue) 
CRC (3/5 weak; 2/5 strong expression) 
Pancreas (5/10 weak; 5/10 strong) PDAC (22/39 weak; 17/39 strong) 
Oesophagus (1/1 weak diffuse) Oesophageal cancer (1/1 weak) 
Table 3.3 BACE2 expression in normal and cancer tissues. The number of sections that showed 
positive BACE2 immunoreactivity out of the total number analysed is listed in brackets.  
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IL20RA expression 
Normal tissue  Corresponding cancer tissue  
Duodenum (2/2 strong expression) - 
Gastric (1/1 weak expression) - 
Liver (1/1 weak diffuse) - 
Colon (2/2 strong in epithelial layer) CRC (5/5 strong expression) 
Pancreas (2/2 strong diffuse) PDAC (5/5 moderate to strong membrane 
immunoreactivity) 
Oesophagus (1/1 weak diffuse) Oesophageal cancer (1/1 weak diffuse) 
Tonsil (8/8 strong) - 
Table 3.4 IL20RA expression in normal and cancer tissues. The number of sections that showed 
positive IL20RA immunoreactivity out of the total number analysed is listed in brackets.  
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Figure 3.13 IHC analysis of BACE2 expression in normal and cancer tissues. Representative 
images showing: (A) Normal duodenum with some weak immunoreactivity. (n=1) (B) Normal colon 
with weak to strong BACE2 immunoreactivity depending on the area. (n=3) (C) Normal oesophagus 
with weak and diffuse BACE2 immunoreactivity. (n=1) (D) Malignant oesophagus with weak 
immunoreactivity. (n=1) (E) Normal pancreas with strong diffuse cytoplasmic immunoreactivity. 
(n=10) (F) PDAC with strong cytoplasmic BACE2 immunoreactivity. (n=39) Original magnification 
400x. The scale bars represent 100µm. 
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Figure 3.14 IHC analysis of IL20RA expression in normal and cancer tissues. Representative 
images showing: (A) Normal duodenum with strong immunoreactivity. (n=2) (B) Normal colon with 
strong immunoreactivity in the epithelial layer. (n=2) (C) Normal oesophagus with weak and diffuse 
immunoreactivity. (n=1) (D) Malignant oesophagus with weak/negligible immunoreactivity. (n=1) 
(E) Normal pancreas with strong diffuse cytoplasmic immunoreactivity. (n=2) (F) PDAC with strong 
membrane IL20RA immunoreactivity. (n=5) Original magnification of A-E: 200x, scale bars 
represent 200µm; F: 400x, scale bars represent 100µm. 
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3.3. Summary 
Out of the seven candidate gene targets chosen for validation at the protein level in normal 
colon and colon adenocarcinoma tissue sections, only two targets, LY6G6F and IL1RAPL1, 
met the criteria of 1) the protein is expressed and 2) the protein is expressed at a higher level 
in colon cancer vs. normal colon. The IHC analysis confirmed LY6G6F protein is 
overexpressed in colon adenocarcinoma vs. normal colon tissue sections. Minimal expression 
was observed in normal colon, with strong LY6G6F immunoreactivity observed in the cancer 
tissues. Similarly, IL1RAPL1 was found to be strongly expressed in colon adenocarcinoma 
tissues with negative or minimal expression in normal colon. IL1RAPL1 protein expression 
has been exclusively described in neuronal cells to date, with no links to CRC. Additionally, 
both LY6G6F and IL1RAPL1 protein expression was confirmed in the panel of colon cancer 
cell lines, which will enable in vitro functional analysis. Therefore, LY6G6F and IL1RAPL1 
were selected to pursue for further validation and investigation as potential molecular targets 
for therapeutic antibody targeting. 
Two candidate targets (EPHX4 and LRRC8E) could not be pursued further due to the 
inability to validate protein expression by IHC analysis. Due to the unconvincing IHC results 
for NTM (similar levels of expression observed in normal colon and CRC tissues) and the 
poor Western blot results, it was decided not to pursue NTM further as a candidate target at 
this stage. The expression of IL20RA was confirmed at the protein level and was the only 
target validated to show distinct membrane localisation in both CRC and PDAC tumours (an 
important feature for molecular targets to be utilised as ADC targets). However, IL20RA 
expression was also found to be high in normal colon and pancreatic tissues. BACE2 
exhibited a similar pattern, with strong expression observed in some CRC and PDAC 
tumours, but also in corresponding normal tissues. These results indicate that IL20RA and 
BACE2 are endogenously expressed at high levels in these tissue types, and as no distinct 
overexpression in the cancer tissues was observed, it appears that they would be unsuitable 
molecular targets for therapeutic targeting of these cancers. Therefore, IL20RA and BACE2 
were not selected to pursue further. 
Further validation of the expression of targets LY6G6F and IL1RAPL1 in colon cancer and 
also other cancer types, in particular PDAC, which has a high unmet need for new treatment 
strategies, is described in Chapters 4 and 5. The tissue expression pattern and cellular 
localisation of LY6G6F and IL1RAPL1 will be assessed, to establish if they represent 
molecular targets that may be amenable to therapeutic antibody targeting.  
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Chapter 4. LY6G6F 
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4.1. LY6G6F 
LY6G6D/F was identified from the gene microarray datasets as being significantly 
overexpressed in colon adenoma and colon adenocarcinoma compared to normal colon 
(Section 3.2.1). The preliminary IHC analysis with a commercial antibody specifically 
directed against LY6G6F confirmed this result at the protein level, with strong LY6G6F 
immunoreactivity observed in colon adenocarcinoma and minimal to weak expression 
observed in normal colon, see Section 3.2.1.2. On the basis of this observed differential 
expression in normal and cancer tissue, LY6G6F was selected to follow up for more 
extensive validation and investigation. 
The confusion in the literature surrounding the inability to distinguish between genes 
LY6G6D and LY6G6F, stems from the gene discovery and annotation. Both were originally 
annotated as G6D and G6F, and discovered as novel surface molecules encoded within the 
class III region of the human major histocompatibility complex (MHC). They are members 
of two different super-families, with G6D belonging to the lymphocyte antigen-6 superfamily 
and LY6G6F to the immunoglobulin (Ig) superfamily. (Ribas, Neville and Campbell, 2001) 
Figure 4.1 shows the genomic structure of G6F and G6D, with G6F consisting of 6 exons, 
G6D of 3 exons and they are separated by the gene LY6G6E. The confusion arises after they 
were annotated, LY6G6F and LY6G6D. A splice variant was discovered by Beliakov, 
Karakasheva and Mazurenko (2009), that contained exons from both G6F and G6D. They 
called this the MEGT1 transcript that consists of exons 1-4 of G6F, which then splice to 
exons 2 and 3 of G6D. This led them to annotate LY6G6D as one gene, containing transcripts 
G6F, G6D and MEGT1. There was considerable confusion from then on, with these genes 
listed as aliases of one another, and making it difficult to ascertain which transcript was being 
referred to when talking about LY6G6D. 
 
Figure 4.1 Genomic structure of the G6F, LY6G6E and LY6G6D genes. (Adapted from 
Calvanese et al., 2008) 
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However, this MEGT1 transcript has not been characterised and does not have its own gene 
accession number. The general consensus now when talking about these genes, refers to the 
original discovery of the distinct genes, with LY6G6F consisting of exons 1-6, LY6G6D of 
1-3, with no exons in common between the two genes. However, the persistence of the aliases 
for these genes (i.e. LY6G6D is listed as an alias of LY6G6F) still leads to considerable 
confusion. Table 4.1 shows the approved name, the chromosomal location and exon number 
for these genes. (Loughner et al., 2016) 
To clarify, the gene investigated in this study, is LY6G6F (Gene ID: 259215) with an exon 
count of 6, corresponding to the mRNA transcript for LY6G6F (Accession number: 
NM_00100369), which is 898bp in length, translating to a 297 amino acid (AA) long protein. 
With the confusion over aliases, it was ensured that all siRNA, antibodies, Taqman probes 
etc. used in this study correspond to this gene or protein transcript.  
 
 
Approved gene 
symbol (NCBI 
Gene ID #) 
Gene Name Aliases Genomic 
Location 
Number 
of exons 
LY6G6D 
(58530) 
Lymphocyte antigen 6 
complex, locus G6D 
G6D; NG25; LY6-D; 
MEGT1; C6orf23 
6p21.3 3 
LY6G6F 
(259215) 
Lymphocyte antigen 6 
complex, locus G6D 
G6f; NG32; LY6G6D; 
C6orf21 
6p21.33 6 
Table 4.1 Name, chromosomal location and number of exons for human LY6G6D and LY6G6F 
genes. (Adapted from Loughner et al., 2016) 
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LY6G6F is a type 1 transmembrane protein and as already described belongs to the Ig 
superfamily. LY6G6F contains two extracellular domains, the most N-terminal of which is a 
putative V-type Ig domain and contains a cytoplasmic tail that could be involved in signal 
transduction. (Ribas, Neville and Campbell, 2001; de Vet, Aguado and Campbell, 2003) G6F 
was identified as a novel megakaryocyte (MK) plasma membrane protein, with a suggested 
activatory role in platelet and MK signalling. Expression of G6F on the platelet surface was 
confirmed by flow cytometry on fixed platelets. (Macaulay et al., 2007) In another study the 
G6f protein was shown to be capable of interacting with both Grb2 and Grb7 (where Grb 
stands for growth-factor-receptor-bound protein), linking to downstream signal transduction 
pathways. They established that the cytoplasmic tail of G6f can bind the signalling adaptor 
proteins Grb2 and Grb7 and that these interactions are dependent on the phosphorylation of 
Y281 of G6f. The coupling of G6f with the Ras-MAP kinase pathway is strongly suggested 
following its interaction with Grb2. This pathway is involved in a variety of functions such 
as proliferation, differentiation, survival and apoptosis. The downstream pathways that 
connect with Grb7 are not well defined although its association with focal adhesion kinase 
(FAK) in a cell-adhesion-dependent manner suggests a role for Grb7 in integrin signalling. 
Further work is required to fully elucidate the effect of LY6G6F activation on cellular 
function, and a potential extracellular ligand for LY6G6F is yet to be discovered. (de Vet, 
Aguado and Campbell, 2003) 
In relation to cancer, LY6G6F gene expression has been listed as being significantly 
differentially expressed within microsatellite instable (MSI) colon tumours vs. microsatellite 
stable (MSS) tumours, being down-regulated in MSI tumours. (Slattery et al., 2015) LY6G6F 
was also reported as one of 29 proteins giving a Mucin 5AC (MUC5AC) hyposecretory 
phenotype in the human colonic adenocarcinoma cells HT29-18N2. (Mitrovic et al., 2013) 
Mucin genes, including MUC5AC, have been shown to be up-regulated in MSI tumours. 
(Pastrello et al., 2005) 
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4.2. Preliminary Analysis of LY6G6F Expression in PDAC, Oesophageal Cancer and 
Breast Cancer  
LY6G6F expression was confirmed to be overexpressed in a small number of colon 
adenocarcinomas compared to normal colon, as described in Section 3.2.1, which led to 
LY6G6F being selected for further investigation as a candidate cancer target. The next step 
was to investigate LY6G6F expression in a larger number of colon cancers, to determine if 
this overexpression compared to normal colon can be deemed significant. Before this a 
preliminary screen of other cancer types, including pancreatic cancer and breast cancer, was 
also carried out to determine if LY6G6F shows any differential expression in other cancer 
types, that would warrant further investigation. The results of this preliminary screen are 
described below. 
 
4.2.1. Immunohistochemical Analysis  
We had access to a limited number of tissue sections from a variety of different cancers, as 
well as normal tissue sections from those organs. Figure 4.2 shows representative 
photomicrographs of the results obtained for IHC analysis of LY6G6F expression in PDAC, 
breast cancer and oesophageal cancer. In the PDAC sections analysed, LY6G6F showed 
intense immunoreactivity in all cases, with negative or minimal immunoreactivity in normal 
pancreas. Some weak LY6G6F positive expression was observed in the ducts of normal 
breast, with a similar weak expression level observed in the majority of invasive breast cancer 
tissue sections analysed. Similarly, normal oesophagus displayed a negative/weak diffuse 
expression pattern for LY6G6F and the expression in the malignant oesophagus section 
analysed was also very weak. Therefore, increased expression of LY6G6F does not appear 
to be present in breast cancer or oesophageal cancer. However further investigation of 
LY6G6F expression was warranted in PDAC, as strong expression in PDAC compared to 
normal pancreas was observed.  
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Figure 4.2 IHC analysis of LY6G6F expression in normal and cancer tissues. Representative 
images showing: (A) Normal pancreas with negative LY6G6F immunoreactivity. (B) PDAC with 
strong LY6G6F immunoreactivity. (C) Normal breast with some weak and diffuse LY6G6F 
immunoreactivity in ductal tissue. (D) Breast cancer with moderate cytoplasmic immunoreactivity in 
areas. (E) Normal oesophagus with negligible LY6G6F immunoreactivity. (F) Malignant oesophagus 
with negligible immunoreactivity. Original magnification 200x. The scale bars represent 200µm. 
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4.2.2. LY6G6F Expression in PDAC and Breast Cancer Cell Line Panels  
LY6G6F expression in both the whole cell and membrane enriched fractions of colon cancer 
cell lines was confirmed, see Section 3.2.1.1. The expression of LY6G6F in a panel of PDAC 
cell lines and breast cancer cell lines was also investigated by Western blot analysis. A panel 
of eight PDAC cell lines was used in this study. Table 4.2 lists the original source of these 
cell lines, as well as indicating if mutations in the four major driver genes associated with 
PDAC – KRAS, TP53, p16 and SMAD4 are present in these cell lines. KRAS activating 
mutations are found in approximately 90% of PDAC tumours. One cell line in the panel is 
KRAS wildtype, the BXPC-3 cell line. Collisson et al., (2011) defined three pancreatic 
cancer subtypes, denoted as classical, quasi-mesenchymal (QM) and exocrine-like, based on 
their interpretation of subtype specific gene expression in tumour samples. The classical 
subtype had high expression of adhesion-associated and epithelial genes, the QM subtype 
had high expression of mesenchyme associated genes and the exocrine-like subtype showed 
relatively high expression of digestive enzyme genes. When they examined these subtypes 
in pancreatic cancer cell lines, they found no representative for the exocrine-like subtype, 
hypothesising that this subtype may have been an artefact of normal adjacent pancreas tissue 
in their analysis. Of the cell lines used in this study, three cell lines (BXPC-3, HPAC and 
Capan-2) represent the classical subtype, and the remainder (PANC-1, MIA PaCa-2, AsPC-
1, Capan-1 and SW1990) represent the QM subtype. Figure 4.3 shows the results of the 
Western blot analysis. There is no apparent association between LY6G6F expression and any 
mutational status or subtype classification. Higher LY6G6F expression is observed in the 
KRAS WT BXPC-3 cell line, along with Capan-2, Capan-1 and AsPC-1. Lower expression 
is observed in MIA PaCa-2, PANC-1 and SW1990 cell lines. LY6G6F is also detected in the 
membrane enriched fraction of all cell lines.  
A panel of eight breast cancer cell lines was also used in this study. Table 4.3 lists the original 
source of these cell lines and some of the subtype classifications associated with breast 
cancer.  Four of the cell lines (MDA-MB-468, BT20, MDA-MB-157 and MDA-MB-231) 
are Basal-like/triple negative, lacking the ER, PR and HER receptors. Two cell lines 
represent the Luminal A and HER2 amplified subtype (BT474 and MDA-MB-361), with the 
remaining two the Luminal B subtype (MCF-7 and T47D). Figure 4.4 shows the results of 
the Western blot analysis. LY6G6F is detected in the whole cell lysate and membrane 
enriched fraction of all cell lines, with a lower level of expression in all four Basal subtype 
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cell lines compared to the other four Luminal subtype cell lines, which have a similar 
expression level. 
 
Table 4.2 Pancreatic cancer cell line panel showing the original source of the cell lines and their 
mutational status in the four major driver genes associated with PDAC. Mutations in TP53, p16 
and SMAD4 are inactivating gene mutations; KRAS is an activating mutation. WT, wildtype 
genotype; MT, mutant genotype. 
 
 
Figure 4.3 Representative Immunoblot showing LY6G6F expression in the whole cell and 
membrane enriched fraction of a panel of PDAC cell lines. LY6G6F has a MW of ~32kDa. α-
tubulin confirms equal loading of total proteins in the whole cell lysate. (n=2) 
Cell	line	 KRAS	 TP53	 p16	 SMAD4	 Source	
BxPC-3	 WT	 MT	 WT	 MT	 Pancreas	adenocarcinoma	
MIA	PaCa-2	 G12C	 MT	 MT	 WT	 Pancreas	adenocarcinoma	
PANC-1	 G12D	 MT	 MT	 WT	 Pancreas	adenocarcinoma	
HPAC	 G12D	 WT	 MT	 WT	 Pancreas	adenocarcinoma	
AsPC-1	 G12D	 MT	 WT	 WT	 Ascites	 metastatic	 site	 of	
pancreas	adenocarcinoma	
Capan-1	 G12V	 MT	 MT	 MT	 Liver	 metastasis	 of	 pancreas	
adenocarcinoma	
Capan-2	 G12V	 WT	 WT	 WT	 Pancreas	adenocarcinoma	
SW1990	 G12D	 WT	 MT	 WT	 Spleen	metastasis	of	pancreas	
adenocarcinoma	
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Table 4.3 Breast cancer cell line panel showing the original source of the cell lines and some of 
the classifications associated with them. 
 
 
Figure 4.4 Western blot analysis showing LY6G6F expression in the whole cell and membrane 
enriched fraction of a panel of breast cancer cell lines. Lower LY6G6F expression is observed in 
the Basal subtype cell lines. α-tubulin confirms equal loading of total proteins in the whole cell lysate. 
(n=1) 
Cell	line	 Classification	 Source	
MCF-7	 Luminal	A	(ER+,	PR+/-,	HER2-)	 Pleural	effusion	metastatic	site	of	
breast	adenocarcinoma		
T47D	 Luminal	A	(ER+,	PR+/-,	HER2-)	 Pleural	effusion	metastatic	site	of	
breast	ductal	carcinoma	
BT474	 Luminal	B	(ER+,	PR+/-,	HER2+)	 Breast	ductal	carcinoma	
MDA-MB-361	 Luminal	B	(ER+,	PR+/-,	HER2+)	 Brain	 metastasis	 of	 breast	
adenocarcinoma	
MDA-MB-468	 Basal	A	(ER-,	PR-,	HER2-)	 Pleural	effusion	metastatic	site	of	
breast	adenocarcinoma	
BT20	 Basal	A	(ER-,	PR-,	HER2-)	 Breast	carcinoma	
MDA-MB-157	 Basal	B	(ER-,	PR-,	HER2-)	 Breast/medulla	carcinoma	
MDA-MB-231	 Basal	B	(ER-,	PR-,	HER2-)	 Pleural	effusion	metastatic	site	of	
breast	adenocarcinoma	
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4.2.3. Summary of Analysis of LY6G6F Expression across Various Cancer Types 
In addition to CRC, further IHC validation studies indicated LY6G6F is highly expressed in 
PDAC. Intense LY6G6F immunoreactivity was observed in PDAC tumours with minimal 
expression in normal pancreas. Despite no apparent overexpression observed in breast cancer 
in the IHC analysis, Western blot analysis showed that LY6G6F may have differential 
expression associated with different subtypes of breast cancer. However, for our purpose of 
identifying targets upregulated in cancer vs. normal tissues that could have potential as 
therapeutic targets, CRC and PDAC cancer types will be investigated further for LY6G6F 
expression. 
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4.3. LY6G6F Expression in Normal Colon and CRC Tissues 
In order to investigate LY6G6F expression in a larger patient cohort of CRC by 
Immunohistochemical analysis, a combination of commercial tissue microarray (TMA) and 
full-face tissue sections was used. TMAs contain small 1mm diameter cores of tissues on a 
single glass slide, enabling rapid analysis of large patient cohorts for target expression. The 
full-face tissue sections contain much larger pieces of tissue and can give a broader picture 
of target expression in the tumour and surrounding tissue. We had access to a small number 
of full-face colon adenocarcinoma tissue sections obtained from our collaboration with St. 
Vincent’s University Hospital – 9 KRAS mutant (MT) phenotype and 9 KRAS wildtype 
(WT) colon adenocarcinoma sections, as well as 2 each of BRAF MT and BRAF WT tissue 
sections. A number of normal colon sections were also available.  
A colon disease spectrum TMA (CO2081, Biomax US) was used to investigate LY6G6F 
expression across a broad spectrum of colon disease, from benign to cancerous tissues. This 
TMA includes colon adenocarcinoma, which the majority of CRCs are classified as, as well 
as mucinous adenocarcinoma and carcinoid tumours. Mucinous colon carcinoma is a distinct 
form of CRC, accounting for 10-15% of cases, and has been associated with inferior response 
to treatment compared to adenocarcinoma. Carcinoid tumours arise from neuroendocrine 
cells of the colon, and are a much rarer form of CRC. Colon cancers from lymph node 
metastases are also on the TMA. The benign spectrum is represented with cores from normal 
colon, normal cancer adjacent tissue (NAT), chronic inflammation of mucosa, hyperplasia of 
glandular epithelium, polyps and adenomas. The layout of this TMA is shown in Figure 4.5. 
In addition, a small TMA with 12 colon adenocarcinoma and 12 matched normal cancer 
adjacent colon specimens (Accumax A713 VIII) was also analysed. Some cores of TMAs 
can be missing from the slide, therefore the combined numbers of CRC, benign, and normal 
sections analysed (from the full-face tissue sections and TMAs) are displayed in Table 4.4. 
The pathological grade diagnosis was available for some of the full-face colon 
adenocarcinoma tissue sections, as well as the cancer specimens on the TMAs. However, no 
survival data was available for any of the cancer specimens.  
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Normal and Benign Spectrum Specimens  Cancer Specimens  
Normal Colon - 21 Adenocarcinoma – 50 (includes the KRAS 
and BRAF MT and WT specimens) 
NAT Colon - 21 Mucinous Adenocarcinoma - 15 
Chronic Inflammation – 10 Carcinoid - 2 
Hyperplasia - 7 Metastatic Adenocarcinoma – 19  
Polyps - 6  
Adenoma - 5  
Table 4.4 Total number of normal, benign and colon cancer specimens analysed for LY6G6F 
expression.  
 
 
 
 
 
 
 
 
 
 
Figure 4.5 CO2081 colon disease spectrum (colon cancer progression) tissue array. Duplicate 
cores of each case are present. NAT: Normal cancer adjacent tissue. (US Biomax, Inc) 
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The tissue sections were analysed by IHC for LY6G6F expression, as described in Section 
2.6. Sections were then scored for intensity of LY6G6F immunoreactivity in the tumour cells 
or normal tissues, as outlined in Table 4.5. Slides were scored by two independent examiners 
(EMC, AML). These scores were then grouped into those tumours with negative or low levels 
of LY6G6F expression (0-1+) and those tumours showing high LY6G6F expression (2-3+) 
for analysis. Table 4.6 shows the LY6G6F expression results for the colon cancer 
progression spectrum analysed. Normal colon and normal cancer adjacent colon were 
negative for LY6G6F or displayed weak diffuse stain in the majority of cases. A small 
number showed some strong LY6G6F immunoreactivity. 47.6% (10/21) of normal colon 
scored as 0 for LY6G6F immunoreactivity, 23.8% (5/21) scored as 1+, 23.8% (5/21) scored 
as 2+ and 4.8% (1/21) scored as 3+. 47.6% (10/21) of NAT colon scored as 0 for LY6G6F, 
42.8% (9/21) scored as 1+, 4.8% (1/21) scored as 2+ and 4.8% (1/21) scored as 3+. In order 
to determine if there is any significant association between the low expression found in 
normal colon (including NAT colon) and the expression levels found in both the benign and 
cancer spectrum, a Chi-square test to compare the expression of every other specimen with 
normal colon was carried out. The p-value results for this test are also listed in Table 4.6. 
 
Table 4.5 Scoring system used for target IHC immunoreactivity. 
 
 
 
 
Score Level of target immunoreactivity 
0 Negative staining 
1+ Weak staining  
2+  Moderate staining  
3+  Strong (intense) staining  
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 LY6G6F expression  
Specimen: 
No. of 
cases 
Low (0-1+) High (2-3+) p-value 
Normal colon 21 15 (71.4%) 6 (28.6%)  
NAT colon 21 19 (90.5%) 2 (9.5%)  
Chronic 
Inflammation 
10 7 (70%) 3 (30%) NS 
Hyperplasia 7 0 7 (100%) <0.0001 
Polyps 6 0 6 (100%) <0.0001 
Adenoma 5 1 (20%) 4 (80%) 0.0031 
Adenocarcinoma 50 15 (30%) 35 (70%) <0.0001 
- KRAS MT 9 0 9 (100%)  
- KRAS WT 9 1 (11.1%) 8 (88.9%)  
- BRAF MT 2 0 2 (100%)  
- BRAF WT 2 0 2 (100%)  
Mucinous 
adenocarcinoma 
15 11 (73.3%) 4 (26.7%) NS 
Carcinoid 2 2 (100%) 0 NS 
Metastatic 
adenocarcinoma 
19 12 (63.2%) 7 (36.8%) NS 
Table 4.6 LY6G6F expression in the colon disease spectrum. The number of each specimen that 
scored as LY6G6F low and LY6G6F high expressing is listed. The association between expression 
levels observed in normal colon specimens (including NAT colon) and all of the other cases both 
benign and cancerous was estimated for significance by Chi-square test. P-values are noted for those 
with significant correlations. NS = not significant.  
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4.3.1. LY6G6F Expression in Normal Colon vs. Colon Cancer Spectrum 
Four different colon cancer types have been assessed for LYG6F expression – Colon 
adenocarcinoma, mucinous adenocarcinoma, carcinoid and metastatic adenocarcinoma. The 
initial scoring revealed that 86% (43/50) of adenocarcinomas express LY6G6F, with 14% 
(7/50) scored as 0. In mucinous adenocarcinoma this drops to 60% (9/15) of cases expressing 
LY6G6F, with 40% (6/15) scored as 0. There were only 2 carcinoid cores for analysis, with 
50% (1/2) scored as 0 and 50% (1/2) scored as 1+, indicating low LY6G6F expression in this 
rare subtype of CRC. Metastatic adenocarcinoma (derived from lymph nodes) showed 63.2% 
(12/19) expressed LY6G6F, with 36.8% (7/19) scored as 0.  
The grouped scores of low (0-1+) and high (2-3+) LY6G6F expression for analysis then, as 
shown in Table 4.6, shows that the majority (70%) of adenocarcinomas analysed express 
high levels of LY6G6F. LY6G6F is significantly overexpressed in colon adenocarcinoma vs. 
normal colon, as determined by Chi-square test (p-value <0.0001). In contrast the majority 
(73.3%) of mucinous adenocarcinomas show low LY6G6F expression. The sample size of 
carcinoid tumours was very small (n=2), with 100% of these showing low LY6G6F 
expression. Finally, in the metastatic adenocarcinoma group, 63.2% display low LY6G6F 
expression. Therefore, the majority of mucinous adenocarcinoma, carcinoid and metastatic 
adenocarcinomas show low LY6G6F expression, with no significant correlation found 
between these and the expression in normal colon, as determined by Chi-square test.  
Therefore, LY6G6F overexpression appears to be a characteristic of adenocarcinomas, 
irrespective of KRAS or BRAF mutational status, as both the wildtype and mutated 
KRAS/BRAF specimens showed high (2-3+) LY6G6F expression in the majority of cases. 
(Table 4.6) High LY6G6F expression is not associated with metastatic adenocarcinoma, 
mucinous adenocarcinoma or carcinoid tumours. As well as being significantly 
overexpressed compared to normal colon, LY6G6F is also significantly overexpressed in 
adenocarcinoma compared to these other 3 cancer types, with a p-value of 0.0027 found in 
this comparison by Chi-square test. Strong granular cytoplasmic LY6G6F immunoreactivity 
is observed in colon adenocarcinomas. Whereas in normal colon, if LY6G6F 
immunoreactivity is present, it tends to be weak and diffuse. Figure 4.7 shows representative 
photomicrographs of this pattern of LY6G6F immunoreactivity observed in the colon disease 
spectrum.   
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4.3.2. LY6G6F Expression in Normal Colon vs. Benign Disease 
The benign spectrum includes normal cancer adjacent colon, chronic inflammation of 
mucosa, polyps, hyperplasia of glandular epithelium and adenoma. The normal adjacent 
colon showed low LY6G6F expression in 90.5% (19/21) of cases, showing similar 
expression to normal colon. In some instances, normal cancer adjacent tissue can be affected 
by close proximity to the tumour microenvironment. The majority of sample tissues 
representing chronic inflammation of mucosa (70%) also exhibited low LY6G6F expression. 
In contrast, the majority of polyps (100%), hyperplasia of glandular epithelium (100%) and 
adenoma (80%) had high LY6G6F expression (2-3+ score). LY6G6F is significantly 
overexpressed in polyps (p-value <0.0001), hyperplasia (p-value <0.0001) and adenoma (p-
value 0.0031), as determined by Chi-square test, and shown in Table 4.6. Representative 
photomicrographs of the pattern of LY6G6F stain observed in the colon disease spectrum are 
shown in Figure 4.6. 
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Figure 4.6 IHC analysis of LY6G6F expression in normal, diseased and malignant colon. 
Representative images showing: (A) Normal colon exhibiting negative immunoreactivity. (B) 
Chronic inflammation of colon mucosa exhibiting negative immunoreactivity. (C) Adenoma 
exhibiting weak LY6G6F immunoreactivity. (D) Adenoma showing strong granular cytoplasmic 
immunoreactivity. (E) Hyperplasia of glandular epithelium with strong granular cytoplasmic 
immunoreactivity. (F) Colon adenocarcinoma (KRAS MT, moderately differentiated) with strong 
granular cytoplasmic immunoreactivity in tumour cells. Original magnification 400x. The scale bars 
represent 100µm. 
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Figure 4.7 IHC analysis of LY6G6F expression in normal and malignant colon. Representative 
images showing: (A) NAT colon with minimal LY6G6F immunoreactivity observed. (B) Moderately 
differentiated colon adenocarcinoma (KRAS WT) showing weak LY6G6F immunoreactivity. (C) 
Colon adenocarcinoma (BRAF WT) with moderate LY6G6F immunoreactivity. (D) Moderately 
differentiated colon adenocarcinoma (KRAS MT) showing strong granular cytoplasmic 
immunoreactivity. (E) Colon adenocarcinoma (BRAF MT) showing strong granular cytoplasmic 
immunoreactivity. (F) Metastatic colon adenocarcinoma with weak-moderate immunoreactivity. 
Original magnification 400x. The scale bars represent 100µm. 
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4.3.3. Association between LY6G6F Expression and CRC Tumour Grade 
In order to determine if LY6G6F expression correlates with the histopathological grade of 
CRC, the score was analysed in the specimens that this information was available for. 
Tumours are pathologically diagnosed from Grade 1-3; Grade 1 or well differentiated denotes 
tumours with cells that appear normal and are not rapidly growing; Grade 2 or moderately 
differentiated denotes tumours with cells that appear slightly different than normal; Grade 3 
or poorly differentiated denotes tumours with cells that appear abnormal and tend to grow 
and spread more aggressively. The grade diagnosis was known for 63 of the cancer specimens 
analysed: 30 adenocarcinomas, 15 mucinous adenocarcinomas and 18 metastatic 
adenocarcinomas. Combining the score for all of these and grouping into Grades 1-3, showed 
that the majority (55.6%) of tumours analysed were Grade 2, followed by Grade 3 at 31.7% 
and Grade 1 representing 12.7% of tumours. Table 4.7 shows the LY6G6F expression pattern 
for the three grades across these combined colon cancer types. There appears to be no 
correlation with LY6G6F expression and tumour grade, with a fairly even distribution 
between low and high LY6G6F expression in all three grades. 
As high LY6G6F expression has been shown to significantly correlate with colon 
adenocarcinoma, with low expression observed in the majority of both mucinous and 
metastatic adenocarcinoma, the correlation between grade and LY6G6F expression was also 
assessed for each of these cancer types separately. These results are shown in Table 4.8. 
LY6G6F expression does not correlate to grade in adenocarcinoma, with a similar level of 
high expression shown in Grade 1, 2 and 3. There similarly appears to be no correlation in 
metastatic adenocarcinoma, with similar percentages of low and high expression observed in 
both Grade 2 and 3 (no Grade 1 present). Mucinous adenocarcinoma, which shows low 
LY6G6F expression in the majority (73.3%) of cases, does show some differences in the 
LY6G6F expression pattern between grades. The level of LY6G6F expression appears to 
increase as the grade increases, with 0% of Grade 1 tumours showing high expression, 22.2% 
of Grade 2 showing high expression and then 66.7% of Grade 3 tumours showing high 
LY6G6F expression, however this trend wasn’t deemed significant by a Chi-square test. 
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  LY6G6F expression 
Grade  No of cases  Weak (0-1+) Strong (2-3+) 
1 8 4 (50%) 4 (50%) 
2 35 17 (48.6%) 18 (51.4%) 
3 20 8 (40%) 12 (60%) 
Table 4.7 Association between LY6G6F expression and CRC tumour grade. (Results for 
adenocarcinoma, mucinous and metastatic adenocarcinoma combined) 
 
Adenocarcinoma (n=30) 
Grade  No of cases  Weak (0-1+) Strong (2-3+) 
1 5 1 (20%) 4 (80%) 
2 16 4 (25%) 12 (75%) 
3 9 2 (22.2%) 7 (77.8%) 
Mucinous Adenocarcinoma (n=15) 
Grade  No of cases  Weak (0-1+) Strong (2-3+) 
1 3 3 (100%) 0 
2 9 7 (77.8%) 2 (22.2%) 
3 3 1 (33.3%) 2 (66.7%) 
Metastatic Adenocarcinoma (n=18) 
Grade  No of cases  Weak (0-1+) Strong (2-3+) 
1 0 - - 
2 10 6 (60%) 4 (40%) 
3 8 5 (62.5%) 3 (37.5%) 
Table 4.8 Association between LY6G6F expression and tumour grade in each CRC subtype. 
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4.3.4. Summary of LY6G6F Expression in Colon Disease Spectrum 
v LY6G6F expression is either absent or weak in the majority of normal colon tissues. 
v LY6G6F is significantly overexpressed in colon adenocarcinoma vs. normal colon 
(p-value <0.0001), irrespective of tumour grade or KRAS/BRAF mutational status. 
v However, LY6G6F is weakly expressed in the metastatic adenocarcinoma cohort. 
v LY6G6F is weakly expressed in chronic inflammation of colon tissues, but is 
significantly overexpressed in the rest of the benign spectrum – hyperplasia, polyps 
and adenoma, indicating an association between LY6G6F expression and the 
adenocarcinoma progression profile. 
v LY6G6F shows weak expression in mucinous adenocarcinoma, with no significance 
in expression compared to normal colon.  
v LY6G6F is also weakly expressed in the rare carcinoid tumour subtype.  
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4.4. LY6G6F Expression in Normal Pancreas and PDAC  
The preliminary analysis in Section 4.2, showed high LY6G6F expression in PDAC 
compared to normal pancreas, warranting investigation in a larger patient cohort. Specimens 
obtained from 57 patients undergoing pancreaticoduodenectomy in St. Vincent’s University 
Hospital between 2007 and 2013 for PDAC were available for this study. Information on the 
pathological features and survival rates for this cohort was also provided. All specimens are 
PDAC, which accounts for ~95% of pancreatic cancer cases, and were all located in the head 
of the pancreas. To assess the expression of LY6G6F in normal pancreas alongside this 
cohort, 3 full-face tissue sections of normal pancreas were used and a commercially sourced 
TMA (PAN241a, US Biomax) containing 4 normal pancreas cores and 16 normal adjacent 
tissue (NAT) cores, which are derived from cancer adjacent normal tissue, giving a total of 
7 normal pancreas and 16 NAT pancreas for analysis.  
Tissues were stained for LY6G6F expression and assigned an intensity score from 0-3+, as 
described in Table 4.5. Slides were scored by two independent examiners (EMC, AML). It 
was observed that LY6G6F strongly stained the stroma of a number of the PDAC specimens. 
Therefore, the score for LY6G6F stain in both the tumour cells and the stroma was noted, as 
outlined in Table 4.9. Overall LY6G6F expression is either absent or displays a weak and 
diffuse cytoplasmic pattern of expression in normal pancreas and normal cancer adjacent 
pancreas. In contrast, high LY6G6F expression is observed in the majority of PDAC tumour 
ducts, with 78.9 % (45/57) scored 2-3+. Only 5.3% (3/57) showed no LY6G6F expression, 
and 15.8% (9/57) scored as 1+. LY6G6F overexpression in PDAC compared to normal 
pancreas is highly significant, with a p-value of <0.0001 obtained by Chi-square test. 
LY6G6F expression in the PDAC tumours is for the most part, observed as granular 
cytoplasmic-like staining, localised to the apical membrane (the membrane that faces inward 
to the lumen) of ducts. A combination of membrane-like, and cytoplasmic-like stain is 
observed in a small number of specimens, with membrane–like immunoreactivity more likely 
to be observed in smaller tumour ducts or tumour buds. Tumour budding is where individual 
malignant cells and/or small clusters of malignant cells are found in the tumour stroma at the 
invasive front of the tumour and is an adverse prognostic factor in PDAC. (Karamitopoulou 
et al., 2013) Strong stromal LY6G6F immunoreactivity was observed in 40.4% (23/57) of 
the PDAC specimens analysed. A small number of normal pancreas (3/7) and normal cancer 
adjacent pancreas (2/16) also displayed some strong LY6G6F immunoreactivity in the 
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stroma, but to a much smaller extent than that observed in PDAC. The difference in LY6G6F 
stromal expression between normal pancreas and PDAC was not deemed significant (by Chi-
square test). Figure 4.8 and Figure 4.9 show some representative photomicrographs of 
LY6G6F immunoreactivity observed in normal pancreas and PDAC. 
 
  
Score of LY6G6F immunoreactivity in pancreatic tumour 
ducts and normal pancreas tissue 
Specimen: 
No. of 
cases 
0 1+ 2+ 3+ 
Normal 
Pancreas 
7 4 (57.1%) 3 (42.9%) 0 0 
NAT pancreas 16 4 (25%) 12 (75%) 0 0 
PDAC 57 3 (5.3%) 9 (15.8%) 24 (42.1%)* 21 (36.8%)* 
  
Score of LY6G6F immunoreactivity in the stroma of 
PDAC and normal pancreas 
Specimen: 
No. of 
cases 
0 1+ 2+ 3+ 
Normal 
Pancreas 
7 4 (57.1%) 0 3 (42.9%) 0 
NAT pancreas 16 14 (87.5%) 0 2 (12.5%) 0 
PDAC 57 12 (21%) 22 (38.6%) 7 (12.3%) 16 (28.1%) 
Table 4.9 LY6G6F expression in normal pancreas and PDAC. The IHC score is outlined for 
normal pancreas, normal cancer adjacent (NAT) pancreas and PDAC specimens. The LY6G6F 
immunoreactivity score is described for both the tumour ducts / normal pancreas tissue and also for 
stromal immunoreactivity observed in these tissues. *LY6G6F is significantly overexpressed in 
PDAC tumours vs. normal pancreas (p-value: <0.0001; estimated by Chi-square test)  
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Figure 4.8 IHC analysis of LY6G6F expression in normal pancreas and PDAC. Representative 
images showing: (A) Normal pancreas with negative LY6G6F immunoreactivity. (B) PDAC 
exhibiting strong cytoplasmic and membrane-like LY6G6F immunoreactivity. (C-E) PDAC tumours 
surrounded by stroma with strong LY6G6F immunoreactivity. Black arrows indicate the tumour ducts 
and red arrows the surrounding stroma. Weaker LY6G6F immunoreactivity is observed in the ducts 
of C and D, with strong immunoreactivity in the tumour ducts in E. Strong immunoreactivity is 
observed in the stroma of all. (F) PDAC with strong cytoplasmic and membrane-like LY6G6F 
immunoreactivity. Original magnification 200x. The scale bars represent 200µm. 
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Figure 4.9 IHC analysis of LY6G6F expression in normal pancreas and PDAC. Representative 
images showing: (A) Normal pancreas with very weak and diffuse LY6G6F immunoreactivity. (B) 
PDAC showing weak LY6G6F immunoreactivity. (C) PDAC exhibiting strong granular cytoplasmic 
LY6G6F immunoreactivity localised to the apical membrane side of a malignant duct. (D) PDAC 
with strong cytoplasmic and membrane-like LY6G6F immunoreactivity observed in tumour ducts. 
(E) Small clusters of PDAC tumour ducts showing strong cytoplasmic and membranous LY6G6F 
immunoreactivity. (F) PDAC exhibiting moderate-strong cytoplasmic LY6G6F immunoreactivity. 
Original magnification 400x. The scale bars represent 100µm. 
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4.4.1. Association between LY6G6F Expression and PDAC Clinicopathological 
Features 
Information on the clinicopathological features associated with PDAC was available for the 
57 patient cohort. The mean age at time of diagnosis was 62.6 years in this group. 64.4% 
(37/57) of patients were male and 35.1% (20/57) were female. The majority (84.9%) of the 
tumours were moderately differentiated, with 26.3% poorly differentiated and 8.8% well 
differentiated. The average maximum pathological tumour axis was 2.98cm. The tumour 
staging ranged from T1-3, where the higher the number indicates the larger the tumour has 
grown and extended into nearby tissues; 89.4% (51/57) were T3, 5.3% were T2 and 5.3% 
were T1. 68.4% of cases were diagnosed as N1 stage and 31.6% as N0, where N1 indicates 
the presence of regional lymph node metastasis and N0 indicates no cancer is present in the 
regional lymph nodes. Lymphovascular invasion (LVI) was present in 63% (36/57) of cases 
and perineural invasion (PNI) was present in 82.5% (47/57) of cases. Portal vein involvement 
(PVI) was present in only 3.5% (2/57) of cases.  
LY6G6F expression in this cohort was grouped into LY6G6F low (0-1+ IHC score) and 
LY6G6F high (2-3+ IHC score) expression for analysis. Table 4.10 shows the association 
between LY6G6F expression and the clinicopathological features of this PDAC cohort. 
Overall, LY6G6F is highly expressed in this PDAC patient cohort, with 78.9% displaying 
strong LY6G6F immunoreactivity. No significant correlation was found between LY6G6F 
expression and any of the clinicopathological features examined. There are some notable 
differences in expression in some of the clinicopathological features despite not being 
deemed significant. T3 stage tumours highly express LY6G6F in 80.4% of cases, whilst 
66.7% of T1-2 stage tumours highly express LY6G6F.  LY6G6F is more highly expressed 
in cases where lymphovascular invasion is present (83.3%) compared to cases where it is 
absent (71.4%) and it is also more highly expressed in the cases with perineural invasion – 
81% have high LY6G6F expression, compared to 70% of cases where PNI is absent having 
high LY6G6F expression. The sample size is very small for those with portal vein 
involvement (2/57), with 100% of these showing high LY6G6F expression, compared to 
78.2% in cases without PVI. There is some differential expression observed across the 
different histological grades, with 100% of well differentiated tumours highly expressing 
LY6G6F, 81% of moderately differentiated and 67% of poorly differentiated tumours highly 
expressing LY6G6F.  
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Feature 
 LY6G6F expression  
No. of 
patients Low (0-1+) High (2-3+) p-value* 
Overall  57 n=12 (21.1%) n=45 (78.9%)  
Sex     0.132 
Male 37 10 (27%) 27 (73%)  
Female 20 2 (10%) 18 (90%)  
Age (years)    0.443 
< 60 23 6 (26.1%) 17 (73.9%)  
³ 60 34 6 (17.6%) 28 (82.4%)  
Tumour size     0.569 
< 4 cm 44 10 (22.7%) 34 (77.3%)  
³ 4 cm 13 2 (15.4%) 11 (84.6%)  
Tumour 
differentiation    0.247 
Well 5 0 5 (100%)  
Moderate 37 7 (19%) 30 (81%)  
Poor 15 5 (33%) 10 (67%)  
pT stage     0.435 
T1-2 6 2 (33.3%) 4 (66.7%)  
T3 51 10 (19.6%) 41 (80.4%)  
pN stage    0.581 
N0 18 3 (16.7%) 15 (83.3%)  
N1 39 9 (23.1%) 30 (76.9%)  
Lymphovascular 
invasion    0.288 
Absent 21 6 (28.6%) 15 (71.4%)  
Present  36 6 (16.7%) 30 (83.3%)  
Perineural 
invasion    0.445 
Absent 10 3 (30%) 7 (70%)  
Present  47 9 (19%) 38 (81%)  
Portal vein 
involvement    0.457 
Absent 55 12 (21.8%) 43 (78.2%)  
Present 2 0 2 (100%)  
R-status    0.592 
R0 54 11 (20.4%) 43 (79.6%)  
R1 3 1 (33.3%) 2 (66.7%)  
Table 4.10 Association between LY6G6F expression in PDAC and the clinicopathological 
features of pancreatic cancer. T, tumour; N, lymph node. *Significance estimated with Chi-square 
test.  
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4.4.2. Correlation between LY6G6F Expression and Survival in PDAC 
Survival analysis was carried out for the PDAC patient cohort comparing those with LY6G6F 
low (0-1+) and LY6G6F high (2-3+) expressing tumours. At the time of analysis 66.7% 
(38/57) of patients had succumbed to PDAC and 33.3% (19/57) of patients were alive. The 
median survival for those that died from PDAC was 532 days. Figure 4.10 shows the Kaplan-
Meier survival analysis for LY6G6F low and high expression in the whole patient cohort. 
There is a distinct trend towards patients with high LY6G6F expression having a poorer 
prognosis compared to those with low LY6G6F expression. However, this was not found to 
be a statistically significant correlation (p=0.182). The median survival for LY6G6F low 
expressing tumours was 1305 days. The median survival for LY6G6F high expressing 
tumours was 628 days. Therefore, even though not deemed significant, there is a trend 
towards the tumours exhibiting higher levels of LY6G6F immunoreactivity having poorer 
survival than the LY6G6F low expressing tumour cohort.  
 
 
Figure 4.10 Kaplan-Meier survival analysis of PDAC patients after surgical resection grouped 
according to LY6G6F expression. (n=57) Patients with high LY6G6F expression show poorer 
survival vs. patients with low LY6G6F expression. LY6G6F low = (0-1+ score); LY6G6F high = (2-
3+ score). (p=0.182; logrank test) Survival analysis performed using GraphPad Prism version 7. 
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4.4.3. Summary of LY6G6F Expression in Normal Pancreas and PDAC 
v LY6G6F expression is absent in the majority of normal pancreas, and shows weak 
and diffuse expression in the cases where it is present. 
v LY6G6F is highly expressed in the majority (78.9%) of PDAC and this was found to 
be a highly significant overexpression (p-value <0.0001) compared to normal 
pancreas. 
v Strong LY6G6F expression was also observed in the stroma of 40.4% of the PDAC 
cases analysed. 
v LY6G6F was observed to be more highly expressed in cases where lymphovascular 
invasion, perineural invasion and portal vein involvement were present.  
v There is a trend towards higher LY6G6F expression being associated with poorer 
survival in this PDAC patient cohort (n=57). 
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4.5. LY6G6F Expression in Gastric Cancer 
The preliminary IHC analysis of normal oesophagus and malignant oesophagus (Section 4.2) 
showed no apparent overexpression of LY6G6F in oesophageal cancer. However, we wanted 
to assess LY6G6F expression in other cancers of the gastrointestinal (GI) tract. High 
LY6G6F gene expression was shown to be significantly associated with poorer survival in 
gastric cancer patients, using the KM plotter website analysis. (Szász et al., 2016) Figure 
4.11 shows the corresponding Kaplan-Meier survival analysis for LY6G6F low and high 
mRNA expression based on data from 631 gastric cancer patients. Therefore, to investigate 
LY6G6F expression at the protein level in gastric cancer tumours, a small gastric 
adenocarcinoma and normal gastric tissue TMA (ST721, US Biomax, Inc) was examined for 
LY6G6F expression. In addition, we also had 8 normal gastric epithelium tissue sections 
available for analysis. This gave a total of 16 gastric adenocarcinomas, 3 normal cancer 
adjacent and 11 normal gastric epithelium specimens for analysis. 
 
Figure 4.11 Kaplan-Meier overall survival analysis for LY6G6F low and high gene expression 
in gastric cancer. (n=631) High LY6G6F gene expression is significantly associated with poorer 
survival in gastric cancer. (kmplot.com) 
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The sections were scored for LY6G6F expression, as previously described in Table 4.5. The 
results obtained are shown in Table 4.11. Normal gastric and normal cancer adjacent tissue 
both showed some weak LY6G6F immunoreactivity (as shown in Figure 4.12), 9/11 normal 
stomach and 3/3 NAT stomach scored as 1+, with this characterised as weak diffuse staining. 
Table 4.12 shows the two normal scores combined and along with the adenocarcinoma score, 
grouped into low LY6G6F and high LY6G6F expression for analysis. Compared to normal 
gastric epithelium, which showed weak diffuse LY6G6F immunoreactivity in the majority 
of cases, 50% of the gastric adenocarcinomas showed high LY6G6F immunoreactivity. An 
estimation of the significance of this result, by Chi-square test, showed higher LY6G6F 
expression is significantly correlated with gastric adenocarcinoma vs. normal gastric tissue 
(p-value 0.002), as high LY6G6F expression was not observed in any of the normal gastric 
tissues analysed. The LY6G6F immunoreactivity observed in gastric adenocarcinoma was a 
combination of granular cytoplasmic staining, with some membrane localisation observed in 
some specimens. Figure 4.12 shows representative images of LY6G6F immunoreactivity 
observed in normal gastric tissue and gastric adenocarcinoma.   
Out of the 16 gastric adenocarcinomas analysed, 18.75% (3/16) were classified as Grade 2 
and 81.25% (13/16) as Grade 3 tumours, however there was no significant association found 
between LY6G6F expression and grade in this small sample size. 66.7% (2/3) of Grade 2 
tumours had low LY6G6F expression (0-1+), with high LY6G6F expression in 33.3% (1/3) 
of cases. Grade 3 tumours had high LY6G6F expression in 53.8% (7/13) of cases and low 
LY6G6F in 46.2% (6/7). Therefore, there is a trend towards higher expression in the higher 
grade tumours. 
  LY6G6F Score 
Specimen: 
No. of 
cases 
0 1+ 2+ 3+ 
Normal Gastric 11 2 9 0 0 
NAT Gastric 3 0 3 0 0 
Gastric Adenocarcinoma 16 5 3 4 4 
Table 4.11 LY6G6F expression by IHC score in normal gastric tissue, cancer adjacent normal 
gastric tissue and gastric adenocarcinoma.  
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  LY6G6F expression 
Specimen: No of cases Weak (0-1+) Strong (2-3+) 
Normal Gastric + 
NAT Gastric 
14 14 0 
Gastric 
Adenocarcinoma 
16 8 8 ** 
Table 4.12 Association between LY6G6F expression in gastric cancer vs. normal gastric tissue. 
High LY6G6F expression is associated with gastric cancer; ** p-value 0.002 as estimated by Chi-
square test. 
 
 
 
4.5.1. Summary of LY6G6F Expression in Normal Gastric Tissue and Gastric Cancer  
v The majority of normal gastric epithelium displays some weak and diffuse LY6G6F 
immunoreactivity. 
v LY6G6F was found to be highly expressed in 50% of gastric cancer specimens, a 
significant overexpression vs. normal gastric tissue (p-value 0.002). 
v Kaplan-Meier survival analysis (kmplot.com) shows that high LY6G6F gene 
expression is significantly associated with poorer survival compared to low LY6G6F 
gene expression in gastric cancer. 
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Figure 4.12 IHC analysis of LY6G6F expression in normal and malignant gastric tissue. 
Representative images showing: (A) Normal gastric epithelium with negligible LY6G6F 
immunoreactivity. (B) Normal cancer adjacent gastric tissue with weak immunoreactivity. (C) 
Gastric cancer with negative immunoreactivity. (D) Gastric cancer with moderate cytoplasmic 
immunoreactivity. (E) Gastric cancer with strong cytoplasmic and membrane-like immunoreactivity. 
(F) Gastric cancer with strong granular cytoplasmic and membrane-like immunoreactivity. Original 
magnification 400x. The scale bars represent 100µm. 
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4.6. LY6G6F Expression in Normal Tissues  
The expression pattern of LY6G6F in normal tissues will be an important factor in assessing 
its potential as a molecular target for potential therapeutic antibody targeting. An excellent 
candidate target would ideally have negative expression in normal tissues, particularly vital 
organs, with expression exclusively in cancer cells. However, it is very difficult to find 
proteins with such an expression pattern. Therefore, minimal target expression can be 
tolerated in some normal tissues, if the target candidate has a much stronger expression 
pattern in cancer cells.  The absence or minimal expression of target in the proliferating cells 
of normal tissues is also required, to minimise off target toxicities.  
To investigate LY6G6F expression in normal tissues, a number of TMAs with normal tissues 
(described in Section 2.6.1), as well as full-face tissue sections, if available, were analysed 
for LY6G6F expression. Table 4.13 displays the results of LY6G6F expression in the range 
of normal tissues analysed. In general, if LY6G6F was expressed in normal tissues it showed 
weak or diffuse cytoplasmic staining. The only exception is normal colon, where a small 
number (8/42) of cases did show some strong LY6G6F expression. Then as previously noted 
in some normal pancreas specimens and more so in PDAC, LY6G6F strongly stained the 
stroma of some normal tissues analysed, with these results also displayed in Table 4.13. 
LY6G6F expression was observed in the stroma of normal bladder, kidney, larynx, salivary 
gland and pancreas tissue. Figure 4.13 shows representative images of LY6G6F 
immunoreactivity observed in some normal tissues.  
To investigate LY6G6F expression in highly proliferating cells of normal tissues, serial tissue 
sections of a range of proliferative tissues, including colon, duodenum, tonsil and skin, were 
stained for LY6G6F and Ki67, a cellular marker of proliferation. Figure 4.14 shows some of 
the representative results of this analysis. In general, LY6G6F did not appear to be present 
in the same cells as those stained for Ki67. However, in some of the serial sections it was a 
bit more difficult to determine the exact same cellular location. A dual IHC set up, where a 
single section is stained for both LY6G6F and Ki67 would be required for absolute 
determination of localisation. 
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Normal tissues with negative or minimal LY6G6F immunoreactivity 
Colon     
(14/42)* 
Pancreas 
(15/23) 
Duodenum 
(0/3) 
Stomach 
(12/14) 
Oesophagus 
(3/3) 
Tonsil 
(8/10) 
Liver 
(2/4) 
Breast 
(2/2) 
Lung 
(0/2) 
Thyroid 
(1/3) 
Spleen 
(2/3) 
Uterus 
(0/1) 
Cervix 
(0/2) 
Ovary 
(0/1) 
Skin 
(3/3) 
Testis          
(1/2) 
Prostate       
(2/2) 
Pituitary gland 
(1/1) 
Adrenal gland 
(1/1) 
Parathyroid 
gland (1/1) 
Bone marrow 
(1/1) 
Placenta      
(2/3) 
Muscle, 
skeletal (0/1) 
Heart muscle 
(1/1) 
Omentum      
(0/1) 
Peripheral 
nerve (0/1) 
Cerebellum 
(0/1) 
Thymus       
(0/1) 
Cerebral cortex 
(1/1) 
 
Normal tissues with strong LY6G6F immunoreactivity in the stroma 
Bladder      
(1/1) 
Kidney       
(1/1) 
Larynx        
(1/1) 
Salivary gland 
(2/2) 
Pancreas     
(5/23) 
Table 4.13 LY6G6F expression in normal tissues. The number of sections that stained out of the 
total number analysed is listed. Tissues that displayed strong stromal stain had negative / weak 
LY6G6F expression in the glandular tissue. * Normal colon also showed some strong expression in 
8/42 cases.  
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Figure 4.13 IHC analysis of LY6G6F expression in normal tissues. Representative images 
showing: (A) Salivary gland with strong LY6G6F immunoreactivity in the stroma. (B) Thyroid with 
negligible immunoreactivity. (C) Liver with very weak and diffuse immunoreactivity. (D) Spleen 
with negative immunoreactivity. (E) Lung with negative immunoreactivity. (F) Testis with negative 
immunoreactivity. Original magnification 200x. The scale bars represent 200µm. 
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Figure 4.14 IHC analysis of LY6G6F expression in proliferating cells of normal tissues. 
Representative images of colon, duodenum and gastric epithelium stained for Ki67 and LY6G6F. (A-
B) Normal colon (C-D) Normal duodenum. (E-F) Normal gastric epithelium. Red and black arrows 
indicate the approximate same location in the Ki67 and LY6G6F stained serial sections. LY6G6F 
immunoreactivity appears to be absent or minimal in proliferating cells. Original magnification 200x. 
The scale bars represent 200µm. 
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4.7. Imaging of LY6G6F in Cancer Cell Lines 
In order to further investigate the localisation of LY6G6F in cancer cell lines, 
Immunofluorescence and Immunocytochemical staining for LY6G6F in the MIA PaCa-2 cell 
line was carried out as described in Sections 2.7-2.8. Cells were fixed and permeabilised with 
methanol for both methods. Figure 4.15 shows representative images of the 
Immunofluorescent analysis. The LY6G6F stain was visualised with a green-fluorescent dye 
labelled secondary antibody and the cells nuclei were stained blue with DAPI. These two 
images were then merged, to allow better interpretation of the cellular localisation of 
LY6G6F. The Immunofluorescent analysis shows mainly cytoplasmic LY6G6F staining in 
this cell line, with some perinuclear stain also observed, and possibly some plasma membrane 
immunoreactivity. Similarly, in the Immunocytochemical analysis shown in Figure 4.16, 
cytoplasmic stain is observed in the majority of MIA PaCa-2 cells, with no distinct membrane 
localisation observed. Further optimisation of these methods is required to determine if a 
better picture of LY6G6F subcellular location in colon cancer and PDAC cell lines can be 
determined, and whether the cell-surface localisation of LY6G6F can be confirmed in these 
cancer cell lines.  
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Figure 4.15 Immunofluorescent analysis of LY6G6F expression in MIA PaCa-2 cells. 
Representative images showing: (A) MIA PaCa-2 cells fixed with methanol and stained for LY6G6F. 
(B) The nuclei were stained blue with DAPI. (C) The merged LY6G6F and DAPI image.  
Cytoplasmic, perinuclear and possibly some membranous LY6G6F staining is observed in these cells. 
Original magnification 400x.  
 
 
 
 
Figure 4.16 Immunocytochemical analysis of LY6G6F expression in MIA PaCa-2 cells. 
Representative images show (A-B) MIA PaCa-2 cells fixed with methanol and stained for LY6G6F 
and a negative control (no primary antibody). LY6G6F cytoplasmic immunoreactivity is observed in 
some cells, with no immunoreactivity observed in the negative control. Original magnification 600x. 
Scale bars represent 50µm.  
  
A.																	LY6G6F				 B.																		DAPI				 C.																			Merge
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4.8. Functional Analysis of LY6G6F Knockdown by RNAi 
LY6G6F has been found to be significantly overexpressed in CRC and PDAC tumours 
compared to normal colon and pancreas by IHC analysis. Therefore, to investigate the 
functional role of LY6G6F in the colon cancer and pancreatic cancer cell phenotype, siRNA 
mediated knockdown (KD) of LY6G6F was carried out in vitro. The HCT116 colon cancer 
cell line and MIA PaCa-2 PDAC cell line were selected for functional analysis. Transfection 
conditions were optimised for each cell line, as described in Section 2.4.1. The siRNA target 
LY6G6F mRNA for destruction, leading to protein knockdown, and the effect this has on the 
cells is then assessed by a number of different functional assays. Three different LY6G6F 
siRNAs (#1, #2 and #3) were used in this analysis. Controls for the comparison of LY6G6F 
knockdown, include cells only control (no transfection reagents) and cells transfected with a 
Negative siRNA (siRNA that does not code for any known mRNA sequence).  
 
4.8.1. Knockdown of LY6G6F in the Colon Cancer Cell Line HCT116 
The HCT116 cell line was chosen for functional analysis as it shows a moderate level of 
LY6G6F expression in the colon cancer cell line panel (see Figure 3.1) and it also has a 
suitable level of migration and invasion, for assessing any effect LY6G6F KD has on these 
phenotypes. HCT116 cells transfected with siRNAs were assayed for protein knockdown 
after 72hrs by Western blot analysis. Figure 4.17 shows a representation of the amount of 
protein knockdown achieved in these cells, with a bar chart of densitometry analysis 
visualising the approximate LY6G6F protein levels relative to cells only control. Complete 
protein knockdown was never achieved for this target, and further optimisations did not 
increase the amount of protein KD observed. Therefore, cells were set up for functional 
assays at the 72hr time point, to determine what effect the partial protein knockdown has on 
proliferation, 2D colony formation, migration and invasion of these cells.   
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Figure 4.17 LY6G6F expression in HCT116 cells following siRNA treatment. A: Representative 
Immunoblot showing HCT116 cells probed for LY6G6F in cells only control, Negative siRNA 
transfected cells, and cells transfected with LY6G6F siRNA #1, 2, 3 (30nM siRNA concentration). 
α-tubulin was used as a loading control. B: Densitometry analysis of the representative blot shown in 
A, with results graphed as relative density of bands compared to cells only. Analysis performed using 
ImageJ software. 
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4.8.1.1. Proliferation of HCT116 Cells post LY6G6F Knockdown 
Proliferation of HCT116 cells was measured 72hrs post transfection by the acid phosphatase 
assay as described in Section 2.5.1. Figure 4.18 shows the percentage proliferation of cells 
relative to the Negative siRNA transfected cells. The transfection procedure (Lipofectamine 
only cells; and Negative siRNA treated cells) had negligible effects on proliferation 
compared to cells only. Knockdown of LY6G6F was found to significantly reduce 
proliferation compared to the Negative siRNA, with all 3 siRNAs used. LY6G6F siRNA #3 
transfected cells had a 21% reduction in proliferation compared to the Negative control. 
Whilst LY6G6F siRNA #1 and #2 transfected cells showed an even bigger decrease, with a 
36% and a 38% growth inhibition. 
 
 
 
Figure 4.18 Proliferation assay on HCT116 cells following LY6G6F knockdown. Results graphed 
as % survival (mean ± SD) relative to the Negative control siRNA. (n=5) The proliferation of HCT116 
cells was significantly reduced after LY6G6F knockdown compared to the Negative control. (siRNA 
#1 p-value: 0.0002, #2 p-value: 0.00017, #3 p-value: 0.00059. Students t-test unequal variance)  
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4.8.1.2. 2D Colony Formation of HCT116 Cells post LY6G6F Knockdown 
The 2D colony formation assay assesses the ability of single cells to survive and proliferate 
into colonies. Cells are set up at an optimised cell number in 6 well plates, as described in 
Section 2.5.2, 72hrs post transfection. Colony formation is then assessed after 12 days, by 
fixing cells and staining with crystal violet. Clonogenic assays are commonly manually 
counted, however the data presented in this study uses a plugin for ImageJ software, which 
calculates the percentage area of the 6 well covered by colonies and also the intensity stain. 
These calculations equate to the number of colonies formed (area covered) and also the size 
of colonies (with stronger intensity indicating more cells in a colony). Therefore using these 
parameters, the effect of LY6G6F protein knockdown compared to Negative siRNA treated 
cells can be determined.  
Figure 4.19 shows representative results of this analysis, with representative images of the 
colony formation in 6 well plates and the percentage area covered and percentage intensity 
of colonies relative to the Negative siRNA transfected cells graphed. All three LY6G6F 
siRNA treated cells showed a decrease in both the area covered and intensity of colonies 
formed compared to the Negative siRNA, with siRNA #1 showing the biggest decrease, with 
a 58.4% decrease in colony area and 59.9% decrease in intensity, indicating fewer and 
smaller colonies formed, compared to the Negative siRNA treated cells. The average 
decrease observed in LY6G6F siRNA #2 and #3 treated cells was smaller, with a 25.9% 
decrease in colony area for #2 and a 29.4% decrease in area for #3. However due to the high 
standard deviations between triplicate experiments, these reductions were not deemed 
significant for any of the siRNAs. However, there is a trend towards a decrease in colony 
forming ability following knockdown with all 3 siRNAs.  
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Figure 4.19 2D colony formation of HCT116 cells following LY6G6F knockdown. (A) 
Representative images showing the 2D colony formation in 6 well plates of HCT116 cells only, cells 
transfected with Negative siRNA and LY6G6F siRNAs #1, 2 and 3. (B) Results graphed as % area 
covered and % intensity of colonies (mean ± SD) relative to the Negative control siRNA. (n=3) The 
2D colony formation of HCT116 cells was reduced after LY6G6F knockdown compared to the 
Negative control. (Not significant, Students t-test unequal variance) 
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4.8.1.3. Migration of HCT116 Cells post LY6G6F Knockdown  
Migration assays were set up 72hrs post transfection and carried out as described in Section 
2.5.4, with cells allowed to migrate through the membrane for 30hrs before being fixed and 
stained with crystal violet. Figure 4.20 shows these results graphed as percentage migration 
relative to the Negative siRNA treated cells. A significant reduction in migration was 
observed for 2 out of the 3 siRNAs used in the analysis. LY6G6F siRNA #2 treated cells had 
a 73% significant reduction in migration, with siRNA #1 showing a 48% significant 
reduction. Although the effect caused by siRNA #3 was not found to be significant, it does 
follow the same trend towards a decrease, with an average 54% reduction in migration. The 
higher SD in this case possibly prevented significance. As 2/3 siRNAs show a significant 
result, it can be concluded that knockdown of LY6G6F significantly reduces the migratory 
ability of HCT116 cells. 
 
 
Figure 4.20 Migration assay results for HCT116 cells following LY6G6F knockdown. Results 
graphed as % migration (± SD) relative to the Negative siRNA. (n=3) The migration of HCT116 cells 
was significantly reduced after LY6G6F knockdown compared to the Negative control.  Statistics: 
unpaired t-test (siRNA #1 p-value: 0.006, #2 p-value: 0.005, #3 p-value: 0.06) 
  140 
4.8.1.4. Invasion of HCT116 Cells post LY6G6F Knockdown 
Invasion assays were set up 72hrs post transfection and carried out as described in Section 
2.5.3, with cells allowed to migrate through the Matrigel coated membrane for 30hrs before 
being fixed and stained with crystal violet. High variability between replicates was found in 
this assay. The Negative siRNA control appeared to increase invasion compared to control 
cells only, however the effect of LY6G6F knockdown was still compared to the Negative 
siRNA in this experiment to test for significance, as it was deemed the most appropriate 
control. Figure 4.21 shows the percentage invasion of cells relative to the Negative siRNA 
treated cells. A significant reduction in invasion was observed for 2 out of the 3 siRNAs used 
in the analysis. Both LY6G6F siRNA #2 and #1 treated cells showed a significant reduction 
in invasion levels, with a 70% and 59% reduction in invasion observed for each respectively. 
The higher variability observed for siRNA #3 resulted in a lack of significance, however it 
does follow the same trend towards a decrease in invasion, with a 33% average decrease in 
invasion. Therefore as 2/3 siRNAs show significance, it appears that LY6G6F knockdown 
significantly inhibits invasion of HCT116 cells.  
 
 
Figure 4.21 Invasion assay results for HCT116 cells following LY6G6F knockdown. Results 
graphed as % invasion (± SD) relative to the Negative siRNA (n=3). The invasion of HCT116 cells 
was significantly reduced after LY6G6F knockdown compared to the Negative control. Statistics: 
unpaired t-test (siRNA #1 p-value: 0.03, #2 p-value: 0.006, #3 p-value: 0.28) 
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4.8.2. Knockdown of LY6G6F in the PDAC Cell Line MIA PaCa-2 
Attempts were made to achieve protein knockdown of LY6G6F in the BxPC-3 PDAC cell 
line, one of the more highly LY6G6F expressing cell lines, as shown in Figure 4.3. However, 
no obvious protein knockdown was observed, therefore the MIA PaCa-2 cell line, one of the 
more lowly LY6G6F expressing cell lines was selected for functional analysis. The MIA 
PaCa-2 cell line displays sufficient levels of migration and invasion for analysis, with some 
of the other PDAC cells lines being very lowly invasive or display a clumpy growth 
morphology that would make counting migrated cells very difficult. Similar to the HCT116 
cell line, complete knockdown of LY6G6F protein was not achieved in the MIA PaCa-2 cell 
line. Figure 4.22 shows a representation of the amount of protein knockdown achieved in 
these cells 72hrs post transfection, with a bar chart of densitometry analysis visualising the 
approximate LY6G6F protein levels relative to cells only control. Cells were set up for 
functional assays at the 72hr time point, to determine what effect the partial protein 
knockdown has on proliferation, 2D colony formation, migration and invasion of these cells.   
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Figure 4.22 LY6G6F expression in MIA PaCa-2 cells following siRNA treatment. A: 
Representative Immunoblot showing MIA PaCa-2 cells probed for LY6G6F in cells only control, 
Negative siRNA transfected cells, and cells transfected with LY6G6F siRNA #1, 2, 3 (30nM siRNA 
concentration). α-tubulin was used as a loading control. B: Densitometry analysis of the representative 
blot shown in A, with results graphed as relative density of bands compared to cells only. Analysis 
performed using ImageJ software. 
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4.8.2.1. Proliferation of MIA PaCa-2 Cells post LY6G6F Knockdown 
Proliferation of MIA PaCa-2 cells was measured 72hrs post transfection by the acid 
phosphatase assay as described in Section 2.5.1. Figure 4.23 shows the percentage 
proliferation of cells relative to the Negative siRNA transfected cells. Knockdown of 
LY6G6F was found to significantly reduce proliferation compared to the Negative siRNA, 
with all 3 siRNAs used. The reduction in proliferation was minimal from 11% decrease with 
siRNA #2 to 20% with siRNA #1, and the largest decrease of 24% observed in siRNA #3 
treated cells. 
 
 
 
Figure 4.23 Proliferation assay on MIA PaCa-2 cells following LY6G6F knockdown. Results 
graphed as % survival (mean ± SD) relative to the Negative control siRNA. (n=5) The proliferation 
of MIA PaCa-2 cells was significantly reduced after LY6G6F knockdown compared to the Negative 
control. (siRNA #1 p-value: 0.0085, #2 p-value: 0.045, #3 p-value: 0.01. Students t-test unequal 
variance)  
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4.8.2.2. 2D Colony Formation of MIA PaCa-2 Cells post LY6G6F Knockdown 
2D colony formation assays were set up 72hrs post transfection, and colony formation 
analysed after 12 days.  Figure 4.24 shows representative results of this analysis, with 
representative images of the colony formation in 6 well plates and the percentage area 
covered and percentage intensity of colonies relative to the Negative siRNA transfected cells 
graphed. Knockdown of LY6G6F with two of the siRNAs was found to significantly 
decrease the colony forming ability of MIA PaCa-2 cells, with both the area and intensity of 
colonies reduced. The results for both LY6G6F siRNA #1 and #3 were deemed significant. 
LY6G6F siRNA #1 showed a 51.1% decrease in colony area and a 48.9% decrease in 
intensity. LY6G6F siRNA #3 gave a 31.7% decrease in colony area and a 40.4% decrease in 
intensity. Whilst the results for siRNA #2 were not found to be significant (due to high SD 
between replicates), it does follow the same trend with an average decrease of 30.4% in 
colony area and a 36.4% decrease in colony intensity. Therefore as 2/3 siRNAs show 
significance, it appears that knockdown of LY6G6F in the MIA PaCa-2 cell line, significantly 
reduces both the number (area) and size (intensity) of colonies formed compared to Negative 
siRNA treated cells.  
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Figure 4.24 2D colony formation of MIA PaCa-2 cells following LY6G6F knockdown. (A) 
Representative images showing the 2D colony formation in 6 well plates of MIA PaCa-2 cells only, 
cells transfected with Negative siRNA and LY6G6F siRNAs #1, 2 and 3. (B) Results graphed as % 
area covered and % intensity of colonies (mean ± SD) relative to the Negative control siRNA. (n=3) 
The 2D colony formation of MIA PaCa-2 cells was significantly reduced after LY6G6F knockdown 
compared to the Negative control. (siRNA #1: area p-value: 0.0014, intensity p-value 0.009; #3 area 
p-value: 0.016, intensity p-value: 0.015. Students t-test unequal variance) 
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4.8.2.3. Migration of MIA PaCa-2 Cells post LY6G6F Knockdown 
Migration assays were set up 72hrs post transfection and carried out as described in Section 
2.5.4, with cells allowed to migrate through the membrane for 40hrs before being fixed and 
stained with crystal violet. Figure 4.25 shows these results graphed as percentage migration 
relative to the Negative siRNA treated cells. No overall significant effect on the migration of 
these cells was observed. A significant reduction of 15% compared to the Negative siRNA 
was found for LY6G6F siRNA #3. However, siRNA #1 and 2 had no effect. Therefore, it 
appears that LY6G6F knockdown has no effect on MIA PaCa-2 cell migration. 
 
 
Figure 4.25 Migration assay results for MIA PaCa-2 cells following LY6G6F knockdown. 
Results graphed as % migration (± SD) relative to the Negative siRNA. (n=3) The migration of MIA 
PaCa-2 cells was significantly reduced after LY6G6F knockdown with siRNA #3 compared to the 
Negative control. However, no significant difference was found between LY6G6F siRNAs #1 and #2 
and the Negative control, indicating that overall the migration of MIA PaCa-2 cells is not affected by 
LY6G6F knockdown. Statistics: unpaired t-test (siRNA #1 p-value: 0.2, #2 p-value: 0.9, #3 p-value: 
0.01)  
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4.8.2.4. Invasion of MIA PaCa-2 Cells post LY6G6F Knockdown 
Invasion assays were set up 72hrs post transfection and carried out as described in Section 
2.5.3 with cells allowed to migrate through the Matrigel coated membrane for 40hrs before 
being fixed and stained with crystal violet. Figure 4.26 shows these results graphed as 
percentage invasion relative to the Negative siRNA treated cells. A significant reduction in 
invasion was observed for 2 out of the 3 siRNAs used in the analysis, with siRNA #3 showing 
the biggest decrease of 34%, followed by #1 showing a 26% decrease in invasion. LY6G6F 
siRNA #2 also showed a similar decrease of 25%, however this was not found to be 
significant. However as 2/3 siRNAs show significance, it appears that LY6G6F knockdown 
significantly inhibits invasion of MIA PaCa-2 cells.  
 
 
Figure 4.26 Invasion assay results for MIA PaCa-2 cells following LY6G6F knockdown. Results 
graphed as % invasion (± SD) relative to the Negative siRNA. (n=3) The invasion of MIA PaCa-2 
cells was significantly reduced after LY6G6F knockdown compared to the Negative control.  
Statistics: unpaired t-test (siRNA #1 p-value: 0.048, #2 p-value: 0.07, #3 p-value: 0.01) 
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4.8.3. Effect of LY6G6F Knockdown on FAK Activation and PARP Cleavage in 
HCT116 and MIA PaCa-2 Cells 
LY6G6F protein knockdown was found to significantly decrease the proliferation, migration 
and invasion of HCT116 and MIA PaCa-2 cells, as described in the previous Sections 4.8.1-
4.8.2. Therefore, it was decided to next examine various signalling pathways that may be 
affected and contributing to these phenotypic changes, in particular the activation of the 
p44/42 MAPK signalling pathway and the activation of FAK, as previous studies have 
strongly suggested the coupling of LY6G6F with these pathways. In order to determine the 
effect of LY6G6F knockdown on p44/42 MAPK and FAK activation, antibodies specific to 
phosphorylated forms and total protein were used for Western blot analysis 72hrs post 
LY6G6F siRNA transfection. In both cell lines, the effect of LY6G6F knockdown on the 
levels of phosphorylated p44/42 MAPK were inconsistent across triplicate experiments. 
(Data not shown) However, there was a marked decrease in the levels of phosphorylated-
FAK in both the HCT116 and MIA PaCa-2 cell lines, compared to the stable levels of total 
FAK, following knockdown of LY6G6F, as shown in Figure 4.27. A decrease in FAK 
activation was observed for all three LY6G6F siRNAs in the HCT116 cell line, and 
predominantly with just siRNA #1 and #3 in the MIA PaCa-2 cell line. This is consistent 
with the functional assay results for MIA PaCa-2 cells, were siRNAs #1 and #3 gave a higher 
and more significant reduction in proliferation, migration and invasion compared to the 
results for siRNA #2.  
Furthermore, to examine whether the decrease in proliferation observed in both cell lines is 
due to an increase in apoptotic cell death or cell cycle arrest, the expression of a small number 
of apoptotic and cell cycle markers was also assessed by Western blot analysis. The levels of 
the cell cycle markers, Cyclin A, which is expressed at a higher level in the G1/S phase 
transition of the cell cycle and p27, which controls cell cycle progression at G1, showed no 
apparent difference or inconsistent differences in expression between control cells and 
LY6G6F siRNA treated cells. (Data not shown) Therefore no conclusion can be made on 
whether LY6G6F knockdown leads to cell cycle arrest in these cell lines. To examine 
whether LY6G6F knockdown leads to an increase in apoptotic cell death, an antibody that 
recognises both full length (116kDa) Poly(ADP-ribose) polymerase (PARP) and also the 
89kDa fragment of cleaved PARP was used for Western blot analysis. PARP cleavage is a 
marker of cells undergoing apoptosis. These results are also shown in Figure 4.27. An 
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increase in the levels of cleaved PARP was observed in both cell lines, with LY6G6F siRNAs 
#1and #2 showing the biggest increase in the HCT116 cell line and LY6G6F siRNAs #1and 
#3 showing the biggest increase in the MIA PaCa-2 cell line vs. Negative siRNA treated 
cells. These results are consistent with the proliferation assay results for both cell lines, where 
siRNAs #1and #2 gave the biggest decrease in proliferation in the HCT116 cell line and 
siRNAs #1and #3 gave the biggest decrease in the MIA PaCa-2 cell line.  
Overall, LY6G6F knockdown has been shown to decrease FAK activation and increase 
apoptosis levels in the HCT116 and MIA PaCa-2 cell lines, indicating that the inhibitory 
effects observed on cell growth, migration and invasion may potentially be mediated by these 
pathways.  
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Figure 4.27 The effect of LY6G6F knockdown on FAK activation and PARP cleavage in 
HCT116 and MIA PaCa-2 cells. Representative Immunoblots showing the levels of phosphorylated 
and total FAK (A) and cleaved PARP (B) in HCT116 and MIA PaCa-2 cells transfected with LY6G6F 
siRNAs #1,2,3. (n=3) The levels of phosphorylated FAK are decreased with all three LY6G6F 
siRNAs in the HCT116 cell line, and reduced in LY6G6F siRNA #1 and #3 treated cells in the MIA 
PaCa-2 cell line compared to Negative siRNA treated cells. There is an increase in the levels of 
cleaved PARP in LY6G6F siRNA #1 and #2 treated HCT116 cells and in LY6G6F siRNA #1 and #3 
treated MIA PaCa-2 cells compared to the Negative siRNA control cells.  
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4.8.4. Summary of Functional Analysis of LY6G6F Protein Knockdown 
v LY6G6F protein knockdown was found to significantly decrease the proliferation of 
both HCT116 and MIA PaCa-2 cells, as determined by both the acid phosphatase 
assay and the 2D colony formation assay. This decrease in proliferation was 
significant for both the acid phosphatase assay and 2D colony formation assay in the 
MIA PaCa-2 cell line. In the HCT116 cell line, the decrease found in the acid 
phosphatase assay was significant, with the 2D colony formation assay showing a 
trend towards decreased colony formation.  
v A significant reduction in the migration and invasion of HCT116 cells was observed. 
v No overall effect was observed on the migration of MIA PaCa-2 cells, but a 
significant reduction in invasion was observed. 
v A decrease in FAK activation, and an increase in apoptosis (as determined by the 
presence of increased PARP cleavage), was observed in both the HCT116 and MIA 
PaCa-2 cell lines following LY6G6F knockdown, indicating that these are some of 
the mechanisms of action mediating the phenotypic effects observed.  
v Taken together with the IHC analysis, which showed a significant increase in 
LY6G6F expression in colon adenocarcinoma and PDAC tumours compared to 
normal tissues, with decreased survival observed in the PDAC patients with high 
LY6G6F expression vs. low LY6G6F expression, a role for LY6G6F in the growth 
and survival of these cancers is implicated.  
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4.9. LY6G6F mRNA Expression 
4.9.1. LY6G6F mRNA Expression in HCT116 and MIA PaCa-2 Cells post LY6G6F 
siRNA Transfection  
The amount of LY6G6F protein knockdown achieved in the HCT116 and MIA PaCa-2 cell 
lines was often variable. Therefore qRT-PCR was used to determine what effect the LY6G6F 
siRNAs have on the mRNA levels in these cell lines. Total mRNA was extracted from cells 
48hrs post transfection as described in Section 2.9.1, and converted to cDNA template for 
qRT-PCR. The LY6G6F siRNAs #1, 2, 3 and the Negative siRNA that were used in the 
functional analysis in Section 4.8, as well as siRNAs sourced from another company 
(Ambion), labelled Negative siRNA A, LY6G6F siRNAs A1, A2 and A3, were used in this 
analysis. Table 4.14 shows the Ct (threshold cycle) values obtained for each of these samples 
with a concentration of 40ng cDNA per well. The Ct values indicate the number of cycles it 
took to detect a real signal from the sample, with higher Ct values indicating lower amounts 
of target nucleic acid in the sample. The Ct values for cells only of both HCT116 and MIA 
PaCa-2 are quite high (>35). In general samples with a Ct of 30 or higher are not considered 
reliable data, or indicate that if the transcript is present, it’s at low levels. 
However as shown in Table 4.14 there are some differences in Ct values for the siRNA 
treated samples, with all LY6G6F siRNA treated cells having higher Ct values than cells only 
(some are not determined: CT > 40). The relative quantitation (RQ) of LY6G6F expression 
was calculated in the samples compared to cells only and normalised to the endogenous 
control gene B2M. Figure 4.28 shows this RQ for each sample in the HCT116 cell line 
graphed as fold change (FC) relative to cells only (LY6G6F siRNA #1 was undetermined, Ct 
>40; therefore, this is not represented on the graph). These results show that whilst both of 
the Negative siRNAs analysed show LY6G6F mRNA levels similar to cells only, there is a 
decrease in the amount of LY6G6F mRNA detected in all of the LY6G6F siRNA treated 
cells. Figure 4.29 shows the FC results for the MIA PaCa-2 cell line (LY6G6F siRNA #3 
was undetermined and siRNA A1 was not tested, therefore these are not graphed). Combined 
with the Negative siRNA result there is no apparent change in LY6G6F mRNA level with 
siRNAs #1 and #2. There is however a decrease with the second set of siRNAs, A2 and A3. 
These results represent only one biological experiment.  
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Sample HCT116 Ct value MIA PaCa-2 Ct value 
Cells only 36.1 36.8 
Negative siRNA 36.3 37.7 
LY6G6F siRNA #1 Undetermined 37.1 
LY6G6F siRNA #2 36.7 37.4 
LY6G6F siRNA #3 37.6 Undetermined 
Negative siRNA A 36 37.1 
LY6G6F siRNA A1 36.2 - 
LY6G6F siRNA A2 37.5 37.9 
LY6G6F siRNA A3 37.5 38.7 
Table 4.14 Results from qRT-PCR analysis of LY6G6F mRNA expression, showing the average 
Ct values for HCT116 and MIA PaCa-2 cells only and cells treated with Negative siRNAs and 
LY6G6F siRNAs. (n=1) 
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Figure 4.28 Relative quantitation of LY6G6F mRNA in HCT116 siRNA transfected cells 
compared to cells only and normalised to B2M by qRT-PCR. (Results represent one biological 
experiment) 
 
 
 
Figure 4.29 Relative quantitation of LY6G6F mRNA in MIA PaCa-2 siRNA transfected cells 
compared to cells only and normalised to B2M by qRT-PCR. (Results represent one biological 
experiment) 
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These results are not conclusive as the Ct values are >30 and the RQ was carried out for 1 
biological experiment. However, the increased Cts observed in the LY6G6F siRNA treated 
cells could indicate that LY6G6F mRNA transcript is present and being reduced by siRNA 
treatment. To determine if lower Ct values could be obtained, the amount of cDNA template 
for HCT116 and MIA PaCa-2 cells only samples was increased from 40ng to 140ng cDNA 
per PCR reaction well. (100ng was actually the maximum amount indicated to use in the 
mastermix protocol) These results are shown in Table 4.15 and indicate that even though the 
Ct values are >30, LY6G6F mRNA transcript is present in the cells, as the Ct value decreases 
upon the addition of more cDNA template. The Ct values decrease by 2 in both cell lines 
(36.8 to 34.8 in MIA PaCa-2; 36.1 to 34.1 in HCT116), which is what could be expected 
upon the addition of 3.5 times the amount of template, as 1 Ct value is roughly equivalent to 
a doubling in template cDNA.  
Additionally, the no template control (NTC) sample did not give a signal in the qRT-PCR 
reaction (undetermined result), which increases confidence that the signal observed for 
LY6G6F is due to the transcript being present and not a non-specific signal. The NTC 
contains all of the reagents in the qRT-PCR reaction minus the cDNA template. A signal 
from this sample could indicate contamination or primer-dimer formation. The No RT control 
(everything except reverse transcriptase enzyme) also detected no signal in the qRT-PCR 
reaction. This suggests that LY6G6F mRNA is present at low abundance in HCT116 and 
MIA PaCa-2 cells, which makes it difficult to detect knockdown at the mRNA level. 
However, the preliminary RQ does show a decrease in LY6G6F mRNA with all siRNAs in 
the HCT116 cell line, and some of the siRNAs in the MIA PaCa-2 cell line. 
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Sample Ct value 
MIA PaCa-2 (40ng cDNA) 36.8 
MIA PaCa-2 (140ng cDNA) 34.8 
HCT116 (40ng cDNA) 36.1 
HCT116 (140ng cDNA) 34.1 
Table 4.15  LY6G6F mRNA expression in MIA PaCa-2 and HCT116 cells determined by qRT-
PCR analysis. The average Ct values for MIA PaCa-2 and HCT116 cells are shown, when the amount 
of cDNA template is increased from 40-140ng in the PCR reaction.  
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4.9.2. LY6G6F mRNA Expression in Cell Lines 
To ensure that the low level of LY6G6F mRNA detected in HCT116 and MIA PaCa-2 cells 
wasn’t due to inefficiency of the LY6G6F Taqman assay used, a second LY6G6F assay was 
obtained for analysis. These Taqman assays contain primers specific to LY6G6F for 
amplification and fluorescent probes specific to different areas of the LY6G6F mRNA 
sequence. The release of these probes upon LY6G6F amplification is what gives the gene 
expression signal in the qRT-PCR analysis. The PDAC cell lines MIA PaCa-2 and BXPC-3, 
the colon cancer cell lines SW480 and HT29, and the CML cell line K562 (a LY6G6F 
expressing cell line according to the literature), were analysed for LY6G6F mRNA 
expression using both probes by qRT-PCR. Figure 4.30 shows the Ct values obtained in this 
analysis. Both probes give nearly the same result in the MIA PaCa-2 cell line (34.4 with 
probe 1 and 32.8 with probe 2) indicating that LY6G6F mRNA is lowly abundant in this cell 
line. LY6G6F mRNA appears to be lowly abundant in the BXPC-3, SW480 and HT29 cell 
lines using probe 1 also, with probe 2 giving a similar result in the HT29 cell line. However, 
probe 2 does differ from probe 1 in the Ct values obtained for BXPC-3 and SW480 cells. The 
second probe gives a Ct value <30 for both cell lines. This discrepancy between probes could 
perhaps be due to varying primer efficiency rates. Both probes detect LY6G6F mRNA in the 
K562 cell line at a similar level, with a Ct value of 28. Therefore, LY6G6F mRNA appears 
to be present at low levels in the PDAC and colon cancer cell lines analysed.  
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Figure 4.30 LY6G6F mRNA expression in a cell line panel determined by qRT-PCR analysis. 
The average Ct values obtained using two independent LY6G6F Taqman assays are shown for five 
cell lines: MIA PaCa-2, BXPC-3, SW480, HT29 and K562. (100ng cDNA/well; Results represent 
one biological experiment) 
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4.10. Overexpression of LY6G6F in MIA PaCa-2 and SW480 Cell Lines 
To further investigate the functional role of LY6G6F in the CRC and PDAC cancer cell 
phenotype, it was decided to overexpress LY6G6F by vector transformation. A commercial 
transfection ready cloning vector containing the LY6G6F sequence (Acc no: 
NM_001003693) was obtained (GenScript). Figure 4.31 shows the map of the vector used. 
The vector contains Amp and Neo genes for antibiotic selection of bacterial and mammalian 
transformed cells. The LY6G6F overexpressed protein will contain a C-terminal 
DYKDDDDK tag (FLAG-tag), which will allow confirmation of overexpression by Western 
blot analysis. An anti-FLAG-tag antibody should detect a band at the corresponding MW of 
the target protein i.e. at ~ 32kDA for LY6G6F. An empty vector control – the same vector 
containing everything except target ORF sequence was also obtained.  
The PDAC cell line MIA PaCa-2 and the CRC cell line SW480 were chosen for 
overexpression as they both express lower levels of LY6G6F protein (see Figure 4.3 and 
Figure 3.1). Overexpression of LY6G6F in these cell lines followed by in vitro functional 
analysis will enable us to determine if overexpression of LY6G6F has any effect on the 
phenotype of these cells. LY6G6F overexpressing cells can also be used as a positive control 
for qRT-PCR analysis. Transfection optimisation was carried out as described in Section 
2.10.1. Following vector transfection cells were placed under G418 antibiotic selection, with 
the optimal concentration for each cell line having been previously determined by setting up 
a kill curve (Section 2.10.2).   
Following selection qRT-PCR analysis of the MIA PaCa-2 and SW480 empty vector (E.V.) 
and LY6G6F overexpression (O.E.) cell lines was carried out as described in Section 2.9. 
The two independent LY6G6F Taqman assays, described in Section 4.9.2, were used. Figure 
4.32 shows the Ct value results of this analysis for the MIA PaCa-2 cell line. Both probes 
confirm overexpression of LY6G6F mRNA compared to both cells only and E.V. control, 
with a big increase in the amount of LY6G6F mRNA in the overexpression cells. In the 
SW480 cell line the two independent Taqman assays had given different results, as shown in 
Figure 4.30. The Ct value results of the overexpression in this cell line are shown in Figure 
4.33, with the varying Ct values between the two assays again observed for cells only and 
E.V samples. LY6G6F probe 2 gives a substantially lower Ct value in these samples 
compared to probe 1 (~9 Cts lower). Both probes then give a similar result in the O.E. 
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samples. They both confirm overexpression of LY6G6F mRNA, yielding Ct values of 18.2 
and 19.3 respectively. It is not clear why they also do not differ by ~9 Ct values, like the 
other samples. But regardless overexpression has been confirmed.  
LY6G6F mRNA overexpression was confirmed in both cell lines, however overexpression 
at the protein level was not. Figure 4.34 shows representative Western blot images of MIA 
PaCa-2 cells only, E.V. and LY6G6F O.E. cell lysates, and SW480 E.V. and LY6G6F O.E 
cell lysates probed for LY6G6F. Western blot images of these samples probed for FLAG-tag 
is also shown. No increase in LY6G6F protein was observed in either the MIA PaCa-2 or 
SW480 cell lines (in duplicate biological experiments). It could not be confirmed whether 
the vector expressed version of LY6G6F protein was present at all in the samples, as the 
FLAG-tag blot gave inconclusive results. The FLAG-tag is attached to the C-terminal end of 
LY6G6F overexpressed protein, therefore a band around the same MW as LY6G6F should 
appear (the FLAG-tag is so small it shouldn’t visibly effect the MW of LY6G6F). However, 
the FLAG-tag probed blot gave a strange result, with multiple bands appearing in all samples. 
Samples were only probed for FLAG-tag once, the antibody may need to be diluted to give 
a better result.  
Therefore, without a clear FLAG-tag result, it cannot be concluded if following 
overexpression, the LY6G6F vector derived protein is being expressed or not. The Western 
blot analysis does not show any increase in LY6G6F protein, despite high LY6G6F mRNA 
overexpression in these cells. Preliminary functional analysis of the effect of LY6G6F 
mRNA overexpression on proliferation of MIA PaCa-2 cells is shown in Figure 4.35, with 
no effect observed on the proliferation rate compared to cells only. Post-translational 
regulation could be inhibiting the translation of the overexpressed mRNA into protein. The 
FLAG-tag analysis needs to be repeated to try and get a conclusive result. 
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Figure 4.31 Vector map of the LY6G6F overexpression vector. The target ORF (LY6G6F; 
NM_001003693) expression is driven by a CMV promoter. Kozak sequence initiates the mRNA 
translation process into protein.  A C-terminal DYKDDDDK tag (FLAG-tag) is attached to the 
LY6G6F sequence.  
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Figure 4.32 LY6G6F mRNA expression in MIA PaCa-2 cells only and cells transfected with an 
empty vector and LY6G6F overexpression vector, determined by qRT-PCR analysis. The 
average Ct values obtained using two independent LY6G6F Taqman assays are shown. (100ng 
cDNA/well; Results represent one biological experiment) 
 
 
Figure 4.33 LY6G6F mRNA expression in SW480 cells only and cells transfected with an empty 
vector and LY6G6F overexpression vector, determined by qRT-PCR analysis. The average Ct 
values obtained using two independent LY6G6F Taqman assays are shown. (100ng cDNA/well; 
Results represent one biological experiment) 
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Figure 4.34 Representative Western blot probing for LY6G6F and FLAG-tag. Results are shown 
for MIA PaCa-2 cells only, E.V. and LY6G6F O.E. on the first blot and SW480 E.V. and LY6G6F 
O.E. on the second blot, both probed for LY6G6F, with no apparent protein overexpression of 
LY6G6F observed. The same samples probed for FLAG-tag, which should only be detected at 
LY6G6F MW in the LY6G6F O.E. samples, gave an inconclusive result, as multiple bands are visible 
in all wells. (n=2) 
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Figure 4.35 Proliferation assay on MIA PaCa-2 cells only and MIA PaCa-2 E.V. and LY6G6F 
O.E cells. Results graphed as % proliferation relative to cells only.  (n=1) 
 
 
 
 
 
 
 
 
 
 
 
 
  165 
4.11. Attempted Immunoprecipitation of LY6G6F 
To further investigate the role of LY6G6F in the cancer cell phenotype, co-
immunoprecipitation (Co-IP) of LY6G6F was attempted. Co-IP involves using a specific 
antibody to a target to isolate it from a complex mixture (e.g. cell lysate) along with any 
interacting proteins or ligands that may be bound to the target protein. Co-IP can identify 
complex partners, signalling molecules, structural proteins etc. that are bound to the protein 
of interest. An IP lysis buffer is used which will effectively solubilise cellular proteins but 
won’t disrupt protein complexes. Two different methods were used in the attempt to 
immunoprecipitate LY6G6F from both MIA PaCa-2 and HCT116 cell lysates: cross-linked 
Co-IP and traditional Co-IP, which were carried out as described in Section 2.11. 
Traditional Co-IP involves the use of Protein A/G (immunoglobulin binding proteins) 
agarose beads, to isolate the antibody-protein of interest complex. This method results in both 
the antibody and the protein of interest (and any interacting proteins) ending up in the elution. 
The contaminating antibody in the elution, results in antibody heavy chain (55kDa) and light 
chain (25kDa) fragments showing up in Western blot analysis, which can be a problem for 
target protein detection, if it has a similar MW. The cross-linked Co-IP method involves 
covalently immobilising the antibody by cross-linking to an agarose resin in a column. This 
allows target protein isolation and elution without antibody contamination, and the antibody 
column can also be reused.  
Both methods however were unsuccessful in LY6G6F precipitation from MIA PaCa-2 and 
HCT116 lysates. Two independent LY6G6F antibodies were used (neither listed IP as a 
proven application). LY6G6F was never detected in the elutions by either method. Figure 
4.36 shows a representative blot of traditional Co-IP of MIA PaCa-2 cells. LY6G6F was 
detected in the control lysate, confirming the antibody can detect LY6G6F protein from cells 
lysed with a less stringent lysis buffer. However, in the LY6G6F elutions, no LY6G6F band 
was detected. As the LY6G6F antibody was produced in rabbit, a rabbit IgG control antibody 
was also used, to confirm that any proteins isolated were not from non-specific rabbit IgG 
interactions. Strong heavy and light chain antibody fragments were observed in the LY6G6F 
and Rabbit IgG elutions.  
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Figure 4.36 Western blot probing for LY6G6F in MIA PaCa-2 samples following traditional IP 
with Protein G agarose beads. Lanes 1 and 2 show MIA PaCa-2 IP lysate control, with LY6G6F 
detected in between 30 and 40kDa. Non-specific bands higher up, are also observed. Lanes 3 and 4 
show the first and second elution from LY6G6F Co-IP, with no LY6G6F band detected. Lanes 5 and 
6 show the first and second elution from the Rabbit IgG control. Heavy and light chain antibody 
fragments at 55kDa and 25kDa are visible in LY6G6F and Rabbit IgG elutions.   
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4.12. Summary  
LY6G6F has been found to be significantly overexpressed in colon adenocarcinoma, PDAC 
and gastric adenocarcinoma compared to corresponding normal tissues. Weak expression 
was observed in the small number of breast cancer and oesophageal cancer specimens 
analysed. LY6G6F is significantly overexpressed in colon adenocarcinoma, irrespective of 
KRAS or BRAF mutational status vs. normal colon. LY6G6F is also significantly 
overexpressed in the benign spectrum that precedes cancer, with strong expression observed 
in hyperplasia, polyps and adenoma vs. normal colon. Weak LY6G6F expression was 
observed in the majority of the other CRC subtypes analysed: mucinous adenocarcinoma, 
carcinoid cancer and metastatic adenocarcinoma.  
In PDAC, LY6G6F is highly expressed in the majority of tumours, with intense 
immunoreactivity observed compared to negative or weak immunoreactivity in normal 
pancreas. Strong LY6G6F immunoreactivity has also been observed in the stroma of PDAC 
specimens. The majority of normal gastric epithelium specimens analysed did show some 
weak and diffuse LY6G6F immunoreactivity. However the strong expression observed in 
50% of the gastric adenocarcinomas analysed was found to be a significant overexpression 
compared to normal tissue expression.  
High LY6G6F expression has been associated with poorer survival in both gastric cancer and 
PDAC. Data from the online KM plotter analysis showed that high LY6G6F gene expression 
is significantly associated with poorer survival in gastric cancer patients. Our data of 
LY6G6F protein expression in PDAC patients showed a trend towards high LY6G6F 
expression and poorer survival in this patient cohort, compared to patients with low LY6G6F 
expression, this did not reach significance however. 
The analysis of LY6G6F expression in normal tissues showed a predominantly negative or 
weak expression pattern, with no apparent expression in highly proliferating cells of normal 
tissues. In a small subset of normal tissues (pancreas, bladder, kidney, larynx and salivary 
gland) some stronger LY6G6F immunoreactivity was observed in the stroma of the tissues.  
LY6G6F was shown to be expressed in all CRC and PDAC cell lines analysed, with 
expression also detected in the membrane enriched fraction of these cells lines. Expression 
was also detected in a panel of breast cancer cell lines, with lower expression observed in the 
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Basal subtype. In the Immunohistochemical analysis, the localisation of LY6G6F was mainly 
observed as strong granular cytoplasmic immunoreactivity, with membrane-like 
immunoreactivity only observed in a small number of specimens. Immunofluorescence and 
Immunocytochemical analysis of MIA PaCa-2 cells, to further investigate the cellular 
localisation of LY6G6F, also showed mainly cytoplasmic localisation in these cells.  
Transient protein knockdown of LY6G6F in the HCT116 and MIA PaCa-2 cell lines, 
followed by functional analysis, showed a significant decrease in proliferation in both cell 
lines. There was also a significant decrease in the 2D colony formation of MIA PaCa-2 cells, 
with a decrease also observed in the HCT116 cell lines, which failed to reach significance, 
due to high variability between biological replicates. LY6G6F protein knockdown was also 
found to decrease the migration and invasion of both cell lines. In the HCT116 cell line, a 
significant reduction was observed in both the migration and invasion of cells. In the MIA 
PaCa-2 cell line, a significant decrease was found in the invasion of cells, and a trend towards 
a decrease in migration. Subsequently, the potential mechanism of action of these observed 
phenotypic effects, was determined to be due to a decrease in FAK activation and an increase 
in apoptotic cell death in these cells following LY6G6F knockdown. This indicates a 
potential role for LY6G6F in FAK activation and apoptosis regulation.  
Analysis of LY6G6F mRNA expression levels in these cell lines was not carried out until 
after functional analysis had been started, and unexpectedly showed that LY6G6F appears to 
have quite low mRNA abundance levels in these cells. The analysis indicates LY6G6F 
mRNA is present at low levels, but the protein knockdown observed by Western blot 
analysis, indicates that the LY6G6F siRNAs are sufficiently targeting LY6G6F mRNA for 
destruction, with the effect this has on HCT116 and MIA PaCa-2 cells shown in the 
functional analysis. 
Attempts to determine the effect LY6G6F protein overexpression has on the functional 
phenotype of SW480 and MIA PaCa-2 cells, by transfection with a LY6G6F overexpression 
vector, could not be completed. High overexpression of LY6G6F mRNA was confirmed in 
these cells by qRT-PCR analysis, however protein overexpression was not observed. 
Unfortunately, time did not allow for optimisation, therefore functional analysis could not be 
carried out. Attempts at further investigation of the functional role of LY6G6F in the cancer 
cell phenotype by Co-IP, to try and identify protein-protein interactions involving LY6G6F, 
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also proved unsuccessful. LY6G6F was not successfully immunoprecipitated, which may 
have been due to the commercial antibodies used, with none listing IP as a proven application. 
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Chapter 5. IL1RAPL1 
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5.1. IL1RAPL1  
IL-1 receptor accessory protein-like 1 (IL1RAPL1) was first identified as a novel member of 
the IL-1R family, in a search of DNA sequence databases for genes involved in mental 
retardation and named for its homology to IL-1 receptor accessory protein (IL1RAP). 
IL1RAPL1 is located on chromosome Xp and encodes a protein of 696 amino acids and has 
structural and sequence homology with other molecules of the IL-1R family, except for an 
unusually long intracytoplasmic portion. A 150 amino acid long C-terminal extension 
specific to IL1RAPL1 was found to have no significant homology with any protein of known 
function. IL1RAPL1 was originally found to not bind any of the IL-1 family cytokines and 
did not show IL-1R like signalling capacity. (Chelly et al., 1999; Born et al., 2000; Bahi et 
al., 2003)   
IL1RAPL1 is abundantly expressed in the brain, in particular in the structures of the 
hippocampal memory system, leading to a hypothesis for a potential role in brain 
development and/or physiological processes underlying memory and learning. Mutations in 
IL1RAPL1 were found to be associated with X-linked intellectual disability, autism and 
schizophrenia. (Piton et al., 2008) Studies in an artificial cell transfection system showed that 
alone IL1RAPL1 is unable to activate pathways classically involved in IL-1 signalling, such 
as, NF-κB, or the MAP kinases ERK and p38, but was able to activate JNK. (Khan et al., 
2004) Further studies of the activation of JNK by IL1RAPL1 suggest it is independent of the 
TIR domain, as truncation mutants missing part of or even the entire TIR domain were found 
to be able to activate JNK to the same extent as the full-length receptor. IL1RAPL1 may be 
able to activate JNK by recruiting other molecules through its extracellular domain. 
IL1RAPL1 was shown to be present in dendritic spine, where it interacts with PSD-95, a 
major scaffold protein of excitatory post-synaptic density. IL1RAPL1 is reported to regulate 
the synaptic localisation of PSD-95 by controlling JNK activity and PSD-95 phosphorylation. 
Despite previous reports suggesting IL1RAPL1 is not capable of binding IL-1, it has 
subsequently been shown that the activation of the JNK pathway in neurons by IL-1 is 
mediated by IL1RAPL1. (Pavlowsky et al., 2010; Boraschi and Tagliabue, 2013)  
The 150 amino acid C-terminal extension of IL1RAPL1 was later found to interact with the 
neuronal calcium sensor 1 (NCS-1) protein (which is upregulated in schizophrenic and 
bipolar patients). Via the NCS-1 interaction, IL1RAPL1 plays a role in the down-regulation 
  172 
of voltage-dependent calcium channels activity, in calcium-dependent exocytosis and nerve 
growth factor (NGF)-induced neurite outgrowth. IL1RAPL1 was shown to be an important 
regulator of synapse formation and stabilisation in cortical neurons. Therefore IL1RAPL1 
has an important role in cognitive functions. (Khan et al., 2004; Piton et al., 2008) 
IL1RAPL1 has been reported as being a common fragile site (CFS) gene contained within 
the FRAXC CFS region. Common fragile sites (CFSs) are large regions of profound genomic 
instability found in all individuals. They are biologically significant due to their role in a 
number of genomic alterations that are frequently found in many different types of cancer. 
IL1RAPL1 is abundantly expressed in normal brain but was found to be dramatically 
underexpressed in every brain tumour cell line and xenograft, derived from an intracranial 
model of glioblastoma multiforme (GBM), examined in one study. (Smith et al., 2006; 
McAvoy et al., 2007) However another study that classified GBM into different subtypes, 
linked IL1RAPL1 expression to the proneural subtype. (Cruceru et al., 2013) In summary, 
IL1RAPL1 has mainly been linked with cognitive impairments due to mutations in the gene. 
It has been reported as both downregulated in brain tumours and associated with a particular 
genetic subset, the proneural subtype. IL1RAPL1 expression in other types of cancer has not 
been widely reported on.  
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5.2. Preliminary Analysis of IL1RAPL1 Expression in PDAC, Oesophageal Cancer and 
Breast Cancer    
IL1RAPL1 was found to be overexpressed in a small cohort of colon adenocarcinomas vs. 
normal colon, as described in Section 3.2.2. In addition to investigating the expression of 
IL1RAPL1 further in CRC, a preliminary screen of several other cancers was also carried 
out, to determine if IL1RAPL1 is differentially expressed in any of those. The results of this 
preliminary screen are described below.   
 
5.2.1. Immunohistochemical Analysis  
As described already in Section 4.2.1, we had access to a limited number of tissue sections 
from a variety of different cancers, as well as normal tissue sections from those organs, 
enabling a screen for IL1RAPL1 expression across these cancer types by IHC analysis. 
IL1RAPL1 expression was examined in breast cancer (n=4), oesophageal cancer (n=1) and 
PDAC (n=7). Figure 5.1 shows some representative photomicrographs of the results 
obtained. IL1RAPL1 showed negative immunoreactivity in normal oesophagus (n=1) but 
was strongly expressed in a malignant oesophagus tissue section. Some weak IL1RAPL1 
positive expression was observed in the ducts of normal breast (n=3), with stronger 
expression observed in one of the invasive breast cancer specimens analysed, but the majority 
of breast cancer sections did not show stronger expression vs. normal breast. Normal 
pancreas (n=2) displayed negative to weak diffuse immunoreactivity in some areas, with the 
majority of PDAC sections analysed showing negative-weak IL1RAPL1 expression. 
Therefore, increased expression of IL1RAPL1 does not appear to be present in breast cancer 
or PDAC. However, the strong expression in oesophageal cancer compared to negative 
expression in normal oesophagus, suggests further investigation of IL1RAPL1 expression in 
this cancer types should be carried out.  
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Figure 5.1 IHC analysis of IL1RAPL1 expression in normal and cancer tissues. Representative 
images showing: (A) Normal pancreas with negative IL1RAPL1 immunoreactivity. (B) PDAC with 
negative immunoreactivity. (C) Normal breast with weak immunoreactivity in ducts. (D) Breast 
cancer with strong cytoplasmic immunoreactivity. (E) Normal oesophagus with negligible 
IL1RAPL1 immunoreactivity. (F) Malignant oesophagus with strong immunoreactivity. Original 
magnification 200x. The scale bars represent 200µm. 
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5.2.2. IL1RAPL1 Expression in PDAC and Breast Cancer Cell Line Panels  
IL1RAPL1 expression in both the whole cell and membrane enriched fraction of colon cancer 
cell lines has already been confirmed, see Section 3.2.2.1. The expression of IL1RAPL1 in a 
panel of PDAC cell lines and breast cancer cell lines was also investigated by Western blot 
analysis, refer to Table 4.1 and Table 4.2 for information on the source and mutational status 
of these cell lines. Figure 5.2 shows the results of the Western blot analysis of the breast 
cancer cell line panel. IL1RAPL1 is expressed in the whole cell and membrane enriched 
fraction of all cell lines analysed, with no apparent differential expression according to 
subtype.  
Figure 5.3 shows the results of the Western blot analysis for some of the PDAC cell line 
panel and also includes conditioned medium (CM) samples from MIA PaCa-2 and BXPC-3 
cells on the end of each blot. The CM was prepared as described in Section 2.3.3, and contains 
proteins that are secreted by the cell lines. IL1RAPL1 is observed in the whole cell and 
membrane enriched fraction of all PDAC cell lines analysed at the expected MW of ~69kDa, 
with no apparent differential expression. A second lower band (in between the 50 and 60kDa 
MW marker) is also observed in the whole cell lysate of all cell lines, and corresponds to the 
single band observed in the CM samples. This indicates a secreted form of IL1RAPL1 is 
produced by these cells.  
The original Western blot analysis of the colon cancer cell line panel did not reveal a second 
lower band, however repeat analysis, shown in Figure 5.4, detected the lower band in three 
of the cell lines, SW480, SW620 and CaCo-2. Therefore, the lower band identified in the 
Western blot analysis could be a soluble form of IL1RAPL1.   
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Figure 5.2 Western blot analysis showing IL1RAPL1 expression in the whole cell and 
membrane enriched fraction of a panel of breast cancer cell lines. α-tubulin confirmed equal 
loading of total proteins in the whole cell lysate. (n=1) 
 
 
Figure 5.3 Western blot analysis showing IL1RAPL1 expression in the whole cell and 
membrane enriched fraction of a panel of PDAC cell lines and CM from MIA PaCa-2 and 
BXPC-3 cells. IL1RAPL1 is detected at the predicted MW of ~69kDA. A lower band that is the only 
one present in CM samples, indicates a secreted form of IL1RAPL1 is expressed by these cell lines.  
α-tubulin confirmed equal loading of total proteins in the whole cell lysate (blot not shown). (n=1)  
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Figure 5.4 Representative Immunoblot showing IL1RAPL1 expression in the whole cell lysate 
of a panel of colon cancer cell lines. IL1RAPL1 bands are detected at the predicted MW of ~69kDA, 
in between the 60 and 80 kDa MW marker. A second lower band, in between 50 and 60kDA, is also 
detected in the SW480, SW620 and CaCo2 cell lines. This is potentially a secreted isoform of 
IL1RAPL1.  
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5.2.3. Summary of Analysis of IL1RAPL1 Expression across Various Cancer Types 
In addition to CRC, further IHC validation studies indicated IL1RAPL1 is highly expressed 
in oesophageal cancer, compared to negligible expression in normal oesophagus. IL1RAPL1 
does not appear to be highly expressed in PDAC tissues, however it was found to be 
expressed in all PDAC cell lines analysed. Western blot analysis revealed a potential 
soluble/secreted isoform of IL1RAPL1 expressed in all of the PDAC cell lines and some of 
the colon cancer cell lines. IL1RAPL1 is expressed in all breast cancer cell lines analysed, 
with some breast cancer tissues showing strong expression. However, with the majority of 
breast cancer sections showing weak immunoreactivity, it was decided to focus on CRC and 
oesophageal cancer in this study, (both gastrointestinal malignancies), for further 
investigation of IL1RAPL1 expression. 
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5.3. IL1RAPL1 Expression in Normal Colon and CRC 
In order to investigate IL1RAPL1 expression in a larger patient cohort of CRC by 
Immunohistochemical analysis, a combination of commercial tissue microarray (TMA) and 
full-face tissue sections was used, as described in Section 4.3. The same commercial TMAs 
- colon disease spectrum TMA (CO2081, Biomax US) and the small CRC TMA (Accumax 
A713 VIII), that was used in the LY6G6F analysis, was used in the IL1RAPL1 analysis. The 
colon cancer disease spectrum TMA contains samples from normal colon, normal cancer 
adjacent (NAT) colon, chronic inflammation of mucosa, hyperplasia of glandular epithelium, 
polyps, adenoma, colon adenocarcinoma, mucinous adenocarcinoma, carcinoid tumours and 
metastatic adenocarcinoma, as outlined in Figure 4.4. The full-face tissue sections consisted 
of: 9 KRAS MT phenotype, 9 KRAS WT, 2 BRAF MT and 2 BRAF WT colon 
adenocarcinoma tissue sections. A number of normal colon sections were also available. 
Tissues were scored for IL1RAPL1 immunoreactivity as outlined in Table 4.4. The total 
number of each specimen analysed and their IL1RAPL1 immunoreactivity score from 0-3+ 
is outlined in Table 5.1. The majority of normal colon and NAT colon were negative for 
IL1RAPL1 expression. Combining these two groups, 66.7% (28/42) of normal colon were 
negative for IL1RAPL1 immunoreactivity, 28.6% (12/42) scored as 1+ and just 4.7% (2/42) 
scored as 3+. The scores for the whole spectrum were grouped into those specimens with 
negative or low levels of IL1RAPL1 expression (0-1+) and those showing high IL1RAPL1 
expression (2-3+) for analysis. The expression levels observed in the benign and cancer 
spectrum were compared to the expression in normal colon (including NAT colon) by Chi-
square test, to determine whether there is any significant association between IL1RAPL1 
expression in any of the specimens. These results are shown in Table 5.2.  
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Specimen: 
No. of 
cases 
IL1RAPL1 Score  
0 1+ 2+ 3+ 
Normal colon 20 12 6 - 2 
NAT colon 22 16 6 - - 
Chronic 
Inflammation 
10 8 2 - - 
Hyperplasia 7 3 4 - - 
Polyps 6 3 3 - - 
Adenoma 5 2 3 - - 
Adenocarcinoma 51 2 15 18 16 
- KRAS MT 9 - 3 3 3 
- KRAS WT 9 - 1 5 3 
- BRAF MT 2 - - - 2 
- BRAF WT 2 - - - 2 
Mucinous 
adenocarcinoma 
15 2 6 5 2 
Carcinoid 2 - - - 2 
Metastatic 
adenocarcinoma 
19 - 10 8 1 
Table 5.1 IL1RAPL1 expression by IHC score in the colon disease spectrum.  
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 IL1RAPL1 expression  
Specimen: 
No. of 
cases 
Low (0-1+) High (2-3+) p-value 
Normal colon + 
NAT colon  
42 40 (95.2%) 2 (4.8%)  
Chronic 
Inflammation 
10 10 (100%) 0 NS 
Hyperplasia 7 7 (100%) 0 NS 
Polyps 6 6 (100%) 0 NS 
Adenoma 5 5 (100%) 0 NS 
Adenocarcinoma 51 17 (33.3%) 34 (66.7%) <0.0001 
- KRAS MT 9 3 (33.3%) 6 (66.7%)  
- KRAS WT 9 1 (11.1%) 8 (88.9%)  
- BRAF MT 2 0 2 (100%)  
- BRAF WT 2 0 2 (100%)  
Mucinous 
adenocarcinoma 
15 8 (53.3%) 7 (46.7%) 0.0001 
Carcinoid 2 0 2 (100%) <0.0001 
Metastatic 
adenocarcinoma 
19 10 (52.6%) 9 (47.2%) <0.0001 
Table 5.2 IL1RAPL1 expression in the colon disease spectrum. The number of each specimen that 
scored as IL1RAPL1 low and high expressing is listed. The association between expression levels 
observed in normal colon specimens and all of the other cases both benign and cancerous was 
estimated for significance by Chi-square test. P-values are noted for those with significant 
correlations. NS = not significant.  
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5.3.1. IL1RAPL1 Expression in Normal Colon vs. Benign Disease 
The majority of normal colon (including NAT colon) was negative for IL1RAPL1 
immunoreactivity (66.7%), and where IL1RAPL1 expression was present it showed mainly 
weak and diffuse immunoreactivity (28.6%). Only 2 normal colon specimens (4.6%) showed 
some strong IL1RAPL1 immunoreactivity in areas. The benign spectrum includes chronic 
inflammation of mucosa, polyps, hyperplasia of glandular epithelium and adenoma. All 
specimens from the benign spectrum showed negative or weak IL1RAPL1 
immunoreactivity. The majority of sample tissues representing chronic inflammation of 
mucosa (80%) were negative for IL1RAPL1 immunoreactivity, with the remainder (20%) 
showing weak expression. Hyperplasia of glandular epithelium was negative for IL1RAPL1 
expression in 42.9% of specimens, with 57.1% showing weak immunoreactivity. The polyp 
specimens had weak IL1RAPL1 immunoreactivity in 50% of cases, with negative expression 
in the remainder. Adenoma specimens were negative for IL1RAPL1 in 40% of cases, with 
the rest showing weak expression. Representative photomicrographs of IL1RAPL1 
expression in some of the benign specimens are shown in Figure 5.5.  
 
 
 
 
 
 
 
 
 
 
 
 
  183 
5.3.2.  IL1RAPL1 Expression in Normal Colon vs. Colon Cancer Spectrum 
IL1RAPL1 was found to be significantly overexpressed in all of the cancer specimens 
analysed, as shown in Table 5.2. 96.1% of adenocarcinomas analysed express IL1RAPL1, 
with 66.7% showing high IL1RAPL1 expression, a significant upregulation compared to 
normal colon (p-value <0.0001). Within colon adenocarcinoma, IL1RAPL1 expression does 
not appear to correlate with KRAS or BRAF mutational status, with 66.7% of KRAS MT 
and 88.9% of KRAS WT specimens showing strong IL1RAPL1 immunoreactivity, and 
100% of both BRAF MT and BRAF WT showing strong expression. In the mucinous 
adenocarcinoma specimens, 86.7% express IL1RAPL1, 46.7% highly, which is a significant 
overexpression compared to normal colon (p-value 0.0001). The number of carcinoid tumour 
specimens analysed was quite low (n=2), however 100% of these showed strong IL1RAPL1 
immunoreactivity, which was deemed significant by Chi-square test compared to normal 
colon (p-value <0.0001). 100% of metastatic adenocarcinoma express IL1RAPL1, with 
47.2% showing high expression, which was deemed significant compared to normal colon 
(p-value <0.0001).  
IL1RAPL1 has been observed as having mainly cytoplasmic immunoreactivity in the 
majority of cancer specimens, with some membranous immunoreactivity possibly observed 
in a small number of specimens. It was also observed in some cancer specimens that 
IL1RAPL1 expression may potentially be associated with immune cells in CRC. The 
observation by a pathologist examining one section, was that inflammatory cells that are 
responding to the tumour stained strongly for IL1RAPL1 (Refer to image B in Figure 5.6). 
This potential immune cell cohort showing strong IL1RAPL1 immunoreactivity was 
subsequently observed in other CRC sections and single immune cells in some normal colon 
specimens were also observed to show strong IL1RAPL1 immunoreactivity. As this cell type 
hasn’t been confirmed to be a particular immune cell, for the moment they are hypothesised 
“immune” cells. Figure 5.6 shows representative photomicrographs of the pattern of 
IL1RAPL1 immunoreactivity observed in CRC tumours and also in the “immune” cells of 
some specimens. 
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Figure 5.5 IHC analysis of IL1RAPL1 expression in diseased and malignant colon. 
Representative images showing: (A) Chronic inflammation of colon mucosa with negative 
IL1RAPL1 immunoreactivity. (B) Inflammatory polyp with negligible immunoreactivity. (C) 
Hyperplasia of glandular epithelium with negative immunoreactivity. (D) Adenoma with negative 
immunoreactivity. (E) Mucinous colon adenocarcinoma with weak-moderate IL1RAPL1 
immunoreactivity. (F) Carcinoid tumour with strong cytoplasmic IL1RAPL1 immunoreactivity. 
Original magnification 400x. The scale bars represent 100µm. 
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Figure 5.6 IHC analysis of IL1RAPL1 expression in normal and malignant colon. Representative 
images showing: (A) Normal colon with IL1RAPL1 immunoreactivity in “immune” cells (red arrow). 
(B) Moderately differentiated colon adenocarcinoma with strong cytoplasmic and membrane-like 
immunoreactivity in the tumour (black arrow) and also in “immune” cells (red arrow) responding to 
the tumour. (C) Colon adenocarcinoma (BRAF WT) with strong cytoplasmic and membrane-like 
IL1RAPL1 immunoreactivity (green arrow). (D) Colon adenocarcinoma (BRAF MT) with moderate-
strong cytoplasmic immunoreactivity in the tumour (black arrow) and strong immunoreactivity in 
“immune” cells (red arrow). (E) Moderately differentiated colon adenocarcinoma (KRAS MT) with 
strong cytoplasmic immunoreactivity. (F) Poorly differentiated colon adenocarcinoma (KRAS WT) 
with weak cytoplasmic immunoreactivity. Original magnification 400x. The scale bars represent 
100µm. 
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5.3.3. Association between IL1RAPL1 Expression and CRC Tumour Grade 
In order to determine if IL1RAPL1 expression correlates with the histopathological grade of 
CRC, the score was analysed in the specimens that this information was available for. The 
grade diagnosis was known for 63 of the cancer specimens analysed – 30 adenocarcinomas, 
15 mucinous adenocarcinomas and 18 metastatic adenocarcinomas. Combining the score for 
all of these and grouping into Grades 1-3, showed that the majority (55.6%) of tumours 
analysed were Grade 2, followed by Grade 3 at 31.7% and Grade 1 representing 12.7% of 
tumours. Table 5.3 shows the IL1RAPL1 expression pattern for the three grades across the 
combined colon cancer types. There is a small increase in the number of Grade 3 tumours 
strongly expressing IL1RAPL1 compared to Grade 1 and 2, with 65% of Grade 3 tumours 
strongly expressing IL1RAPL1, 57.1% of Grade 1 and 55.5% of Grade 2 strongly expressing 
IL1RAPL1. This was not deemed a significant correlation however.  
Table 5.4 shows the result of IL1RAPL1 expression in the three grades for each cancer type 
separately. IL1RAPL1 expression does not significantly correlate with tumour grade in any 
of the cancer types examined – adenocarcinoma, mucinous adenocarcinoma or metastatic 
adenocarcinoma, as determined by Chi-square test. In adenocarcinoma 88.9% of Grade 3 
tumours strongly express IL1RAPL1, with 58.8% of Grade 2 and 75% of Grade 1 tumours 
strongly expressing IL1RAPL1. In mucinous adenocarcinoma Grade 2 tumours most highly 
express IL1RAPL1 (55.6%), with 33.3% of both Grade 1 and Grade 2 tumours strongly 
expressing IL1RAPL1. IL1RAPL1 expression is split 50:50 between low and high 
expression in Grade 2 and Grade 3 tumours in metastatic adenocarcinoma.   
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  IL1RAPL1 expression 
Grade  No of cases  Weak (0-1+) Strong (2-3+) 
1 7 3 (42.9%) 4 (57.1%) 
2 36 16 (44.4%) 20 (55.5%) 
3 20 7 (35%) 13 (65%) 
Table 5.3 Association between IL1RAPL1 expression and CRC tumour grade. (Results for 
adenocarcinoma, mucinous and metastatic adenocarcinoma combined) 
 
Adenocarcinoma (n=30) 
Grade  No of cases  Weak (0-1+) Strong (2-3+) 
1 4 1 (25%) 3 (75%) 
2 17 7 (41.2%) 10 (58.8%) 
3 9 1 (11.1%) 8 (88.9%) 
Mucinous Adenocarcinoma (n=15) 
Grade  No of cases  Weak (0-1+) Strong (2-3+) 
1 3 2 (66.7%) 1 (33.3%) 
2 9 4 (44.4%) 5 (55.6%) 
3 3 2 (66.7%) 1 (33.3%) 
Metastatic Adenocarcinoma (n=18) 
Grade  No of cases  Weak (0-1+) Strong (2-3+) 
1 0 - - 
2 10 5 (50%) 5 (50%) 
3 8 4 (50%) 4 (50%) 
Table 5.4 Association between IL1RAPL1 expression and tumour grade in each CRC subtype. 
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5.3.4. Summary of IL1RAPL1 Expression in Colon Disease Spectrum 
• IL1RAPL1 expression is absent in the majority of normal colon tissues analysed and 
shows mainly weak expression in the remainder of specimens. 
• IL1RAPL1 is not upregulated in the benign spectrum of colon disease – chronic 
inflammation of mucosa, hyperplasia, polyps and adenoma all showed negative or 
weak IL1RAPL1 expression. 
• IL1RAPL1 is significantly overexpressed in the colon cancer spectrum. 
o Colon adenocarcinoma vs. normal colon (p-value <0.0001) 
o Mucinous adenocarcinoma vs. normal colon (p-value 0.0001) 
o Carcinoid tumours vs. normal colon (p-value <0.0001) 
o Metastatic adenocarcinoma vs. normal colon (p-value <0.0001) 
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5.4. IL1RAPL1 Expression in Normal Oesophagus and Oesophageal Cancer  
The preliminary analysis in Section 5.2 showed high IL1RAPL1 expression in oesophageal 
cancer compared to normal oesophagus, in a very small sample size (n=1). Therefore, to 
assess IL1RAPL1 expression in a larger cohort, a commercially sourced oesophageal cancer 
test TMA (T022a, US Biomax Inc) was obtained for analysis. This small TMA contains 12 
cases – 2 normal oesophagus, 1 carcinoma in situ, 4 squamous cell carcinoma, 2 
adenocarcinoma, 1 small cell undifferentiated carcinoma, 1 carcinoma sarcomatodes, and 1 
carcinosarcoma. Three other normal oesophagus sections were available to us for analysis, 
giving a combined number of 5 normal oesophagus specimens. The two main subtypes of 
oesophageal cancer are squamous cell carcinoma, which arises from the epithelial cell lining 
of the oesophagus and adenocarcinoma, which arises from glandular cells in the lower part 
of the oesophagus.  
Table 5.5 shows the IL1RAPL1 IHC immunoreactivity score from 0-3+ in this cohort. 
Normal oesophagus does show some weak IL1RAPL1 expression, with 60% (3/5) of cases 
showing some weak and diffuse immunoreactivity, with the remainder negative. There was 
only one specimen each of carcinoma in situ, small cell undifferentiated carcinoma, 
carcinoma sarcomatodes and carcinosarcoma, which all showed negative or weak IL1RAPL1 
immunoreactivity. The two adenocarcinoma specimens both showed weak IL1RAPL1 
immunoreactivity. IL1RAPL1 is distinctly strongly expressed in only one group, squamous 
cell carcinoma. Table 5.6 shows the scores grouped into those specimens with negative or 
low levels of IL1RAPL1 expression (0-1+) and those showing high IL1RAPL1 expression 
(2-3+) for analysis. The results are grouped into all oesophageal cancers combined, and also 
squamous cell carcinoma by itself, as this is the only group that appears to show differential 
expression compared to normal oesophagus. Combining all cancer types shows no significant 
correlation between IL1RAPL1 expression in cancer vs. normal, with 40% of cancers highly 
expressing IL1RAPL1. However, 100% (4/4) of squamous cell carcinoma specimens highly 
express IL1RAPL1, compared to 100% of normal oesophagus specimens showing negative 
or weak expression. This was found to be a significant overexpression (p-value 0.0027), as 
determined by Chi-square test. IL1RAPL1 showed strong cytoplasmic and in some areas 
membrane-like immunoreactivity in squamous cell carcinoma. Figure 5.7 shows 
representative photomicrographs of IL1RAPL1 immunoreactivity observed in normal 
oesophagus and oesophageal cancer. 
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  IL1RAPL1 Score 
Specimen: 
No. of 
cases 
0 1+ 2+ 3+ 
Normal Oesophagus 5 2 3 0 0 
Carcinoma in situ 1  1   
Squamous cell carcinoma 4   3 1 
Adenocarcinoma 2  2   
Small cell undifferentiated 
carcinoma 
1 1    
Carcinoma sarcomatodes 1 1    
Carcinosarcoma 1  1   
Table 5.5 IL1RAPL1 expression by IHC score in normal oesophagus and cancer spectrum  
 
  IL1RAPL1 expression 
Specimen: No of cases Weak (0-1+) Strong (2-3+) 
Normal 
Oesophagus 
5 5 (100%) 0 
Oesophagus 
carcinoma (all 
types) 
10 6 (60%) 4 (40%) 
Squamous cell 
carcinoma  
4 0 4 (100%) ** 
Table 5.6 IL1RAPL1 expression in normal oesophagus and oesophageal cancer. The number of 
each specimen that scored as LY6G6F low and high expressing is listed. The association between 
expression levels observed in the whole cancer cohort and squamous cell carcinoma by itself was 
estimated for significance by Chi-square test. (** IL1RAPL1 is significantly overexpressed in 
squamous cell carcinoma vs. normal oesophagus; p-value 0.0027)  
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Figure 5.7 IHC analysis of IL1RAPL1 expression in normal and malignant oesophagus. 
Representative images showing: (A) Normal oesophagus with negative IL1RAPL1 
immunoreactivity. (B) Carcinoma in situ with weak diffuse immunoreactivity. (C) Small cell 
undifferentiated oesophageal cancer with negative immunoreactivity. (D) Oesophagus 
adenocarcinoma with negative to weak immunoreactivity.  (E) Squamous cell carcinoma with strong 
cytoplasmic and membrane-like IL1RAPL1 immunoreactivity. (F) Squamous cell carcinoma with 
strong cytoplasmic and membrane-like immunoreactivity. Original magnification 400x. The scale 
bars represent 100µm. 
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5.4.1. Summary of IL1RAPL1 Expression in Normal Oesophagus and Oesophageal 
Cancer  
• IL1RAPL1 expression is absent or shows weak and diffuse immunoreactivity in the 
normal oesophagus specimens analysed. 
• IL1RAPL1 is not strongly expressed in oesophageal carcinoma in situ, small cell 
undifferentiated carcinoma, carcinoma sarcomatodes, carcinosarcoma, or 
adenocarcinoma specimens, with all showing negative or weak expression. 
• IL1RAPL1 is strongly expressed in all oesophageal squamous cell carcinoma 
specimens analysed and was found to be significantly overexpressed in this cancer 
type vs. normal oesophagus (p-value 0.0027). 
• However, sample size was very small, and investigation of IL1RAPL1 expression in 
a larger cohort of normal oesophagus and the different oesophageal cancer subtypes 
is required, to determine if high IL1RAPL1 expression is associated specifically with 
the squamous cell carcinoma subtype in a larger patient cohort 
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5.5. IL1RAPL1 Expression in Normal Tissues  
In order for a protein to be a potential candidate therapeutic target, it must have no or minimal 
expression in normal tissues, particularly in vital organs. The absence or minimal expression 
of target in the proliferating cells of normal tissues is also required, to minimise off target 
toxicities. IL1RAPL1 expression in normal tissues was examined in a number of normal 
tissue TMAs, as well as full-face tissue sections, if they were available by 
Immunohistochemical analysis. Table 5.7 lists the tissues that had negative or weak 
IL1RAPL1 immunoreactivity. Some normal tissues did display some stronger IL1RAPL1 
immunoreactivity in some specimens and these are listed in Table 5.8. The majority of 
normal colon were negative for IL1RAPL1 expression, however a small number (2/42) did 
show some stronger immunoreactivity. All of the normal duodenum and gastric epithelium 
specimens analysed showed IL1RAPL1 expression, with 1/4 duodenum specimens showing 
some strong immunoreactivity. Strong IL1RAPL1 immunoreactivity was observed in certain 
collections of individual cells in 3/5 gastric epithelium tissues. Cerebral cortex and bone 
marrow (only n=1) showed some strong IL1RAPL1 immunoreactivity in isolated cells. 
Salivary gland displayed weak-moderate cytoplasmic immunoreactivity. Representative 
images of IL1RAPL1 immunoreactivity in some of the normal tissues analysed are shown in 
Figure 5.8.  
To investigate IL1RAPL1 expression in highly proliferating cells of normal tissues, serial 
tissue sections of a range of proliferative tissues, including colon, tonsil and gastric tissue, 
were stained for IL1RAPL1 and Ki67, a cellular marker strictly associated with proliferation. 
Figure 5.9 shows representative images for the results of this analysis in normal colon, 
duodenum and gastric epithelium. In general, if IL1RAPL1 immunoreactivity is observed in 
normal colon it is not in the proliferating cells of colonic crypts. The normal duodenum tissue 
shown in Figure 5.9 shows strong Ki67 immunoreactivity in the cells lining the crypts of the 
duodenum. Strong IL1RAPL1 immunoreactivity is observed in the luminal space of these 
crypts, therefore IL1RAPL1 could be expressed in the same cells. The gastric epithelium 
shows some weak IL1RAPL1 immunoreactivity, but it is more difficult to determine the 
same cellular location of Ki67 positive cells in this tissue. Overall, in normal colon 
IL1RAPL1 does not appear to be expressed in the proliferating cells. It is more difficult to 
determine the exact same cellular location in the other tissues. Further investigation is 
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required, such as a dual IHC set up, where a single section is stained for both IL1RAPL1 and 
Ki67, as this would enable a more accurate determination of the same cell localisation.  
 
Normal tissues with negative or minimal IL1RAPL1 immunoreactivity 
Oesophagus 
(3/3) 
Pancreas     
(2/2) 
Kidney       
(2/2) 
Liver          
(2/3) 
Tonsil 
(7/10) 
Breast         
(2/3) 
Lung          
(0/3) 
Thyroid      
(2/3) 
Larynx       
(0/1) 
Bladder 
(0/1) 
Spleen        
(1/3) 
Uterus         
(0/1) 
Cervix       
(1/2) 
Ovary        
(1/1) 
Skin       
(0/1) 
Testis         
(0/1) 
Prostate      
(0/1) 
Placenta     
(2/3) 
Adrenal gland 
(1/1) 
Parathyroid 
gland (1/1) 
Thymus      
(0/1) 
Cerebellum 
(0/1) 
Muscle, 
skeletal (0/1) 
Heart muscle 
(0/1) 
Omentum 
(0/1) 
Peripheral 
nerve (0/1) 
    
Table 5.7 Normal tissues that showed negative or weak IL1RAPL1 expression. The number of 
sections that stained out of the total number analysed is listed.  
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Normal tissues displaying weak to strong IL1RAPL1 immunoreactivity 
Tissue  No. negative No. weak  No. strong 
Colon 28/42 
negative  
12/42 weak 
diffuse 
2/42 some strong granular 
positivity 
Duodenum - 3/4 weak diffuse 1/4 strong positivity 
Gastric  -  2/5 weak diffuse 3/5 some strong positivity in 
certain cells 
Salivary 
gland 
- 1/2 weak diffuse 1/2 stronger cytoplasmic diffuse 
Pituitary 
gland  
- - 1/1 strong granular diffuse 
Cerebral 
cortex 
- - 1/1 isolated cells stained strongly 
Bone 
marrow 
- - 1/1 strong stain in isolated cells  
Table 5.8 Normal tissues that showed strong IL1RAPL1 expression in some specimens.  The 
normal tissues that displayed strong IL1RAPL1 immunoreactivity in some specimens is listed, with 
the number of sections that positively stained out of the total number analysed indicated. The number 
for each specimen that showed negative or weak IL1RAPL1 immunoreactivity is also indicated.  
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Figure 5.8 IHC analysis of IL1RAPL1 expression in normal tissues. Representative images 
showing: (A) Gastric epithelium with strong IL1RAPL1 immunoreactivity in certain cell populations. 
(B) Salivary gland with weak immunoreactivity. (C) Kidney with negative immunoreactivity. (D) 
Pancreas with weak diffuse immunoreactivity. (E) Lung with negative immunoreactivity. (F) Small 
intestine with negative immunoreactivity. Original magnification 200x. The scale bars represent 
200µm. 
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Figure 5.9 IHC analysis of IL1RAPL1 expression in proliferating cells of normal tissues. 
Representative images of colon, duodenum and gastric epithelium stained for Ki67 and IL1RAPL1, 
with red and black arrows indicating the approximate same location in the Ki67 and IL1RAPL1 
stained serial sections. (A-B) Normal colon showing negligible IL1RAPL1 immunoreactivity in 
proliferating cells. (C-D) Normal duodenum showing strong Ki67 and IL1RAPL1 immunoreactivity, 
potentially in the same cells. (E-F) Normal gastric epithelium showing weak IL1RAPL1 
immunoreactivity, which could potentially be in some proliferating cells. Original magnification 
200x. The scale bars represent 200µm. 
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5.6. Imaging of IL1RAPL1 in Cancer Cell Lines 
IL1RAPL1 protein expression was confirmed in colon cancer and PDAC cell lines by 
Western blot analysis, with expression in the membrane fractions suggesting an association 
with membrane localisation. To further investigate the localisation of IL1RAPL1 in some of 
these cancer cell lines, Immunocytochemical analysis staining for IL1RAPL1 in the HCT116 
and MIA PaCa-2 cell lines was carried out as described in Section 2.7. Cells were fixed and 
permeabilised with either methanol alone or formalin followed by methanol. 
Immunofluorescent analysis staining for IL1RAPL1 was carried out in the HCT116 and 
SW480 cell lines (formalin and methanol fixed) as described in Section 2.8. Negative 
controls (secondary antibody only) were included in both analyses.  
Figure 5.10 shows representative images of the Immunocytochemical analysis. Strong 
cytoplasmic IL1RAPL1 stain is observed in both the MIA PaCa-2 and HCT116 cells. The 
strong nuclear stain observed in some HCT116 cells appears to be non-specific stain due to 
the fixation procedure. Figure 5.11 shows representative images of the Immunofluorescent 
analysis. Again, strong cytoplasmic stain is observed, with possibly some membranous 
staining in both the HCT116 and SW480 cell lines. Live cell immunofluorescence was 
attempted to try and confirm IL1RAPL1 localisation on the cell surface, however this was 
unsuccessful to date. Therefore, IL1RAPL1 was shown to be located in the cytoplasm, with 
no exclusive membrane localisation observed in these cells.  
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Figure 5.10 Immunocytochemical analysis of IL1RAPL1 expression in HCT116 and MIA 
PaCa-2 cells. Representative images show (A) HCT116 cells stained with IL1RAPL1 and (B) 
HCT116 cells negative control (no primary antibody). HCT116 cells were fixed with formalin and 
methanol. Some non-specific nuclear stain is observed in the negative control from this fixation 
method (black arrows). Therefore, discounting this nuclear stain, granular cytoplasmic IL1RAPL1 
stain is observed in HCT116 cells. (C-D) MIA PaCa-2 cells fixed with methanol and stained for 
IL1RAPL1 and negative control. Cytoplasmic IL1RAPL1 immunoreactivity is observed. No 
immunoreactivity is observed in the negative control. Original magnification 600x. Scale bars 
represent 50µm.  
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Figure 5.11 Immunofluorescent analysis of IL1RAPL1 expression in HCT116 and SW480 cells. 
Representative images show (A) HCT116 cells and (B) SW480 cells stained for IL1RAPL1. Negative 
controls (secondary antibody only) showed no immunofluorescence (images not shown). IL1RAPL1 
is observed as having cytoplasmic and possibly some membranous localisation in these cells. 
(Formalin and methanol fixation of cells) Original magnification 400x.  
 
 
 
 
 
 
 
 
 
 
 
A.									HCT116	(IL1RAPL1)								 B.	 SW480	(IL1RAPL1)
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5.7. Attempted Functional Analysis of IL1RAPL1 Knockdown by RNAi 
IL1RAPL1 has been found to be significantly overexpressed in CRC tumours compared to 
normal colon by IHC analysis. Therefore, to investigate the functional role of IL1RAPL1 in 
the colon cancer cell phenotype, siRNA mediated protein knockdown of IL1RAPL1 was 
attempted in the SW480 and HCT116 colon cancer cell lines, to be followed by in vitro 
functional analysis of the effect on proliferation, 2D colony formation, migration and 
invasion of these cells. However, protein knockdown of IL1RAPL1 was never observed by 
Western blot analysis. Attempts were also made in the PDAC cell line MIA PaCa-2. 
Transfection optimisation was carried out as described in Section 2.4.1, with a number of 
optimisations carried out in the attempt to achieve IL1RAPL1 protein knockdown.  
A total of six independent IL1RAPL1 siRNAs were used in this analysis, with optimisations 
involving increasing the siRNA concentration (a range from 10nM-100nM was tested), as 
well as assaying for protein knockdown at various time-points post transfection (48hrs, 72hrs 
and 93hrs). However, no obvious protein knockdown was observed in either the 69kDa MW 
protein or the identified soluble form (~58kDa) of IL1RAPL1, if it was present, in any of the 
cell lines examined by Western blot analysis. To determine if the siRNAs were sufficiently 
reducing IL1RAPL1 mRNA levels, qRT-PCR analysis was carried out on MIA PaCa-2 cells 
transfected with all six siRNAs and taken down 48hrs post transfection. The relative 
quantitation (RQ) of IL1RAPL1 mRNA in siRNA treated cells (IL1RAPL1 and Negative 
siRNA at 30nM concentration) compared to untreated cells is shown in Figure 5.12. This 
analysis was only carried out once, but shows that the IL1RAPL1 siRNAs are decreasing the 
mRNA levels, to varying degrees. The biggest reduction is observed with siRNA #3, however 
protein knockdown was still not achieved with the most effective siRNAs determined from 
the qRT-PCR analysis. Figure 5.13 shows representative Western blots of MIA PaCa-2 cells 
assayed for protein knockdown 48, 72 and 93hrs post transfection, with no reduction in the 
amount of IL1RAPL1 protein observed. Therefore unfortunately, the effect of IL1RAPL1 
protein knockdown on the functional phenotype of colon cancer could not be determined.  
 
 
  202 
 
Figure 5.12 Relative quantitation of IL1RAPL1 mRNA in MIA PaCa-2 siRNA transfected cells 
compared to cells only and normalised to B2M by qRT-PCR. (30nM siRNA, assayed 48hrs post 
transfection) (Results represent one biological experiment) 
 
 
Figure 5.13 Western blot analysis showing MIA PaCa-2 cells probed for IL1RAPL1 in cells 
only control, cells transfected with Negative siRNA and IL1RAPL1 siRNA (si1 and si2) treated 
cells, assayed at 48hrs, 72hrs and 93hrs post transfection. (30nM siRNA) α-tubulin was used as a 
loading control. No protein knockdown is observed.  
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5.8. Overexpression of IL1RAPL1 in SW480 Cells 
As the attempts to knockdown IL1RAPL1 protein in cancer cells were unsuccessful, it was 
decided to try IL1RAPL1 protein overexpression, to determine if any functional role for 
IL1RAPL1 in the CRC cell phenotype could be determined this way. The colon cancer cell 
line SW480 was selected for IL1RAPL1 overexpression, as it expresses IL1RAPL1 at a 
lower level compared to some of the other cell lines (Figure 3.3). As described in Section 
4.10, a commercial transfection ready cloning vector containing the IL1RAPL1 sequence 
(Acc no: NM_014271.3) was obtained (GenScript), with the vector map shown in Figure 
4.31. Transfection optimisation is described in Section 2.10.1.  
Following antibiotic selection, qRT-PCR analysis of the SW480 empty vector (E.V.) and 
IL1RAPL1 overexpression (O.E.) cell lines, as well as a cells only control, was carried out 
as described in Section 2.9. Table 5.9 shows the Ct value results of this analysis. An accurate 
determination of whether IL1RAPL1 is overexpressed at the mRNA level could not be 
carried out, as the Ct value for the endogenous control gene (B2M) was higher in the 
IL1RAPL1 O.E. cells compared to cells only and E.V. cells. IL1RAPL1 overexpression 
could possibly be affecting B2M levels. Excluding the B2M result, the Ct values for 
IL1RAPL1 do decrease in the O.E. cells compared to cells only and E.V., indicating some 
mRNA overexpression could be present (Ct of 22 compared to 26). However, this was only 
carried out once, the qRT-PCR needs to be repeated with a different endogenous control, to 
determine if IL1RAPL1 mRNA overexpression can be confirmed.  
Western blot analysis to determine if IL1RAPL1 overexpression can be detected at the 
protein level is shown in Figure 5.14. This was only carried out once to date and no 
IL1RAPL1 protein overexpression was observed. Similar to the overexpression of LY6G6F 
in Section 4.10, the FLAG-tag blot gave inconclusive results, with multiple bands observed 
in all lanes. Therefore, it could not be confirmed whether the vector expressed version of 
IL1RAPL1 protein was present at all in the samples. Without confirmation of IL1RAPL1 
protein overexpression, functional analysis could not be carried out. The qRT-PCR analysis 
first needs to be repeated to accurately determine if mRNA overexpression is present, and if 
so, the Western blot analysis needs to be repeated to confirm if this is translated into protein. 
Then functional analysis can be carried out. 
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Sample IL1RAPL1 Ct value B2M Ct value 
SW480 cells only 26.8 17.8 
SW480 Empty Vector 26.7 18.3 
SW480 IL1RAPL1 O.E. 22.9 23.7 
Table 5.9 Results of qRT-PCR analysis of IL1RAPL1 and B2M mRNA expression in SW480 
cells. The average Ct values for IL1RAPL1 and the endogenous control B2M in SW480 cells only, 
E.V. and IL1RAPL1 O.E. cells are shown. (n=1) 
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Figure 5.14 Western blot probing for IL1RAPL1 and FLAG-tag. Results are shown for SW480 
cells only, E.V. and IL1RAPL1 O.E. cells. (The X lane on the IL1RAPL1 probed blot is a different 
protein O.E. cell line) No apparent protein overexpression of IL1RAPL1 is observed. The same 
samples probed for FLAG-tag, which should only be detected at IL1RAPL1 MW in the IL1RAPL1 
O.E. sample, gave an inconclusive result, as multiple bands are visible in all wells. (n=1) 
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5.9. Attempted Immunoprecipitation of IL1RAPL1  
To try and identify a functional role for IL1RAPL1 in the cancer cell phenotype, co-IP was 
carried out as described similarly for LY6G6F in Section 4.11. Both traditional and cross-
linked IP with two independent IL1RAPL1 antibodies were used for Co-IP in the attempt to 
isolate IL1RAPL1 and any associated proteins from the cell lysate of a number of cell lines 
(including HCT116 and MIA PaCa-2). However, IL1RAPL1 was not successfully 
immunoprecipitated using either method.  
Figure 5.15 shows representative Western blot analysis of the result obtained from cross-
linked IP of IL1RAPL1 from MIA PaCa-2 cell lysate. A mouse IL1RAPL1 antibody was 
used for the IP, therefore a mouse IgG was used as a negative control. The Western blot was 
probed with a different rabbit IL1RAPL1 antibody, for detection of IL1RAPL1 in the cell 
lysate and IP elutions. IL1RAPL1 is detected in the MIA PaCa-2 IP buffer lysate, confirming 
the antibody can detect IL1RAPL1 from cell lysate made with a less stringent lysis buffer. 
IL1RAPL1 is also detected in the unbound fractions of both IL1RAPL1 and Mouse IgG 
control, with no band detected in the first or second elution from the IL1RAPL1 column. 
This shows that IL1RAPL1 protein was not pulled out from the cell lysate with the antibody 
used.  
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Figure 5.15 Western blot analysis probing for IL1RAPL1 in MIA PaCa-2 samples following 
cross-linked Co-IP. Lane 1: MIA PaCa-2 control IP lysate. Lane 2: Flow-through following 
IL1RAPL1 antibody coupling to column. Lane 3: IL1RAPL1 Co-IP unbound fraction. Lanes 4 and 
5: First and second elution from IL1RAPL1 Co-IP. Lane 6: Flow-through following Mouse IgG 
control antibody coupling to column. Lane 7: Mouse IgG Co-IP unbound fraction. Lanes 8 and 9: 
First and second elution from Mouse IgG Co-IP.  
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5.10. Summary  
IL1RAPL1 has been found to be significantly overexpressed in both CRC and oesophageal 
squamous cell carcinoma compared to corresponding normal tissues. The majority of normal 
colon tissues analysed were negative for IL1RAPL1 expression, with mainly weak and 
diffuse immunoreactivity observed if it was present. IL1RAPL1 expression is also absent or 
weak in all specimens from the benign colon disease spectrum analysed: chronic 
inflammation of mucosa, hyperplasia, polyps and adenoma. In contrast IL1RAPL1 is 
strongly expressed in the majority of adenocarcinoma and carcinoid tumours, a significant 
upregulation compared to normal colon. Whilst slightly less than 50% of mucinous 
adenocarcinoma and metastatic adenocarcinoma specimens were found to strongly express 
IL1RAPL1, this was still found to be a significant overexpression compared to normal colon. 
IL1RAPL1 immunoreactivity was also potentially observed in immune cells in both some 
normal colon specimens, and to a greater extent in the microenvironment of CRC specimens. 
In the small cohort of normal oesophagus and oesophageal cancer analysed, IL1RAPL1 was 
found to be significantly overexpressed in the squamous cell carcinoma subtype. IL1RAPL1 
expression is absent or weak in normal oesophagus, carcinoma in situ, small cell 
undifferentiated carcinoma, carcinoma sarcomatodes, carcinosarcoma and adenocarcinoma 
specimens. In contrast IL1RAPL1 is strongly expressed in 100% of oesophageal squamous 
cell carcinoma specimens analysed.  
IL1RAPL1 expression was found to be absent or minimally expressed in the majority of 
normal tissues analysed. However, some normal tissues did show some stronger 
immunoreactivity. One section of duodenum analysed (out of four) showed strong 
immunoreactivity within the goblet cells that line the crypts, showing IL1RAPL1 could be 
expressed in the proliferating cells of this tissue. Isolated cells in some other tissues, 
including gastric tissue and cerebral cortex, were also found to have some strong IL1RAPL1 
immunoreactivity. The Immunohistochemical analysis revealed mainly cytoplasmic 
localisation of IL1RAPL1 in the tissues. The Immunocytochemical analysis of HCT116 and 
MIA PaCa-2 cells and the Immunofluorescent analysis of HCT116 and SW480 cells, also 
showed mainly cytoplasmic localisation for IL1RAPL1.  
Despite showing no strong expression in the majority of PDAC and breast cancer tissues 
analysed, IL1RAPL1 was found to be expressed in all PDAC and breast cancer cell lines 
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analysed. Western blot analysis detected IL1RAPL1 at the expected MW of ~69kDa in both 
the whole cell lysate and membrane enriched fraction of all colon cancer and PDAC cell lines 
analysed. A lower MW band was also detected in three of the colon cancer lines and all of 
the PDAC cell lines, which correspond with the single band detected in the conditioned 
medium from MIA PaCa-2 and BXPC-3 cell lines. This indicates that a soluble form of 
IL1RAPL1 is produced by these cells. 
Attempts at achieving transient siRNA mediated protein knockdown of IL1RAPL1, to assess 
the effect on the functional phenotype of colon cancer in vitro, were unfortunately 
unsuccessful. Despite carrying out a number of optimisations and confirming knockdown of 
IL1RAPL1 at the mRNA level by qRT-PCR analysis, no IL1RAPL1 protein knockdown was 
ever achieved. IL1RAPL1 protein may have a very long half-life, which didn’t allow for the 
protein level to be reduced under the time-points assessed in our experimental set-up. SW480 
cells were transfected with an IL1RAPL1 overexpression vector, to assess the functional 
effect of IL1RAPL1 protein overexpression in a colon cancer cell line that expresses 
IL1RAPL1 at a lower level to some of the other cell lines. However, to date, no apparent 
IL1RAPL1 protein overexpression was detected. The qRT-PCR analysis to confirm mRNA 
overexpression needs to be repeated, as this was only carried out once, and a big difference 
in the levels of endogenous control gene (B2M) was detected between cells only and 
IL1RAPL1 O.E. cells. The attempts at elucidating a possible function for IL1RAPL1 in the 
cancer cell phenotype by identifying interacting proteins by Co-IP were also unsuccessful. 
The antibodies used did not list IP as a proven application. Therefore, IL1RAPL1 has been 
shown to be significantly overexpressed in CRC and oesophageal squamous cell carcinoma, 
but a functional role in the cancer cell phenotype could not be determined to date.  
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Chapter 6. Discussion 
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6.1. Introduction 
Gastrointestinal malignancies have a high incidence rate worldwide and are also a leading 
cause of cancer related deaths. CRC is the 3rd  most commonly diagnosed cancer worldwide, 
and ranks 4th in mortality. (Karsa et al., 2010) Oesophageal cancer is the 8th most commonly 
diagnosed and ranks 6th in mortality. (Zhang, 2013) Gastric cancer is the 5th most commonly 
diagnosed and ranks 3rd in mortality. (Harvey, 2017) Whilst pancreatic cancer is the 12th most 
commonly diagnosed and ranks 7th in mortality. Pancreatic cancer also has a dismal 5 year 
survival rate of just 5%. (Wood and Hruban, 2015) Chemotherapy remains the mainstay of 
treatment for most advanced GI cancers and despite significant advances in cancer 
management over the years, there has been little change in the overall survival of patients 
diagnosed with advanced stage GI cancers. The only targeted therapeutics approved for use 
in CRC, are unconjugated mAbs that target EGFR and VEGF. These therapies are used in 
combination with chemotherapy for the treatment of metastatic CRC, where they can prolong 
overall survival by ~5 months. (Dattatreya, 2013) Overall, currently approved therapeutics 
have limited efficacy. The identification of molecular targets overexpressed in these cancer 
types compared to normal tissues, could have the potential for the development of targeted 
therapeutics, such as ADCs, that could show greater therapeutic benefit than currently 
available therapies. 
This study aimed to identify membrane-localised proteins overexpressed in CRC vs. normal 
colon, and also to determine whether any of the identified targets show relevance in other 
cancer types. Identified targets would also be assessed for their suitability as potential 
molecular targets for therapeutic antibody targeting, in particular ADCs, which are highly 
potent therapeutic agents. The identification of molecular targets for ADC targeting can be 
quite complex, with the basic criteria of 1) higher target expression in tumours vs. normal 
tissues, 2) target localisation to the plasma membrane, 3) internalisation of the target into the 
cell upon ADC binding. It can be difficult to identify targets that fit all of these criteria. 
Additionally, targets identified from mRNA expression data may not be expressed as 
assumed, there may be cases in which mRNA is not translated to protein, protein is produced 
but not presented on the cell surface, or protein is cell surface localised but does not 
internalise. Therefore, significant validations are required to determine if overexpressed 
proteins have the potential to be utilised as molecular targets for antibody-based therapeutic 
targeting.  
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6.2. Identification of Candidate Protein Targets Overexpressed in CRC  
The first aim of this study was to identify novel membrane-localised proteins overexpressed 
in CRC vs. normal colon and to investigate their potential as molecular targets that could be 
amenable to therapeutic antibody targeting. Identified proteins would also be assessed for 
expression in other cancer types, e.g. PDAC, which is in desperate need of new treatment 
strategies. Potential cancer targets were identified by analysis of colon cancer gene 
expression microarray data available for download from the Gene Expression Omnibus 
(GEO) database, as described in Section 2.1. Searching for mRNA datasets that contained 
data from normal human colon and colon carcinoma tissue sections (not cell line data), a 
dataset by Skrzypczak et al., (2010) was chosen for analysis. This dataset contains whole 
tissue section samples from 24 normal colon, 45 colon adenoma and 36 colon 
adenocarcinoma specimens. In-house bioinformatics analysis of this dataset, produced two 
lists of genes upregulated in (1) colon adenocarcinoma vs. normal colon and (2) colon 
adenoma vs. normal colon, with 1238 upregulated genes identified in colon adenocarcinoma 
and 1078 upregulated genes in adenoma. These genes were then annotated for membrane 
localisation, as we are in search of cell-surface proteins, with a fold change of ≥ 2 and an 
adjusted p-value of ≤ 1E-5 considered significant. This produced the final lists of predicted 
membrane localised genes, with 127 genes found to be upregulated in adenocarcinoma and 
154 genes upregulated in adenoma compared to normal colon. In hindsight, it would have 
been beneficial to validate the expression of these genes in other independent colon cancer 
datasets, to increase confidence in the identified targets. However, as we are interested in 
protein overexpression, which mRNA overexpression does not always equate to, the protein 
validation steps are the most important aspect of this study. Potential candidate targets were 
selected for validation from these lists by manually identifying relatively novel targets by 
literature review and also depending on commercial antibody availability. 
This resulted in the identification of 7 genes for validation: Lymphocyte antigen 6 complex, 
locus G6F (LY6G6F), Interleukin 1 receptor accessory protein-like 1 (IL1RAPL1), 
Neurotrimin (NTM), Leucine rich repeat containing 8 family, member E (LRRC8E), Epoxide 
hydrolase 4 (EPHX4), Beta-site APP-cleaving enzyme 2 (BACE2) and Interleukin 20 
receptor, subunit Alpha (IL20RA). Validation of candidate target expression at the protein 
level was assessed in a panel of six colon cancer cell lines, that represent a range of the 
mutational subsets found in CRC, and also in CRC and normal colon tissue sections. This 
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would determine if the protein is expressed in CRC and if it is expressed at a higher level 
than normal colon, as mRNA overexpression does not always correlate to protein 
overexpression. The initial Western blot analysis of all targets in both the whole cell and 
membrane enriched fraction of the colon cancer cell lines revealed that all 7 targets are 
expressed in both fractions, indicating an association with the membrane. Two targets, 
EPHX4 and LRRC8E, could not be validated at the protein level in tissue sections, and it is 
uncertain if this is due to poor antibody quality or an example of the mRNA overexpression 
from the datasets not corresponding to protein expression in the tissues analysed. Therefore, 
EPHX4 and LRRC8E were not pursued further for the time being. It was also decided not to 
pursue NTM further as a candidate target, as similar protein expression levels were observed 
in normal colon and CRC tissue sections in the Immunohistochemical analysis. Despite 
showing a 5.4 fold increase in expression at the mRNA level vs. normal colon, this does not 
appear to correlate to protein overexpression of NTM in the CRC specimens analysed.  
Two other targets, IL20RA and BACE2, were also ultimately decided not to pursue further, 
due to high expression in normal tissues. IL20RA initially showed promise due to its strong 
membrane localised expression in CRC tissues, including metastatic CRC, and it also showed 
higher expression in the SW620 metastatic cancer cell line vs. the SW480 primary tumour 
cell line. IL20RA was identified solely from the adenoma gene list, with a 4.2 fold increase 
in expression vs. normal colon, therefore we sought to validate whether this overexpression 
is maintained in CRC. However, despite further preliminary analysis showing strong IL20RA 
expression in both CRC and PDAC tissue specimens, a similar level of expression was 
observed in the corresponding normal tissues. IL20RA was reported in the literature to be 
expressed at the mRNA level in colon, colonic supepithelial myofibroblasts and colonic 
epithelial cell lines. (Blumberg et al., 2001) This correlates with the strong immunoreactivity 
observed in the epithelium of normal colon and also duodenum tissue sections in this 
analysis. Therefore, it appears that IL20RA is expressed at a high level endogenously in 
normal colon and pancreas, with no overexpression observed in cancer tissues.  
BACE2 was not as highly expressed in normal colon as IL20RA, however a similar level of 
immunoreactivity was observed in CRC tissue sections, indicating that BACE2 is not 
overexpressed at the protein level in CRC. BACE2 also showed stronger expression in the 
SW620 metastatic cancer cell line vs. the SW480 primary tumour cell line by Western blot 
analysis. BACE2 was identified from both the adenoma and adenocarcinoma gene lists, with 
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a higher fold change present in the adenoma dataset (6 fold increase) than the 
adenocarcinoma list (2.7 fold increase). No adenoma tissue sections were available for the 
preliminary analysis, therefore it could not be confirmed if this higher overexpression in 
adenoma validates at the protein level. BACE2 also showed some promise in PDAC, with 
strong cytoplasmic and membrane immunoreactivity observed in some specimens, but again 
the expression in normal pancreas was also high. Therefore, it appears that IL20RA and 
BACE2 would be unsuitable molecular targets for therapeutic targeting due to their high 
normal tissue expression and were not pursued further.  
Out of the initial seven identified candidate targets, two were selected for wider validations 
and analysis – LY6G6F and IL1RAPL1. Both targets showed negative/minimal expression 
in normal colon and strong expression in the CRC tissue sections analysed, indicating protein 
overexpression in CRC. The protein expression of both targets was also confirmed in both 
the whole cell and membrane enriched fraction of all the colon cancer cell lines analysed, 
indicating an association with the membrane. Expression in cell lines will also allow for in 
vitro functional analysis to be carried out. 
The fact that only two of the seven selected candidate targets showed tissue expression levels 
that warranted further investigation, shows some of the difficulties that can arise in using 
mRNA expression datasets to look for corresponding protein levels. The reliance on 
commercially available antibodies, which can sometimes be of poor quality (e.g. potentially 
the case for EPHX4 and LRRC8E) can also hinder successful protein validations. The mRNA 
dataset used also did not have a very large sample size. If this dataset had been combined 
with other suitable datasets for the bioinformatic analysis to identify genes upregulated in 
CRC vs. normal colon, this may have yielded more stringent results, and perhaps increased 
the likelihood that candidate gene targets would validate at the protein level. The method 
used however did successfully identify two targets upregulated in CRC vs normal colon.  The 
subsequent investigation into the expression of LY6G6F and IL1RAPL1 in a larger cohort 
of CRC tissue specimens and other cancer types, as well as the investigation into their 
functional role will be discussed in the following two sections, 6.3 LY6G6F and 6.4 
IL1RAPL1.  
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6.3. LY6G6F 
LY6G6F was identified from the microarray data, as being significantly upregulated at the 
gene level in both adenoma (9.8 fold up) and adenocarcinoma (17.6 fold up) tissues compared 
to normal colon. The subsequent validation in this study, confirmed this upregulation at the 
protein level, with LY6G6F found to be significantly overexpressed in adenoma and 
adenocarcinoma tissues vs. normal colon. LY6G6F was also found to be significantly 
overexpressed in two other cancers of the digestive system, gastric cancer and PDAC. The 
expression of LY6G6F was first reported as a novel membrane protein in platelets and 
megakaryocytes (platelet producing cells in the bone marrow), with LY6G6F expression and 
function mainly being reported in blood cells to date. The mRNA expression of LY6G6F 
was investigated in purified populations of platelets, B-cells, T-cells, monocytes and 
granulocytes, with expression only detected in the megakaryocytes and platelets. LY6G6F 
was also detected in K562 cells (myelogenous leukemia cell line), with LY6G6F shown to 
recruit the proteins Grb2 and Grb7 upon phosphorylation of its cytoplasmic tail. The coupling 
of LY6G6F with the Ras-MAP kinase pathway is strongly suggested following its interaction 
with Grb2 and with FAK following its interaction with Grb7. (de Vet, Aguado and Campbell, 
2003; Macaulay et al., 2007) A ligand for LY6G6F has not been described to date.  
The expression of LY6G6F in cancer has not been reported on widely in the literature. 
LY6G6F was reported as one of 29 proteins giving a Mucin 5AC hyposecretory phenotype 
in the human colonic adenocarcinoma cells HT29-18N2. (Mitrovic et al., 2013) LY6G6F 
was also listed as a significantly downregulated gene in MSI vs. MSS CRC tumours. (Slattery 
et al., 2015) However, a specific functional role for LY6G6F in GI cancers has not been 
reported in the literature. 
During the course of this study, a report was published by Sewda et al., (2016) that employed 
a similar method to ours, to identify cell-surface markers for colon adenocarcinoma by 
profiling the publicly available mRNA expression microarray datasets. Their objective was 
to identify cell-surface targets for molecular imaging agents for the non-invasive detection 
of CRC by molecular imaging-based colonoscopy using CT, MRI or fluorescence. They 
identified six markers for validation, including the candidate target which they designated 
LY6G6D/F, underpinning again the confusion surrounding LY6G6D and LY6G6F, as 
discussed in Section 4.1. They state that LY6G6D and LY6G6F proteins cannot be 
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distinguished from each other by the available antibodies, even though they have no exons 
in common. They have actually used an LY6G6F antibody for their analysis and a qRT-PCR 
primer targeting LY6G6D mRNA (NM_021246). They also incorrectly state that LY6G6D 
is a 133 residue truncated version of the 297 AA LY6G6F, when they are in fact completely 
separate transcripts with no amino acids in common (see Figure 4.1). Therefore, their study 
looking at LY6G6D/F incorporates mRNA and protein data from two different genes. 
However, their finding for LY6G6F protein expression does match ours, showing that 
LY6G6F is overexpressed in colon adenocarcinoma vs. normal colon. They also state that 
LY6G6F expression is significantly correlated with proximal tumour location (vs. distal) and 
with expression of mismatch repair genes PMS2 and MSH6, indicating MSS genotype, 
which correlates with previous reports of LY6G6F being expressed in MSS, but 
downregulated in MSI CRC tumours. (Slattery et al., 2015) 
 
6.3.1. LY6G6F Expression in Cell Lines  
6.3.1.1. Protein Expression 
LY6G6F expression was detected in the whole cell and membrane enriched fraction across 
the whole CRC, PDAC and breast cancer cell line panel analysed by Western blot analysis. 
This indicates an association between the membrane and LY6G6F in these cell lines. In the 
CRC panel, differential expression of LY6G6F was observed, with the T84 and HT29 cell 
lines displaying the strongest expression, with weaker expression observed in the other cell 
lines. This expression pattern doesn’t appear to correlate with any of the mutational subsets 
listed (e.g. KRAS or BRAF mutational status) for the colon cancer cell line panel. There was 
also some differential expression observed in the PDAC cell lines, with higher expression 
observed in the BXPC-3, Capan-2, Capan-1 and AsPC-1 cell lines, with again no apparent 
correlation to a mutational subset or the classical and quasi-mesenchymal classifications.  
Breast cancer is a complex, heterogeneous disease, with constant reclassification of the 
molecular subtypes associated with it. Recent studies divide breast cancer into four major 
molecular subtypes: Luminal A, Luminal B, Triple negative/Basal-like and HER2 type. The 
panel of breast cancer cell lines used in this study represent Luminal A, Luminal B and Basal 
(triple negative) subtypes. The majority of basal-like breast cancers lack or show low levels 
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of ER and PR, lack HER2 protein overexpression and HER2 gene amplification, whereas 
they express genes and proteins usually found in 'basal'/myoepithelial cells of the normal 
breast. Luminal tumours represent cancer cells that initiate in the inner (luminal) cell lining 
of mammary ducts. Luminal A is characterised as ER-positive and HER2-negative, whilst 
Luminal B tumours tend to be ER-positive and may be HER2-negative or HER2-positive. 
Luminal B tumours tend to have worse prognosis factors than Luminal A, including poorer 
tumour grade and lymph node metastasis. Basal/Triple negative subtype tumours are often 
aggressive and have a poorer prognosis compared to the Luminal subtype tumours. Western 
blot analysis (Figure 4.4) showed that LY6G6F expression is detected in all eight breast 
cancer cell lines analysed, but with lower expression observed in all of the Basal-like cancer 
cell lines (MDA-MB-468, BT20, MDA-MB-157 and MDA-MB-231) compared to the 
Luminal subtype cell lines. Therefore, low LY6G6F expression could possibly be a feature 
of the Basal cancer subtype. Using the online tools, MTCI BreastMark and KM plotter 
analysis (kmplot.com), low LY6G6F gene expression was found to be significantly 
associated with poorer survival vs. high LY6G6F gene expression in breast cancer patients. 
Both of these analyses grouped all breast cancer subtypes together, and possibly links in with 
our finding of lower LY6G6F expression in the Basal subtype, as this subtype has a poorer 
prognosis overall vs. the other subtypes. 
 
6.3.1.2. mRNA Expression 
As we were interested in whether candidate targets validated at the protein level, the mRNA 
expression levels of LY6G6F in cell lines were not examined until after siRNA mediated 
knockdown and subsequent functional analysis had been started. The qRT-PCR analysis of 
MIA PaCa-2 and HCT116 cells surprisingly revealed that LY6G6F mRNA transcript is 
present at very low abundance levels in these cell lines. The Ct values were >30, which is 
commonly taken as unreliable data. However, the fact that the Ct values decrease upon the 
addition of more cDNA template, and that the NTC samples gave no signal, indicates the 
signal observed is for LY6G6F transcript, and not due to non-specific signal. Additionally, 
the Ct values did increase in the siRNA treated samples, showing the siRNA is successfully 
targeting the mRNA, leading to the protein knockdown observed. 
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The mRNA expression levels were also analysed in the BXPC-3, SW480 and HT29 cell lines, 
and in the K562 cell line, which was used as a positive control, with LY6G6F mRNA 
detected at a Ct <30 in this cell line, showing that the Taqman assay is working correctly. A 
second LY6G6F Taqman assay was also obtained to ensure that the first one is working 
efficiently. There were differences in the Ct values between the two assays for two of the cell 
lines analysed (SW480 and BXPC-3), which is not fully explainable, but could be due to 
varying primer efficiency rates between the two assays in these cell lines. The qRT-PCR 
analysis of the MIA PaCa-2, BXPC-3, SW480 and HT29 cell lines showed that mRNA 
expression does not appear to correspond to protein expression in these cell lines. In the 
PDAC cell lines, BXPC-3 has higher protein expression than MIA PaCa-2 cells (as 
determined by Western blot analysis), but they both have similar mRNA levels, with in fact 
the BXPC-3s having a slightly higher Ct value of 36.9 vs. 34.4 in the MIA PaCa-2 cell line. 
Similarly, in the colon cancer cell lines, HT29 cells have a higher level of LY6G6F protein 
expression compared to SW480 cells, but the mRNA expression levels are similar, with a Ct 
value of 36 in HT29 cells and 34.2 in SW480 cells. This indicates that the level of LY6G6F 
protein expression is likely regulated after translation in these cell lines.  
 
6.3.2. LY6G6F Expression in Normal and Cancer Tissues  
LY6G6F was found to be significantly overexpressed in three GI cancers – Gastric cancer, 
CRC and PDAC vs. corresponding normal tissues by Immuohistochemical analysis. 
LY6G6F does not appear to be strongly expressed in oesophageal cancer, however a very 
small sample size was analysed (n=1). The subtype was not known in the breast cancer 
specimens analysed, with all cases showing a weak expression level similar to that observed 
in normal breast, therefore it could not be determined if the lower expression observed in the 
Basal cancer cell lines corresponds to tissues also. Wider analysis could be carried out in 
breast cancer to determine if LY6G6F does display differential expression between subtypes. 
However, for our purpose of identifying overexpressed molecular targets that could 
potentially be amenable to therapeutic antibody targeting, LY6G6F does not appear to be a 
candidate target in breast cancer.  
The majority of normal colon and NAT colon specimens analysed were negative for LY6G6F 
or displayed weak and diffuse immunoreactivity, with a small number showing some strong 
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LY6G6F immunoreactivity. In the colon disease spectrum analysed, LY6G6F was found to 
be significantly overexpressed in colon adenocarcinoma (p-value <0.0001), as well as the 
benign spectrum representing: polyps (p-value <0.0001), hyperplasia (p-value <0.0001) and 
adenoma (p-value 0.0031) vs. normal colon. This validates the microarray data, that LY6G6F 
is overexpressed in both adenoma and adenocarcinoma tissues. LY6G6F is weakly expressed 
in the tissue samples representing chronically inflamed colon, where the colon epithelium 
itself has not transformed abnormally. This indicates that LY6G6F expression could be 
associated with the early stages of normal colon transformation, and the progression of CRC 
from polyp to adenoma to adenocarcinoma. LY6G6F was found to be strongly expressed in 
70% of the adenocarcinoma specimens analysed, irrespective of tumour grade or mutational 
status. No differential expression was observed between the BRAF MT and WT subtypes, as 
all showed high expression. In the KRAS MT and WT groups, 100% of the KRAS MT 
showed high expression, with 88.9% of the KRAS WT highly expressing LY6G6F, which is 
not a significant difference. Therefore, LY6G6F expression appears to be associated with 
adenocarcinoma, regardless of the mutational subtype, which correlates with the expression 
pattern observed in the colon cancer cell lines. 
Despite being strongly expressed in colon adenocarcinoma, low LY6G6F expression was 
observed in the majority (63.2%) of metastatic adenocarcinoma cases. These metastatic 
cancer specimens were derived from lymph node metastases. This could potentially indicate 
that LY6G6F is not highly expressed in the cancer cell populations that go on to metastasise 
or high expression is not maintained once the cancer cells have metastasised to a different 
microenvironment. However, an analysis of paired patient samples (tissue specimens from 
the primary tumour and metastatic site of the same patient) would be required to conclusively 
determine whether LY6G6F expression decreases in the metastatic vs. primary tumours. As 
a relatively small sample size (n=19) of metastatic adenocarcinoma specimens derived 
exclusively from lymph node metastases was used in this analysis, LY6G6F expression 
should be examined in a larger metastatic adenocarcinoma cohort, including other sites of 
metastases e.g. liver, the predominant site of CRC metastasis. If LY6G6F is found to 
consistently be lowly expressed in metastatic adenocarcinoma, then a potential LY6G6F 
targeting therapeutic agent would have no application in the metastatic disease setting.  
LY6G6F was found to be weakly expressed in 100% of the carcinoid tumour specimens, a 
rare subtype of CRC arising from neuroendocrine cells in the colon. This indicates LY6G6F 
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overexpression is not associated with this subtype, however the very small sample size (n=2) 
analysed, means that a larger cohort would need to be examined to definitively conclude that. 
In the mucinous adenocarcinoma cohort, LY6G6F was found to be weakly expressed in the 
majority (73.3%) of cases, showing no significant overexpression vs. normal colon. 
Mucinous adenocarcinoma is a distinct form of CRC, characterised by abundant mucous 
secretion comprising at least 50% of the tumour volume and accounts for approximately 10-
15% of CRC cases. (Hugen et al., 2015) The observation of low LY6G6F expression in 
mucinous adenocarcinomas in this study, fits in with what has been reported about LY6G6F 
expression in CRC in the literature. LY6G6F expression was linked to the downregulation 
of Mucin 5AC in the colon cancer cell line HT29-18N2, therefore it makes sense that 
LY6G6F would be lowly expressed in CRC tumours with excessive mucin secretion. 
(Mitrovic et al., 2013) LY6G6F was also listed as a significantly downregulated gene in MSI 
vs. MSS tumours, and mucinous adenocarcinomas have a higher propensity for MSI 
genotype. (Slattery et al., 2015) Therefore, LY6G6F overexpression appears to be a specific 
feature of adenocarcinoma with MSS phenotype (the most commonly diagnosed form of 
CRC). MSS CRC tumours are associated with a higher rate of recurrence and poorer 
prognosis compared to MSI tumours. (Jung, Kim and Kim, 2016)  
LY6G6F was shown to be highly expressed in PDAC vs. normal pancreas in the preliminary 
IHC screen. To investigate LY6G6F expression further, PDAC tissue specimens were 
obtained from a 57 patient cohort in collaboration with St.Vincent’s University Hospital. 
Information on the pathological features and survival rates for this cohort was also provided. 
89.4% of the tumours were at stage T3, representing the fact that PDAC is commonly not 
diagnosed until a late stage of tumour growth. LY6G6F was found to be significantly 
overexpressed in PDAC vs. normal pancreas (p-value <0.0001), with 78.9% of tumours 
highly expressing LY6G6F. In normal pancreas LY6G6F showed negative or weak and 
diffuse immunoreactivity. Whilst not deemed significant, higher LY6G6F expression was 
observed in T3 vs. T1-2 stage tumours, and in tumours where LVI, PNI, and PVI were 
present. Together with the Kaplan-Meier survival analysis in this patient cohort, which 
showed a distinct trend towards decreased survival in patients with high LY6G6F expression 
vs. low LY6G6F expression, this strongly suggests a potential role for LY6G6F in PDAC 
carcinogenesis. 
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LY6G6F was observed to be mainly localised in the cytoplasm of PDAC tumours, showing 
granular cytoplasmic immunoreactivity, localised to the apical membrane of ducts. 
Membrane localisation was only observed in a few specimens, with membrane–like 
immunoreactivity more likely to be observed in smaller tumour ducts or tumour buds. 
Tumour budding is a phenomenon encountered in various cancers, including PDAC and 
CRC, where individual malignant cells and/or small clusters of malignant cells, which have 
detached from the main tumour mass, are observed in the tumour stroma. Tumour budding 
is associated with poor outcomes in all of the cancers in which it has been described, and was 
found to be a highly unfavourable prognostic factor in PDAC. (Karamitopoulou et al., 2013) 
Tumour buds have been suggested to undergo partial EMT, with the partial downregulation 
of epithelial markers and upregulation of mesenchymal markers described. Higher levels of 
stem-cell markers are also described in tumour buds, where they could be considered a form 
of the proposed migrating cancer stem cells theory. (Grigore et al., 2016) The observation 
that LY6G6F is more likely to be membrane localised in tumour buds compared to the main 
tumour mass, could indicate a different function for LY6G6F in these cell populations, with 
LY6G6F perhaps only localised to the membrane in response to the activation of certain 
cellular pathways or tumour microenvironmental factors. However, this strong membrane 
localisation observed in tumour buds potentially conflicts with the observation that LY6G6F 
is more lowly expressed in metastatic CRC tumours, if tumour buds do represent the initial 
metastatic front of cancer cells. LY6G6F is potentially involved in the early spread/local 
invasion of tumours, but not distant metastases. It remains to be determined whether the 
membrane localisation observed in tumour buds, correlates to a different functional role for 
LY6G6F in these cells, compared to the cytoplasmic localisation observed in the main 
tumour mass. 
Strong membrane localised LY6G6F immunoreactivity was also observed in the stroma of 
40.4% of the PDAC specimens analysed. PDAC is characterised by an intense stromal 
desmoplastic reaction surrounding cancer cells, which includes a-SMA positive cancer-
associated fibroblasts. (Nielsen, Mortensen and Detlefsen, 2016) PDAC tissue specimens 
could be stained for a-SMA to determine whether the LY6G6F immunoreactivity observed 
is consistent with this cell type. There is significant interest in stromal targeting in PDAC, to 
destroy the dense desmoplastic stroma and enable easier delivery of chemotherapeutic agents 
to the tumour. Therefore, LY6G6F could be relevant as a potential molecular target for both 
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PDAC tumour cells and the surrounding stroma. LY6G6F immunoreactivity was also 
observed in the stroma of some normal tissues. Some of the normal pancreas sections 
displayed strong stromal LY6G6F immunoreactivity in areas, but to a much smaller extent 
than that observed in PDAC. Strong LY6G6F immunoreactivity was also observed in the 
stroma surrounding the glandular tissue in bladder, kidney, larynx, and salivary gland. 
Therefore, LY6G6F may be expressed in some normal tissue fibroblasts, with stronger 
expression observed in the amplified cancer-associated fibroblast component of PDAC. 
Further investigation is required to determine the precise cellular component showing 
LY6G6F immunoreactivity in the stroma.  
LY6G6F gene expression was investigated in gastric cancer using the online tool KM plotter. 
(Szász et al., 2016) The resulting Kaplan-Meier survival analysis found that high LY6G6F 
mRNA levels are significantly associated with poorer survival in gastric cancer patients. 
Therefore, we decided to carry out preliminary analysis of LY6G6F expression at the protein 
level using a small gastric adenocarcinoma and normal gastric epithelium TMA. Gastric 
adenocarcinoma accounts for approximately 95% of gastric cancer cases. Gastric cancer has 
an extremely high mortality rate, with approximately 90% of the people diagnosed with 
gastric cancer, succumbing to the disease. (GE4GAC Group, 2017) LY6G6F was found to 
be weakly expressed in the majority (12/14) of normal gastric epithelium specimens, however 
in contrast 50% (8/16) of the gastric adenocarcinoma specimens strongly express LY6G6F. 
This was determined to be a significant overexpression (p-value 0.002). Again, a mixture of 
mainly cytoplasmic, with some membrane-like immunoreactivity was observed. LY6G6F 
expression should be examined in a larger cohort of gastric cancer patients, to determine if 
high LY6G6F expression correlates with any particular feature/subtype of gastric cancer, as 
half of the cancer specimens analysed showed weak LY6G6F immunoreactivity. The 
analysis of a gastric cancer patient cohort with survival information, would also enable us to 
determine if the high LY6G6F mRNA levels associated with poorer survival in the KM 
plotter analysis, corresponds to a similar association at the protein level.  
An important feature of candidate therapeutic targets, is that they have minimal expression 
in normal tissues, particularly vital organs, with negative or minimal expression in the highly 
proliferating cells of normal tissues, to minimise off target toxicities. LY6G6F expression 
was investigated in the highly proliferating cells of normal proliferative tissues including 
colon, duodenum, gastric tissue and tonsil by staining serial tissue sections for Ki67, a marker 
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of cell proliferation. In general, LY6G6F did not appear to be present in the same cells as 
those stained for Ki67. Negative or minimal LY6G6F immunoreactivity was observed in 
most of the normal tissues analysed, apart from some stronger expression observed in a small 
number of normal colon specimens (8/42) and the strong stromal stain noted in some tissues, 
as discussed above. As already noted however, LY6G6F expression has been reported in 
megakaryocytes and platelets. The one bone marrow specimen analysed, did show some 
LY6G6F immunoreactivity in isolated cells (possibly megakaryocytes). ADC targeting of 
LY6G6F could potentially cause toxicity in these cells. Therefore, the expression of LY6G6F 
in blood cells and normal tissues, would have to be much more extensively examined for 
investigation of its potential as a molecular target for antibody-based therapeutics. 
This study represents the first investigation of LY6G6F expression in PDAC and gastric 
cancer tissue specimens. Whilst LY6G6F overexpression in CRC tumours has already been 
reported (Sewda et al., 2016), a functional role for LY6G6F in the colon cancer cell 
phenotype has not been described. This study showed that LY6G6F is highly expressed in 
these GI cancers, with 70% of colon adenocarcinoma, 78.9% of PDAC and 50% of gastric 
adenocarcinoma specimens highly expressing LY6G6F. These expression levels are 
comparable to other targets that are currently in clinical development as therapeutic targets 
for GI cancers. For example, the transmembrane cell surface receptor guanylyl cyclase C 
(GCC) is currently being evaluated as an ADC target for GI cancers in a Phase 1 trial. GCC 
is expressed in approximately 60-70% of pancreatic, gastric and oesophageal cancers and by 
95% of CRCs. (Almhanna et al., 2016)  
Survival analysis of the PDAC patient cohort showed a trend towards decreased survival in 
the patients with high LY6G6F expressing tumours. If we had access to a larger patient cohort 
this may have reached significance. For the CRC analysis, we unfortunately did not have 
access to a patient cohort with survival information provided. We had access to 22 full-face 
CRC specimens, with information on their pathological grade diagnosis and KRAS/BRAF 
mutational status provided. Commercial TMAs made up the rest of the analysis. It would be 
beneficial to look at LY6G6F expression in a larger PDAC cohort, as well as CRC and gastric 
cancer patient cohorts that include survival information, to determine if there is a significant 
association between high LY6G6F expression and decreased survival in these GI cancers. 
However, the differential tumour/normal tissues expression of the target is on its own enough 
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to warrant investigation of LY6G6F as a therapeutic target in these cancers, an association 
with decreased survival is not a requirement.  
 
6.3.3. LY6G6F Cellular Localisation 
An association between LY6G6F and the membrane of CRC, PDAC and breast cancer cell 
lines was indicated from Western blot analysis of membrane enriched fractions of these cell 
lines. However, the Immunofluorescent and Immunocytochemical analysis of fixed MIA 
PaCa-2 cells showed mainly cytoplasmic and possibly inner plasma membrane LY6G6F 
localisation. No distinct membrane localisation was observed. However, this study was quite 
limited by the commercial antibodies available, with an antibody validated for 
Immunofluorescence only sourced towards the end of this study. Therefore, further 
optimisations and attempts at live cell immunofluorescence may have been able to show more 
distinct membrane localisation. Interestingly, in the study by Sewda et al., (2016), that 
identified LY6G6D/F as a marker for CRC, they also failed to show LY6G6F expression on 
the surface of colon cancer cells by Immunofluorescence analysis. They tried to confirm 
LY6G6F expression on the cell surface of non-permabilised colon cancer cell lines, but 
LY6G6F was not observed on the surface of any of the cell lines surveyed. They state that 
this doesn’t necessarily mean that surface expression will not be observed in CRC, since 
tumour microenvironmental factors can also affect gene expression and sub-cellular 
localisation. From our observations in the Immunohistochemical analysis of tissue sections, 
this could perhaps be true, with LY6G6F membrane-like expression more likely to be 
observed in smaller tumour ducts/ tumour buds at the invasive front of both PDAC and CRC, 
suggesting localisation to the membrane occurs only in particular circumstances. The 
prevalent type of LY6G6F immunoreactivity observed in the main tumour body of CRC, 
PDAC and gastric cancer was granular cytoplasmic, often localised to the apical membrane 
side of the tumour ducts.  
Membrane localisation was observed in the stromal component of PDAC and some normal 
tissues, and it remains to be determined if these represent fibroblast cells or some other 
stromal cell component present in both normal and cancer tissues (and as previously 
mentioned, staining of PDAC for a-SMA, could confirm if LY6G6F is expressed on the 
cancer-associated fibroblasts). Studies in the literature did confirm cell surface localisation 
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of LY6G6F on the surface of platelets and K562 cells. (de Vet, Aguado and Campbell, 2003; 
Macaulay et al., 2007) Again, perhaps indicating LY6G6F is only localised to the membrane 
in certain cell types or in response to certain intra/extracellular factors. Based on the 
cytoplasmic cellular localisation observed in the majority of cancer tissues analysed, it would 
previously have been assumed that LY6G6F would not be amenable to therapeutic antibody 
targeting, which requires cell-surface localisation of the target. However, recent studies have 
shown that mAbs generated against an intracellular antigen can show therapeutic efficacy, 
and there are also emerging strategies to target intracellular proteins via the presentation of 
peptides on the cell-surface in the context of HLA, such as TCRm mAbs mentioned in 
Section 1.3.4. (Dubrovsky et al., 2016; Thura et al., 2016) 
 
6.3.4. Function of LY6G6F in the Cancer Cell Phenotype  
Following on from the observation that LY6G6F is significantly overexpressed in CRC and 
PDAC tumours, the functional role for LY6G6F in these cancers was assessed in vitro. 
Transient protein knockdown of LY6G6F was carried out in the colon cancer cell line 
HCT116 and the PDAC cell line MIA PaCa-2, followed by analysis of the functional effect 
on the proliferation, 2D colony formation, migration and invasion of these cells. Three 
independent LY6G6F siRNAs were used, which gave varying amounts of protein 
knockdown in these cells, with complete protein knockdown never achieved. However, the 
effect of the partial protein knockdown was assessed, with the use of three siRNAs giving 
more confidence in the results found. LY6G6F protein knockdown was found to significantly 
decrease the proliferation of both cell lines, as determined by the acid phosphatase assay and 
the 2D colony formation assay. The acid phosphatase assay determines cell growth based on 
the quantification of cytosolic acid phosphatase activity, enabling comparison of 
proliferation rates between control and siRNA treated cells. Whereas, the 2D colony 
formation assay assesses the ability of single cells to survive and proliferate into colonies. 
LY6G6F KD was found to significantly decrease the proliferation of HCT116 cells, with a 
21%, 36% and 38% decrease in proliferation vs. Negative siRNA control found for the three 
siRNAs. There was also a big decrease in the colony forming ability of these cells, with a 
reduction of 58.4%, 25.9% and 29.4% in the area covered vs. Negative control, but these 
results failed to reach significance due to high SDs. There was a more minimal reduction in 
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the proliferation of MIA PaCa-2 cells, with an 11%, 20% and 24% decrease observed, which 
was a significant decrease vs. Negative control. The effect on the colony forming ability of 
MIA PaCa-2 cells was even greater, with a significant decrease of 51.1% and 31.7% in the 
area covered vs. Negative control. The third siRNA also showed a decrease of 30.4%, but 
this failed to reach significance. Therefore, LY6G6F appears to have a role in the 
proliferation of both HCT116 and MIA PaCa-2 cells.  
LY6G6F protein knockdown also decreased the migration and invasion of these cells. In the 
HCT116 cell line, LY6G6F KD led to a significant reduction in migration, with a decrease 
of 73%, 48% and 54% (this siRNA result is a trend, not significant) vs. Negative control. 
There was also a significant decrease in invasion, with a 70% and 59% reduction for two 
siRNAs, with the 3rd showing a 33% reduction in invasion, this siRNA result didn’t reach 
significance however.  In the MIA PaCa-2 cell line, no apparent effect was observed on 
migration, with just a 1%, 10% and 15% (this siRNA result was deemed significant) 
reduction observed. The effect on invasion was bigger, with a significant decrease of 26% 
and 34% found, and a trend to a 25% decrease with one of the siRNAs. Studies have shown 
that the processes of invasion and proliferation in cells are mutually exclusive, with cells 
required to stop dividing in order to invade. (Matus et al., 2015) Therefore, it can be 
concluded that the decrease in migration and invasion following LY6G6F KD, is not simply 
due to the decrease in proliferation observed. In addition, there were only minimal effects on 
the migration of MIA PaCa-2 cells, but a significant decrease in invasion levels, increasing 
confidence that the decrease in proliferation is not the cause of the other functional assay 
results. This is the first study to show that knockdown of LY6G6F in a colon and pancreatic 
cancer cell line, decreases their proliferation, migration and invasion in vitro. 
The association found between LY6G6F and proliferation, migration and invasion in the 
CRC and PDAC cell lines is substantiated by evidence found in the literature. A potential 
ligand for LY6G6F activation has still not been identified, but it has been shown to interact 
with the proteins Grb2 and Grb7 in the K562 cell line, upon phosphorylation of the single 
tyrosine residue present in the intracellular tail of LY6G6F. The tyrosine residue is present 
in a consensus-binding motif (YXN) for the Src homology 2 domains of Grb2 and Grb7. (de 
Vet, Aguado and Campbell, 2003) Grb2 and Grb7 have both been associated with cell 
proliferation and migration. Grb7 has been shown to interact with FAK, with the FAK-Grb7 
complex involved in integrin signalling. Grb2 is a key molecule in intracellular signal 
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transduction, linking activated receptors to downstream targets and can activate the Ras 
MAPK pathway. (Giubellino, Burke and Bottaro, 2008) Antibody cross-linking of LY6G6F 
in the K562 cell line resulted in the phosphorylation of p42/44 MAPK. (de Vet, Aguado and 
Campbell, 2003) The MAPK cascade functions in cellular proliferation, differentiation and 
survival. 
Therefore, to assess whether LY6G6F knockdown is affecting any of these pathways in the 
HCT116 and MIA PaCa-2 cells, potentially mediating the phenotypic effects observed, 
Western blot analysis was carried out to determine the activation levels of FAK and p42/44 
MAPK. The results for p42/44 MAPK were inconclusive, with inconsistencies between 
triplicate experiments, perhaps due to the often variable amounts of protein knockdown 
achieved. However, there was a marked decrease in the levels of phosphorylated-FAK in 
both cell lines, following LY6G6F knockdown. FAK is an intracellular, highly conserved, 
non-receptor tyrosine kinase, which is overexpressed and activated in a wide variety of 
cancers including colon and pancreatic cancer. FAK activation results in the induction of 
multiple signalling molecules, involved in multiple cellular functions, including cell 
proliferation, survival, motility and invasion. (Hochwald et al., 2009; Kanteti et al., 2015) 
Constitutive phosphorylation of FAK has been associated with resistance to the 
chemotherapeutic gemcitabine in pancreatic cancer cell lines. (Huanwen et al., 2009) High 
levels of FAK, in combination with Src, have been associated with tumour recurrence and 
metastasis in colorectal cancer. (de Heer et al., 2008) LY6G6F could have a potential role in 
FAK activation in colon and pancreatic cancer cell lines, due to the decrease observed in 
FAK phosphorylation following LY6G6F knockdown. This decrease in FAK activation in 
the HCT116 and MIA PaCa-2 cell lines, following LY6G6F KD, could also be the mediator 
of the inhibitory effects observed on cell proliferation, migration and invasion, as FAK 
activation has previously been associated with these mechanisms in colon and pancreatic 
cancer. 
To determine if the decrease in proliferation observed was due to cell cycle arrest or an 
increase in apoptotic cell death following LY6G6F knockdown, a small number of cell cycle 
and apoptosis markers were also assessed by Western blot analysis. The results for the cell 
cycle markers Cyclin A and p27 were inconsistent. However, the results did show that there 
is an increase in apoptosis following LY6G6F knockdown, confirmed by an increase in the 
levels of cleaved PARP, a marker of apoptosis. This increase in apoptosis could also be 
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mediated by the decrease in FAK activation, as studies have also linked FAK to an anti-
apoptotic role in anchorage-dependent cells. (Sonoda et al., 2000) The pro-proliferative and 
anti-apoptotic functions of FAK have been shown to enhance tumour growth. (Sulzmaier, 
Jean and Schlaepfer, 2014) Inhibition of FAK phosphorylation has been shown to increase 
apoptosis of both colon and pancreatic cancer cell lines. (Hochwald et al., 2009; Heffler et 
al., 2013) 
Therefore, these results link LY6G6F to a role in FAK activation, with the decrease in FAK 
activation following LY6G6F knockdown being the potential mediator of the observed 
increase in apoptosis and decrease in cell proliferation, colony formation, migration and 
invasion. These functional studies and the information from the literature also tie in with the 
fact that higher LY6G6F expression was associated with poorer prognosis vs. low LY6G6F 
expression in the PDAC patient cohort (n=57) analysed in the Immunohistochemical analysis 
and in gastric cancer patients in the KM plotter analysis, suggesting a role for LY6G6F in 
the growth and survival of these GI cancers.  
Unfortunately, time did not allow for the investigation into other potential pathways affected 
by LY6G6F knockdown in these cell lines. Further investigation should be carried out to 
determine if any other pathways alongside FAK are affected by LY6G6F knockdown in 
colon and pancreatic cancer cell lines. The Co-Immunoprecipitation of LY6G6F from cancer 
cell lysates was also unfortunately unsuccessful, meaning that LY6G6F-protein interactions 
in the colon and pancreatic cancer cells lines could not be determined. Instead of the Western 
blot analysis for a small number of cell cycle and apoptosis markers, it would have been 
beneficial to carry out more in depth cell cycle and apoptosis assays to gather more 
information on the effects of LY6G6F knockdown. For example, the increase in apoptosis 
observed could be further verified by an Annexin-V Apoptosis assay (e.g. TUNEL assay), 
which enables the quantification of live, dead and early or late apoptotic cells in a sample. 
Analysis of cell cycle arrest by BrdU staining of cells for DNA content, would allow analysis 
of the cells through the full cycle (G0/G1, S and G2/M), as the two markers (Cyclin A and 
p27) assessed by Western blot analysis did not allow for this, and with the inconsistent result 
observed, no conclusion could be made on whether LY6G6F has any role in cell cycle arrest, 
as well as apoptosis.  
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The attempt at LY6G6F protein overexpression by vector transformation in MIA PaCa-2 and 
SW480 cells was also unsuccessful to date, therefore it could not be determined whether 
LY6G6F overexpression in cell lines with lower endogenous protein levels causes an 
increase in cell proliferation, migration or invasion. Despite achieving high LY6G6F 
overexpression at the mRNA level, this did not translate into any noticeable protein 
overexpression, as determined by Western blot analysis. It could not be determined whether 
the vector expressed version of LY6G6F protein was being translated at all, as the Western 
blot analysis for the FLAG-tag attached to the vector expressed LY6G6F did not work as 
anticipated. The expression of LY6G6F may be highly regulated at the translational level, 
meaning protein overexpression could not be achieved, despite the increase in LY6G6F 
mRNA observed in vector transformed cells. This could be happening by microRNA 
(miRNA) induced silencing of the overexpressed LY6G6F mRNA. Regulation of translation 
by miRNA can occur by mRNA degradation or the prevention of mRNA translation into 
protein. Or if the vector expressed version of LY6G6F is getting translated into protein, the 
process of ubiquitination may be maintaining protein levels at a similar level to non-vector 
transformed cells. The binding of the ubiquitin regulatory protein to another protein can 
amongst other things lead to the protein’s degradation via the proteasome. Therefore, if 
overexpressed LY6G6F is being quickly degraded, it may not show up on Western blot 
analysis.  
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6.4. IL1RAPL1  
IL1RAPL1 was not identified as a potential cancer target in a conventional way, as IL1RAP 
was the gene identified from the microarray dataset of genes upregulated in colon cancer vs. 
normal colon. However, the error in examining IL1RAPL1 rather than IL1RAP in the 
preliminary analysis, led to the discovery that IL1RAPL1 is in fact strongly expressed in 
colon cancer with minimal expression in normal colon. A link between IL1RAPL1 
expression and colon cancer has not been previously reported in the literature. Indeed, 
IL1RAPL1 expression has mainly been associated with the brain and cognitive impairment. 
Therefore, it was decided to investigate the expression of this potentially novel colon cancer 
target further. 
IL1RAPL1 belongs to a novel class of the IL-1/Toll receptor family, characterised by the 
presence of a 150 amino acid long C-terminal extension that has no significant homology 
with any protein of known function. IL1RAPL1 was hypothesised to play a similar role to 
that of IL-1R in the CNS, i.e. binding to IL-1 and initiating signalling events, including 
activation of JNK and NF-κB, which regulates the expression of many pro-inflammatory 
genes in the nucleus. However, IL1RAPL1 was initially found to not interact with IL-1 and 
signalling experiments showed IL1RAPL1 was unable to activate the transcription factor NF-
κB, or the MAP kinases ERK and p38, but could activate JNK. Therefore, it was suggested 
that almost all physiological and biological features remain to be defined for this novel class, 
including their ligand(s) and downstream partners. (Chelly et al., 1999; Born et al., 2000) 
IL1RAPL1 is abundantly expressed in the brain and high levels of expression are found in 
the CNS during development. IL1RAPL1 is a 696 AA protein consisting of an extracellular 
domain of three Ig-like domains and a cytoplasmic domain, containing a TIR (Toll/IL1R) 
domain and the specific 150 amino acids at the C-terminal end. This 150-amino acid 
extension was subsequently found to interact with the neuronal calcium sensor 1 (NCS-1) 
protein, taking part in downregulating the activity of voltage-dependent calcium channels, in 
calcium-dependent exocytosis and NGF induced neurite outgrowth. IL1RAPL1 has also been 
shown to interact in dendritic spine with PSD-95, a major scaffold protein of excitatory post-
synaptic density. IL1RAPL1 is reported to regulate the synaptic localisation of PSD-95 by 
controlling JNK activity and PSD-95 phosphorylation. The activation of the JNK pathway in 
neurons by IL-1 was found to be mediated by IL1RAPL1, despite previous reports stating 
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that IL1RAPL1 was incapable of IL-1 interaction.  Therefore, the function of IL1RAPL1 in 
neurons has been linked to synapse formation and stabilisation. (Pavlowsky et al., 2010; 
Boraschi and Tagliabue, 2013) Reduced synapse formation has been proposed as a common 
pathogenic mechanism of cognitive impairment, which follows the finding that IL1RAPL1 
gene deletions and non-sense mutations have been identified in patients suffering from X-
linked intellectual disability. Mutations in IL1RAPL1 have also been associated with autism 
and schizophrenia. (Piton et al., 2008) 
IL1RAPL1 has been reported as being a common fragile site (CFS) gene contained within 
the FRAXC CFS region. Common fragile sites are large regions of profound genomic 
instability found in all individuals. They are biologically significant due to their role in a 
number of genomic alterations that are frequently found in many different types of cancer. 
IL1RAPL1 is abundantly expressed in normal brain but was found to be dramatically 
underexpressed in every brain tumour cell line and xenograft (derived from an intracranial 
model of GBM) examined. This suggests IL1RAPL1 may function as a tumour suppressor 
in this cancer type. (Smith et al., 2006; McAvoy et al., 2007) However another study that 
classified GBM into different subtypes, linked IL1RAPL1 expression to the proneural 
subtype. (Cruceru et al., 2013) The expression of IL1RAPL1 in other cancer types has not 
been widely reported on and no functional studies in cancer have been carried out. 
 
6.4.1. IL1RAPL1 Expression in Cell Lines  
Western blot analysis detected IL1RAPL1 expression in all colon cancer, PDAC and breast 
cancer cell line panels analysed, at the predicted MW of ~69kDa. IL1RAPL1 was detected 
in both the whole cell lysate and the membrane enriched fraction of cells, indicating an 
association with the membrane in these cell lines. No notable differential expression between 
cell lines was observed. The Western blot analysis also revealed the presence of a lower MW 
isoform of IL1RAPL1 in all of the PDAC cell lines, and three of the colon cancer cell lines 
analysed. This band at ~58kDa, was also detected in conditioned medium from MIA PaCa-
2 and BXPC-3 cell lines. Therefore, there appears to be a soluble form of IL1RAPL1 
produced and secreted by these cell lines. The three colon cancer cell lines that express the 
lower MW isoform are SW480, SW620 and CaCo-2, which are distinguished from the other 
three cell lines (HCT116, T84 and HT29) by the expression of wildtype PIK3CA (refer to 
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Table 3.2). Therefore, perhaps the expression of this lower MW isoform is linked to a 
mutational subset of colon cancer. A smaller isoform produced by the IL1RAPL1 gene was 
originally reported in the discovery of the gene, which was suggested to not contain the 
transmembrane domain, a feature that was previously found in the mouse isoform. It was 
suggested to correspond to a soluble form of the putative extracellular domain of IL1RAPL1, 
with an unknown function. Cell-surface proteins can be proteolytically cleaved to release 
their biologically active extracellular domains into the extracellular milieu, in a process 
known as ectodomain shedding. Ectodomain shedding can rapidly downregulate the 
expression of cell surface proteins, and the released soluble extracellular ectodomains can 
then function in an autocrine or paracrine fashion. (Hayashida et al., 2010) A function for the 
soluble form of IL1RAPL1 has not been reported yet. The potential secretion of soluble 
IL1RAPL1 by tumour cells could have implications for potential antibody targeting of 
tumour cells. Soluble antigen in the tumour microenvironment can bind ADCs, thus limiting 
the amount of ADC free to bind tumour cells and therefore decreasing efficacy. Therefore, 
further investigation into this soluble form of IL1RAPL1, and whether it is produced in vivo 
is required. If IL1RAPL1 was secreted highly in vivo, then it could have potential as a serum 
biomarker for CRC diagnosis or monitoring of recurrence. 
 
6.4.2. IL1RAPL1 Expression in Normal and Cancer Tissues  
The Immunohistochemical analysis of IL1RAPL1 expression in normal and cancer tissues, 
found that IL1RAPL1 is significantly upregulated in CRC and oesophageal squamous cell 
carcinoma vs. corresponding normal tissues. IL1RAPL1 was not found to be highly 
expressed in the small cohort of PDAC specimens analysed. And most of the breast cancer 
specimens showed weak immunoreactivity, with only one section displaying some stronger 
immunoreactivity compared to normal breast. Information on the subtype of the breast cancer 
specimens analysed was not available, therefore IL1RAPL1 could potentially be 
differentially expressed between different breast cancer subtypes, however it was decided to 
focus on cancers of the GI tract for this study and examine IL1RAPL1 expression further in 
CRC and oesophageal cancer.  
IL1RAPL1 was found to have limited expression in normal colon, with the majority (28/42) 
of specimens negative for IL1RAPL1 expression, with the remainder (12/42) mainly showing 
  233 
weak and diffuse immunoreactivity. Just 2/42 specimens showed some strong 
immunoreactivity. IL1RAPL1 is also lowly expressed in the benign spectrum of colon 
disease. All benign specimens analysed (chronic inflammation of mucosa, polyps, 
hyperplasia of glandular epithelium and adenoma) showed either negative or weak and 
diffuse IL1RAPL1 immunoreactivity, indicating that IL1RAPL1 is not upregulated in the 
initial stages of normal colon transformation.  
In contrast IL1RAPL1 was found to be strongly expressed in all CRC specimens analysed 
(adenocarcinoma, mucinous adenocarcinoma, carcinoid cancer and metastatic 
adenocarcinoma), which was determined to be a significant overexpression vs. normal colon 
by Chi-square test. 100% of the carcinoid cancer subtype showed strong IL1RAPL1 
immunoreactivity (p-value <0.0001). Carcinoid cancer arises from neuroendocrine cells and 
is a rare subtype of CRC, with an incidence of approximately 2.5-5 cases per 100,000 CRC 
cases annually. (Ni, Sheng and Du, 2010) The sample size was very small (n=2), however as 
IL1RAPL1 has been predominantly found to be expressed in neurons, it is perhaps not 
surprising that it is strongly expressed in cancer arising from neuroendocrine cells, which 
interact with the neuronal system. Investigation of a larger patient cohort of carcinoid 
tumours would need to be carried out to determine if this is a consistent overexpression in 
this subtype.  
The majority (66.7%) of colon adenocarcinoma specimens analysed highly overexpress 
IL1RAPL1 vs. normal colon (p-value <0.0001). There is no apparent association between 
IL1RAPL1 expression and a particular mutational subset, with the majority of KRAS MT 
and WT, and BRAF MT and WT specimens showing strong IL1RAPL1 expression. 
Mucinous adenocarcinoma accounts for approx. 10-15% of CRC cases and is characterised 
by abundant mucous secretion comprising at least 50% of the tumour volume. (Hugen et al., 
2015) IL1RAPL1 was found to be strongly expressed in 46.7% of mucinous specimens 
analysed (p-value 0.0001). The metastatic cancer specimens were derived from lymph node 
metastases, with 47.2% of specimens showing strong IL1RAPL1 immunoreactivity (p-value 
<0.0001). IL1RAPL1 expression was not associated with the histopathological grade 
diagnosis of adenocarcinoma, mucinous or metastatic adenocarcinoma, but a higher 
percentage of the Grade 3 adenocarcinoma specimens showed strong IL1RAPL1 expression 
compared to Grade 1 and Grade 2 tumours. IL1RAPL1 expression is significantly associated 
with CRC, regardless of subtype. It appears to be specifically associated with malignant 
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transformation of colon cells, as low IL1RAPL1 expression was found in all specimens of 
the benign spectrum.  
IL1RAPL1 expression was also assessed in oesophageal cancer, another cancer of the GI 
tract, as increased expression was found in oesophageal cancer vs. normal oesophagus in the 
preliminary IHC analysis. Oesophageal cancer is the eight most common form of cancer 
worldwide, and ranks sixth among all cancers in mortality. Despite advances in diagnostics 
and therapeutics, the prognosis for oesophageal cancer remains poor. There remains a need 
to elucidate further on the molecular mechanisms underlying this cancer type. The two main 
subtypes of oesophageal cancer are oesophageal squamous cell carcinoma (OSCC) and 
oesophageal adenocarcinoma (OAC). OSCC comprises approximately 90% of oesophageal 
cancer cases worldwide, however the incidence of OAC is increasing in Western countries. 
OAC arises from glandular cells in the distal oesophageal epithelium, with risk factors 
including exposure to tobacco smoke and the presence of gastroesophageal reflux disease, 
which triggers chronic inflammation and the development of intestinal metaplasia (Barrett’s 
oesophagus), the precursor lesion to OAC. OSCC arises from the epithelial cell lining of the 
oesophagus and nearly 90% of the risk in developing OSCC can be attributed to tobacco and 
alcohol in Western countries. (Kato and Nakajima, 2013; Lin et al., 2016) 
A small oesophageal cancer test TMA was obtained to investigate the expression of 
IL1RAPL1, following the preliminary finding of increased IL1RAPL1 expression in a 
malignant oesophagus specimen vs. normal oesophagus (n=1). The test TMA had very small 
sample numbers, with 12 cases representing normal oesophagus and various oesophagus 
cancer subtypes. The majority of normal oesophagus specimens analysed did show some 
weak and diffuse IL1RAPL1 immunoreactivity, with negative expression observed in the 
remainder. The rarer cancer subtypes present on the TMA, including small cell 
undifferentiated carcinoma and carcinosarcoma, also showed negative or weak IL1RAPL1 
immunoreactivity. Carcinoma in situ and OAC specimens both showed weak IL1RAPL1 
expression. IL1RAPL1 was strongly expressed however in every OSCC specimen analysed, 
which was deemed a significant overexpression vs. normal oesophagus (p-value 0.0027). 
Therefore, IL1RAPL1 expression appears to be a specific feature of OSCC, and could 
perhaps have potential diagnostic application for this cancer type. However, as only a very 
small patient cohort was analysed for IL1RAPL1 expression, analysis in a larger patient 
cohort should be carried out to determine with more certainty if IL1RAPL1 overexpression 
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is specifically associated with OSCC, and found at low levels in the other oesophageal cancer 
types.  
This study is the first investigation into IL1RAPL1 expression in CRC and oesophageal 
cancer, with IL1RAPL1 overexpression in CRC and OSCC a novel finding. As already 
discussed for LY6G6F, it would have been beneficial to have access to a larger CRC patient 
cohort, including larger numbers of the rarer subtypes (i.e. carcinoid tumours) to determine 
if IL1RAPL1 is consistently highly expressed across all CRC subtypes. Access to survival 
information also would have enabled us to determine if there is any association between 
IL1RAPL1 expression and survival in CRC patients. The investigation into IL1RAPL1 
expression in oesophageal cancer was very preliminary, to determine if further investigation 
was warranted. It would have been beneficial to have access to a larger cohort of oesophageal 
cancer patient specimens, to follow up on the finding that IL1RAPL1 is specifically 
overexpressed in OSCC.  
The expression of IL1RAPL1 in normal tissues was assessed by IHC analysis of a number 
of full-face tissue sections available to us from our collaboration with SVUH, and also 
commercial normal tissue TMAs. Most normal tissues showed negative or weak and diffuse 
IL1RAPL1 immunoreactivity. However stronger expression was noted in some normal 
tissues. Strong granular diffuse IL1RAPL1 immunoreactivity was observed in the pituitary 
gland, and isolated cells in the cerebral cortex were observed to have strong IL1RAPL1 
immunoreactivity. This is not surprising, considering IL1RAPL1 is known to be localised in 
the brain. For the development of an antibody-based therapeutic against IL1RAPL1, the high 
expression of IL1RAPL1 in the brain should not be a cause for concern, as in general 
antibody therapeutics are too large to cross the blood brain barrier, which would limit the 
chances of off target toxicity. (Pardridge, 2005) Some strong IL1RAPL1 immunoreactivity 
was also observed in some of the normal tissues of the GI tract; 2/42 normal colon, 1/4 
duodenum and 3/5 gastric specimens analysed showed some strong IL1RAPL1 
immunoreactivity. In gastric epithelium, certain collections of individual cells were strongly 
positive for IL1RAPL1 expression with the remainder of the tissue showing negligible 
expression. This indicates that perhaps only a certain type of gastric cell is expressing 
IL1RAPL1, and the opinion of a pathologist will be sought, to determine if these IL1RAPL1 
expressing cells represent a particular subset of gastric cells. In the colon and duodenum 
sections that displayed stronger staining, it was present in the luminal space of goblet cells 
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that line the crypts of these tissues, and it was difficult to determine in some cases if the 
immunoreactivity was in the cells or the extracellular space. This also resulted in difficulty 
in definitively determining if IL1RAPL1 is expressed in the highly proliferating cells of these 
tissues. The IHC analysis comparing serial normal tissue sections stained for IL1RAPL1 and 
Ki67, a marker of cellular proliferation, showed that IL1RAPL1 does not appear to be present 
in the proliferating cells of normal colon, but the results for duodenum and gastric epithelium 
were less clear cut. This analysis should be repeated on further tissue sections, to try and 
conclusively determine if IL1RAPL1 is present in highly proliferating normal cells. The 
reason for this analysis was to further assess if IL1RAPL1 could be a potential molecular 
target for therapeutic targeting, as minimal expression in the highly proliferating cells of 
normal tissues is a requirement to limit off-target toxicities. However, the limited expression 
of IL1RAPL1 overall in all normal tissues analysed, along with the strong expression in CRC 
and OSCC, indicates IL1RAPL1 could still have potential as a molecular target amenable to 
targeted therapeutics in these cancer types.   
Strong IL1RAPL1 immunoreactivity was potentially observed in immune cells responding 
to the invasive front of a CRC tumour (see Figure 5.6), with IL1RAPL1 expression also 
observed in the “immune” cells of several other CRC tumours and also to a lesser extent in 
some normal colon specimens. Innate immune cells, such as macrophages, NK cells and 
dendritic cells can respond to inflammatory signals generated by damaged tissue and cancer 
cells. As discussed in Section 1.1.3, colon cancer is associated with the infiltration of a variety 
of different immune cells, which can play an important role in CRC pathogenesis, promoting 
angiogenesis, tumour proliferation and invasion. A study on cultured macrophages suggest 
that they respond to IL-38 through IL1RAPL1, as these cells were found to not express the 
IL-36 receptor but did express IL1RAPL1. (Mora et al., 2016) Macrophages compose the 
largest immune population found in the tumour microenvironment and are also resident in 
normal colon, as part of the innate immune system. As discussed in Section 1.1.3.2, 
macrophages can polarise into two distinct subsets: pro-inflammatory M1 macrophages and 
anti-inflammatory M2 macrophages. M1 are anti-tumour and M2 are pro-tumour. Resident 
macrophages in normal colon are considered to be M2 macrophages as they are recruited 
from circulating monocytes which exhibit an inflammatory phenotype, but are subsequently 
polarised into anti-inflammatory macrophages in response to signals from the intestinal 
mucosa. IL1RAPL1 immunoreactivity was not observed in “immune” cells of any of the 
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chronic inflammation of colon mucosa tissue specimens. Chronic inflammation in colon (e.g. 
inflammatory bowel disease) is associated with massive infiltrate of pro-inflammatory/M1 
macrophages. (Smith et al., 2011; Kühl et al., 2015) Therefore based on the observations in 
this study of IL1RAPL1 immunoreactivity in the colon specimens, and the fact that 
IL1RAPL1 has been reported as being expressed in cultured macrophages, IL1RAPL1 
expression could be associated in particular with M2 macrophages.  
However, it also must be said that IL1RAPL1 immunoreactivity in “immune” cells was more 
likely to be observed in the full-face tissue sections as opposed to TMA cores, as these 
provide much larger sections of tissue. All of the chronic inflammation tissues were from the 
TMA, therefore it could be possible that these didn’t offer a big enough tissue section to 
observe any potential “immune” cells with IL1RAPL1 immunoreactivity. As there is no 
definite evidence that the IL1RAPL1 expression is on macrophages, IL1RAPL1 could be 
expressed on a number of other immune cells found in the colon microenvironment, such as 
dendritic cells, NK cells, mast cells or T-cells. Confirmation of the exact cell type observed 
to have IL1RAPL1 expression needs to be carried out. The CRC tissue sections could be 
stained for specific markers of immune cells to identify the type with IL1RAPL1 
immunoreactivity. Barros et al., (2013) described a double-staining IHC approach for the 
identification of M1 and M2 macrophages in tissues. They found that CD68 or CD163 in 
combination with pSTAT1 or RBP-J can be used to identify M1 macrophages, while in 
combination with CMAF they can identify M2 macrophages. Other immune cells can also 
be identified by a variety of markers, e.g. dendritic cells (CD11c+, HLA-DR+), NK cells 
(CD3-, CD56+, CD94+, NKp46+) and Treg cells (CD8+, CD4+, Foxp3+). If IL1RAPL1 is 
expressed on tumour associated immune cells, then this could also have therapeutic potential, 
as there is increasing interest in targeting elements of the tumour microenvironment that 
contribute to tumour growth and invasiveness. For example, the high density of TAMs found 
in triple-negative breast cancer has been proposed as a potential target to control tumour 
growth. TAM targeted therapy in a mouse model of triple negative breast cancer was shown 
to decrease TAM population in tumours and inhibit tumour growth. (Niu et al., 2016)  
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6.4.3. IL1RAPL1 Cellular Localisation 
The predicted cellular localisation of IL1RAPL1 at the membrane, was confirmed by Bahi et 
al., (2003) by Immuofluorescence staining of an IL1RAPL1 stably transfected CHO cell line. 
Our findings linked IL1RAPL1 to an association with the membrane of CRC, PDAC and 
breast cancer cell lines, with detection of IL1RAPL1 in the membrane enriched fraction of 
these cell lines by Western blot analysis. The Immunocytochemical analysis of fixed 
HCT116 and MIA PaCa-2 cells, showed only cytoplasmic localisation of IL1RAPL1 
however. The Immunofluorescence analysis of fixed HCT116 and SW480 cells, also showed 
cytoplasmic localisation, with possibly some membrane localisation also. Overall the 
localisation of IL1RAPL1 on the surface of these cancer cell lines could not be confirmed. 
Attempts at optimisation of live cell Immunofluorescence to confirm if IL1RAPL1 is 
expressed on the cell surface are ongoing.  
Similarly, the Immunohistochemical analysis of IL1RAPL1 expression in CRC and OSCC, 
showed mainly cytoplasmic immunoreactivity, with some membrane-like immunoreactivity 
observed in only a small number of cases. Therefore, despite being a predicted membrane 
localised protein, IL1RAPL1 does not appear to be localised to the membrane of the cancer 
tissues and cell lines analysed in this study. IL1RAPL1 may only be localised to the cell 
surface in response to certain stimuli/cellular signals.  
 
6.4.4. Function of IL1RAPL1 in the Cancer Cell Phenotype  
IL1RAPL1 has been shown to be significantly overexpressed in both CRC and OSCC 
compared to normal tissues in this study, which has not been previously reported in the 
literature. However, attempts to determine a possible function for IL1RAPL1 in the colon 
cancer cell phenotype in vitro were unsuccessful. Despite achieving transient siRNA 
mediated knockdown of IL1RAPL1 at the mRNA level, this was never translated into 
observable protein knockdown. Despite varying the time-points assayed post transfection 
(from 48-93hrs), no IL1RAPL1 protein knockdown was observed. Therefore, the effect of 
IL1RAPL1 knockdown on the cancer cell phenotype could not be assessed. IL1RAPL1 may 
have a long protein half-life in these cells, meaning the protein levels were not reduced even 
93hrs post mRNA knockdown. The process of deubiquitination could have prevented the 
degradation of the protein already in the cell before mRNA knockdown. Ubiquitination is a 
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post-translational modification that generally directs proteins for degradation by the 
proteasome or by lysosomes, and deubiquitination can lead to protein stabilisation. (Stringer 
and Piper, 2011) Experiments were planned (but not yet carried out) to try and determine the 
protein half-life of IL1RAPL1 in these cells. Treating cells with a protein synthesis inhibitor, 
such as cycloheximide, in a time-course experiment, followed by Western blot analysis of 
the cell lysate for IL1RAPL1, could show at what time-point IL1RAPL1 protein degradation 
begins, with a comparison Western blot to a protein with a known short protein half-life.  
In hindsight, a lot of time was spent optimising transfection conditions in the attempt to 
achieve siRNA mediated protein knockdown of IL1RAPL1, which could have been better 
spent on alternative methods to try and achieve this. Instead of transient knockdown with 
siRNA, stable knockdown of IL1RAPL1 could have been attempted by plasmid transfection 
of a short hairpin RNA (shRNA) sequence into the cells. The shRNA sequence would work 
in a similar way to the siRNA, targeting IL1RAPL1 mRNA to prevent protein translation, 
but as the shRNA sequence would be continuously expressed by the cells, unlike siRNA, it 
would allow for prolonged gene silencing. Therefore, if the issue was that IL1RAPL1 protein 
has a long half-life, this would allow time for the degradation of IL1RAPL1 already present 
in the cell at the time of vector transformation. The stable transfection of cells is quite time 
consuming initially, and it would be preferable to insert an shRNA sequence that is known 
to give high knockdown of IL1RAPL1 mRNA. However, if it worked, the effect of 
IL1RAPL1 protein knockdown on cellular function could have been assessed. Another 
method that could have been utilised is the CRISPR/Cas9 gene editing tool, to remove the 
IL1RAPL1 gene from the genome, and thus assess the impact on cellular function.    
A different method that was considered to investigate the functional role of IL1RAPL1 in 
vitro, was antibody blocking, to inhibit the function of IL1RAPL1, rather than knocking it 
down. Treating cancer cells with an antibody directed against the extracellular domain of 
IL1RAPL1, could potentially block its function, allowing for subsequent functional analysis 
to assess the effect on cellular proliferation, migration and invasion. However, this was 
determined to not be a viable option in this study, as the costs of commercially available 
antibodies to IL1RAPL1 for such a large scale experiment would have been prohibitive. If 
we had generated our own mAb to IL1RAPL1, this could have been more easily achieved. 
Also, the analysis of the cellular localisation of IL1RAPL1 in the cancer cell lines examined 
in this study, casts some doubt on the suitability of the antibody blocking method, as no clear 
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membrane localisation of IL1RAPL1 was detected. If IL1RAPL1 is not expressed on the 
cell-surface, then the antibody would not be able to bind to inhibit its function.  
The attempt to elucidate on a role for IL1RAPL1 in the colon cancer cell phenotype, by 
IL1RAPL1 overexpression in the SW480 cell line was also unsuccessful to date. IL1RAPL1 
protein overexpression was not observed by Western blot analysis, however mRNA 
overexpression was also not conclusively confirmed, and the qRT-PCR and Western blot 
analysis was only carried out for one biological experiment to date. Time did not allow for 
further optimisation to try and successfully achieve protein overexpression for functional 
analysis. Similar to the LY6G6F overexpression experiment, if IL1RAPL1 mRNA was 
successfully overexpressed, then miRNA induced silencing of mRNA translation or post-
translational modifications such as ubiquitination leading to excess protein degradation, 
could have prevented successful IL1RAPL1 overexpression. Co-Immunoprecipitation 
experiments to try and identify IL1RAPL1 interacting proteins, were also unsuccessful, 
which may have been due to the antibodies used not being suitable for IP. Therefore 
unfortunately, no function for IL1RAPL1 in the cancer cell phenotype could be determined. 
IL1RAPL1 expression has mainly been reported in the brain to date, with a function in 
synapse formation and stabilisation reported. Compared to this expression in normal brain, 
IL1RAPL1 was reported to be underexpressed in brain tumour cell lines and xenograft 
models examined. (Smith et al., 2006; McAvoy et al., 2007) And its expression was also 
associated with the proneural subtype of glioblastoma multiforme. (Cruceru et al., 2013) The 
overexpression of IL1RAPL1 in cancer has not been widely reported, with no known 
function for IL1RAPL1 in cancer pathogenesis. IL1RAPL1 has been shown to activate JNK 
in neuronal cells, therefore it potentially has a similar function in cancer cells. The JNK 
pathway represents one sub-group of MAP kinases that is activated primarily by cytokines 
and exposure to environmental stress, and has been implicated in oncogenic transformation. 
It’s role in tumour development remains controversial however as various studies have linked 
JNK to both pro-oncogenic roles and tumour suppression. (Weston and Davis, 2007) High 
levels of JNK activity are found in several cancer cell lines however and a mouse model of 
intestinal cancer showed that ablation of the cJun gene or mutation of the JNK 
phosphorylation sites, reduced tumour number and size, and prolonged lifespan. (Nateri, 
Spencer-Dene and Behrens, 2005) Therefore if IL1RAPL1 is involved in JNK activation in 
CRC or OSCC, it could contribute to the cancer phenotype this way.  
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Additionally, miRNA involved in IL1RAPL1 gene silencing have been implicated in CRC 
pathogenesis. An analysis of the transcription factors (TF) and miRNA that regulate the 
expression of 158 IQ-related genes, found that IL1RAPL1 is a target for the TF MEF2 and 
the miRNAs hsa-miR-15b and hsa-miR-195. miRNA can regulate mRNA expression at the 
post-transcriptional level, by degradation or translational repression by binding the target 
gene with small complementary sequences. Both hsa-miR-15b and hsa-miR-195 belong to 
the miR-15 family, and can mediate wide gene silencing in the cell, with IL1RAPL1 a target 
for silencing for them both. (Zhao, Kong and Qu, 2014) Deregulated miRNAs and their role 
in cancer have attracted much attention in recent years. And miRNA hsa-miR-15b and hsa-
miR-195 have both been reported to be downregulated in CRC. One study found that miR-
195 was downregulated in CRC tissues and that restoration of miR-195 in the CRC cell lines 
HT29 and LoVo could reduce cell viability, promote cell apoptosis and suppress 
tumourigenicity. (Liu et al., 2010) Another study showed that downregulation of miR-195 
correlates with lymph node metastasis and poor prognosis in CRC and was an independent 
predictor of overall survival. (Wang et al., 2012) In gastric cancer the downregulation of 
miR-15b was found to be concurrent with the upregulation of Bcl-2 protein, with a role 
suggested in the development of multi-drug resistance in gastric cancer. (Xia et al., 2008) 
Another study found that miR-15b is significantly downregulated in the progression from 
non-neoplastic tissue to dysplasia and from dysplasia to cancer in CRC progression. (Kanaan 
et al., 2012) Therefore the downregulation of these miRNAs in CRC suggests a potential 
mechanism for IL1RAPL1 overexpression in CRC.  
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6.5. Potential for LY6G6F and IL1RAPL1 as Molecular Targets for Therapeutic 
Antibody Targeting 
LY6G6F and IL1RAPL1 have been investigated as potential molecular targets for antibody-
based targeted therapeutics. They have both been found to show higher expression in tumours 
vs. normal tissues by Immunohistochemical analysis. LY6G6F has been shown to be 
overexpressed in colon adenocarcinoma, PDAC and gastric adenocarcinoma compared to 
normal tissues. IL1RAPL1 has been shown to be overexpressed in both OSCC and all 
subtypes of CRC. They also both show relatively limited expression in normal tissues and 
highly proliferating normal cells, which would enable selective targeting of cancer cells and 
limit off target toxicities. Target cell-surface localisation has been viewed as an important 
characteristic of potential molecular targets for therapeutic antibody targeting, with targets 
ideally expressed homogenously and at high density on the cancer cell surface. For potential 
ADC targets, it is also important that the antibody-antigen complex is internalised upon 
antibody binding. Despite predicted membrane localisation, to date we could not generate 
evidence by Immunofluorescence analysis (using commercial antibodies) that LY6G6F and 
IL1RAPL1 are presented on the cell surface of the CRC and PDAC cell lines analysed, even 
though membrane association was strongly suggested with observed expression of both 
targets in membrane enriched cell fractions. Intense LY6G6F membrane staining was 
observed in a number of tumours in the IHC analysis and was more likely to be associated 
with smaller groups of tumour cells e.g. tumour budding, an adverse prognostic factor in GI 
cancers. However, in the rest of the tumours, both LY6G6F and IL1RAPL1 showed mainly 
cytoplasmic staining. The failure to demonstrate cell-surface expression in PDAC and colon 
cancer cell lines, meant that target density on the cell surface and internalisation of the target 
upon antibody binding, could not be assessed.  
The potential lack of cell-surface expression of LY6G6F and IL1RAPL1 in the cancers 
analysed, may not mean they are not amenable to therapeutic antibody targeting. Recent 
studies have shown that cell-surface localisation may not be necessary for antibodies to show 
therapeutic efficacy. Thura et al., (2016) generated a mAb (PRL3-zumab) against an 
intracellular target, the tumour associated phosphatase PRL3, which is upregulated in 
multiple human cancers. Focusing on gastric cancer, they showed that despite being 
generated against an intracellular antigen, PRL3-zumab showed effective tumour 
suppression in a mouse model. Three possible mechanisms of anti-tumour activity by mAbs 
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against intracellular antigens were proposed: Antibody penetration into cells (anti-PRL3 
antibodies were observed to be internalised by PRL3 expressing tumour cells in vitro; 
however this mode of action remains poorly defined), antibody binding to externalised 
antigen (supposed intracellular antigens have been reported to be externalised via secretion 
or cell surface re-localisation) and antibody recognition of MHC-bound antigen-derived 
peptides. The TCRm mAbs, mentioned in Section 1.3.4., also utilise intracellular antigen-
derived peptides, presented on the cell-surface in the context of HLA, to target cancer cells. 
Therefore, intracellular antigens can be amenable to therapeutic antibody targeting in certain 
circumstances. 
Both LY6G6F and IL1RAPL1 were observed as highly expressed in colon adenocarcinoma 
regardless of the presence of mutations in KRAS and BRAF genes (in the small number of 
tissues analysed with known KRAS/BRAF mutational status), suggesting their potential as 
targets in a large range of CRC tumours. The only currently approved antibody therapy that 
directly targets CRC tumour cells, is the unconjugated anti-EGFR mAb, Cetuximab (the 
other approved mAb, Bevacizumab, targets VEGF in the tumour microenvironment). EGFR 
and its associated downstream signalling pathways are involved in many malignant 
processes, including growth and invasion. Therefore, inhibition of EGFR activation, has been 
considered an important therapeutic target. EGFR is expressed in approximately 70-80% of 
CRC tumours, however only those that also express the KRAS wildtype gene are suitable for 
anti-EGFR therapy. Patients with activating KRAS mutations do not respond to Cetuximab. 
KRAS mutation testing is currently used as standard of care in metastatic CRC patients, to 
identify those that will benefit from anti-EGFR therapy. Recent studies suggest that patients 
with BRAF mutations are also associated with a lack of response to anti-EGFR therapy. 
(Watkins and Cunningham, 2007; Gonzalez-Pons and Cruz-Correa, 2015) As KRAS and 
BRAF mutations are present in approximately 40% and 5-10% of CRCs respectively, there 
is a significant patient population that cannot benefit from the only currently approved mAb 
targeting CRC tumour cells. (Fearon, 2011) Both mAbs currently approved (Cetuximab and 
Bevacizumab), are approved for metastatic CRC patients only, and overall have limited 
clinical efficacy. Therefore, there is a desperate need for the identification of other targets in 
CRC, that could be targeted by specific mAbs to improve survival of CRC patients. LY6G6F 
and IL1RAPL1 expression needs to be investigated in larger cohorts of CRC tumours with 
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wildtype and mutated KRAS and BRAF genes, to determine if they are consistently 
expressed regardless of mutational status.  
This study has shown that knockdown of LY6G6F in a colon and pancreatic cancer cell line, 
led to a decrease in FAK activation, an increase in apoptosis and a significant reduction in 
the proliferation, migration and invasion of these cells in vitro, a finding which has not been 
previously reported in the literature. Higher LY6G6F expression was also associated with 
poorer prognosis vs. low LY6G6F expression in the PDAC patient cohort analysed in the 
Immunohistochemical analysis and in gastric cancer patients in the KM plotter analysis. 
Therefore, LY6G6F could potentially be utilised as an unconjugated mAb target, similar to 
EGFR, to inhibit LY6G6F activation and potentially inhibit tumour growth and invasion. 
Inhibitory mAbs are generally more effective however, when they also engage host defence 
mechanisms, resulting in CDC or ADCC of the tumour cells.  
The potentially secreted form of IL1RAPL1 observed in this study (the lower molecular 
weight band detected in conditioned medium from cancer cells by Western blot analysis; see 
Figure 5.3) could have implications for its suitability as a potential molecular target for 
antibody based therapy. It has generally been assumed that the secretion of target antigen by 
cancer cells, is not an ideal characteristic, in particular for ADC targets, as soluble antigen in 
the tumour microenvironment can bind ADCs, thus limiting the amount of ADC free to bind 
tumour cells and therefore decreasing efficacy. However, recent studies have shown that 
ADCs that either do not internalise or that target elements in the tumour microenvironment, 
can still show potent anti-tumour activity, through the release of cytotoxic drug at the tumour 
site, exposing the tumour cells to drug indirectly or helping to dismantle the tumour 
microenvironment. (Gébleux et al., 2017) Further investigation into this potentially secreted 
form of IL1RAPL1 is required, however if IL1RAPL1 is secreted highly in vivo then it could 
have potential as a serum biomarker for CRC diagnosis or monitoring of recurrence. There 
are currently only two blood-based biomarkers available to monitor CRC patients, 
carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9). CA19-9 is less 
sensitive and specific for CRC compared to CEA, which is the only acceptable tumour 
marker to monitor CRC recurrence to date. Elevated CEA serum levels are a poor prognostic 
factor for resectable CRC and correlate with cancer progression. CEA levels decrease after 
tumour resection, which are then monitored to check for disease recurrence. CEA is not 
suitable as a diagnostic marker for CRC screening as elevated levels are only detected in 
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advanced stages of a fraction of all CRC patients. The discovery of an effective blood-based 
screening method for CRC diagnosis would be ground breaking and likely increase patient 
adherence over current screening methods, such as the faecal occult blood testing and 
colonoscopy. (Gonzalez-Pons and Cruz-Correa, 2015) IL1RAPL1 was not expressed by 
100% of all CRC specimens analysed, therefore if it is secreted in vivo, it is not likely to have 
potential as a single marker for CRC screening. A panel of serum biomarkers is likely to 
show more sensitivity and specificity for CRC diagnosis over a single biomarker. 
There is increasing interest in targeting elements of the tumour microenvironment that 
contribute to tumour growth and progression, including tumour-infiltrating immune cells, 
and antigens in the tumour vasculature and stroma. Several target antigens in the tumour 
stroma are currently under research as potential therapeutic targets, including Collagen IV, 
Fibronectin extra-domain B and Tenascin C. (Diamantis and Banerji, 2016) Targeting of 
tumour-associated macrophages in a mouse model of triple negative breast cancer has been 
shown to inhibit tumour growth. (Niu et al., 2016) Both LY6G6F and IL1RAPL1 expression 
has been observed in the stroma of tumour specimens; LY6G6F in possibly fibroblast-like 
cells in the stroma of PDAC and IL1RAPL1 in potentially immune cells of the CRC 
microenvironment. The precise cellular component displaying target immunoreactivity needs 
to be confirmed for both targets, but shows that LY6G6F and IL1RAPL1 could also have 
potential as targets for therapeutic targeting of the tumour microenvironment.  
Overall this study has identified LY6G6F and IL1RAPL1 as novel targets overexpressed in 
GI cancers vs. normal tissues. LY6G6F was found to be overexpressed in 70% of colon 
adenocarcinoma, 78.9% of PDAC and 50% of gastric adenocarcinoma tumour specimens 
analysed. IL1RAPL1 was found to be overexpressed in 66.7% of colon adenocarcinoma, 
100% of colon carcinoid and 100% of oesophageal squamous cell carcinoma specimens 
analysed. These expression levels are comparable to other targets that are currently in clinical 
development as ADC targets in GI cancers, e.g. GCC, which is expressed in approximately 
60-70% of pancreatic, gastric and oesophageal cancers and by 95% of CRCs. (Almhanna et 
al., 2016). Further investigation of LY6G6F and IL1RAPL1, and elucidation of their role in 
these cancers will be required to ascertain their full potential as targets for therapeutic 
antibody targeting.  
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6.6. Conclusions 
Two lists were generated in-house by profiling of publicly available colon cancer gene 
expression microarray data from normal colon, adenoma and adenocarcinoma tissue sections. 
(1) A list of 1078 genes upregulated in adenoma vs. normal colon. (2) A list of 1238 genes 
upregulated in adenocarcinoma vs. normal colon. These gene lists were then annotated for 
membrane localisation and a fold change of ≥ 2 and an adjusted p-value of  ≤  1E-5 was 
considered significant. This produced the final lists of predicted membrane localised genes. 
(1) 154 genes upregulated in adenoma vs. normal colon. (2) 127 genes upregulated in 
adenocarcinoma vs normal colon. Candidate targets were selected for validation based on 
relative novelty in CRC by literature review and also based on commercial antibody 
availability. Seven candidate targets were identified for validation of expression at the protein 
level in CRC, and if promising, for subsequent investigation in further cancer types and 
investigation of their potential as molecular targets that may be amenable to therapeutic 
antibody targeting. 
 
• The seven candidate targets selected for validation of expression at the protein level 
in colon cancer cell lines and normal colon and CRC tissue sections were: LY6G6F, 
IL1RAPL1, IL20RA, BACE2, NTM, EPHX4 and LRRC8E.  
• The expression of all seven targets was detected in both the whole cell lysate and 
membrane enriched fraction of a panel of six colon cancer cell lines. This indicates 
an association with the membrane in these cell lines.  
• Expression in normal colon and CRC tissues specimens could not be assessed for two 
of the targets, EPHX4 and LRRC8E. Therefore, they were not pursued further. 
• NTM showed strong immunoreactivity in some of the CRC tissue specimens 
analysed. However, a similar level of expression was observed in normal colon. 
Therefore, NTM does not appear to be upregulated in CRC and was not chosen to 
pursue further. 
• IL20RA showed strong membrane immunoreactivity in CRC tissues, and also in 
PDAC tissues. However strong expression was also detected in normal tissues 
including colon, pancreas and duodenum. Therefore, IL20RA does not appear to be 
upregulated in CRC or PDAC compared to corresponding normal tissues, and does 
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not fit the criteria for a molecular target to be amenable to therapeutic antibody 
targeting, and was not pursued further. 
• BACE2 showed strong immunoreactivity in some CRC and PDAC tissues, with 
strong expression also detected in normal colon and pancreas however. Weak BACE2 
immunoreactivity was observed in normal duodenum, gastric tissue and oesophagus. 
Therefore, BACE2 appears to be endogenously expressed at a higher level in normal 
colon and pancreas, with no overall overexpression detected in CRC or PDAC. 
Therefore, BACE2 was not pursued further as a candidate target. 
• Two targets, LY6G6F and IL1RAPL1, successfully met the criteria in the initial 
validations to warrant further analysis of their expression in cancer and investigation 
of their potential as molecular targets amenable to therapeutic antibody targeting. 
Both LY6G6F and IL1RAPL1 showed minimal immunoreactivity in normal colon 
and strong immunoreactivity in CRC tissue sections. Their expression was also 
detected in both the whole cell and membrane enriched fraction across the colon 
cancer cell line panel analysed.  
 
 
1) LY6G6F was found to be significantly overexpressed in colon adenocarcinoma, gastric 
adenocarcinoma and PDAC compared to corresponding normal tissues. Functional studies 
on LY6G6F in any of these cancer types have not previously been reported in the literature.  
• LY6G6F is significantly overexpressed in both the benign spectrum of colon disease 
and colon adenocarcinoma tissue specimens. High LY6G6F expression was found in 
tissues representing hyperplasia of glandular epithelium, polyps, adenoma and 
adenocarcinoma. This suggests a role for LY6G6F in the initial abnormal 
transformation of normal colon cells, and potential to be utilised as an early diagnostic 
marker.  
• High LY6G6F expression is not associated with the other CRC subtypes analysed. 
Low expression was detected in metastatic adenocarcinoma, mucinous 
adenocarcinoma and carcinoid tumours.  
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• LY6G6F is significantly overexpressed in PDAC vs. normal pancreas, with a trend 
towards decreased survival observed in patients with high LY6G6F expression vs. 
low LY6G6F expression. 
• LY6G6F is significantly overexpressed in gastric adenocarcinoma vs. normal gastric 
epithelium in the small cohort analysed. This could be assessed further in a larger 
patient cohort. 
• LY6G6F shows minimal expression in the majority of normal tissues and does not 
appear to be expressed in the highly proliferating cells of normal tissues. Strong 
LY6G6F expression was observed in the stroma of PDAC and some normal tissues. 
The identification of this cell type needs to be confirmed.  
• LY6G6F expression was detected in the whole cell and membrane enriched fraction 
of every CRC and PDAC cell line analysed by Western blot analysis. Subsequent 
qRT-PCR analysis revealed that the LY6G6F mRNA transcript is expressed at low 
abundance levels in these cells and did not correspond to protein levels observed. 
This suggests LY6G6F protein expression levels are likely regulated after translation 
in these cell lines.   
• Transient siRNA knockdown of LY6G6F in the colon cancer cell line HCT116 and 
the PDAC cell line MIA PaCa-2 was found to significantly decrease the proliferation 
of these cells, as determined by both the acid phosphastase assay and the 2D colony 
formation assay. A significant decrease in migration and invasion levels was also 
observed. 
• The knockdown of LY6G6F in these cells was subsequently found to cause an 
increase in apoptosis (determined by an increase in PARP cleavage) and a decrease 
in FAK activation. The reduction of FAK activation could potentially be the mediator 
of the increase in apoptosis, and decrease in cell proliferation, migration and invasion 
observed following LY6G6F knockdown. 
• Taken together with the Kaplan-Meier survival analysis of the PDAC patient cohort, 
which showed decreased survival in patients with high LY6G6F expression, these 
functional studies implicate LY6G6F in the growth and survival of these cancers.  
• To date, the localisation of LY6G6F in cancer cell lines and tissues was mainly 
observed to be cytoplasmic. Localisation on the surface of cancer cells was not 
confirmed by Immunohistochemical or Immunofluorescence analysis.  
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2) IL1RAPL1 was identified as a novel overexpressed protein in CRC and OSCC. IL1RAPL1 
overexpression in these cancers has not previously been reported in the literature and no 
functional studies on IL1RAPL1 in cancer have been carried out to date.  
• IL1RAPL1 is lowly expressed in normal colon and the benign spectrum of colon 
disease (chronic inflammation, hyperplasia, polyps and adenoma). 
• IL1RAPL1 is significantly overexpressed in all CRC subtypes analysed, with the 
highest degree of overexpression observed in carcinoid tumours, followed by 
adenocarcinoma, metastatic adenocarcinoma and mucinous adenocarcinoma 
specimens.  
• IL1RAPL1 may have particular relevance in the carcinoid tumour subtype, which 
arises from neuroendocrine cells, as 100% of these specimens showed high 
IL1RAPL1 expression (although sample size was very small; n=2), and as IL1RAPL1 
is known for its expression in neurons. 
• High IL1RAPL1 expression is significantly associated with OSCC compared to 
normal oesophagus and other oesophageal cancer subtypes, including OAC. 
However, sample size was very small and these results should be confirmed in a larger 
patient cohort.  
• The majority of normal tissues analysed showed weak IL1RAPL1 immunoreactivity. 
However, the strong expression observed in cells of some normal tissues (e.g. isolated 
cells in gastric epithelium, potentially immune cells in normal colon and CRC) needs 
to be investigated further. The presence of IL1RAPL1 expression in the highly 
proliferating cells of some normal tissues could also not be conclusively determined, 
with possible expression in the proliferating cells of normal duodenum and gastric 
tissue observed.  
• IL1RAPL1 expression was detected in the whole cell lysate and membrane enriched 
fraction of all cell lines analysed in the CRC, PDAC and breast cancer cell line panels. 
Western blot analysis also revealed the presence of a potentially soluble/secreted 
isoform of IL1RAPL1 detected in cancer cell conditioned medium and expressed by 
all PDAC cell lines and three of the colon cancer cell lines.  
• Transient siRNA knockdown of IL1RAPL1 successfully reduced mRNA levels, as 
determined by qRT-PCR analysis. However, protein knockdown could not be 
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observed by Western blot analysis, despite numerous optimisations, including time-
course experiments. This suggests IL1RAPL1 may have a long protein half-life. 
• Investigation of the functional role of IL1RAPL1 in the colon cancer cell phenotype 
in vitro, could not be determined due to the lack of protein knockdown observed.  
• To date, the localisation of IL1RAPL1 in cancer cell lines and tissues was mainly 
observed to be cytoplasmic.  
 
 
v Overall two novel candidate targets, LY6G6F and IL1RAPL1, successfully validated 
out of the seven selected from the microarray data and were found to be significantly 
overexpressed in a number of GI cancers.  
v The overexpression of IL1RAPL1 in CRC and OSCC and the protein overexpression 
of LY6G6F in PDAC and gastric cancer is a novel finding. 
v LY6G6F is potentially involved in the proliferation and survival of CRC, PDAC and 
gastric cancer.  
v Both LY6G6F and IL1RAPL1 show preliminary potential as molecular targets that 
may be amenable to therapeutic antibody targeting, however further investigation is 
required. 
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6.7. Future Work 
1) LY6G6F was found to be overexpressed in colon adenocarcinoma, PDAC and gastric 
adenocarcinoma compared to normal tissues, with a functional role in colon cancer and 
PDAC cell lines. There are a number of follow up experiments which could be carried out to 
further clarify the expression and functional role of LY6G6F. 
• Generation of mAbs against either the whole LY6G6F protein or a peptide sequence 
of LY6G6F predicted to be highly immunogenic (peptide prediction studies have 
been carried out in collaboration with CRB, UK.) by hybridoma technology would 
facilitate further localisation and functional studies. A good antibody is crucial for 
further investigation of this target and a phenotypic hybridoma screen could isolate a 
functional blocking antibody and antibody suitable for localisation studies. 
• Further investigation of the cellular localisation of LY6G6F could be carried out with 
a generated mAb using confocal microscopy and flow cytometry. If such studies can 
confirm membrane localisation then the density of LY6G6F on the cell surface can 
be determined by quantitative flow cytometry. 
• If cell-surface localisation is confirmed, then internalisation of the antigen-antibody 
complex can be investigated by time-lapse microscopy using a fluorescently tagged 
mAb or using an assay such as the Fab-ZAP antibody internalisation kit.  
• LY6G6F was found to be significantly overexpressed in gastric adenocarcinoma vs. 
normal gastric epithelium. However, the overexpression was observed in just 50% of 
the cancer specimens and in a small patient cohort. Therefore, LY6G6F expression 
could be investigated in a larger patient cohort to assess whether it is consistently 
overexpressed in gastric adenocarcinoma and whether LY6G6F overexpression is 
associated with a particular subtype, pathological feature or survival in gastric cancer.  
• LY6G6F was found to be significantly overexpressed in colon adenocarcinoma 
regardless of KRAS or BRAF mutational status and also appears to be associated with 
MSS phenotype. However, this sample size was very small, therefore LY6G6F 
expression should be investigated in larger cohorts of CRC tumours to determine if 
LY6G6F is consistently expressed regardless of mutational status and if consistently 
associated with MSS over MSI phenotype. Any association between LY6G6F 
expression and survival in CRC should also be investigated. 
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• In the PDAC patient cohort analysed, high LY6G6F expression showed a trend 
towards decreased survival. Analysis of a larger PDAC patient cohort may lead to a 
significant association between high LY6G6F expression and decreased survival in 
PDAC. 
• LY6G6F expression was observed in the stroma of PDAC and some normal tissues. 
The precise cell type should be determined; PDAC sections could be stained for 
various cell markers e.g. a-SMA on CAFS, and markers of various immune cells, 
such as TAMs (CD68, CD163) and Treg cells (CD8+, CD4+, Foxp3+). 
• Lower LY6G6F expression was observed in the metastatic CRC tumours derived 
from lymph node metastases. LY6G6F expression should be investigated in a larger 
metastatic CRC cohort and also in PDAC metastases, to determine if LY6G6F is 
consistently lowly expressed in metastatic tumours and thus whether a potential 
LY6G6F targeted therapeutic could have application in the metastatic disease setting.  
• LY6G6F was more likely to be observed as membrane-localised in smaller tumour 
ducts and budding of CRC and PDAC. Tumour budding is associated with partial 
EMT. Therefore, serial tissue sections could be stained for markers of EMT (e.g. 
mesenchymal markers, vimentin and N-cadherin) to determine if LY6G6F expression 
is associated with tumour cells undergoing EMT. 
• Transient siRNA knockdown of LY6G6F in HCT116 and MIA PaCa-2 cells 
decreased the proliferation, migration and invasion of these cells. Further functional 
assays could be carried out with both siRNA and a LY6G6F blocking antibody from 
the mAb generation. Anoikis assays and 3D soft agar colony formation assays could 
further elucidate on the function of LY6G6F in these cells. 
• Preliminary Western blot analysis of signalling pathways affected by LY6G6F 
knockdown, showed a decrease in FAK phosphorylation in both the HCT116 and the 
MIA PaCa-2 cell line. Reverse phase protein array (RPPA) profiling could be carried 
out to look at a wider range of phosphorylated protein changes following both siRNA 
transfections and functional antibody blocking of cells (in collaboration with Prof. 
Bryan Hennessey’s group in RCSI, Beaumont, Dublin). 
• The ADCC activity of a mAb targeting LY6G6F could also be assessed using an in 
vitro ADCC assay. The activation of ADCC is important for the therapeutic efficacy 
of unconjugated mAbs. 
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• Transient siRNA knockdown of LY6G6F in HCT116 and MIA PaCa-2 cells caused 
an increase in apoptosis, as determined by increased PARP cleavage detected by 
Western blot analysis. More extensive apoptosis and cell cycle assays should be 
carried out. E.g Annexin-V Apoptosis assay (TUNEL assay), which enables the 
quantification of live, dead and early or late apoptotic cells in a sample. Cell cycle 
arrest could be analysed by BrdU staining of cells for DNA content, which would 
allow analysis of the cells through the full cycle (G0/G1, S and G2/M).  
• In vivo studies could be carried out to further investigate the function of LY6G6F. 
LY6G6F gene knockout mice could be generated to observe any phenotypic changes, 
and thus elucidate further on the function of LY6G6F in normal tissues.  
• Patient derived xenograft (PDX) models of PDAC have already been established in 
DCU. The biodistribution of LY6G6F in these tumour xenograft mouse models of 
PDAC could potentially be assessed using a radiolabelled mAb or antibody-targeted 
nanoparticles, in collaboration with Dr. Sandra Roche.  
• PDX cell lines have also been established from these PDAC xenograft mouse models, 
which are low passage, and could be examined for LY6G6F expression and used for 
further functional studies.   
 
 
 
 
 
 
 
 
 
  254 
2) IL1RAPL1 was found to be overexpressed in CRC and OSCC. A role for IL1RAPL1 in 
the cancer cell phenotype could not be determined. Follow up work that could be carried out 
includes: 
• As already described for LY6G6F, generation of mAbs against IL1RAPL1 would 
facilitate further localisation and functional studies. The localisation of IL1RAPL1 
could be further investigated using confocal microscopy and flow cytometry. If such 
studies can confirm membrane localisation then the density of IL1RAPL1 on the cell-
surface and investigation of internalisation can be carried out as described for 
LY6G6F.  
• A functional role for IL1RAPL1 in the colon cancer cell phenotype could not be 
assessed, as siRNA mediated knockdown of IL1RAPL1 protein could not be 
achieved. A generated mAb targeting IL1RAPL1 could potentially be used for 
functional blocking to assess the effect on the cancer cell phenotype, including in 
vitro proliferation, 2D and 3D colony formation, migration, invasion and anoikis 
assays. 
• IL1RAPL1 was found to be strongly expressed in the rare carcinoid subtype of CRC, 
however sample size was very small, therefore a larger patient cohort should be 
analysed for IL1RAPL1 expression.  
• IL1RAPL1 was found to be significantly overexpressed in a small sample size of 
colon adenocarcinoma regardless of KRAS or BRAF mutational status. IL1RAPL1 
expression should be investigated in larger cohorts of CRC tumours to determine if 
IL1RAPL1 is consistently expressed regardless of mutational status and should also 
be investigated in MSS and MSI tumours. Any association between IL1RAPL1 
expression and survival in CRC could also be investigated. 
• IL1RAPL1 was found to be specifically overexpressed in OSCC, compared to other 
oesophageal cancer subtypes. However, this analysis was in a very small patient 
cohort. Investigation of IL1RAPL1 expression in a larger patient cohort of all 
oesophageal cancer subtypes, would show if IL1RAPL1 overexpression is 
consistently associated with the OSCC subtype. 
• IL1RAPL1 expression was potentially observed in immune cells of normal colon and 
CRC. These tissue sections could be stained for markers associated with different 
types of immune cells e.g. TAMs (CD68, CD163), dendritic cells (CD11c+, HLA-
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DR+), NK cells (CD3-, CD56+, CD94+, NKp46+) and Treg cells (CD8+, CD4+, 
Foxp3+), to identify the cell type and further elucidate on the expression of 
IL1RAPL1 in normal and cancer tissues.  
• IL1RAPL1 protein knockdown could not be achieved, possibly due to a long protein 
half-life. The protein half-life of IL1RAPL1 in the colon cancer cell lines could be 
determined by carrying out protein half-life experiments i.e. by treating cells with 
cycloheximide in a time-course experiment. 
• The potential soluble isoform of IL1RAPL1 needs to be investigated further, and 
could be investigated in CRC patient serum samples. 
• Further optimisation of the IL1RAPL1 overexpression work that was started could be 
carried out. The qRT-PCR needs to be repeated with a different endogenous control 
gene to determine if IL1RAPL1 mRNA was overexpressed. Then if protein 
overexpression is achieved, the effect on the cancer cell phenotype can be determined 
by a number of in vitro functional assays, including proliferation, migration and 
invasion assays.  
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